var images_info;if (!images_info) images_info =[]; images_info["107"]={"107000":{"type":"graphic_diagnosticimage","displayName":"MS flow acceleration","title":"MS flow acceleration","html":"<div class=\"graphic\"><div style=\"width: 840px\" class=\"figure\"><div class=\"ttl\">MS flow acceleration</div><div class=\"cntnt\"><img style=\"width:820px; height:570px;\" src=\"images/ANEST/107000_MS_flow_acceleration_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mid-esophageal four-chamber view with a focus on the mitral valve shows aliasing of the color-flow Doppler signal in diastole on the left atrial side of the mitral valve. The presence of high-velocity aliased flow through the mitral valve in diastole should prompt further evaluation of the degree of mitral stenosis.</div><div id=\"graphicVersion\">Graphic 107000 Version 1.0</div></div></div>"},"107002":{"type":"graphic_table","displayName":"Hydroxyurea dosing in SCD","title":"Approach to hydroxyurea administration in patients with sickle cell disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to hydroxyurea administration in patients with sickle cell disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Laboratory testing</td> <td class=\"subtitle1\">Dosing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Initiating hydroxyurea therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>CBC with differential and PLT</li> <li>Reticulocyte count </li> <li>Quantitative measure of HbF (eg, HPLC) </li> <li>Kidney and liver function tests </li> <li>Pregnancy test for females of childbearing potential </li> </ul> </td> <td> <ul> <li>Infants younger than one year: Start at&nbsp;15 mg/kg daily </li> <li>Older children, adolescents and adults with CrCl &#62;60 mL/min: Start at 20 mg/kg daily </li> <li>Patients with chronic kidney disease: Start at half the normal dose (eg, 5 to 10 mg/kg daily) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Transitioning from chronic prophylactic transfusion to hydroxyurea therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>All baseline testing listed above for starting hydroxyurea </li> <li>Every month: CBC with differential and PLT, ANC, ARC, HbF, kidney and liver function tests </li> </ul> </td> <td> <ul> <li>Wean transfusion by lowering the post-transfusion target&nbsp;hemoglobin to 11.5 g/dL </li> <li>Increase hydroxyurea dose every eight weeks by 5 mg/kg daily to a maximum of 35 mg/kg or 2500 mg daily using MTD parameters below </li> <li>Continue weaning transfusions. Reduce the target post-transfusion&nbsp;hemoglobin to 11 g/dL at two months and to&nbsp;10.5 g/dL at four months </li> <li>Discontinue transfusions when stable MTD is reached; initiate phlebotomy or continue chelation therapy if there is transfusional iron overload </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Titrating hydroxyurea to MTD</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>CBC with differential and reticulocyte count at least every month </li> </ul> </td> <td>Criteria for MTD with good response: <ul class=\"decimal_heading\"> <li>Target ANC: 1500 to 3000/microL* </li> <li>Target PLT: &#8805;80,000/microL </li> <li>Target hemoglobin: &#8805;8 g/dL off transfusion </li> <li>Target ARC: 80,000 to 100,000/microL </li> <li>Target HbF: &#62;20% of total hemoglobin; no upper limit </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chronic maintenance therapy</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>CBC with differential, PLT, and reticulocyte count every two to three months </li> <li>HbF, serum ferritin and creatinine levels, and liver function tests every three to six months </li> <li>Urine pregnancy tests as appropriate </li> <li>For hematologic toxicity, weekly CBC until resolution </li> </ul> </td> <td> <ul> <li>Reinforce importance of dose adherence </li> <li>Reinforce need for contraception if appropriate<sup>&#182;</sup> </li> <li>For hematologic toxicity, hold dose until recovery into target range and reinitiate at the same or lower dose (eg, previous dose reduced by 2.5 mg/kg/day), depending on the severity and duration of toxicity </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For infants and young children taking a liquid formulation, the dose can be rounded to the nearest 2.5 mg/kg. For individuals able to take pills, the dose is rounded off to the nearest pill size. All patients of childbearing potential (male and female) should be counseled about the need for contraception while taking hydroxyurea. Six months of therapy at MTD may be required before a response is seen. If there is no apparent response, it may be appropriate to assess&nbsp;MCV and HbF; however, some patients who are taking the medication correctly will not have a response, and lack of an increase in MCV or&nbsp;HbF is not an indication to discontinue therapy if clinical benefit is seen. Refer to UpToDate topics on SCD and hydroxyurea use for information about appropriate indications and additional details of administration.</div><div class=\"graphic_footnotes\">SCD: sickle cell disease; CBC: complete blood count; PLT: platelet count;&nbsp;HbF: hemoglobin F; HPLC: high performance liquid chromatography; ANC: absolute neutrophil count; ARC: absolute reticulocyte count;&nbsp;MTD: maximum tolerated dose;&nbsp;CrCl: creatinine clearance; MCV: mean cell volume.<br />* Infants and young children with lower baseline ANCs can tolerate an on-therapy ANC as low as 1000/microL.<br /><SUP>¶ </SUP>Applies to males and females.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ware RE. Optimizing hydroxyurea therapy for sickle cell anemia. Hematology Am Soc Hematol Educ Program 2015; 2015:436.</li>&#xD;&#xA;    <li>Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 107002 Version 4.0</div></div></div>"},"107003":{"type":"graphic_table","displayName":"Stroke prevention trials SCD","title":"Stroke prevention trials in sickle cell disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stroke prevention trials in sickle cell disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Trial</td> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Findings</td> <td class=\"subtitle1\">PubMed ID&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Primary prevention</td> </tr> <tr> <td class=\"indent1\">STOP-1</td> <td>Children with abnormal TCDs</td> <td>Prophylactic transfusions versus observation</td> <td>Reduction in stroke risk with transfusions</td> <td><a href=\"http://www.ncbi.nlm.nih.gov/pubmed?term=9647873&#38;TransSchema=title&amp;#38;cmd=detailssearch\" spellcheck=\"true\"><span style=\"color: #0000ff;\">9647873</span></a></td> </tr> <tr> <td class=\"indent1\">STOP-2</td> <td>Children receiving transfusions for abnormal TCDs</td> <td>Discontinuation of transfusions versus continued transfusions</td> <td>Increase in stroke risk after discontinuation of transfusions</td> <td><a href=\"http://www.ncbi.nlm.nih.gov/pubmed?term=16382063&#38;TransSchema=title&amp;#38;cmd=detailssearch\" spellcheck=\"true\"><span style=\"color: #0000ff;\">16382063</span></a></td> </tr> <tr> <td class=\"indent1\">SIT</td> <td>Children with SCI</td> <td>Prophylactic transfusions versus observation</td> <td>Reduction in stroke risk with transfusions</td> <td><a href=\"http://www.ncbi.nlm.nih.gov/pubmed?term=25140956&#38;TransSchema=title&amp;#38;cmd=detailssearch\" spellcheck=\"true\"><span style=\"color: #0000ff;\">25140956</span></a>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">TWiTCH</td> <td>Children receiving transfusions for abnormal TCDs</td> <td>Transition to&nbsp;hydroxyurea versus continued transfusions</td> <td>Stroke risk not increased with transition to hydroxyurea</td> <td><a href=\"http://www.ncbi.nlm.nih.gov/pubmed?term=26670617&#38;TransSchema=title&amp;#38;cmd=detailssearch\" spellcheck=\"true\"><span style=\"color: #0000ff;\">26670617</span></a></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Secondary prevention</td> </tr> <tr> <td class=\"indent1\">SWiTCH</td> <td>Children receiving transfusions for prior stroke</td> <td>Transition to hydroxyurea versus continued transfusions</td> <td>Trend towards increased stroke risk with transition to hydroxyurea</td> <td><a href=\"http://www.ncbi.nlm.nih.gov/pubmed?term=22318199&#38;TransSchema=title&amp;#38;cmd=detailssearch\" spellcheck=\"true\"><span style=\"color: #0000ff;\">22318199</span></a></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Only randomized trials are listed. Refer to UpToDate content on stroke prevention in sickle cell disease for our approach as well as further important information about these trials and discussions of other evidence to guide therapy.</div><div class=\"graphic_footnotes\">STOP: stroke prevention in sickle cell anemia; SIT: silent infarct transfusion; TWiTCH: TCD with transfusions changing to hydroxyurea; SWiTCH: stroke with transfusions changing to hydroxyurea; TCD: transcranial Doppler; SCI: silent cerebral infarction.</div><div id=\"graphicVersion\">Graphic 107003 Version 1.0</div></div></div>"},"107004":{"type":"graphic_table","displayName":"Venous air embolism during craniotomy: Rapid overview","title":"Venous air embolism during craniotomy: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Venous air embolism during craniotomy: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Risk factors</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Craniotomy in the sitting position </li> <li>Surgery involving major intracranial venous sinuses; air entry possible from any venous opening above the level of the heart </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Clinical signs</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Air visible on TEE </li> <li>Change in precordial Doppler tone </li> <li>Decrease in ETCO<sub>2</sub>* </li> <li>Decrease in SPO<sub>2</sub>* </li> <li>Hypotension* </li> <li>Increase in CVP* </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Notify surgeon <ul> <li>Flood field with saline </li> <li>Repair site of air entry </li> </ul> </li> <li>Lower the head <ul> <li>May result in bleeding from air entry site </li> <li>May limit surgical access to operative site </li> </ul> </li> <li>Discontinue N<sub><span style=\"font-size: 13px;\">2</span></sub>O and administer 100 percent O<sub><span style=\"font-size: 13px;\">2</span></sub></li> <li>Aspirate air from central venous catheter </li> <li>Discontinue PEEP </li> <li>Cardiovascular support <ul> <li>IV fluids </li> <li>Vasopressors as needed </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; ETCO<SUB>2</SUB>: end-tidal carbon dioxide; SPO<SUB>2</SUB>: oxygen saturation; CVP: central venous pressure; N<SUB>2</SUB>O: nitrous oxide; O<SUB>2</SUB>: oxygen; PEEP: positive end-expiratory pressure; VAE: venous air embolism.<br />* Clinical signs depend on severity of VAE.</div><div id=\"graphicVersion\">Graphic 107004 Version 3.0</div></div></div>"},"107005":{"type":"graphic_table","displayName":"High risk findings suggesting traumatic brain injury in children","title":"Clinical findings associated with a high risk for clinically important traumatic brain injury in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings associated with a high risk for clinically important traumatic brain injury in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical findings that warrant urgent neuroimaging</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Suspicion of child abuse (infants) </li> <li>Persistent vomiting </li> <li>Seizure </li> <li>Altered mental status* </li> <li>Prolonged loss of consciousness </li> <li>Bulging fontanelle (infants) </li> <li>Focal neurologic findings </li> <li>Skull fracture </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Lethargy or irritability in infants; in older patients, agitation, lethargy, repetitive questioning, or slow response to verbal questioning.</div><div id=\"graphicVersion\">Graphic 107005 Version 2.0</div></div></div>"},"107006":{"type":"graphic_table","displayName":"Findings of moderate risk for traumatic brain injury in children","title":"Moderate risk findings of clinically important traumatic brain injury in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Moderate risk findings of clinically important traumatic brain injury in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical finding warranting observation or neuroimaging</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Vomiting that is self-limited </li> <li>Loss of consciousness that is uncertain, or isolated and very brief (less than a few seconds) </li> <li>Headache (older, verbal child) </li> <li>History of lethargy or, in infants,&nbsp;irritability, now resolved&nbsp;</li> <li>Behavioral change reported by caregiver (infants)&nbsp;</li> <li>Injury caused by high-risk mechanism of injury* </li> <li>Scalp hematoma (particularly nonfrontal) in infants younger than 2 years of age </li> <li>Skull fracture more than 24 hours old (nonacute) </li> <li>Unwitnessed trauma of concern<sup>&#182;</sup> </li> <li>Age younger than three months with nontrivial trauma </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Severe mechanism of injury includes a fall more than three feet (infants younger than 2 years) or five feet (patients 2 years and older); motor vehicle collision with patient ejection, death of a passenger, rollover; or high-impact head injury. <br /><br />¶&nbsp; Unwitnessed trauma of concern&nbsp; includes a fall heard in adjacent room with possible loss of consciousness or similar nontrivial trauma</div><div id=\"graphicVersion\">Graphic 107006 Version 2.0</div></div></div>"},"107009":{"type":"graphic_figure","displayName":"Techniques for mitochondrial replacement during IVF","title":"Techniques for mitochondrial replacement ","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Techniques for mitochondrial replacement </div><div class=\"cntnt\"><img style=\"width:541px; height:464px;\" src=\"images/OBGYN/107009_Techniques_for_mitochondrial_replacement_during_IVF.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Falk MJ, Decherney A, Kahn JP. Mitochondrial replacement techniques- implications for the clinical community. N Engl J Med 2016.</div><div id=\"graphicVersion\">Graphic 107009 Version 1.0</div></div></div>"},"107011":{"type":"graphic_figure","displayName":"Woman in candy cane stirrups and 90 degree flexion ","title":"Woman in candy cane stirrups and 90 degree flexion","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Woman in candy cane stirrups and 90 degree flexion</div><div class=\"cntnt\"><img style=\"width:518px; height:513px;\" src=\"images/OBGYN/107011_Woman_in_candy_cane_stirrups_-and_90_degree_flexion.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 107011 Version 1.0</div></div></div>"},"107012":{"type":"graphic_figure","displayName":"Arms tucked for laparoscopy","title":"Arms tucked for laparoscopy","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Arms tucked for laparoscopy</div><div class=\"cntnt\"><img style=\"width:463px; height:349px;\" src=\"images/OBGYN/107012_Arms_tucked_for_laparoscopy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 107012 Version 1.0</div></div></div>"},"107013":{"type":"graphic_figure","displayName":"Boot-type stirrups for gynecologic surgery","title":"Boot-type stirrups for gynecologic surgery","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Boot-type stirrups for gynecologic surgery</div><div class=\"cntnt\"><img style=\"width:546px; height:343px;\" src=\"images/OBGYN/107013_Boot-type_stirrups_for_gynecologic_surgery.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 107013 Version 1.0</div></div></div>"},"107014":{"type":"graphic_table","displayName":"Body Dysmorphic Disorder Questionnaire (BDDQ)","title":"Body Dysmorphic Disorder Questionnaire (BDDQ)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Body Dysmorphic Disorder Questionnaire (BDDQ)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><br /> Name:</td> <td colspan=\"2\"><br /> Date:</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Please read each question carefully and circle the answer that is true for you. Also write in answers where indicated.</td> </tr> <tr> <td> <ol> <li>Are you worried about how you look? </li> </ol> </td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>If yes: Do you think about your appearance problems a lot and wish you could think about them less? </li> </ul> </td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent4\" colspan=\"3\"> <p>&#8226; If yes: Please list the body areas you don't like:<br /> <br /> <br /> </p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent4\" colspan=\"3\"> <p><em>Examples of disliked body areas include: your skin (for example, acne, scars, wrinkles, paleness, redness); hair; the shape or size of your nose, mouth, jaw, lips, stomach, hips, etc; or defects of your hands, genitals, breasts, or any other body part.</em></p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">NOTE: If you answered \"No\" to either of the above questions, you are finished with this questionnaire. Otherwise continue.</td> </tr> <tr> <td> <ol start=\"2\"> <li>Is your <strong><em>main</em></strong> concern with how you look that you aren't thin enough or that you might get too fat? </li> </ol> </td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"3\"> <ol start=\"3\"> <li>How has this problem with how you look affected your life? </li> </ol> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Has it often upset you a lot? </li> </ul> </td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Has it often gotten in the way of doing things with friends, dating, your relationships with people, or your social activities? </li> </ul> </td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent4\" colspan=\"3\"> <p>&#8226; If yes: Describe how:<br /> <br /> <br /> </p> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Has it caused you any problems with school, work, or other activities? </li> </ul> </td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent4\" colspan=\"3\"> <p>&#8226; If yes: What are they?<br /> <br /> <br /> </p> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Are there things you avoid because of how you look? </li> </ul> </td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent4\" colspan=\"3\"> <p>&#8226; If yes: What are they?<br /> <br /> <br /> </p> </td> </tr> <tr> <td colspan=\"3\"> <ol start=\"4\"> <li>On an average day, how much time do you usually spend thinking about how you look? (Add up all the time you spend in total in a day, then circle one.) </li> </ol> </td> </tr> <tr> <td class=\"indent3\"> <p>(a) Less than 1 hour a day</p> <p>(b) 1 to 3 hours a day</p> <p>(c) More than 3 hours a day</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Phillips KA. Understanding Body Dysmorphic Disorder: an Essential Guide, Oxford University Press, New York 2009. By permission of Oxford University Press, USA. Copyright &copy; 2009. <a href=\"http://www.oup.com/\" target=\"_blank\">www.oup.com</a>.</div><div id=\"graphicVersion\">Graphic 107014 Version 1.0</div></div></div>"},"107016":{"type":"graphic_figure","displayName":"Phase response curves to light and melatonin","title":"Phase response curves to light and melatonin","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Phase response curves to light and melatonin</div><div class=\"cntnt\"><img style=\"width:560px; height:422px;\" src=\"images/SLEEP/107016_Phase_curvs_light_melatonin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the phase response curves to light and melatonin. Circadian time point 0 reflects the temperature nadir. Light exposure prior to the temperature nadir results in a delay of circadian rhythms, whereas light exposure after the temperature nadir causes phase advances. Note that there is a dead zone in the middle of the day where bright light exposure has no effect on the timing of circadian rhythms. In contrast, melatonin administered in the beginning of the night advances the circadian rhythm, while melatonin in the morning delays the circadian rhythm.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lewy AJ, Bauer VK, Ahmed S, et al. The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol Int 1998; 15:71.</li>&#xD;&#xA;    <li>Khalsa SB, Jewett ME, Cajochen C, Czeisler CA. A phase response curve to single bright light pulses in human subjects. J Physiol 2003; 549(Pt 3):945.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Zee PC, Manthena P. The brain's master circadian clock: Implications and opportunities for therapy of sleep disorders. Sleep Med Rev 2007; 11:59. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107016 Version 1.0</div></div></div>"},"107019":{"type":"graphic_algorithm","displayName":"CALA algorithm","title":"Algorithm for management of congenital abnormalities of the lower airway","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of congenital abnormalities of the lower airway</div><div class=\"cntnt\"><img style=\"width:684px; height:428px;\" src=\"images/PEDS/107019_CALA_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CPAM: congenital pulmonary airway malformation (also known as congenital cystic adenomatoid malformation; CCAM); BPS: bronchopulmonary sequestration; PPB: pleuropulmonary blastoma; CT: computed tomography; MRI: magnetic resonance imaging.<br />* This pathway also applies to asymptomatic patients in whom a congenital abnormality of the lower airway is identified as an incidental finding on chest radiograph.<br />&para; Either CT or MRI may be used for advanced thoracic imaging. Doppler ultrasound can be considered if contrast-enhanced imaging is not used to identify the vascular supply of the lesion.<br />&Delta; PPB risk factors include family history, bilateral or multifocal cysts, and pneumothorax.<br /><span class=\"lozenge\">&loz;</span> There is no consensus among experts in this field regarding observation versus elective surgical resection for asymptomatic infants with low-risk characteristics. Refer to topic text for discussion.</div><div class=\"graphic_reference\">Courtesy of Christopher Oermann, MD.</div><div id=\"graphicVersion\">Graphic 107019 Version 1.0</div></div></div>"},"107034":{"type":"graphic_algorithm","displayName":"Approach to the patient with suspected unintentional weight loss","title":"Stepwise approach to the patient with suspected unintentional weight loss","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Stepwise approach to the patient with suspected unintentional weight loss</div><div class=\"cntnt\"><img style=\"width:532px; height:727px;\" src=\"images/PC/107034_Apprch_sspct_unntnt_wght_lss.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBC: complete blood count; HbA1c: hemoglobin A1c; TSH: thyroid-stimulating hormone; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HIV: human immunodeficiency virus; HCV: hepatitis C virus; CXR: chest radiograph.<br />* Interval of follow-up may vary depending on the patient's age and comorbidities.<br />&para; Refer to the UpToDate topic on unintentional weight loss.<br />&Delta; For patients who are in high-risk groups:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Those with a history of illicit injection drug use or intranasal cocaine use, even if only used once.</li>&#xD;&#xA;    <li>Those who received clotting factors made before 1987.</li>&#xD;&#xA;    <li>Those who received blood/organs before July 1992.</li>&#xD;&#xA;    <li>Those who have been informed that they received blood from a donor who later tested positive for HCV.</li>&#xD;&#xA;    <li>Children born to HCV-infected mothers.</li>&#xD;&#xA;    <li>Those with a needle stick injury or mucosal exposure to HCV-positive blood.</li>&#xD;&#xA;    <li>Those who are a current sexual partner of an HCV-infected person.</li>&#xD;&#xA;    <li>Those with evidence of liver disease (persistently elevated alanine aminotransferase [ALT] level).</li>&#xD;&#xA;    <li>Those born in the United States between 1945 and 1965.</li>&#xD;&#xA;    <li>Those who were ever on chronic hemodialysis.</li>&#xD;&#xA;    <li>Those infected with HIV.</li>&#xD;&#xA;    <li>Incarcerated individuals.</li>&#xD;&#xA;</ul>&#xD;&#xA;<span class=\"lozenge\">&loz;</span>​ Refer to the UpToDate topic on preventive health care for adults.</div><div class=\"graphic_reference\">Adapted from: Wong CJ. Involuntary weight loss. Med Clin North Am 2014; 98:625.</div><div id=\"graphicVersion\">Graphic 107034 Version 2.0</div></div></div>"},"107035":{"type":"graphic_figure","displayName":"Stroke incidence in SCD by age","title":"Incidence of stroke in individuals with sickle cell disease according to patient age","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Incidence of stroke in individuals with&nbsp;sickle cell disease according to patient age</div><div class=\"cntnt\"><img style=\"width:531px; height:380px;\" src=\"images/HEME/107035_Strk_incdnc_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The graph illustrates the rates of ischemic and hemorrhagic stroke in a cohort of 255 hospitalized patients with sickle cell disease and stroke. Refer to UpToDate content on stroke in sickle cell disease for further details.</div><div class=\"graphic_footnotes\">SCD: Sickle cell disease.</div><div class=\"graphic_reference\">From: Strouse JJ, Jordan LC, Lanzkron S, et al. The excess burden of stroke in hospitalized adults with sickle cell disease. Am J Hematol 2009; 84:548. <a href=\"http://onlinelibrary.wiley.com/doi/10.1002/ajh.21476/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1002/ajh.21476/abstract</a>. Copyright &copy;&nbsp;2009 Wiley-Liss, Inc. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 107035 Version 1.0</div></div></div>"},"107036":{"type":"graphic_figure","displayName":"TCD and stroke risk in SCD","title":"Stroke risk according to transcranial Doppler measurements in children with sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Stroke risk according to transcranial Doppler measurements in children with sickle cell disease</div><div class=\"cntnt\"><img style=\"width:468px; height:614px;\" src=\"images/HEME/107036_TCD_strk_rsk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival analysis showing differences in stroke-free survival among patients classified according to their highest velocity in the internal carotid or middle cerebral artery on either side. In cases where multiple transcranial Dopplers (TCDs) were performed, follow-up was computed from the time the TCD first reached the cutoff point. Refer to UpToDate content on stroke prevention in SCD for further discussion of the use of&nbsp;TCD screening.</div><div class=\"graphic_footnotes\">TCD: transcranial Doppler; SCD: sickle cell disease.</div><div class=\"graphic_reference\">From: Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol 1997; 42:699. <a href=\"http://onlinelibrary.wiley.com/doi/10.1002/ana.410420505/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1002/ana.410420505/abstract</a>. Copyright &copy; 1997 American Neurological Association. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 107036 Version 1.0</div></div></div>"},"107037":{"type":"graphic_table","displayName":"Risk factors for recurrent ischemic stroke after TIA","title":"Risk factors for recurrent ischemic stroke after TIA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for recurrent ischemic stroke after TIA</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Age:</td> </tr> <tr> <td class=\"indent1\">Age &#8805;60 years</td> </tr> <tr> <td class=\"subtitle1_single\">History:</td> </tr> <tr> <td class=\"indent1\">Earlier TIA or ischemic stroke within 30 days of index event</td> </tr> <tr> <td class=\"indent1\">History of diabetes</td> </tr> <tr> <td class=\"subtitle1_single\">Blood pressure elevation when first assessed after TIA:</td> </tr> <tr> <td class=\"indent1\">Systolic &#8805;140 mmHg <strong>or</strong> diastolic &#8805;90 mmHg</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features:</td> </tr> <tr> <td class=\"indent1\">Unilateral weakness</td> </tr> <tr> <td class=\"indent1\">Isolated speech disturbance</td> </tr> <tr> <td class=\"indent1\">Duration of TIA symptoms &#62;10 minutes</td> </tr> <tr> <td class=\"subtitle1_single\">Imaging features:</td> </tr> <tr> <td class=\"indent1\">Acute infarction on diffusion-weighted MRI (ie, TIA with infarction)</td> </tr> <tr> <td class=\"indent1\">Acute or chronic ischemic lesions on CT</td> </tr> <tr> <td class=\"indent1\">Multiple acute infarcts</td> </tr> <tr> <td class=\"indent1\">Simultaneous acute infarcts in both hemispheres or in both anterior and posterior circulations</td> </tr> <tr> <td class=\"indent1\">Multiple infarcts of different ages (combination of acute and subacute infarcts)</td> </tr> <tr> <td class=\"indent1\">Isolated cortical infarcts (without accompanying deep or subcortical infarcts)</td> </tr> <tr> <td class=\"subtitle1_single\">TIA etiology:</td> </tr> <tr> <td class=\"indent1\">Large artery atherosclerosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TIA: transient ischemic attack; MRI: magnetic resonance imaging; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 107037 Version 1.0</div></div></div>"},"107053":{"type":"graphic_figure","displayName":"Annual number of ESRD incident cases","title":"Trends in annual number of end-stage renal disease incident cases (in thousands) in the United States population, 1996-2013","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">Trends in annual number of end-stage renal disease incident cases (in thousands) in the United States population, 1996-2013</div><div class=\"cntnt\"><img style=\"width:661px; height:394px;\" src=\"images/NEPH/107053_Annl_nmb_ESRD_incdnt_css.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: United States Renal Data System. 2015 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2015.</div><div id=\"graphicVersion\">Graphic 107053 Version 1.0</div></div></div>"},"107055":{"type":"graphic_table","displayName":"Adjusted survival by age, sex, race, primary cause of ESRD","title":"Adjusted survival (%) by age, sex, race, and primary cause of ESRD for ESRD patients in the 2008 incident cohort (initiating ESRD treatment in 2008)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjusted survival (%) by age, sex, race, and primary cause of ESRD for ESRD patients in the 2008 incident cohort (initiating ESRD treatment in 2008)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">2008 cohort</td> <td class=\"subtitle1\">3 months</td> <td class=\"subtitle1\">12 months</td> <td class=\"subtitle1\">24 months</td> <td class=\"subtitle1\">36 months</td> <td class=\"subtitle1\">60 months</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Age</td> </tr> <tr> <td class=\"indent1\">0 to 21</td> <td class=\"centered\">98.5</td> <td class=\"centered\">95.3</td> <td class=\"centered\">93.2</td> <td class=\"centered\">91.8</td> <td class=\"centered\">88.7</td> </tr> <tr> <td class=\"indent1\">22 to 44</td> <td class=\"centered\">97.6</td> <td class=\"centered\">91.8</td> <td class=\"centered\">86.4</td> <td class=\"centered\">81.7</td> <td class=\"centered\">73.8</td> </tr> <tr> <td class=\"indent1\">45 to 64</td> <td class=\"centered\">95.3</td> <td class=\"centered\">85.6</td> <td class=\"centered\">76.4</td> <td class=\"centered\">68.3</td> <td class=\"centered\">54.5</td> </tr> <tr> <td class=\"indent1\">65 to 74</td> <td class=\"centered\">91.1</td> <td class=\"centered\">75.0</td> <td class=\"centered\">61.8</td> <td class=\"centered\">50.9</td> <td class=\"centered\">34.1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">75+</td> <td class=\"centered\">85.1</td> <td class=\"centered\">62.2</td> <td class=\"centered\">45.6</td> <td class=\"centered\">33.2</td> <td class=\"centered\">17.1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Sex</td> </tr> <tr> <td class=\"indent1\">Male</td> <td class=\"centered\">91.8</td> <td class=\"centered\">77.6</td> <td class=\"centered\">65.9</td> <td class=\"centered\">56.4</td> <td class=\"centered\">42.4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Female</td> <td class=\"centered\">92.0</td> <td class=\"centered\">77.9</td> <td class=\"centered\">66.5</td> <td class=\"centered\">57.2</td> <td class=\"centered\">42.8</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Race</td> </tr> <tr> <td class=\"indent1\">White</td> <td class=\"centered\">91.2</td> <td class=\"centered\">76.3</td> <td class=\"centered\">64.2</td> <td class=\"centered\">54.6</td> <td class=\"centered\">40.2</td> </tr> <tr> <td class=\"indent1\">Black/African American</td> <td class=\"centered\">93.1</td> <td class=\"centered\">79.7</td> <td class=\"centered\">69.1</td> <td class=\"centered\">60.1</td> <td class=\"centered\">46.1</td> </tr> <tr> <td class=\"indent1\">Native American</td> <td class=\"centered\">92.5</td> <td class=\"centered\">78.6</td> <td class=\"centered\">65.8</td> <td class=\"centered\">55.9</td> <td class=\"centered\">42.4</td> </tr> <tr> <td class=\"indent1\">Asian</td> <td class=\"centered\">95.3</td> <td class=\"centered\">85.1</td> <td class=\"centered\">75.4</td> <td class=\"centered\">67.0</td> <td class=\"centered\">53.9</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other</td> <td class=\"centered\">90.1</td> <td class=\"centered\">71.6</td> <td class=\"centered\">57.7</td> <td class=\"centered\">47.2</td> <td class=\"centered\">34.4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Primary cause of ESRD</td> </tr> <tr> <td class=\"indent1\">Diabetes</td> <td class=\"centered\">92.9</td> <td class=\"centered\">78.3</td> <td class=\"centered\">65.2</td> <td class=\"centered\">54.3</td> <td class=\"centered\">37.9</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> <td class=\"centered\">92.2</td> <td class=\"centered\">78.8</td> <td class=\"centered\">67.7</td> <td class=\"centered\">58.6</td> <td class=\"centered\">44.6</td> </tr> <tr> <td class=\"indent1\">Glomerulonephritis</td> <td class=\"centered\">94.4</td> <td class=\"centered\">83.8</td> <td class=\"centered\">74.6</td> <td class=\"centered\">66.8</td> <td class=\"centered\">55.1</td> </tr> <tr> <td class=\"indent1\">Other</td> <td class=\"centered\">90.1</td> <td class=\"centered\">71.6</td> <td class=\"centered\">57.7</td> <td class=\"centered\">47.2</td> <td class=\"centered\">34.4</td> </tr> <tr> <td class=\"indent1\">All patients</td> <td class=\"centered\">91.9</td> <td class=\"centered\">77.7</td> <td class=\"centered\">66.2</td> <td class=\"centered\">56.8</td> <td class=\"centered\">42.6</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Adjusted for age, sex, race, Hispanic ethnicity, and primary diagnosis.</div><div class=\"graphic_footnotes\">ESRD: end-stage renal disease.</div><div class=\"graphic_reference\">Reproduced from: United States Renal Data System. 2015 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2015.</div><div id=\"graphicVersion\">Graphic 107055 Version 1.0</div></div></div>"},"107059":{"type":"graphic_picture","displayName":"Renal histology in C4 dense deposit disease","title":"Renal histology in C4 dense deposit disease","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Renal histology in C4 dense deposit disease</div><div class=\"cntnt\"><img style=\"width:726px; height:541px;\" src=\"images/NEPH/107059_Rnl_hstl_C4_dns_dpst_dss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal histology in a patient with C4 dense deposit disease.<br />(Panels A and B) Light microscopy showing a membranoproliferative glomerulonephritis with mesangial hypercellularity, endocapillary proliferation, and thickened glomerular basement membranes (GBM). Note periodic acid Schiff (PAS)-positive thickened GBM in panel A (arrows point to positive thickened GBM) and B-silver methenamine stain in panel B.<br />(Panel C) Immunofluorescence microscopy showing bright staining for C4d along the capillary walls.<br />(Panel D) Electron microscopy showing dense osmiophilic deposits along the GBM (arrows point to the dense deposits).</div><div class=\"graphic_reference\">Original figure modified for this publication. Sethi S, Quint PS, O'Seaghdha CM, et al. C4 glomerulopathy: A disease entity associated With C4d deposition. Am J Kidney Dis 2016. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107059 Version 1.0</div></div></div>"},"107060":{"type":"graphic_figure","displayName":"Glomerulonephritis classification schema with C4 glomerulopathy","title":"Glomerulonephritis classification schema with C4 glomerulopathy","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Glomerulonephritis classification schema with C4 glomerulopathy</div><div class=\"cntnt\"><img style=\"width:530px; height:218px;\" src=\"images/NEPH/107060_Glmrlnphrts_clssfct_schm_C4.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complement-mediated glomerulonephritis, that is, glomerulonephritis characterized by predominant deposition of complement factors with little or no immunoglobulin (Ig) can therefore be further subdivided into C3 glomerulopathy and C4 glomerulopathy. C3 glomerulopathy is characterized by bright staining for C3 with minimal or no immunoglobulin. However, C4 glomerulopathy is characterized by bright staining for C4d with minimal or no immunoglobulin. The difference in C4 glomerulopathy and C3 glomerulopathy lies in the essentially absent or minimal staining for C3 in C4 glomerulopathy. Why there is no staining for C3, because activation of C4 should presumably lead to the formation of C4 convertase and activation of C3, is not known at this time.</div><div class=\"graphic_footnotes\">GBM: glomerular basement membrane; DDD: dense deposit disease; GN: glomerulonephritis.</div><div class=\"graphic_reference\">Reproduced from: Sethi S, Quint PS, O'Seaghdha CM, et al. C4 glomerulopathy: A disease entity associated With C4d deposition. Am J Kidney Dis 2016. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107060 Version 1.0</div></div></div>"},"107065":{"type":"graphic_algorithm","displayName":"Evaluation of possible TIA or minor ischemic stroke","title":"Evaluation of patient presenting with acute symptoms of possible TIA or minor ischemic stroke","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Evaluation of patient presenting with acute symptoms of possible TIA or minor ischemic stroke</div><div class=\"cntnt\"><img style=\"width:593px; height:669px;\" src=\"images/NEURO/107065_Evltn_pssb_TIA_mnr_ischmc_strk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm should be used in conjunction with UpToDate topics on the initial evaluation and management of TIA and ischemic stroke.</div><div class=\"graphic_footnotes\">CDUS: carotid duplex ultrasonography; CNS: central nervous system; CT: computed tomography; CTA: computed tomography angiography; ECG: electrocardiography; IV: intravenous; MRA: magnetic resonance angiography; MRI: magnetic resonance imaging; TIA: transient ischemic attack; TCD: transcranial Doppler.<br />* Patients who present within the appropriate time window after ischemic symptom onset and have a persistent neurologic deficit that is potentially disabling, despite improvement of any degree, should be treated with intravenous thrombolysis and/or mechanical thrombectomy in the absence of other contraindications. Further management of these patients is similar to that of other patients with a potentially disabling stroke.<br />&para; Can begin aspirin and statin therapy while awaiting results of remaining diagnostic studies if imaging is negative for hemorrhage and other nonischemic cause of symptoms.<br />&Delta; Viable strategies include antihypertensive therapy, antithrombotic therapy, statin therapy, and lifestyle modification; select patients with symptomatic cervical internal carotid artery disease may benefit from carotid revascularization.</div><div id=\"graphicVersion\">Graphic 107065 Version 1.0</div></div></div>"},"107086":{"type":"graphic_table","displayName":"Immunoglobulin levels","title":"Immunoglobulin levels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunoglobulin levels</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"5\">Serum IgG, IgM, IgA, and IgE levels*</td> </tr> <tr> <td class=\"subtitle2\">Age</td> <td class=\"subtitle2\">IgG (mg/dL)</td> <td class=\"subtitle2\">IgM (mg/dL)</td> <td class=\"subtitle2\">IgA (mg/dL)</td> <td class=\"subtitle2\">IgE (international units/mL)<sup>[1]</sup></td> </tr> <tr> <td>Core blood (term)</td> <td class=\"centered\">1121 (636-1606)</td> <td class=\"centered\">13 (6.3-25)</td> <td class=\"centered\">2.3 (1.4-3.6)</td> <td class=\"centered\">0.22 (0.04-1.28)</td> </tr> <tr> <td>1 month</td> <td class=\"centered\">503 (251-906)</td> <td class=\"centered\">45 (20-87)</td> <td class=\"centered\">13 (1.3-53)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>6 weeks</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.69 (0.08-6.12)</td> </tr> <tr> <td>2 months</td> <td class=\"centered\">365 (206-601)</td> <td class=\"centered\">46 (17-105)</td> <td class=\"centered\">15 (2.8-47)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>3 months</td> <td class=\"centered\">334 (176-581)</td> <td class=\"centered\">49 (24-89)</td> <td class=\"centered\">17 (4.6-46)</td> <td class=\"centered\">0.82 (0.18-3.76)</td> </tr> <tr> <td>4 months</td> <td class=\"centered\">343 (196-558)</td> <td class=\"centered\">55 (27-101)</td> <td class=\"centered\">23 (4.4-73)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>5 months</td> <td class=\"centered\">403 (172-814)</td> <td class=\"centered\">62 (33-108)</td> <td class=\"centered\">31 (8.1-84)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>6 months</td> <td class=\"centered\">407 (215-704)</td> <td class=\"centered\">62 (35-102)</td> <td class=\"centered\">25 (8.1-68)</td> <td class=\"centered\">2.68 (0.44-16.3)</td> </tr> <tr> <td>7 to 9 months</td> <td class=\"centered\">475 (217-904)</td> <td class=\"centered\">80 (34-126)</td> <td class=\"centered\">36 (11-90)</td> <td class=\"centered\">2.36 (0.76-7.31)</td> </tr> <tr> <td>10 to 12 months</td> <td class=\"centered\">594 (294-1069)</td> <td class=\"centered\">82 (41-149)</td> <td class=\"centered\">40 (16-84)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>1 year</td> <td class=\"centered\">679 (345-1213)</td> <td class=\"centered\">93 (43-173)</td> <td class=\"centered\">44 (14-106)</td> <td class=\"centered\">3.49 (0.80-15.2)</td> </tr> <tr> <td>2 years</td> <td class=\"centered\">685 (424-1051)</td> <td class=\"centered\">95 (48-168)</td> <td class=\"centered\">47 (14-123)</td> <td class=\"centered\">3.03 (0.31-29.5)</td> </tr> <tr> <td>3 years</td> <td class=\"centered\">728 (441-1135)</td> <td class=\"centered\">104 (47-200)</td> <td class=\"centered\">66 (22-159)</td> <td class=\"centered\">1.80 (0.19-16.9)</td> </tr> <tr> <td>4 to 5 years</td> <td class=\"centered\">780 (463-1236)</td> <td class=\"centered\">99 (43-196)</td> <td class=\"centered\">68 (25-154)</td> <td class=\"centered\">8.58 (1.07-68.9)<sup>&#182;</sup></td> </tr> <tr> <td>6 to 8 years</td> <td class=\"centered\">915 (633-1280)</td> <td class=\"centered\">107 (48-207)</td> <td class=\"centered\">90 (33-202)</td> <td class=\"centered\">12.89 (1.03-161.3)<sup>&#916;</sup></td> </tr> <tr> <td>9 to 10 years</td> <td class=\"centered\">1007 (608-1572)</td> <td class=\"centered\">121 (52-242)</td> <td class=\"centered\">113 (45-236)</td> <td class=\"centered\">23.6 (0.98-570.6)<sup>&#9674;</sup></td> </tr> <tr> <td>14 years</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">20.07 (2.06-195.2)</td> </tr> <tr> <td>Adult</td> <td class=\"centered\">994 (639-1349)</td> <td class=\"centered\">156 (56-352)</td> <td class=\"centered\">171 (70-312)</td> <td class=\"centered\">13.2 (1.53-114)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgM: immunoglobulin M; IgA: immunoglobulin A; IgE: immunoglobulin E.<br />* Numbers in parentheses are the 95% CIs.<br />¶ IgE data for four years.<br />Δ IgE data for seven years.<br /><FONT class=lozenge>◊</FONT> IgE data for 10 years.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kjellman NM, Johansson SG, Roth A. Serum IgE levels in healthy children quantified by a sandwich technique (PRIST). Clin Allergy 1976; 6:51.</li>&#xD;&#xA;</ol>&#xD;&#xA;Modified with permission of the American Association for Clinical Chemistry, from: Jolliff CR, Cost KM, Stivrins PC, et al. Reference intervals for serum IgG, IgA, IgM, C3 and C4 as determined by rate nephelometry. Clin Chem 1982; 28:126; permission conveyed through Copyright Clearance Center, Inc. Copyright &copy; 1982.</div><div id=\"graphicVersion\">Graphic 107086 Version 2.0</div></div></div>"},"107088":{"type":"graphic_algorithm","displayName":"Surgery for cecal volvulus","title":"Surgery for cecal volvulus","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Surgery for cecal volvulus</div><div class=\"cntnt\"><img style=\"width:752px; height:452px;\" src=\"images/SURG/107088_Surgery_cecal_volvulus.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Right colectomy: removal of the terminal ileum, cecum, and ascending colon.<br />&para; Ileocecectomy: removal of the terminal ileum and cecum.<br />&Delta; Cecopexy: suturing of the cecum to the abdominal side wall.<br /><span class=\"lozenge\">&loz;</span> Cecostomy: inserting a tube through the abdominal wall and securing it into the cecum.</div><div id=\"graphicVersion\">Graphic 107088 Version 1.0</div></div></div>"},"107089":{"type":"graphic_table","displayName":"Genetic forms of isolated SRNS","title":"Genetic forms of isolated steroid-resistant nephrotic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic forms of isolated steroid-resistant nephrotic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">Protein function</td> <td class=\"subtitle1\">Genetic transmission</td> <td class=\"subtitle1\">Age at onset of proteinuria</td> <td class=\"subtitle1\">Histology</td> </tr> <tr> <td><em>NPHS1</em></td> <td>Nephrin</td> <td>Podocyte slit diaphragm protein</td> <td>AR</td> <td>0 to 10 years</td> <td>MCD, FSGS</td> </tr> <tr> <td><em>NPHS2</em></td> <td>Podocin</td> <td>Podocyte slit diaphragm protein</td> <td>AR</td> <td>0 to 40 years</td> <td>MCD, FSGS</td> </tr> <tr> <td><em>PLCE1</em></td> <td>Phospholipase C epsilon-1</td> <td>Podocyte differentiation, signalling protein</td> <td>AR</td> <td>0 to 8 years</td> <td>DMS, FSGS</td> </tr> <tr> <td><em>MYO1E</em></td> <td>Myosin 1E</td> <td>Actin function</td> <td>AR</td> <td>2 months to 9 years</td> <td>FSGS</td> </tr> <tr> <td><em>ADCK4</em></td> <td>aarF domain-containing kinase 4</td> <td>Podocyte cytoskeleton</td> <td>AR</td> <td>&#60;1 to 21 years</td> <td>FSGS</td> </tr> <tr> <td><em>TTC21B</em></td> <td>Intraflagellar transport protein IFT139</td> <td>Trafficking regulation in the primary cilium</td> <td>AR</td> <td>9 to 30 years</td> <td>FSGS</td> </tr> <tr> <td><em>CRB2</em></td> <td>Crumbs homolog 2 protein</td> <td>Regulation of podocyte polarity</td> <td>AR</td> <td>9 months to 6 years</td> <td>FSGS</td> </tr> <tr> <td><em>CD2AP</em></td> <td>CD-2 associated protein</td> <td>Podocyte slit diaphragm protein</td> <td>AR</td> <td>1 year</td> <td>FSGS</td> </tr> <tr> <td><em>PTPRO</em></td> <td>Receptor-type tyrosine-protein phosphatase O</td> <td>Podocyte signaling</td> <td>AR</td> <td>5 to 14 years</td> <td>MCD, FSGS</td> </tr> <tr> <td><em>ACTN4</em></td> <td>Alpha-actinin 4</td> <td>Podocyte cytoskeleton</td> <td>AD</td> <td>3 to 54 years</td> <td>FSGS</td> </tr> <tr> <td><em>TRPC6</em></td> <td>Transient receptor potential channel 6</td> <td>Calcium channel</td> <td>AD</td> <td>2 to 75 years</td> <td>FSGS</td> </tr> <tr> <td><em>INF2</em></td> <td>Inverted formin 2</td> <td>Actin regulation</td> <td>AD</td> <td>5 to 72 years</td> <td>FSGS</td> </tr> <tr> <td><em>ARHGAP24</em></td> <td>RHO GTPase-activating protein 24</td> <td>Actin function</td> <td>AD</td> <td>&#60;12 to 20 years</td> <td>FSGS</td> </tr> <tr> <td><em>ANLN</em></td> <td>Anillin</td> <td>Actin function</td> <td>AD</td> <td>9 to 69 years</td> <td>FSGS</td> </tr> <tr> <td><em>PAX2</em></td> <td>Paired box protein 2</td> <td>Kidney development</td> <td>AD</td> <td>7 to 68 years</td> <td>FSGS</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AR: autosomal recessive; MCD: minimal change disease; FSGS: focal segmental glomerulosclerosis; DMS: diffuse mesangial sclerosis; AD: autosomal dominant.</div><div id=\"graphicVersion\">Graphic 107089 Version 1.0</div></div></div>"},"107090":{"type":"graphic_table","displayName":"Genetic forms of syndromic SRNS","title":"Genetic forms of syndromic steroid-resistant nephrotic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic forms of syndromic steroid-resistant nephrotic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">Function</td> <td class=\"subtitle1\">Transmission</td> <td class=\"subtitle1\">Age at onset of proteinuria</td> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Associated features</td> </tr> <tr> <td>Denys-Drash syndrome</td> <td><em>WT1</em></td> <td>Wilms tumor protein</td> <td>Podocyte development</td> <td>AD</td> <td>0 to 10 years</td> <td>DMS</td> <td>Male pseudohermaphroditism, Wilms tumor</td> </tr> <tr> <td>Frasier syndrome</td> <td><em>WT1</em></td> <td>Wilms tumor protein</td> <td>Podocyte development</td> <td>AD</td> <td>1 to 30 years</td> <td>FSGS</td> <td>Male pseudohermaphroditism, gonadoblastoma</td> </tr> <tr> <td>Pierson syndrome</td> <td><em>LAMB2</em></td> <td>Laminin beta-2</td> <td>Links GBM to podocyte cytoskeleton</td> <td>AR</td> <td>0 to 6 years</td> <td>DMS</td> <td>Microcoria, abnormal lens</td> </tr> <tr> <td>Schimke syndrome</td> <td><em>SMARCAL1</em></td> <td>SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A-like protein 1</td> <td>Chromatin bundling and gene transcription</td> <td>AR</td> <td>2 to 12 years</td> <td>FSGS</td> <td>Bone dysplasia, immune deficiency, ischemic cerebral lesions</td> </tr> <tr> <td>Nail-patella syndrome</td> <td><em>LMX1B</em></td> <td>LIM homeodomain transcription factor 1, beta</td> <td>Podocyte and GBM development</td> <td>AD</td> <td>10 to 70 years</td> <td>FSGS</td> <td>Hypoplastic nails and patellae, iliac horns</td> </tr> <tr> <td>Charcot-Marie-Tooth disease</td> <td><em>INF2</em></td> <td>Inverted formin 2</td> <td>Actin regulation</td> <td>AD</td> <td>10 to 45 years</td> <td>FSGS</td> <td>Neuropathy, deafness</td> </tr> <tr> <td>Galloway-Mowat syndrome</td> <td><em>WDR73</em></td> <td>WD40 repeat-containing protein</td> <td>Unknown</td> <td>AR</td> <td>5 to 15 years</td> <td>FSGS</td> <td>Microcephaly, intellectual disability, hiatal hernia, optic atrophy</td> </tr> <tr> <td rowspan=\"4\">Mitochondrial respiratory-chain disease</td> <td><em>MTTL1</em></td> <td>Mitochondrial tRNA leucine 1</td> <td>Mitochondrial tRNA</td> <td>Maternal</td> <td>5 to 50 years</td> <td>FSGS</td> <td>MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms); diabetes mellitus; deafness</td> </tr> <tr> <td><em>COQ2</em></td> <td>Polyprenyltransferase</td> <td>Coenzyme Q10 biosynthesis</td> <td>AR</td> <td>0 to 2 years</td> <td>FSGS</td> <td>Encephalomyopathy, hypotonia, seizures, lactate acidosis</td> </tr> <tr> <td><em>COQ6</em></td> <td>Ubiquinone biosynthesis monooxygenase COQ6</td> <td>Coenzyme Q10 biosynthesis</td> <td>AR</td> <td>0 to 6 years</td> <td>FSGS</td> <td>Sensorineural deafness</td> </tr> <tr> <td><em>PDSS2</em></td> <td>Decaprenyl diphosphate synthase, subunit 2</td> <td>Coenzyme Q10 biosynthesis</td> <td>AR</td> <td>0 to 2 years</td> <td>FSGS</td> <td>Encephalomyopathy, hypotonia, seizures, lactate acidosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: autosomal dominant; DMS: diffuse mesangial sclerosis; FSGS: focal segmental glomerulosclerosis; AR: autosomal recessive;&nbsp;GBM: glomerular basement membrane.</div><div id=\"graphicVersion\">Graphic 107090 Version 1.0</div></div></div>"},"107091":{"type":"graphic_table","displayName":"Brighton criteria for GBS","title":"Brighton criteria for case definition of Guillain-Barré syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Brighton criteria for case definition of Guillain-Barr&eacute; syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Level 1 of diagnostic certainty</td> <td class=\"subtitle1\">Level 2 of diagnostic certainty</td> <td class=\"subtitle1\">Level 3 of diagnostic certainty</td> </tr> <tr> <td> <ul> <li>Bilateral and flaccid weakness of the limbs; <strong>AND</strong> </li> <li>Decreased or absent deep tendon reflexes in weak limbs; <strong>AND</strong> </li> <li>Monophasic illness pattern; and interval between onset and nadir of weakness between 12 hours and 28 days; and subsequent clinical plateau; <strong>AND</strong> </li> <li>Absence of identified alternative diagnosis for weakness; <strong>AND</strong> </li> <li>Cytoalbuminologic dissociation (ie, elevation of CSF protein level above laboratory normal value and CSF total white cell count &#60;50 cells/microL; <strong>AND</strong> </li> <li>Electrophysiologic findings consistent with GBS </li> </ul> </td> <td> <ul> <li>Bilateral and flaccid weakness of the limbs; <strong>AND</strong> </li> <li>Decreased or absent deep tendon reflexes in weak limbs; <strong>AND</strong> </li> <li>Monophasic illness pattern; and interval between onset and nadir of weakness between 12 hours and 28 days; and subsequent clinical plateau; <strong>AND</strong> </li> <li>Absence of identified alternative diagnosis for weakness; <strong>AND</strong> </li> <li>CSF total white cell count &#60;50 cells/microL (with or without CSF protein elevation above laboratory normal value); <strong>OR</strong> electrophysiologic studies consistent with GBS if CSF not collected or results not available </li> </ul> </td> <td> <ul> <li>Bilateral and flaccid weakness of the limbs; <strong>AND</strong> </li> <li>Decreased or absent deep tendon reflexes in weak limbs; <strong>AND</strong> </li> <li>Monophasic illness pattern; and interval between onset and nadir of weakness between 12 hours and 28 days; and subsequent clinical plateau; <strong>AND</strong> </li> <li>Absence of identified alternative diagnosis for weakness </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; GBS: Guillain-Barré syndrome.</div><div class=\"graphic_reference\">Reproduced from: Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barr&eacute; syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29:599. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107091 Version 2.0</div></div></div>"},"107092":{"type":"graphic_table","displayName":"Iron-rich complementary foods","title":"Iron-rich complementary commercial baby foods for infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Iron-rich complementary commercial baby foods for infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Serving size</td> <td class=\"subtitle1\">Elemental iron (mg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Meat</td> </tr> <tr> <td class=\"indent1\">Lamb, junior</td> <td>2.5 ounces (74 g)</td> <td>1.2</td> </tr> <tr> <td class=\"indent1\">Chicken, strained</td> <td>2.5 ounces (74 g)</td> <td>1.0</td> </tr> <tr> <td class=\"indent1\">Lamb, strained</td> <td>2.5 ounces (74 g)</td> <td>0.8</td> </tr> <tr> <td class=\"indent1\">Beef, junior or strained</td> <td>2.5 ounces (74 g)</td> <td>0.7</td> </tr> <tr> <td class=\"indent1\">Chicken, junior</td> <td>2.5 ounces (74 g)</td> <td>0.7</td> </tr> <tr> <td class=\"indent1\">Pork, strained</td> <td>2.5 ounces (74 g)</td> <td>0.7</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ham, strained or junior</td> <td>2.5 ounces (74 g)</td> <td>0.7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cereal</td> </tr> <tr> <td class=\"indent1\">Oatmeal, dry, fortified</td> <td>1 tablespoon (15 mL)</td> <td>2.0</td> </tr> <tr> <td class=\"indent1\">Brown rice, dry, instant</td> <td>1 tablespoon (15 mL)</td> <td>1.8</td> </tr> <tr> <td class=\"indent1\">Rice, dry, fortified</td> <td>1 tablespoon (15 mL)</td> <td>1.3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Barley, dry, fortified</td> <td>1 tablespoon (15 mL)</td> <td>1.1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vegetables</td> </tr> <tr> <td class=\"indent1\">Green beans, junior</td> <td>4 ounces (120 g)</td> <td>1.3</td> </tr> <tr> <td class=\"indent1\">Peas, strained</td> <td>4 ounces (120 g)</td> <td>1.1</td> </tr> <tr> <td class=\"indent1\">Green beans, strained</td> <td>4 ounces (120 g)</td> <td>0.8</td> </tr> <tr> <td class=\"indent1\">Spinach, creamed or strained</td> <td>4 ounces (120 g)</td> <td>0.7</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: United States Department of Agriculture. Agricultural Research Service. USDA National Nutrient Database for Standard Reference. Available at <a href=\"https://ndb.nal.usda.gov/\" target=\"_blank\">https://ndb.nal.usda.gov/</a> (Accessed on March 1, 2016).</div><div id=\"graphicVersion\">Graphic 107092 Version 1.0</div></div></div>"},"107121":{"type":"graphic_table","displayName":"INTERGROWTH-21 regression equations for EFW","title":"Regression equations for calculating fetal weight","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Regression equations for calculating fetal weight</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Head circumference</td> </tr> <tr> <td class=\"indent1\">Mean</td> <td>&ndash;28&sdot;2849 + 1&sdot;69267 &times; GA<sup>2</sup> &ndash; 0&sdot;397485 &times; GA<sup>2</sup> &times; log (GA)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">SD</td> <td>1&sdot;98735 + 0&sdot;0136772 &times; GA<sup>3</sup> &ndash; 0&sdot;00726264 &times; GA<sup>3</sup> &times; log (GA) + 0&sdot;000976253 &times; GA<sup>3</sup> &times; log (GA)<sup>2</sup></td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Biparietal diameter</td> </tr> <tr> <td class=\"indent1\">Mean</td> <td>5&sdot;60878 + 0&sdot;158369 &times; GA<sup>2</sup> &ndash; 0&sdot;00256379 &times; GA<sup>3</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">SD</td> <td>exp (0&sdot;101242 + 0&sdot;00150557 &times; GA<sup>3</sup> &ndash; 0&sdot;000771535 &times; GA<sup>3</sup> &times; log (GA) + 0&sdot;0000999638 &times; GA<sup>3</sup> &times; log (GA)<sup>2</sup>)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Occipitofrontal diameter</td> </tr> <tr> <td class=\"indent1\">Mean</td> <td>&ndash;12&sdot;4097 + 0&sdot;626342 &times; GA<sup>2</sup> &ndash; 0&sdot;148075 &times; GA<sup>2</sup> &times; log (GA)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">SD</td> <td>exp (&ndash;0&sdot;880034 + 0&sdot;0631165 &times; GA<sup>2</sup> &ndash; 0&sdot;0317136 &times; GA<sup>2</sup> &times; log (GA) + 0&sdot;00408302 &times; GA<sup>2</sup> &times; log (GA)<sup>2</sup>)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Abdominal circumference</td> </tr> <tr> <td class=\"indent1\">Mean</td> <td>&ndash;81&sdot;3243 + 11&sdot;6772 &times; GA &ndash; 0&sdot;000561865 &times; GA<sup>3</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">SD</td> <td>&ndash;4&sdot;36302 + 0&sdot;121445 &times; GA<sup>2</sup> &ndash; 0&sdot;0130256 &times; GA<sup>3</sup> + 0&sdot;00282143 &times; GA<sup>3</sup> &times; log (GA)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Femur length</td> </tr> <tr> <td class=\"indent1\">Mean</td> <td>&ndash;39&sdot;9616 + 4&sdot;32298 &times; GA &ndash; 0&sdot;0380156 &times; GA<sup>2</sup></td> </tr> <tr> <td class=\"indent1\">SD</td> <td>exp (0&sdot;605843 &ndash; 42&sdot;0014 &times; GA<sup>&ndash;2</sup> + 0&sdot;00000917972 &times; GA<sup>3</sup>)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Equations for the estimation of the mean and SD (in mm) of each fetal biometry measurement according to exact gestational age (in weeks).<br />All log are natural logarithms.</div><div class=\"graphic_footnotes\">SD: standard deviation; GA: exact gestational age.</div><div class=\"graphic_reference\">Reproduced from: Papageorghiou AT, Ohuma EO, Altman DG, et al. International standards for fetal growth based on serial ultrasound measurements: the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project. Lancet 2014; 384:869. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107121 Version 1.0</div></div></div>"},"107125":{"type":"graphic_figure","displayName":"Mineral/hormone values based on GFR for children with CKD","title":"Mineral and hormone values according to estimated glomerular filtration rate","html":"<div class=\"graphic\"><div style=\"width: 671px\" class=\"figure\"><div class=\"ttl\">Mineral and hormone values according to estimated glomerular filtration rate</div><div class=\"cntnt\"><img style=\"width:651px; height:469px;\" src=\"images/PEDS/107125_Mnrl_hrmn_vls_GFR_chld_CKD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperphosphatemia is defined as phosphorus (Phos) Z-score &gt;1.96 SD, hyperparathyroidism is defined as serum immunoreactive parathyroid hormone (iPTH) &gt;65 pg/mL, and FGF23 excess is defined as plasma FGF23 &gt;101 RU/mL.</div><div class=\"graphic_footnotes\">Phos: phosphorus; iPTH: immunoreactive parathyroid hormone; GFR: glomerular filtration rate; SD: standard deviation.</div><div class=\"graphic_reference\">Reproduced with permission from: Portale AA, Wolf M, J&uuml;ppner H, Messinger S, et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 2014; 9:344. Copyright &copy; 2014 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 107125 Version 1.0</div></div></div>"},"107129":{"type":"graphic_figure","displayName":"Stationary biking exercise","title":"Stationary biking exercise","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Stationary biking exercise</div><div class=\"cntnt\"><img style=\"width:526px; height:702px;\" src=\"images/RHEUM/107129_Stationary_biking_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The stationary bike provides safe, low-impact exercise. The seat height should be adjusted so that the knees are slightly bent at the low point of the downstroke, and no more than 90 degrees flexed on the upstroke. Resistance is increased gradually. Leg cramps during sleep may be prevented by riding the stationary bicycle for a few minutes before retiring.</div><div id=\"graphicVersion\">Graphic 107129 Version 1.0</div></div></div>"},"107130":{"type":"graphic_table","displayName":"CD treatments summary for patients","title":"Crohn disease treatments for pediatric patients, summary for patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Crohn disease treatments for pediatric patients, summary for patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"centered highlight_gray_text\" style=\"vertical-align: middle; border-bottom: black 3px solid;\"><strong>Frequently asked questions</strong></td> <td class=\"centered highlight_gray_text\" style=\"vertical-align: middle; border-bottom: black 3px solid;\"><strong>Immunomodulator</strong><br /> Azathioprine (imuran, azasan); 6-mercaptopurine (6MP, purinethol), methotrexate</td> <td class=\"centered highlight_gray_text\" style=\"vertical-align: middle; border-bottom: black 3px solid;\"><strong>Anti-TNF</strong><br /> Infliximab (remicade); adalimumab (humira); certolizumab pegol (cimzia)</td> <td class=\"centered highlight_gray_text\" style=\"vertical-align: middle; border-bottom: black 3px solid;\"><strong>Combination therapy</strong><br /> Immunomodulator plus anti-TNF</td> </tr> <tr class=\"divider_bottom\"> <td><strong>What type of medication is this?</strong></td> <td>An immunomodulator is a medicine that is taken to regulate or quiet down the immune system, which then decreases inflammation.</td> <td>An anti-tumor necrosis factor (TNF) drug blocks one specific chemical (TNF) in the body. Blocking TNF regulates or quiets down the immune system, which then decreases inflammation.</td> <td>Using an immunomodulator and an anti-TNF drug together.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>How is this treatment administered?</strong></td> <td>Daily, as a pill (azathioprine or 6MP), or weekly as a pill or shot (methotrexate). It may take weeks to months to be fully effective, so your doctor may prescribe a steroid, such as prednisone, to start.</td> <td>Infliximab is given intravenously (injected into the vein) 3 times in the first 6 weeks, then every 6 to 8 weeks. Adalimumab is given subcutaneously (injected under the skin) every other week, and certolizumab is given subcutaneously monthly. These medications act faster than immunomodulators, so you likely won't need steroids.</td> <td>Daily pill (or weekly shots if methotrexate) PLUS injections either intravenous (into the vein) or subcutaneous (under the skin).</td> </tr> <tr class=\"divider_bottom\"> <td rowspan=\"2\"><strong>After 6 months of treatment, how many people get relief of their symptoms and don't need steroids (eg, prednisone)?</strong></td> <td colspan=\"3\">There are no research studies in children directly comparing immunomodulators to anti-TNF drugs to combination therapy. But, we do have good estimates based on research in children and adults for each of these options.</td> </tr> <tr class=\"divider_bottom\"> <td>Approximately 40 people out of 100 (40%).</td> <td>Approximately 55 people out of 100 (55%).</td> <td>Approximately 60 people out of 100 (60%).</td> </tr> <tr class=\"divider_bottom\"> <td><strong>What are some common, but short-lasting, side effects?</strong></td> <td>Approximately 3 people out of 100 (3%) develop pancreatitis, where the pancreas becomes inflamed and painful. Other short-term side-effects may include nausea, fever, fatigue, lowering of the white blood cell count, or increase in liver tests.</td> <td>Allergic reactions like a rash or shortness of breath from an infusion, or pain or swelling at the injection site can occur.</td> <td>With combination therapy, it's possible to get side effects from both immunomodulators and anti-TNF drugs.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>How common are serious infections?</strong></td> <td colspan=\"3\">Approximately 3 to 6% (between 3 to 6 people out of 100) experience serious infections for each treatment option.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>How many people stop taking the medication because of side effects?</strong></td> <td>Approximately 10 out of 100 (10%).</td> <td>Approximately 6 to 7 people out of 100 (6 to 7%).</td> <td>If side-effects occur, it might be possible to stop one of the medications and continue the other.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>What is the risk of getting lymphoma (lymph node cancer)?</strong></td> <td>Approximately 4 people out of 10,000 (0.04%) for azathioprine and 6MP. It is not clear if methotrexate has any risk of lymphoma, but not enough research has been done to prove this.</td> <td>It is not clear that anti-TNF therapy on its own increases the risk of lymphoma at all, but not enough research has been done to prove this.</td> <td>There does not seem to be a meaningful increase in the risk of lymphoma if adding an anti-TNF to an immunomodulator. The risk is approximately 4 people out of 10,000 (0.04%).</td> </tr> <tr class=\"divider_bottom\"> <td><strong>What else should I know about the risks of cancer?</strong></td> <td colspan=\"3\">A rarer form of cancer is <strong>hepatosplenic T-cell lymphoma</strong>. We don't know exactly how often it occurs, but it is very rare (less often than the type of lymphoma described above). It is seen mostly in young males. It is usually not treatable. This lymphoma has occurred in people taking 6MP or azathioprine by itself, or as combination therapy with an anti-TNF drug. There have not been cases reported in Crohn disease with either methotrexate or anti-TNF therapy on its own.</td> </tr> <tr> <td><strong>What is the risk of getting lymphoma if not taking these medications?</strong></td> <td colspan=\"3\">The risk of developing lymphoma in the general pediatric population is 0.0058%. This is equal to approximately 0.58 per 10,000 or 5 to 6 people out of 100,000.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Option grid for the choice between immunomodulators, anti-TNF agents, and combination therapy for the treatment of pediatric Crohn disease. Option grids are intended to be reviewed with patients during an office visit to facilitate a shared decision-making process.</div><div class=\"graphic_footnotes\">6-MP: mercaptopurine; TNF: anti-tumor necrosis factor.</div><div class=\"graphic_reference\">From: Dulai PS, Siegel CA, Dubinsky MC. Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2013; 19:2927. DOI: <a href=\"http://journals.lww.com/ibdjournal/pages/articleviewer.aspx?year=2013&amp;issue=12000&amp;article=00024&amp;type=abstract\" target=\"_blank\">10.1097/MIB.0b013e31829aad16</a>. Copyright &copy; 2013 Crohn's and Colitis Foundation of America, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 107130 Version 1.0</div></div></div>"},"107132":{"type":"graphic_table","displayName":"ISUP Grade Group Classification System","title":"ISUP Grade Group Classification System","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ISUP Grade Group Classification System</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade group</td> <td class=\"subtitle1\">Gleason Score and&nbsp;Pattern</td> </tr> <tr> <td>1</td> <td>Grade 6 (3+3)</td> </tr> <tr> <td>2</td> <td>Grade 7 (3+4)</td> </tr> <tr> <td>3</td> <td>Grade 7 (4+3)</td> </tr> <tr> <td>4</td> <td>Grade 8 (4+4, 3+5, or 5+3)</td> </tr> <tr> <td>5</td> <td>Grade 9 or 10 (4+5, 5+4, or 5+5)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ISUP: International Society of Urological Pathology.</div><div class=\"graphic_reference\">Adapted from: Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016; 40:244.</div><div id=\"graphicVersion\">Graphic 107132 Version 1.0</div></div></div>"},"107133":{"type":"graphic_picture","displayName":"Erosive OA","title":"Erosive osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erosive osteoarthritis</div><div class=\"cntnt\"><img style=\"width:396px; height:441px;\" src=\"images/RHEUM/107133_Erosive_OA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked radial/ulnar instability in a patient with erosive OA. Such instability does not usually occur with common hand OA.</div><div class=\"graphic_footnotes\">OA: osteoarthritis.</div><div class=\"graphic_reference\">Reproduced with permission from: OARSI Online Primer. Edited by Henrotin Y, Hunter D, Kawaguchi H. 2012. Osteoarthritis Research Society International. (http://primer.oarsi.org).</div><div id=\"graphicVersion\">Graphic 107133 Version 1.0</div></div></div>"},"107137":{"type":"graphic_algorithm","displayName":"Our approach to the management of PAH due to PVOD","title":"Our approach to the management of pulmonary arterial hypertension due to pulmonary veno-occlusive disease","html":"<div class=\"graphic\"><div style=\"width: 946px\" class=\"figure\"><div class=\"ttl\">Our approach to the management of pulmonary arterial hypertension due to pulmonary veno-occlusive disease</div><div class=\"cntnt\"><img style=\"width:926px; height:754px;\" src=\"images/PULM/107137_Apprch_mngmnt_PAH_due_PVOD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">All treatments should be performed in a center with expertise in PAH. This algorithm is a representation of our approach. Other centers may have different approaches. All patients with PVOD should be referred at the time of diagnosis for lung transplantation evaluation. If at any time during treatment lung transplantation is offered, medical therapy should be abandoned and transplant performed.</div><div class=\"graphic_footnotes\">CCB: calcium channel blocker; WHO: World Health Organization; PVOD: pulmonary veno-occlusive disease; PAH: pulmonary arterial hypertension; ECMO: extracorporeal membrane oxygenation.<br />* Similar to patients who have class I PAH (eg, idiopathic PAH), patients with PVOD should exercise as tolerated, receive routine vaccinations, be counseled against smoking and pregnancy, and be treated with supportive measures including oxygen and diuretics, when indicated. The administration of anticoagulant therapy is controversial due to a potentially higher risk of alveolar hemorrhage (refer to UTD text for details). We favor limited trials of immunomodulatory medications (eg, corticosteroids, antimetabolites) in patients with PVOD who also have prominent autoimmune features. This preference is based upon anecdotal responses that have occurred with these agents, particularly in the context of limited treatment options.<br />¶ The administration of vasodilators during testing may induce acute pulmonary edema such that this test is avoided by some experts or limited doses of vasodilator are administered during testing (refer to UTD text for details).<br />Δ Most studies report a lack of improvement or the development of pulmonary edema, with only a few case reports suggesting sustained improvement with CCBs. Starting dose is lower than that for patients with class I PAH (refer to UTD text for dosing). For vasoreactive patients who present with WHO functional class IV, some experts avoid CCBs and administer single agent epoprostenol.<br /><FONT class=lozenge>◊</FONT> Sustained response is considered an improvement or stabilization of symptoms that justifies continuing therapy. Patients who deteriorate symptomatically or worsen in WHO functional class are considered to have progressive disease such that therapy should be escalated.<br />§ Advanced therapy is therapy that is directed at the pulmonary hypertension itself. Compared with patients who have class I PAH (eg, idiopathic PAH), advanced therapy in this population has an increased risk of adverse effects including pulmonary edema, respiratory failure, and cardiac arrest. While some experts prefer to avoid advanced therapy, we administer cautious trials of advanced therapy as a bridge to transplant. When this approach is chosen, we initiate low doses of agent together with close monitoring and rapidly available treatment of pulmonary edema with oxygen and high dose diuretics; therapy can then be slowly escalated every one to two weeks to the maximum tolerated dose.<br />¥ Single agent and combined oral therapy (double therapy) increase the risk of adverse effects and may not be tolerated in this population. When using combined therapy, agents from two different classes should be used and only one agent should be added each time. Agent selection is individualized and varies according to the institution, patient preference, and cost. Among the available oral agents, an endothelin receptor antagonist (eg, ambrisentan, macitentan, bosentan) or a phosphodiesterase inhibitor (eg, sildenafil) may be appropriate. Some experts administer a third oral agent or a single agent intravenous epoprostenol for patients who have WHO functional class III and have rapidly progressive disease (refer to UTD text for details).<br />‡ Combined therapy increases the risk of adverse effects and may not be tolerated in this population. Some experts combine intravenous agents with one or two oral agents (double or triple therapy, respectively). Agents from different classes should be used and only added sequentially.<br />† Up to two oral agents can be combined with intravenous prostanoid therapy. Agents from two different classes should be used and only one agent should be added each time. Due to the increased risk of adverse effects, agent selection is individualized and varies according to the institution, patient preference, and cost. Among the available oral agents, an endothelin receptor antagonist (eg, ambrisentan, macitentan, bosentan) or a phosphodiesterase inhibitor (eg, sildenafil) may be appropriate (refer to UTD text for details).<br />** As a bridge to lung transplantation, atrial septostomy, lung assist devices, and ECMO have been used in rare cases of patients with severe PVOD.</div><div id=\"graphicVersion\">Graphic 107137 Version 1.0</div></div></div>"},"107138":{"type":"graphic_picture","displayName":"Location of P6 acupoint","title":"Location of P6 acupoint","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Location of P6 acupoint</div><div class=\"cntnt\"><img style=\"width:561px; height:420px;\" src=\"images/ANEST/107138_Lctn_P6_acpnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">P6 acupressure point location: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Ask the patient to lay his forearm and hand on a flat surface with the palmar aspect facing you.</LI>&#xD;&#xA;<LI>Note the crease at the transition between the wrist and the forearm.</LI>&#xD;&#xA;<LI>Measure three finger-breadths or 5 cm proximally from this crease and position your index finger to mark the site.</LI>&#xD;&#xA;<LI>Ask the patient to flex his wrist, thereby accentuating the palmaris longus tendon. Then move your index finger radially past the palmaris longus tendon and into the groove bounded by the flexor carpi radial tendon. This is the P6 acupressure point.</LI></OL></div><div id=\"graphicVersion\">Graphic 107138 Version 4.0</div></div></div>"},"107141":{"type":"graphic_table","displayName":"Medical record review for medical child abuse","title":"An example of a chart to organize the medical record review for medical child abuse*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">An example of a chart to organize the medical record review for medical child abuse*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Date</td> <td class=\"subtitle1\">Provider</td> <td class=\"subtitle1\">Complaint</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>2-05-07</td> <td>Jones, ENT</td> <td>Recurrent OM</td> <td>Mom says audiogram at Kerman Hosp. shows conductive hearing loss. He snores and mouth breathes. He has had 12 ear infections. <em>Audiogram report says it's normal. He has had 3 documented ear infections.</em> Mother says child has eosinophilic granulama. <em>Not true.</em> Child is allergic to Keflex, penicillin, and erythromycin. <em>No evidence of drug reactions in medical record.</em> MD says based on history, child needs T &#38; A and PE tubes inserted.</td> </tr> <tr> <td>2-17-07</td> <td>Marshall Hosp.<br /> Jones, ENT</td> <td>Recurrent OM</td> <td><strong>Surgery.</strong> T &#38; A, PE tubes. No fluid noted behind ear drums. No unusual tonsilar or adenoidal pathology.</td> </tr> <tr> <td>2-24-07</td> <td>Jones, ENT</td> <td>Postop visit</td> <td>Tubes in place. Doing well.</td> </tr> <tr> <td>3-11-07</td> <td>Marshall Hosp. ED</td> <td>Tube fell out of ear</td> <td>Mom was cleaning child's ear with a water pik. PE tube came out of ear. Ref. to Dr Jones.</td> </tr> <tr> <td>3-15-07</td> <td>Wilson, Pediatric cross cover</td> <td>Ear pain and fever</td> <td>Telephone call from mom. Fever and ear pain. Child allergic to penicillin and erythromycin. Rx: Ceclor.</td> </tr> <tr> <td>3-17-07</td> <td>Jones, ENT</td> <td>Evaluate lost PE tube</td> <td>Missed appointment.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Reviewer's comments are in italics.</div><div class=\"graphic_reference\">From: Roesler TA, Jenny C. Medical Child Abuse: Beyond Munchausen by Proxy. Elk Grove Village, IL: American Academy of Pediatrics; 2009: 179. Copyright &copy; 2009 American Academy of Pediatrics. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 107141 Version 2.0</div></div></div>"},"107143":{"type":"graphic_picture","displayName":"Injured toenail in a runner","title":"Injured toenail (\"black toe\") in a runner","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Injured toenail (\"black toe\")&nbsp;in a runner</div><div class=\"cntnt\"><img style=\"width:480px; height:640px;\" src=\"images/SM/107143_Black_toe_runner.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Runners sometimes sustain toenail injuries from repetitive trauma to the nail or nail bed. This condition is commonly called \"jogger's toenail\", and it most frequently affects the great toe (photo above), which may appear black&nbsp;from subungual bleeding.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 107143 Version 2.0</div></div></div>"},"107170":{"type":"graphic_figure","displayName":"Sleep episodes over 24-hour period in ICU","title":"Sleep episodes over the course of a 24-hour period in the intensive care unit","html":"<div class=\"graphic\"><div style=\"width: 764px\" class=\"figure\"><div class=\"ttl\">Sleep episodes over the course of a 24-hour period in the intensive care unit</div><div class=\"cntnt\"><img style=\"width:744px; height:548px;\" src=\"images/SLEEP/107170_Sleep_epsd_24hr_period_ICU.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Each row represents an individual patient over a 24-hour period while in the intensive care unit. The black areas represent sleep time. The white areas represent awake time.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2001 American Thoracic Society. Freedman NS, Gazendam J, Levan L, et al. Abnormal sleep/wake cycles and the effect of environmental noise on sleep disruption in the intensive care unit. Am J Respir Crit Care Med 2001; 163(2):451-7. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 107170 Version 1.0</div></div></div>"},"107185":{"type":"graphic_figure","displayName":"Cubitus valgus in Turner syndrome","title":"Cubitus valgus in a patient with Turner syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cubitus valgus in a patient with Turner syndrome</div><div class=\"cntnt\"><img style=\"width:434px; height:507px;\" src=\"images/ENDO/107185_Cubitus_valgus_in_Turner_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cubitus valgus (increased carrying angle) in a patient with Turner syndrome. The carrying angle of the elbow averages about 12 degrees in the general female population, and&nbsp;can be&nbsp;20 to 30 degrees or more in patients with Turner syndrome.&nbsp;&nbsp;&nbsp;&nbsp;</div><div id=\"graphicVersion\">Graphic 107185 Version 1.0</div></div></div>"},"107190":{"type":"graphic_figure","displayName":"Growth response to GH in TS","title":"Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens</div><div class=\"cntnt\"><img style=\"width:768px; height:1198px;\" src=\"images/ENDO/107190_Growth_response_GH_TS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Height standard deviation (SD)-score for&nbsp;chronological age&nbsp;(compared with normal Dutch girls) during&nbsp;growth hormone&nbsp;(GH) treatment for group A, group B, and group C,<FONT color=black> respectively.&nbsp;Group A received a GH dose of about 45 micrograms/kg/day, and groups B and C escalated to doses as high as 67 and 90 micrograms/kg/day, respectively,&nbsp;after the first few years of therapy. <br />(B) Height gain (difference in centimeters between&nbsp;final height&nbsp;and modified projected adult height) for group A (n = 19), group B (n = 20), and group C (n = 21), respectively (arrow&nbsp;indicates the mean for each group).<br />Note that growth hormone therapy leads to normalization of final&nbsp;height in most girls with Turner syndrome. This is true even when puberty is induced at a relatively normal pubertal age. Optimal growth hormone dosage depends on height and age at the start of therapy and on the height velocity during the first year of growth hormone therapy. </FONT></div><div class=\"graphic_reference\">Republished with permission of The Endocrine Society, from van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, et al. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003; 88:1119. Copyright &copy; 2003; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 107190 Version 1.0</div></div></div>"},"107233":{"type":"graphic_algorithm","displayName":"Management of Graves disease in children","title":"Overview of the management of Graves' disease in children and adolescents","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Overview of the management of Graves' disease in children and adolescents</div><div class=\"cntnt\"><img style=\"width:716px; height:898px;\" src=\"images/PEDS/107233_ManagementGraveschildren.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm presents the most common treatment approaches for management of Graves' disease in children and adolescents. Surgery and radioactive iodine (RAI) generally are used as second-line options in patients who develop major side effects with antithyroid drug treatment or who fail to enter a remission off drug treatment, though some clinicians recommend RAI or surgery as first-line treatment in selected cases, as shown by the dashed lines.</div><div class=\"graphic_footnotes\">MMI: methimazole; fT4: free thyroxine; T3: triidothyronine; RAI: radioactive iodine; 131-I: iodine 131; WBC: white blood cell count; TSH: thyroid stimulating hormone.<br />* When treating with MMI, initially monitor fT4 and T3 every four to six weeks, and adjust dose of MMI to normalize these values. Once these values are in the normal range, continue to monitor fT4, T3, and TSH every three to four months. During any febrile illness, stop MMI and check WBC, to monitor for development of granulocytopenia.<br />¶ Major side effects of MMI include agranulocytosis, vasculitis (lupus-like syndrome), or hepatitis. Minor side effects include rash, hives, arthralgias, transient granulocytopenia, or gastrointestinal symptoms.<br />Δ Practice varies regarding the length of time a provider will continue to treat with MMI after patients have entered remission. We do not recommend a trial off MMI after an arbitrary period of treatment; we prescribe MMI indefinitely, providing that the antithyroid drug is the preferred treatment choice of the patient and parents, and that no major side effects occur. Refer to UpToDate topic text for details.<br /><FONT class=lozenge>◊</FONT> Patient should be off of MMI for at least seven days before RAI treatment. We suggest using a RAI dose calculated to achieve hypothyroidism.</div><div class=\"graphic_reference\">Courtesy of Stephen LaFranchi, MD.</div><div id=\"graphicVersion\">Graphic 107233 Version 3.0</div></div></div>"},"107234":{"type":"graphic_figure","displayName":"Aortic dissection PI","title":"Aortic dissection","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Aortic dissection</div><div class=\"cntnt\"><img style=\"width:510px; height:627px;\" src=\"images/PI/107234_Aortic_dissection_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The aorta is the main blood vessel that comes out of the heart and carries blood to the body. In an aortic dissection, the inner wall of the aorta gets damaged or tears. Most often, the tear is in the first part of the descending aorta.</div><div id=\"graphicVersion\">Graphic 107234 Version 1.0</div></div></div>"},"107236":{"type":"graphic_table","displayName":"PSQI scoring instructions","title":"Pittsburgh Sleep Quality Index (PSQI) scoring instructions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pittsburgh Sleep Quality Index (PSQI) scoring instructions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">SCORING INSTRUCTIONS FOR THE PITTSBURGH SLEEP QUALITY INDEX:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">The Pittsburgh Sleep Quality Index (PSQI) contains 19 self-rated questions and 5 questions rated by the bed partner or roommate (if one is available). Only self-rated questions are included in the scoring. The 19 self-rated items are combined to form seven \"component\" scores, each of which has a range of 0-3 points. In all cases, a score of \"0\" indicates no difficulty, while a score of \"3\" indicates severe difficulty. The seven component scores are then added to yield one \"global\" score, with a range of 0-21 points, \"0\" indicating no difficulty and \"21\" indicating severe difficulties in all areas.<br /> Scoring proceeds as follows:</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Component 1: Subjective sleep quality</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol> <li>Examine question #6, and assign scores as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Response</strong></td> <td class=\"centered\"><strong>Component 1 score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>\"Very good\" </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>\"Fairly good\" </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>\"Fairly bad\" </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>\"Very bad\" </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"><em>Component 1 score:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Component 2: Sleep latency</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol> <li>Examine question #2, and assign scores as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Response</strong></td> <td class=\"centered\"><strong>Score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>&#8804;15 minutes </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>16-30 minutes </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>31-60 minutes </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>&#62;60 minutes </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent3\"><em>Question #2 score:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"2\"> <li>Examine question #5a, and assign scores as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Response</strong></td> <td class=\"centered\"><strong>Score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Not during the past month </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Less than once a week </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Once or twice a week </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Three or more times a week </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent3\"><em>Question #5a score:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"3\"> <li>Add #2 score and #5a score: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><em>Sum of #2 and #5a:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"4\"> <li>Assign component 2 score as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Sum of #2 and #5a</strong></td> <td class=\"centered\"><strong>Component 2 score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>0 </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>1-2 </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>3-4 </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>5-6 </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"><em>Component 2 score:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Component 3: Sleep duration</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol> <li>Examine question #4, and assign scores as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Response</strong></td> <td class=\"centered\"><strong>Component 3 score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>&#62;7 hours </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>6-7 hours </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>5-6 hours </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>&#60;5 hours </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"><em>Component 3 score:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Component 4: Habitual sleep efficiency</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol> <li>Write the number of hours slept (question #4) here: _____ </li> </ol> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"2\"> <li>Calculate the number of hours spent in bed: </li> </ol> </td> </tr> <tr> <td class=\"indent4\" colspan=\"2\"> <ul> <li>Getting up time (question #3): _____ </li> </ul> </td> </tr> <tr> <td class=\"indent4\" colspan=\"2\"> <ul> <li>Bedtime (question #1): _____ </li> </ul> </td> </tr> <tr> <td class=\"indent4\" colspan=\"2\"> <ul> <li>Number of hours spent in bed: _____ </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"3\"> <li>Calculate habitual sleep efficiency as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\" colspan=\"2\"> <ul> <li> <p>(Number of hours slept/number of hours spent in bed) X 100 = Habitual sleep efficiency (%)</p> <p>( _____ / _____ ) X 100 = _____ %</p> </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"4\"> <li>Assign component 4 score as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Habitual sleep efficiency %</strong></td> <td class=\"centered\"><strong>Component 4 score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>&#62;85% </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>75-84% </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>65-74% </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>&#60;65% </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"><em>Component 4 score:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Component 5: Sleep disturbances</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol> <li>Examine questions #5b-5j, and assign scores for <em>each</em> question as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Response</strong></td> <td class=\"centered\"><strong>Score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Not during the past month </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Less than once a week </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Once or twice a week </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Three or more times a week </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><em>#5b score:</em> </li> </ul> </td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><em>&nbsp; 5c score:</em> </li> </ul> </td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><em>&nbsp; 5d score:</em> </li> </ul> </td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><em>&nbsp; 5e score:</em> </li> </ul> </td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><em>&nbsp; 5f score:</em> </li> </ul> </td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><em>&nbsp; 5g score:</em> </li> </ul> </td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><em>&nbsp; 5h score:</em> </li> </ul> </td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><em>&nbsp; 5i score:</em> </li> </ul> </td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent4\"> <ul> <li><em>&nbsp; 5j score:</em> </li> </ul> </td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"2\"> <li>Add the score for questions #5b-5j: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><em>Sum of #5b-5j:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"3\"> <li>Assign component 5 scores as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Sum of #5b-5j</strong></td> <td class=\"centered\"><strong>Component 5 score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>0 </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>1-9 </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>10-18 </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>19-27 </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"><em>Component 5 score:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Component 6: Use of sleeping medication</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol> <li>Examine question #7 and assign scores as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Response</strong></td> <td class=\"centered\"><strong>Component 6 score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Not during the past month </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Less than once a week </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Once or twice a week </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Three or more times a week </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"><em>Component 6 score:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Component 7: Daytime dysfunction</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol> <li>Examine question #8, and assign scores as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Response</strong></td> <td class=\"centered\"><strong>Score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Never </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Once or twice </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Once or twice each week </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Three or more times each week </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent3\"><em>Question #8 score:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"2\"> <li>Examine question #9, and assign scores as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Response</strong></td> <td class=\"centered\"><strong>Score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>No problem at all </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Only a very slight problem </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>Somewhat of a problem </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>A very big problem </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent3\"><em>Question #9 score:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"3\"> <li>Add the scores for questions #8 and #9: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><em>Sum of #8 and #9:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ol start=\"4\"> <li>Assign component 7 score as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"><strong>Sum of #8 and #9</strong></td> <td class=\"centered\"><strong>Component 7 score</strong></td> </tr> <tr> <td class=\"indent4\"> <ul> <li>0 </li> </ul> </td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>1-2 </li> </ul> </td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>3-4 </li> </ul> </td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent4\"> <ul> <li>5-6 </li> </ul> </td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"><em>Component 7 score:</em></td> <td class=\"centered\">_____</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Global PSQI score</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Add the seven component scores together:</td> </tr> <tr> <td class=\"indent3\"><strong><em>Global PSQI score:</em></strong></td> <td class=\"centered\">_____</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: A New Instrument for Psychiatric Practice and Research. Psychiatry Res 1989; 28:193. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107236 Version 1.0</div></div></div>"},"107237":{"type":"graphic_waveform","displayName":"EPS tracings concealed entrainment","title":"Electrophysiology study (EPS) tracings showing concealed entrainment","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">Electrophysiology study (EPS) tracings showing concealed entrainment</div><div class=\"cntnt\"><img style=\"width:788px; height:379px;\" src=\"images/CARD/107237_EP_stdy_trcng_cncl_entrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pacing from the distal electrode pair of the mapping/ablation catheter during mapping of sustained ventricular tachycardia. On the left side of the figure are the last three stimuli during a train of pacing at a cycle length of 410 msec. Following pacing, the tachycardia (cycle length 430 msec) resumes. The interval from the last paced beat to resumption of tachycardia, measured in the distal ablation catheter (Abl d), is just 10 msec greater than the tachycardia cycle length. Note that the interval from the pacing stimulus to onset of the QRS complex is the same as the interval from the local electrogram to the QRS onset when ventricular tachycardia resumes after pacing. Note also that the paced VT morphology replicates the morphology of the spontaneous tachycardia. This is an example of \"concealed entrainment\" and implies the catheter is within a critical part of a reentrant circuit.<br />(B) Same site on the ablation catheter (Abl d) during sinus rhythm as shown during ventricular tachycardia in figure A. During sinus rhythm, a late potential is present. The vertical line denotes the end of the QRS complex. Delivery of radiofrequency energy at this site resulted in termination of ventricular tachycardia. The tachycardia was no longer inducible after ablation. Sites such as this displaying late potentials may be targeted during \"substrate-guided ablation.\"</div><div id=\"graphicVersion\">Graphic 107237 Version 1.0</div></div></div>"},"107239":{"type":"graphic_table","displayName":"Composition of body fluid","title":"Composition of body fluid","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composition of body fluid</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Secretion</td> <td class=\"subtitle1\" colspan=\"6\">Electrolyte (mEq/L)</td> </tr> <tr> <td class=\"subtitle2\">Na<sup>+</sup></td> <td class=\"subtitle2\">K<sup>+</sup></td> <td class=\"subtitle2\">Cl<sup>&ndash;</sup></td> <td class=\"subtitle2\">&hellip;</td> <td class=\"subtitle2\">H<sup>+</sup></td> <td class=\"subtitle2\">Rate (mL/day)</td> </tr> <tr> <td>Salivary</td> <td class=\"centered\">50</td> <td class=\"centered\">20</td> <td class=\"centered\">40</td> <td class=\"centered\">30</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">100 to 1000</td> </tr> <tr> <td>Basal gastric</td> <td class=\"centered\">100</td> <td class=\"centered\">10</td> <td class=\"centered\">140</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">30</td> <td class=\"centered\">1000</td> </tr> <tr> <td>Stimulated gastric</td> <td class=\"centered\">30</td> <td class=\"centered\">10</td> <td class=\"centered\">140</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">100</td> <td class=\"centered\">4200</td> </tr> <tr> <td>Bile</td> <td class=\"centered\">140</td> <td class=\"centered\">5</td> <td class=\"centered\">100</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">500 to 1000</td> </tr> <tr> <td>Pancreatic</td> <td class=\"centered\">140</td> <td class=\"centered\">5</td> <td class=\"centered\">75</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">1000</td> </tr> <tr> <td>Duodenum</td> <td class=\"centered\">140</td> <td class=\"centered\">5</td> <td class=\"centered\">80</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">100 to 2000</td> </tr> <tr> <td>Ileum</td> <td class=\"centered\">140</td> <td class=\"centered\">5</td> <td class=\"centered\">70</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">100 to 2000</td> </tr> <tr> <td>Colon</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">15</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Wait RB, Alouidor R. Fluids, electrolytes, and acid-base balance. In: Greenfield's Surgery Scientific Principles and Practice, 5th ed, Mulholland MW, Doherty GM, Waier RW, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 107239 Version 1.0</div></div></div>"},"107240":{"type":"graphic_table","displayName":"Turner syndrome karyotypes","title":"Type and frequency of chromosome abnormalities in Turner syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Type and frequency of chromosome abnormalities in Turner syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Karyotype</td> <td class=\"subtitle1\">Percent (%)</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td>45,X</td> <td class=\"centered\">40 to 50</td> <td>Monosomy X</td> </tr> <tr> <td>45,X/46,XX</td> <td class=\"centered\">15 to 25</td> <td>Monosomy X</td> </tr> <tr> <td>45,X/47,XXX; 45,X/46,XX/47,XXX</td> <td class=\"centered\">3</td> <td>Mosaicism with \"Triple X\"</td> </tr> <tr> <td>45,X/46,XY</td> <td class=\"centered\">10 to 12</td> <td>Mixed gonadal dysgenesis</td> </tr> <tr> <td rowspan=\"2\">46,XX, del(p22.3); 46,X,r(X)/46,XX</td> <td class=\"centered\">10 to 12</td> <td>Deletion Xp22.3</td> </tr> <tr> <td class=\"centered\">10 to 12</td> <td>Ring X chromosome</td> </tr> <tr> <td>46,X i(Xq); 46,X,idic(Xp)</td> <td class=\"centered\">(~10)</td> <td>Isochromosome Xq; isodicentric Xp</td> </tr> <tr> <td>X-autosome translocation, unbalanced</td> <td class=\"centered\">Rare</td> <td>Various</td> </tr> <tr> <td>46,XX,del(q24)</td> <td class=\"centered\">Rare</td> <td>Not TS; premature ovarian failure</td> </tr> <tr> <td>46,X,idic(X)(q24)</td> <td class=\"centered\">Rare</td> <td>Not TS; isodicentric Xq24</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Gravholt CH, Andersen NH, Conway GS, etc. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017; 177:G1. Copyright &copy; 2017 BioScientifica Ltd. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107240 Version 2.0</div></div></div>"},"107252":{"type":"graphic_table","displayName":"Etiologies of hypoglycorrhachia","title":"Common and uncommon etiologies of hypoglycorrhachia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common and uncommon etiologies of hypoglycorrhachia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiologies commonly associated with hypoglycorrhachia</td> <td class=\"subtitle1\">Etiologies uncommonly associated with hypoglycorrhachia<br /> (reported but not typical)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Infectious causes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Bacterial meningitis (including <em>Nocardia</em> and <em>Brucella</em>)* </li> <li>Fungal meningitis* </li> <li>Mycobacterial (tuberculous) meningitis* </li> <li>Amebic meningoencephalitis </li> <li>Cytomegalovirus-associated progressive polyradiculopathy or meningoencephalitis </li> </ul> </td> <td> <ul> <li>Syphilitic meningitis </li> <li>Lyme meningitis* </li> <li>Viral meningitis </li> <li>Neurocysticercosis* </li> <li>CNS toxoplasmosis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Noninfectious causes</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Carcinomatous meningitis* </li> <li>Glucose transporter 1 deficiency </li> <li>Leukemia/lymphoma with CNS involvement* </li> <li>Subarachnoid hemorrhage* </li> </ul> </td> <td> <ul> <li>Cholesterol-induced leptomeningitis secondary to Currarino syndrome* </li> <li>Neurosarcoidosis* </li> <li>Rheumatoid meningitis </li> <li>Systemic lupus erythematosus with CNS involvement </li> <li>Neuro-Beh&#231;et's disease </li> <li>Dermoid cyst* </li> <li>Granulomatous angiitis of the central nervous system </li> <li>Malignant atrophic papulosis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.<br />* Etiologies reported to cause severe hypoglycorrhachia, generally defined as cerebrospinal fluid glucose level &le;10 mg/dL.</div><div class=\"graphic_reference\">Original figure modified for this publication. Chow E, Troy SB. The differential diagnosis of hypoglycorrhachia in adult patients. Am J Med Sci 2014; 348:186. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107252 Version 1.0</div></div></div>"},"107269":{"type":"graphic_table","displayName":"Cardiac implantable electronic device Candida infections","title":"Management of <EM innerHtml>Candida</EM> infections involving cardiac implantable electronic devices in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of <EM innerHtml>Candida</EM> infections involving cardiac implantable electronic devices in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"19%\"></colgroup><colgroup span=\"3\" width=\"27%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition or treatment group</td> <td class=\"subtitle1\" colspan=\"3\">Therapy</td> </tr> <tr> <td class=\"subtitle2\">Primary</td> <td class=\"subtitle2\">Step-down</td> <td class=\"subtitle2\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\"><em>Candida</em> infections involving cardiac implantable electronic devices</td> </tr> <tr> <td class=\"indent1\">Implantable cardiac defibrillator or pacemaker</td> <td> <ul> <li> <p>A lipid formulation of amphotericin B (3 to 5 mg/kg IV daily) with or without flucytosine* (25 mg/kg orally four times daily);</p> </li> </ul> <p class=\"indent2\">OR</p> <ul> <li>High-dose echinocandin (caspofungin 150 mg IV daily, micafungin 150 mg IV daily, or anidulafungin 200 mg IV daily). </li> </ul> </td> <td> <ul> <li>For patients who are clinically stable, have isolates that are susceptible to fluconazole, and have negative repeat blood cultures following initiation of a lipid formulation of amphotericin B or high-dose echinocandin therapy, transition to oral fluconazole<sup>&#182;</sup> 400 to 800 mg (6 to 12 mg/kg) daily is appropriate. </li> <li>Oral voriconazole<sup>&#916;</sup> 200 to 300 mg (3 to 4 mg/kg) twice daily or posaconazole<sup>&#916;</sup> delayed-release tablets 300 mg daily can be used for step-down therapy in clinically stable patients who have isolates susceptible to these agents but not susceptible to fluconazole. </li> </ul> </td> <td> <ul> <li>Removal of the entire device is strongly recommended. </li> <li>For infections limited to generator pockets, 4 weeks of antifungal therapy following device removal is recommended. </li> <li>For infections involving device wires, antifungal therapy should continue for at least 6 weeks after wire removal. Some specialists prefer lifelong oral suppressive therapy after lead removal, especially if there is possible endocardial infection or if a new device is implanted. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for&nbsp;adults with normal organ function. The dose of fluconazole and flucytosine must be adjusted in the setting of renal insufficiency; the caspofungin and voriconazole dose may require adjustment in hepatic insufficiency. Refer to the Lexicomp drug-specific monographs for additional information including specific dose adjustment recommendations.</div><div class=\"graphic_footnotes\">IV: intravenous; VAD: ventricular assist device.<br />* Toxic effects on bone marrow and liver require careful monitoring preferably with frequent serum flucytosine levels; refer to accompanying text for discussion of benefits and risks of combined flucytosine and amphotericin B therapy.<br />¶ Since fluconazole is highly bioavailable, oral therapy is appropriate for most patients. IV therapy (at the same dose) should be given to patients who are unable to take oral medications, who are not expected to have good gastrointestinal absorption, or who are severely ill.<br />Δ Therapeutic drug monitoring should be considered; refer to the topic review on pharmacology of azoles for details.<br /><FONT class=lozenge>◊</FONT> In patients with endocarditis caused by a <EM>Candida</EM> species that is not susceptible to fluconazole, oral voriconazole (200 or 300 mg [3 to 4 mg/kg] twice daily) or delayed-release posaconazole tablets (300 mg daily) should be used for chronic suppressive therapy if the organism is susceptible.</div><div class=\"graphic_reference\">Data from: Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2015; 62:e1.</div><div id=\"graphicVersion\">Graphic 107269 Version 1.0</div></div></div>"},"107270":{"type":"graphic_table","displayName":"International birth length centiles","title":"International birth length centiles","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International birth length centiles</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"12\" width=\"7%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"6\">Boys</td> <td class=\"subtitle1\" colspan=\"6\">Girls</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Number of observations</td> <td class=\"subtitle2\" colspan=\"5\">Centiles for&nbsp;length (cm)</td> <td class=\"subtitle2\" rowspan=\"2\">Number of observations</td> <td class=\"subtitle2\" colspan=\"5\">Centiles for&nbsp;length (cm)</td> </tr> <tr> <td class=\"subtitle3\">3<sup>rd</sup></td> <td class=\"subtitle3\">10<sup>th</sup></td> <td class=\"subtitle3\">50<sup>th</sup></td> <td class=\"subtitle3\">90<sup>th</sup></td> <td class=\"subtitle3\">97<sup>th</sup></td> <td class=\"subtitle3\">3<sup>rd</sup></td> <td class=\"subtitle3\">10<sup>th</sup></td> <td class=\"subtitle3\">50<sup>th</sup></td> <td class=\"subtitle3\">90<sup>th</sup></td> <td class=\"subtitle3\">97<sup>th</sup></td> </tr> <tr> <td>33 weeks</td> <td class=\"centered\">33</td> <td class=\"centered\">39.69</td> <td class=\"centered\">41.09</td> <td class=\"centered\">43.81</td> <td class=\"centered\">46.55</td> <td class=\"centered\">47.97</td> <td class=\"centered\">17</td> <td class=\"centered\">39.79</td> <td class=\"centered\">41.01</td> <td class=\"centered\">43.39</td> <td class=\"centered\">45.70</td> <td class=\"centered\">46.85</td> </tr> <tr class=\"highlight_blue_text\"> <td>34 weeks</td> <td class=\"centered\">48</td> <td class=\"centered\">41.05</td> <td class=\"centered\">42.38</td> <td class=\"centered\">44.98</td> <td class=\"centered\">47.59</td> <td class=\"centered\">48.94</td> <td class=\"centered\">65</td> <td class=\"centered\">41.04</td> <td class=\"centered\">42.22</td> <td class=\"centered\">44.55</td> <td class=\"centered\">46.79</td> <td class=\"centered\">47.92</td> </tr> <tr> <td>35 weeks</td> <td class=\"centered\">128</td> <td class=\"centered\">42.26</td> <td class=\"centered\">43.54</td> <td class=\"centered\">46.03</td> <td class=\"centered\">48.53</td> <td class=\"centered\">49.82</td> <td class=\"centered\">111</td> <td class=\"centered\">42.14</td> <td class=\"centered\">43.30</td> <td class=\"centered\">45.57</td> <td class=\"centered\">47.76</td> <td class=\"centered\">48.86</td> </tr> <tr class=\"highlight_blue_text\"> <td>36 weeks</td> <td class=\"centered\">320</td> <td class=\"centered\">43.36</td> <td class=\"centered\">44.58</td> <td class=\"centered\">46.97</td> <td class=\"centered\">49.38</td> <td class=\"centered\">50.62</td> <td class=\"centered\">292</td> <td class=\"centered\">43.13</td> <td class=\"centered\">44.26</td> <td class=\"centered\">46.48</td> <td class=\"centered\">48.62</td> <td class=\"centered\">49.69</td> </tr> <tr> <td>37 weeks</td> <td class=\"centered\">849</td> <td class=\"centered\">44.34</td> <td class=\"centered\">45.52</td> <td class=\"centered\">47.82</td> <td class=\"centered\">50.14</td> <td class=\"centered\">51.34</td> <td class=\"centered\">799</td> <td class=\"centered\">44.01</td> <td class=\"centered\">45.11</td> <td class=\"centered\">47.29</td> <td class=\"centered\">49.39</td> <td class=\"centered\">50.44</td> </tr> <tr class=\"highlight_blue_text\"> <td>38 weeks</td> <td class=\"centered\">2031</td> <td class=\"centered\">45.22</td> <td class=\"centered\">46.37</td> <td class=\"centered\">48.59</td> <td class=\"centered\">50.83</td> <td class=\"centered\">51.99</td> <td class=\"centered\">1786</td> <td class=\"centered\">44.79</td> <td class=\"centered\">45.88</td> <td class=\"centered\">48.01</td> <td class=\"centered\">50.07</td> <td class=\"centered\">51.10</td> </tr> <tr> <td>39 weeks</td> <td class=\"centered\">2983</td> <td class=\"centered\">46.02</td> <td class=\"centered\">47.13</td> <td class=\"centered\">49.29</td> <td class=\"centered\">51.46</td> <td class=\"centered\">52.59</td> <td class=\"centered\">2846</td> <td class=\"centered\">45.49</td> <td class=\"centered\">46.56</td> <td class=\"centered\">48.65</td> <td class=\"centered\">50.68</td> <td class=\"centered\">51.69</td> </tr> <tr class=\"highlight_blue_text\"> <td>40 weeks</td> <td class=\"centered\">2531</td> <td class=\"centered\">46.75</td> <td class=\"centered\">47.83</td> <td class=\"centered\">49.92</td> <td class=\"centered\">52.03</td> <td class=\"centered\">53.13</td> <td class=\"centered\">2486</td> <td class=\"centered\">46.12</td> <td class=\"centered\">47.17</td> <td class=\"centered\">49.23</td> <td class=\"centered\">51.23</td> <td class=\"centered\">52.22</td> </tr> <tr> <td>41 weeks</td> <td class=\"centered\">1146</td> <td class=\"centered\">47.41</td> <td class=\"centered\">48.46</td> <td class=\"centered\">50.50</td> <td class=\"centered\">52.56</td> <td class=\"centered\">53.62</td> <td class=\"centered\">1180</td> <td class=\"centered\">46.68</td> <td class=\"centered\">47.72</td> <td class=\"centered\">49.75</td> <td class=\"centered\">51.72</td> <td class=\"centered\">52.70</td> </tr> <tr class=\"highlight_blue_text divider_bottom\"> <td>42 weeks</td> <td class=\"centered\">202</td> <td class=\"centered\">48.01</td> <td class=\"centered\">49.04</td> <td class=\"centered\">51.03</td> <td class=\"centered\">53.03</td> <td class=\"centered\">54.07</td> <td class=\"centered\">218</td> <td class=\"centered\">47.19</td> <td class=\"centered\">48.21</td> <td class=\"centered\">50.22</td> <td class=\"centered\">52.15</td> <td class=\"centered\">53.12</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>10,271</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>9800</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">International standards for newborn length by gestational age and sex from the Newborn Cross-Sectional Study of the INTERGROWTH-21<SUP>st</SUP> Project. The table shows smoothed centiles for birth length of boys and girls according to gestational age.</div><div class=\"graphic_footnotes\">cm: centimeter.</div><div class=\"graphic_reference\">Reproduced from: Villar J, Cheikh Ismail L, Victora CG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet 2014; 384:857. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107270 Version 1.0</div></div></div>"},"107271":{"type":"graphic_table","displayName":"International birth head circumference centiles","title":"International birth head circumference centiles","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International birth head circumference centiles</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"12\" width=\"7%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"6\">Boys</td> <td class=\"subtitle1\" colspan=\"6\">Girls</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Number of observations</td> <td class=\"subtitle2\" colspan=\"5\">Centiles for head circumference (cm)</td> <td class=\"subtitle2\" rowspan=\"2\">Number of observations</td> <td class=\"subtitle2\" colspan=\"5\">Centiles for head circumference (cm)</td> </tr> <tr> <td class=\"subtitle3\">3<sup>rd</sup></td> <td class=\"subtitle3\">10<sup>th</sup></td> <td class=\"subtitle3\">50<sup>th</sup></td> <td class=\"subtitle3\">90<sup>th</sup></td> <td class=\"subtitle3\">97<sup>th</sup></td> <td class=\"subtitle3\">3<sup>rd</sup></td> <td class=\"subtitle3\">10<sup>th</sup></td> <td class=\"subtitle3\">50<sup>th</sup></td> <td class=\"subtitle3\">90<sup>th</sup></td> <td class=\"subtitle3\">97<sup>th</sup></td> </tr> <tr> <td>33 weeks</td> <td class=\"centered\">33</td> <td class=\"centered\">28.25</td> <td class=\"centered\">29.11</td> <td class=\"centered\">30.88</td> <td class=\"centered\">32.71</td> <td class=\"centered\">33.62</td> <td class=\"centered\">17</td> <td class=\"centered\">27.92</td> <td class=\"centered\">28.76</td> <td class=\"centered\">30.46</td> <td class=\"centered\">32.24</td> <td class=\"centered\">33.14</td> </tr> <tr class=\"highlight_blue_text\"> <td>34 weeks</td> <td class=\"centered\">48</td> <td class=\"centered\">28.93</td> <td class=\"centered\">29.76</td> <td class=\"centered\">31.47</td> <td class=\"centered\">33.23</td> <td class=\"centered\">34.11</td> <td class=\"centered\">65</td> <td class=\"centered\">28.64</td> <td class=\"centered\">29.44</td> <td class=\"centered\">31.08</td> <td class=\"centered\">32.78</td> <td class=\"centered\">33.65</td> </tr> <tr> <td>35 weeks</td> <td class=\"centered\">127</td> <td class=\"centered\">29.56</td> <td class=\"centered\">30.37</td> <td class=\"centered\">32.02</td> <td class=\"centered\">33.73</td> <td class=\"centered\">34.58</td> <td class=\"centered\">111</td> <td class=\"centered\">29.28</td> <td class=\"centered\">30.06</td> <td class=\"centered\">31.64</td> <td class=\"centered\">33.28</td> <td class=\"centered\">34.12</td> </tr> <tr class=\"highlight_blue_text\"> <td>36 weeks</td> <td class=\"centered\">322</td> <td class=\"centered\">30.15</td> <td class=\"centered\">30.93</td> <td class=\"centered\">32.53</td> <td class=\"centered\">34.19</td> <td class=\"centered\">35.02</td> <td class=\"centered\">293</td> <td class=\"centered\">29.87</td> <td class=\"centered\">30.62</td> <td class=\"centered\">32.14</td> <td class=\"centered\">33.74</td> <td class=\"centered\">34.55</td> </tr> <tr> <td>37 weeks</td> <td class=\"centered\">848</td> <td class=\"centered\">30.69</td> <td class=\"centered\">31.46</td> <td class=\"centered\">33.02</td> <td class=\"centered\">34.63</td> <td class=\"centered\">35.43</td> <td class=\"centered\">798</td> <td class=\"centered\">30.40</td> <td class=\"centered\">31.13</td> <td class=\"centered\">32.61</td> <td class=\"centered\">34.15</td> <td class=\"centered\">34.94</td> </tr> <tr class=\"highlight_blue_text\"> <td>38 weeks</td> <td class=\"centered\">2032</td> <td class=\"centered\">31.21</td> <td class=\"centered\">31.95</td> <td class=\"centered\">33.47</td> <td class=\"centered\">35.04</td> <td class=\"centered\">35.83</td> <td class=\"centered\">1783</td> <td class=\"centered\">30.88</td> <td class=\"centered\">31.59</td> <td class=\"centered\">33.03</td> <td class=\"centered\">34.53</td> <td class=\"centered\">35.30</td> </tr> <tr> <td>39 weeks</td> <td class=\"centered\">2985</td> <td class=\"centered\">31.69</td> <td class=\"centered\">32.42</td> <td class=\"centered\">33.90</td> <td class=\"centered\">35.44</td> <td class=\"centered\">36.20</td> <td class=\"centered\">2849</td> <td class=\"centered\">31.32</td> <td class=\"centered\">32.01</td> <td class=\"centered\">33.41</td> <td class=\"centered\">34.88</td> <td class=\"centered\">35.62</td> </tr> <tr class=\"highlight_blue_text\"> <td>40 weeks</td> <td class=\"centered\">2532</td> <td class=\"centered\">32.15</td> <td class=\"centered\">32.86</td> <td class=\"centered\">34.31</td> <td class=\"centered\">35.81</td> <td class=\"centered\">36.56</td> <td class=\"centered\">2486</td> <td class=\"centered\">31.72</td> <td class=\"centered\">32.39</td> <td class=\"centered\">33.76</td> <td class=\"centered\">35.19</td> <td class=\"centered\">35.92</td> </tr> <tr> <td>41 weeks</td> <td class=\"centered\">1147</td> <td class=\"centered\">32.58</td> <td class=\"centered\">33.28</td> <td class=\"centered\">34.70</td> <td class=\"centered\">36.17</td> <td class=\"centered\">36.91</td> <td class=\"centered\">1180</td> <td class=\"centered\">32.08</td> <td class=\"centered\">32.74</td> <td class=\"centered\">34.08</td> <td class=\"centered\">35.48</td> <td class=\"centered\">36.19</td> </tr> <tr class=\"divider_bottom highlight_blue_text\"> <td>42 weeks</td> <td class=\"centered\">204</td> <td class=\"centered\">32.99</td> <td class=\"centered\">33.68</td> <td class=\"centered\">35.07</td> <td class=\"centered\">36.52</td> <td class=\"centered\">37.24</td> <td class=\"centered\">218</td> <td class=\"centered\">32.41</td> <td class=\"centered\">33.06</td> <td class=\"centered\">34.37</td> <td class=\"centered\">35.74</td> <td class=\"centered\">36.44</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>10,278</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>9800</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> <td class=\"centered\"><strong>&ndash;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">International standards for newborn head circumference by gestational age and sex from the Newborn Cross-Sectional Study of the INTERGROWTH-21<SUP>st</SUP> Project. The table shows smoothed centiles for birth head circumference of boys and girls according to gestational age.</div><div class=\"graphic_footnotes\">cm: centimeter.</div><div class=\"graphic_reference\">Reproduced from: Villar J, Cheikh Ismail L, Victora CG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet 2014; 384:857. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107271 Version 1.0</div></div></div>"},"107272":{"type":"graphic_picture","displayName":"Staphylococcal pustulosis","title":"Staphylococcal pustulosis","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Staphylococcal pustulosis</div><div class=\"cntnt\"><img style=\"width:640px; height:480px;\" src=\"images/PEDS/107272_Stphylcccl_pstlss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Community-associated <EM>Staphylococcus aureus</EM> pustulosis in the diaper area of a previously healthy neonate. </div><div class=\"graphic_reference\">Courtesy of Sheldon L Kaplan, MD</div><div id=\"graphicVersion\">Graphic 107272 Version 1.0</div></div></div>"},"107273":{"type":"graphic_table","displayName":"Intimate partner violence resources","title":"Intimate partner violence resources for patients and clinicians","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intimate partner violence resources for patients and clinicians</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Resources for clinicians and patients</td> </tr> <tr> <td class=\"subtitle2_single\">National intimate partner violence resources<span class=\"subtitle2_left\"></span></td> </tr> <tr> <td class=\"indent1\"> <p>National Domestic Violence Hotline (can provide information about local shelters and access to domestic violence advocates)</p> <p>800-799-SAFE<span class=\"sublist1_start\"></span></p> 800-799-7233</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>National Sexual Assault Hotline</p> <p>800-656-HOPE</p> 800-656-4573</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_single\">International intimate partner violence resources</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>HotPeachPages (provides an international directory of resources in more than 110 languages)</p> <a href=\"http://www.hotpeachpages.net/\" spellcheck=\"true\" target=\"_blank\">www.hotpeachpages.net</a></td> </tr> <tr> <td class=\"subtitle2_single\">Other intimate partner violence resources</td> </tr> <tr> <td class=\"indent1\"> <p>Futures without Violence</p> <a href=\"http://www.futureswithoutviolence.org/\" target=\"_blank\">www.futureswithoutviolence.org</a></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Look to End Abuse Permanently</p> <a href=\"http://www.leapsf.org/html/index.shtml\" target=\"_blank\">www.leapsf.org/html/index.shtml</a></td> </tr> <tr> <td class=\"subtitle2_single\">Toxic stress resources</td> </tr> <tr> <td class=\"indent1\"> <p>The American Academy of Pediatrics</p> <p>The Resilience Project</p> <a href=\"https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/resilience/Pages/ACEs-and-Toxic-Stress.aspx\" target=\"_blank\">https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/resilience/Pages/ACEs-and-Toxic-Stress.aspx</a></td> </tr> <tr> <td class=\"indent1\"> <p>The Centers for Disease Control and Prevention (CDC) Division of Violence Prevention</p> <a href=\"http://www.cdc.gov/violenceprevention/childmaltreatment/essentials.html\" target=\"_blank\">www.cdc.gov/violenceprevention/childmaltreatment/essentials.html</a></td> </tr> <tr> <td class=\"subtitle1_single\">Resources for patients</td> </tr> <tr> <td class=\"subtitle2_single\">Intimate partner violence</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Understanding Intimate Partner Violence (CDC)</p> <a href=\"http://www.cdc.gov/ViolencePrevention/pdf/IPV-FactSheet.pdf\" target=\"_blank\">www.cdc.gov/ViolencePrevention/pdf/IPV-FactSheet.pdf</a></td> </tr> <tr> <td class=\"subtitle2_single\">Teen dating resources</td> </tr> <tr> <td class=\"indent1\"> <p>Loveisrespect.org</p> <a href=\"http://www.loveisrespect.org/\" target=\"_blank\">www.loveisrespect.org</a></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Teen Dating Violence (CDC)</p> <a href=\"http://www.cdc.gov/ViolencePrevention/intimatepartnerviolence/teen_dating_violence.html\" target=\"_blank\">www.cdc.gov/ViolencePrevention/intimatepartnerviolence/teen_dating_violence.html</a></td> </tr> <tr> <td class=\"subtitle2_single\">Toxic stress</td> </tr> <tr> <td class=\"indent1\"> <p>The Community &#38; Family Services Division of the Spokane Health District</p> <p>Patient information handout on Understanding Adverse Childhood Experiences</p> <a href=\"http://www.ifapa.org/pdf_docs/ACES_Handout.pdf\" target=\"_blank\">www.ifapa.org/pdf_docs/ACES_Handout.pdf</a></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 107273 Version 1.0</div></div></div>"},"107277":{"type":"graphic_algorithm","displayName":"Initial treatment of ALCL","title":"Initial treatment of systemic anaplastic large cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Initial treatment of systemic anaplastic large cell lymphoma</div><div class=\"cntnt\"><img style=\"width:590px; height:428px;\" src=\"images/HEME/107277_Intl_trtmnt_ALCL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an overview of our approach to the management of newly diagnosed systemic anaplastic large cell lymphoma (ALCL). It should be used in conjunction with other UpToDate content on ALCL. While the general treatment principles for ALCL apply to most disease presentations and patient populations, this algorithm does not apply to patients with primary cutaneous ALCL and patients with breast implant-associated ALCL.</div><div class=\"graphic_footnotes\">PET/CT: positron emission tomography/computed tomography; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; IPI: international prognostic index; ALK: anaplastic lymphoma kinase; HCT: hematopoietic cell transplantation; ECOG: eastern cooperative oncology group.<br />* In patients over age 60, CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone, administered every 21 days) has increased toxicity and no clear benefit over CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone, administered every 21 days) in retrospective analyses. The addition of etoposide for especially fit patients in this age category is considered on an individual basis.<br />¶ The Lugano criteria for response assessment in lymphoma are used to determine complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).<br />Δ For those with limited stage (I/II) disease who achieve a PR after six cycles of induction therapy, we offer radiation therapy in an attempt to achieve complete response. All others proceed with second-line chemotherapy.<br /><FONT class=lozenge>◊</FONT> To calculate the International Prognostic Index (IPI), one point is given for each of the following variables: age &gt;60 years; serum lactate dehydrogenase concentration greater than normal; ECOG performance status of 2 or greater; clinical stage III or IV disease; and &gt;1 involved extranodal site.</div><div id=\"graphicVersion\">Graphic 107277 Version 2.0</div></div></div>"},"107278":{"type":"graphic_table","displayName":"Classification of vitiligo","title":"Classification of vitiligo","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of vitiligo</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of vitiligo</td> <td class=\"subtitle1\">Subtypes </td> <td class=\"subtitle1\">Clinical features </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Nonsegmental vitiligo</td> <td>Generalized</td> <td> <ul> <li>Symmetric, bilateral, depigmented macules in a random distribution over the entire body surface</li> <li>Onset usually before age 30 years</li> <li>Evolving over time</li> </ul> </td> </tr> <tr> <td>Acral or acrofacial</td> <td> <ul> <li>Only extremities and/or face involved</li> </ul> </td> </tr> <tr> <td>Focal</td> <td>&nbsp;</td> </tr> <tr> <td>Mucosal</td> <td> <ul> <li>Multiple mucosal sites involved</li> <li>Usually associated with generalized vitiligo</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Universal</td> <td> <ul> <li>Usually involves 80 to 90% of the body surface area</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Segmental vitiligo </td> <td> <p>Monosegmental</p> <p>Bisegmental</p> Plurisegmental</td> <td> <ul> <li>Unilateral, asymmetric distribution of white macules that match a cutaneous segment (dermatomal distribution)</li> <li>Monosegmental most common</li> <li>Early age of onset</li> <li>Rapid stabilization</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Mixed</td> <td>Combination of nonsegmental and segmental vitiligo</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Rare variants</td> <td>Vitiligo minor</td> <td> <ul> <li>Incomplete depigmentation</li> <li>More common in dark-skinned individuals</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Follicular vitiligo</td> <td>&nbsp;</td> </tr> <tr> <td>Unclassified</td> <td> <p>Multifocal asymmetrical</p> Single mucosal site involved</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kovacevic M, Stanimirovic A, Vucic M, et al. Mixed vitiligo of Blaschko lines: a newly discovered presentation of vitiligo responsive to combination treatment. Dermatol Ther 2016 [Epub ahead of print].</li>&#xD;&#xA;    <li>Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 2012; 25:E1.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 107278 Version 1.0</div></div></div>"},"107283":{"type":"graphic_picture","displayName":"Cribriform pattern","title":"Cribriform pattern","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Cribriform pattern</div><div class=\"cntnt\"><img style=\"width:716px; height:551px;\" src=\"images/ONC/107283_Crbrfrm_pttrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cribriform pattern of prostatic adenocarcinoma should be assigned Gleason pattern 4.</div><div id=\"graphicVersion\">Graphic 107283 Version 1.0</div></div></div>"},"107284":{"type":"graphic_picture","displayName":"Glomeruloid pattern","title":"Glomeruloid pattern","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Glomeruloid pattern</div><div class=\"cntnt\"><img style=\"width:716px; height:516px;\" src=\"images/ONC/107284_Glmrld_pttrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several glomeruloid glands in prostatic adenocarcinoma, characterized by the presence of a cluster of tumor cells within a malignant gland, should be assigned Gleason pattern 4.</div><div id=\"graphicVersion\">Graphic 107284 Version 1.0</div></div></div>"},"107285":{"type":"graphic_picture","displayName":"Mucinous pattern","title":"Mucinous pattern","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Mucinous pattern</div><div class=\"cntnt\"><img style=\"width:716px; height:538px;\" src=\"images/ONC/107285_Mcns_pttrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grading of mucinous prostatic adenocarcinoma should be based on its underlying growth pattern. In this case, it is Gleason pattern 4 because of the fused glands. In other cases, mucinous carcinoma can be Gleason pattern 3 or 5.</div><div id=\"graphicVersion\">Graphic 107285 Version 1.0</div></div></div>"},"107288":{"type":"graphic_table","displayName":"Updated Gleason grading from the ISUP Consensus Conference","title":"Updated Gleason grading from the ISUP Consensus Conference","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Updated Gleason grading from the ISUP Consensus Conference</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major conclusion</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Cribriform glands should be assigned a Gleason pattern 4, regardless of morphology. </li> <li>Glomeruloid glands should be assigned a Gleason pattern 4, regardless of morphology. </li> <li>Grading of mucinous carcinoma of the prostate should be based on its underlying growth pattern. </li> <li>Intraductal carcinoma of the prostate without invasive carcinoma should be not assigned a Gleason grade, and a comment as to its invariable association with aggressive invasive prostatic adenocarcinoma should be made. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Morphologies within Gleason patterns</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Gleason pattern 4 includes cribriform, fused, and poorly formed glands. </li> <li>The term \"hypernephromatoid\" cancer should not be used. </li> <li>For a diagnosis of Gleason pattern 4, it needs to be seen at 10 times lens magnification. </li> <li>Occasional poorly formed or fused glands between well-formed glands are insufficient for a diagnosis of Gleason pattern 4. </li> <li>In the case of borderline morphology between Gleason pattern 3 and pattern 4 with crush artifacts, the lower grade should be favored. </li> <li>Branched glands are allowed in Gleason pattern 3. </li> <li>Small solid cylinders represent Gleason pattern 5. </li> <li>Solid medium or large nests with rosette-like space should be considered Gleason pattern 5. </li> <li>Presence of unequivocal comedo necrosis, even if focal is indicative of Gleason pattern 5. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016; 40:244.</div><div id=\"graphicVersion\">Graphic 107288 Version 1.0</div></div></div>"},"107297":{"type":"graphic_table","displayName":"Oral antibiotic therapy for SIBO","title":"Oral antibiotic therapy for small intestinal bacterial overgrowth (SIBO)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral antibiotic therapy for small intestinal bacterial overgrowth (SIBO)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Adult dose</td> <td class=\"subtitle1\">Pediatric dose*</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Single-agent regimens (7 to 10 days)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Amoxicillin-clavulanate</td> <td>500 mg three times per day<sup>[1]</sup> or 875 mg twice per day</td> <td>25 mg/kg per day (amoxicillin component) in two or three divided doses</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Norfloxacin (no longer available in United States)<sup>&#916;</sup></td> <td>400 mg twice per day<sup>[1]</sup></td> <td>Not adequately evaluated</td> <td>Not recommended in children, older adults, pregnancy, patients at risk for tendinopathy or abnormal cardiac rhythm<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rifaximin</td> <td>550 mg three times per day<sup>[2]</sup></td> <td> <p>Children &#8805;12 years: Refer to adult dosing</p> Children 3 to 11 years: 200 mg three times per day<sup>[3]</sup></td> <td> <p>Less clinical resistance observed relative to other choices</p> Low systemic exposure</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Combination regimens (7 to 10 days)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Metronidazole with a cephalosporin</td> <td> <p>Metronidazole 500 mg three times per day; <strong>plus</strong></p> Cephalexin 500 mg three or four times per day</td> <td> <p>Metronidazole 20 mg/kg per day in two or three divided doses; <strong>plus</strong></p> Cephalexin 30 mg/kg per day in three or four divided doses</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Metronidazole with trimethoprim-sulfamethoxazole (co-trimoxazole)</td> <td> <p>Metronidazole 500 mg three times per day; <strong>plus</strong></p> Trimethoprim-sulfamethoxazole 1 double-strength tablet twice per day<sup>&#9674;</sup></td> <td> <p>Metronidazole 20 mg/kg per day in two or three divided doses; <strong>plus</strong></p> Trimethoprim-sulfamethoxazole 10 to 12 mg/kg per day (trimethoprim component) in two divided doses<sup>[4]</sup></td> <td>Rare serious cutaneous allergic reactions</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Suggested antibiotic regimens for reduction of gut flora overgrowth and symptomatic improvement. Doses listed are for patients with normal renal function. Dose adjustment of norfloxacin and trimethoprim-sulfamethoxazole may be needed in renal impairment. For specific adjustments and additional detail, refer to the Lexicomp drug-specific monographs included within UpToDate.</div><div class=\"graphic_footnotes\">* The pediatric daily dose should not exceed the usual daily dose for adult patients. Pediatric doses listed in this table are for children six years and older except as noted.<br />¶ A single course of 7 to 10 days will often improve symptoms. However, some patients require prolonged therapy before a response is seen and recurrence after treatment is common; refer to accompanying text.<br />Δ Ciprofloxacin 500 mg orally twice per day in adults (or in children 20 to 30 mg/kg per day in two divided doses) is a reasonable alternative where norfloxacin is unavailable and use of a fluoroquinolone is appropriate. Additional information on fluoroquinolone use in children and other populations is provided separately; refer to the UpToDate topic review of fluoroquinolones.<br /><FONT class=lozenge>◊</FONT> One double-strength (DS) tablet contains trimethoprim 320 mg with sulfamethoxazole 800 mg.</div><div class=\"graphic_reference\">Prepared with data from Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved. &#xD;&#xA;<OL>&#xD;&#xA;<LI>Attar A, Flourié B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999; 117:794. </LI>&#xD;&#xA;<LI>Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007; 25:781. </LI>&#xD;&#xA;<LI>Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2013; 17:1314. </LI>&#xD;&#xA;<LI>Tahan S, Melli LC, Mello CS, et al. Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum. J Pediatr Gastroenterol Nutr 2013; 57:316.</LI></OL></div><div id=\"graphicVersion\">Graphic 107297 Version 4.0</div></div></div>"},"107302":{"type":"graphic_table","displayName":"Comparison between RECIST and irRC criteria","title":"Comparison between RECIST v1.1 criteria and the immune-related response criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison between RECIST v1.1 criteria and the immune-related response criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"37.5%\"></colgroup><colgroup width=\"37.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">RECIST v1.1</td> <td class=\"subtitle1\">irRC</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Measurement of tumor burden</strong></td> <td>Unidimensional</td> <td>Bidimensional</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Target lesions</strong></td> <td>Maximum, 5*</td> <td>Maximum, 15 index lesions</td> </tr> <tr class=\"divider_bottom\"> <td><strong>New lesion</strong></td> <td>Results in progressive disease at first appearance</td> <td>Up to 10 new visceral lesions and 5 cutaneous lesions may be added to the sum of the products of the two largest perpendicular diameters of all index lesions at any time point</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Complete response</strong></td> <td colspan=\"2\"> <p>Disappearance of all target and nontarget lesions</p> <p>Nodes must regress to &#60;10 mm short axis</p> <p>No new lesions</p> Confirmation required </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Partial response</strong></td> <td> <p>&#8805;30% decrease in tumor burden compared with baseline</p> Confirmation required </td> <td> <p>&#8805;50% decrease in tumor burden compared with baseline<sup>&#182;</sup></p> Confirmation required </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Progressive disease</strong></td> <td> <p>&#8805;20% + 5 mm absolute increase in tumor burden compared with nadir</p> Appearance of new lesions or progression of nontarget lesions </td> <td> <p>&#8805;25% increase in tumor burden compared with nadir or reset baseline<sup>&#182;</sup></p> <p>New lesions added to tumor burden</p> Confirmation required </td> </tr> <tr> <td><strong>Stable disease</strong></td> <td colspan=\"2\">Neither partial response nor progressive disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RECIST v1.1: Response Evaluation Criteria in Solid Tumors, version 1.1; irRC: immune-related response criteria.<br />* For the present analysis, the maximum number of target lesions was 10.<br />&para; ​If an increase in tumor burden is observed at the first scheduled assessment, the baseline is reset to the value observed at the first assessment.</div><div class=\"graphic_reference\">From: Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol 2016; 34(13):1510-7. Reprinted with permission. Copyright &copy; 2016 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107302 Version 1.0</div></div></div>"},"107303":{"type":"graphic_table","displayName":"Risk factors maternal intimate partner violence","title":"Risk factors for maternal partner violence victimization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for maternal partner violence victimization</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Age 20 to 34 years</td> </tr> <tr> <td>Maternal disability</td> </tr> <tr> <td>History of physical injury during pregnancy</td> </tr> <tr> <td>Mother directly or indirectly refers to intimate partner violence </td> </tr> <tr> <td>Alcohol or substance abuse in the home</td> </tr> <tr> <td>Maternal history of depression, anxiety, suicidality</td> </tr> <tr> <td>Having a child with alleged or confirmed child maltreatment</td> </tr> <tr> <td>Not following through with recommended treatments for self or child(ren)</td> </tr> <tr> <td>Chronically missing appointments for self or child(ren)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 107303 Version 1.0</div></div></div>"},"107318":{"type":"graphic_algorithm","displayName":"Screening for and management of short cervix","title":"Approach to sonographic screening of cervical length in pregnancy and management of pregnant women with a short cervix","html":"<div class=\"graphic\"><div style=\"width: 702px\" class=\"figure\"><div class=\"ttl\">Approach to sonographic screening of cervical length in pregnancy and management of pregnant women with a short cervix</div><div class=\"cntnt\"><img style=\"width:682px; height:443px;\" src=\"images/OBGYN/107318_Scrnmngshrtcrvx.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is the author's approach to monitoring cervical length and management of women with a short cervix. This remains a controversial area, and variations of this approach exist worldwide.</div><div class=\"graphic_footnotes\">TVU: transvaginal ultrasound.<br />* In addition to cervical length screening, offer hydroxyprogesterone caproate beginning at 16 weeks of gestation and continuing through the 36<sup>th</sup> week of gestation to reduce the risk of recurrent spontaneous preterm birth.</div><div id=\"graphicVersion\">Graphic 107318 Version 4.0</div></div></div>"},"107342":{"type":"graphic_figure","displayName":"Management of the patient with ED","title":"Management of the patient with ED","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of the patient with ED</div><div class=\"cntnt\"><img style=\"width:376px; height:256px;\" src=\"images/ENDO/107342_Management_patient_ED.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>This is derived from market research but is consistent with the data reviewed. Approximately 75 percent of those patients receiving treatment for ED are receiving PDE-5 inhibitors.</li>&#xD;&#xA;    <li>Approximately 20 percent are utilizing second-line therapies, while 6 percent or so are undergoing surgical management.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">ED: erectile dysfunction; PDE-5: phosphodiesterase type 5.</div><div class=\"graphic_reference\">Adapted from: Montague DK, Jarow JP, Broderick GA, et al. The Management of Erectile Dysfunction. American Urological Association. Baltimore, MD 2005.</div><div id=\"graphicVersion\">Graphic 107342 Version 1.0</div></div></div>"},"107343":{"type":"graphic_figure","displayName":"Prevalence and severity of ED in the MMAS","title":"Prevalence and severity of ED in the Massachusetts Male Aging Study (MMAS)","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Prevalence and severity of ED in the Massachusetts Male Aging Study (MMAS)</div><div class=\"cntnt\"><img style=\"width:581px; height:349px;\" src=\"images/ENDO/107343_Prvlnc_svrty_ED_MMAS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The overall prevalence of mild, moderate, and severe ED was 17.2, 25.2, and 9.6 percent, respectively.</div><div class=\"graphic_footnotes\">ED: erectile dysfunction.</div><div class=\"graphic_reference\">Original figure modified for this publication. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151:54. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107343 Version 1.0</div></div></div>"},"107344":{"type":"graphic_picture","displayName":"Ehlers-Danlos syndrome","title":"Ehlers-Danlos syndrome","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Ehlers-Danlos syndrome</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/EM/107344_Ehlers_Danlos_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperdistensibility of the skin in a patient with Ehlers-Danlos syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107344 Version 1.0</div></div></div>"},"107345":{"type":"graphic_picture","displayName":"Ehlers-Danlos with scarring","title":"Ehlers-Danlos with characteristic scarring","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Ehlers-Danlos with characteristic scarring</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/EM/107345_Ehlers_Danlos_scarring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin scarring from past trauma in a patient with Ehlers-Danlos syndrome. Note characteristic papyraceous appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107345 Version 1.0</div></div></div>"},"107346":{"type":"graphic_picture","displayName":"Ehlers-Danlos with joint hypermobility","title":"Hypermobility in a patient with Ehlers-Danlos syndrome","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Hypermobility in a patient with Ehlers-Danlos syndrome</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/EM/107346_Ehlers_Danlos_jnt_hyprmblty.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107346 Version 1.0</div></div></div>"},"107347":{"type":"graphic_picture","displayName":"Coining","title":"Coining","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Coining</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/EM/107347_Coining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coining refers to the Vietnamese folk remedy in which the edge of a coin is rubbed on oiled skin. This practice often results in linear erythema, petechiae, or purpura typically located on the back.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107347 Version 1.0</div></div></div>"},"107348":{"type":"graphic_picture","displayName":"Moxibustion","title":"Moxibustion","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Moxibustion</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/EM/107348_Moxibustion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Moxibustion involves therapeutic burning of herbs or yarn on the skin among Southeast Asian cultures. The circular burns can be mistaken for cigarette burns in children.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107348 Version 1.0</div></div></div>"},"107365":{"type":"graphic_table","displayName":"Potential contributions of rehab in various disease phases","title":"Potential contributions of rehabilitation in the various phases of a life-threatening disease such as cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential contributions of rehabilitation in the various phases of a life-threatening disease such as cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Phases of disease</td> <td class=\"subtitle1\">Issues for rehabilitation professionals to address</td> </tr> <tr class=\"divider_bottom\"> <td>I. From diagnosis to treatment planning</td> <td> <ol> <li>What to expect regarding the impact of cancer treatment on function </li> <li>Understanding function and how to preserve it </li> <li>Comprehensive rehabilitation pretreatment (eg, ROM, ADL, strength) </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>II. Treatment</td> <td> <ol> <li>Evaluating the effects of treatments on function (surgery, chemotherapy, radiation, biologic agents) </li> <li>Preserving and restoring function through exercise, edema management, and increased activity </li> <li>Controlling pain using heat, cold, and TENS </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>III. Posttreatment</td> <td> <ol> <li>Developing and supporting a program to help restore daily routines and promote a healthy lifestyle </li> <li>Educating the patient about what to self-monitor (strength, ROM, edema, pain, etc) </li> <li>Supervising a maintenance program of exercise, edema management, and mobility </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>IV. Recurrence</td> <td> <ol> <li>Educating the patient about the impact of recurrence and its effect on function </li> <li>Educating the patient about what to monitor in the context of the new clinical status </li> <li>Supervising the patient in an appropriate program to restore function or prevent its decline </li> <li>Assisting the patient in maintaining activity and quality of life </li> </ol> </td> </tr> <tr> <td>V. End of life</td> <td> <ol> <li>Educating patient/family regarding mobility training, good body mechanics, and assistive devices </li> <li>Pain management (nonpharmacologic treatment) and symptom control </li> <li>Maintaining independence and quality of life </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ROM: range of movement; ADL: activities of daily living; TENS: transcutaneous electrical nerve stimulation.</div><div class=\"graphic_reference\">From: Gerber LH. Cancer rehabilitation into the future. Cancer 2001; 92(4 Suppl):975-9. <a href=\"http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(20010815)92:4%2B%3C975::AID-CNCR1409%3E3.0.CO;2-B/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(20010815)92:4%2B%3C975::AID-CNCR1409%3E3.0.CO;2-B/abstract</a>. Copyright &copy; 2001 American Cancer Society. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 107365 Version 1.0</div></div></div>"},"107367":{"type":"graphic_figure","displayName":"RBC precursors","title":"Stages of erythroid maturation showing red blood cell precursors","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Stages of erythroid maturation showing red blood cell precursors</div><div class=\"cntnt\"><img style=\"width:534px; height:231px;\" src=\"images/HEME/107367_RBC_precursors.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first cell identifiable as an RBC precursor is the proerythroblast. It has a large oval nucleus with homogenous chromatin and distinct nucleoli and darkly basophilic cytoplasm. Subsequent cell divisions and synchronized maturation of the nucleus and cytoplasm lead to coarsening and clumping of the chromatin and shift of the cytoplasmic color as red-staining hemoglobin becomes more abundant&nbsp;and blue-staining RNA becomes less abundant. The orthochromatic normoblast is the last stage before the nucleus is extruded, leaving a reticulocyte (not shown). Refer to UpToDate topics on anemia and erythropoiesis for further discussions of the significance of these cells, their abnormalities, and their evaluation in patients with anemia.</div><div class=\"graphic_footnotes\">RBC: red blood cell.</div><div class=\"graphic_reference\">Derived from image provided by Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 107367 Version 1.0</div></div></div>"},"107377":{"type":"graphic_table","displayName":"Adjuvant GemCap with chemoradiotherapy EHCC or GCBA","title":"Adjuvant gemcitabine and capecitabine (GemCap) followed by concurrent capecitabine and radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjuvant gemcitabine and capecitabine (GemCap) followed by concurrent capecitabine and radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days &times; 4 cycles</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Gemcitabine*</td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (concentration no greater than 40 mg/mL) and administer over 30 minutes.</td> <td>Days 1 and 8</td> </tr> <tr> <td>Capecitabine<sup>&#182;</sup></td> <td>750 mg/m<sup>2</sup> per dose by mouth</td> <td>Twice daily (total dose 1500 mg/m<sup>2</sup> per day). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#916;</sup></td> <td>Days 1 through 14</td> </tr> <tr> <td colspan=\"4\"><strong>Cycle length:</strong> Five to six weeks (chemoradiotherapy<sup>&#9674;</sup>)</td> </tr> <tr> <td>Capecitabine<sup>&#182;</sup></td> <td>665 mg/m<sup>2</sup> per dose by mouth</td> <td>Twice daily (total dose 1330 mg/m<sup>2</sup> per day). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#916;</sup></td> <td>Concurrently (seven days per week) with radiation beginning day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Radiotherapy</td> <td>45 Gy to regional lymph nodes<sup>&#167;</sup> and 54 to 59.4 Gy to preoperative tumor bed</td> <td> <p>Three dimensional: 30 fractions (54 Gy) or 33 fractions for R1 resection (59.4 Gy).</p> IMRT: 25 fractions (52.5 Gy [or 55 Gy for R1 resection]).</td> <td>Five days per week beginning week 1 and continuing through week 6</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW for both chemotherapy and chemoradiotherapy. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of gemcitabine may be needed for patients with liver impairment.<sup>[2]</sup> A lower starting dose of capecitabine may be needed for patients with moderate renal impairment.<sup>[3]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (including serum creatinine) and liver function tests every three weeks prior to each new chemotherapy cycle and weekly during chemoradiotherapy or otherwise as indicated during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea, stomatitis, and cutaneous toxicity (palmar-plantar erythrodysesthesias) during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>This regimen should not be initiated unless neutrophils are &#8805;1500/microL and platelets are &#8805;100,000/microL.<sup>[1]</sup> </li> <li>Reduce the day 8 gemcitabine dose by 25% for an absolute neutrophil count of 500 to 1000/microL or a platelet count of 50,000 to 100,000/microL.<sup>[4,5]</sup> </li> <li>Decrease gemcitabine by 25% for subsequent cycles for febrile neutropenia, grade 4 hematologic toxicity lasting for more than seven days, or bleeding-associated thrombocytopenia.<sup>[5]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported in patients treated with gemcitabine. Discontinue gemcitabine immediately and permanently. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine in individuals who have received a large or small cumulative dose. Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity (including hepatotoxicity)</strong></td> <td colspan=\"3\"> <ul> <li>Hold gemcitabine for &#8805;grade 3 nonhematologic toxicity that is likely related to gemcitabine until it decreases &#8804;grade 1.<sup>[5]</sup> Restart gemcitabine with a 25% dose reduction. </li> <li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> <li>For capecitabine: <ul> <li>Grade 2: For the first, second, and third occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment (first occurrence, no dosage adjustment; second occurrence, 75% of the starting dose; third occurrence, 50% of the starting dose).<sup>[3]</sup> For the fourth occurrence of a grade 2 toxicity, discontinue capecitabine therapy. </li> <li>Grade 3: For the first and second occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment at a reduced dose (first occurrence, 75% of the starting dose; second occurrence, 50% of the starting dose). For the third occurrence of a grade 3 toxicity, discontinue capecitabine therapy. </li> <li>Grade 4: Discontinue capecitabine therapy. Alternatively, hold capecitabine therapy, and begin next treatment at 50% of the starting dose when toxicity resolves to grade 1 or less; discontinue treatment for first recurrence of grade 4 toxicity. </li> </ul> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>Omitted capecitabine doses for toxicity are not replaced or restored. Resume treatment with the planned next cycle.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; Gy: gray; IMRT: intensity-modulated radiotherapy; G-CSF: granulocyte colony stimulating factor; CBC: complete blood count; INR: international normalized ratio; ULN: upper limit normal.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />¶ No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br />Δ Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.<br /><FONT class=lozenge>◊</FONT> Proceed with chemoradiotherapy if no progression on reimaging after four cycles of chemotherapy with gemcitabine and capecitabine.<br />§ Regional lymph nodes include: Retropancreaticoduodenal, celiac, and portal vein nodes.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Ben-Josef E, et al. J Clin Oncol 2015; 33:2617.</LI>&#xD;&#xA;<LI>Gemcitabine injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI>&#xD;&#xA;<LI>Riechelmann RP, et al. Cancer 2007; 110:1307.</LI>&#xD;&#xA;<LI>Knox JJ, et al. J Clin Oncol 2005; 23:2332.</LI></OL></div><div id=\"graphicVersion\">Graphic 107377 Version 10.0</div></div></div>"},"107380":{"type":"graphic_table","displayName":"Functional assessment tools for palliative care patients","title":"Functional assessment tools for palliative care patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Functional assessment tools for palliative care patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Assessment tool</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Utility</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td>Karnofsky performance status</td> <td>100-point scale of general function corresponding to the patient's ability to live at home and/or the need for hospitalization.</td> <td>Commonly used for estimating prognosis in palliative care, even though provides information on general function.</td> <td>Developed and validated in cancer patients. Scores correlate poorly with functional status when used in the rehabilitation setting, particularly in older patients.</td> </tr> <tr class=\"divider_bottom\"> <td>Eastern Cooperative Oncology Group (ECOG) performance status</td> <td>Five-point scale of general function that assesses patient's ability to walk, care for self, and the need for dependence on others or hospitalization.</td> <td>Commonly used for estimating prognosis in palliative care, even though provides information on general function.</td> <td>Developed and validated in cancer patients. Scores correlate poorly with functional status when used in the rehabilitation setting, particularly in older patients.</td> </tr> <tr class=\"divider_bottom\"> <td>Palliative Performance Scale<span style=\"white-space: nowrap;\"> (PPS)<sup>[1]</sup></span></td> <td>Observer-rated assessment scale of ambulation, activity level, self-care, oral intake, and level of consciousness.</td> <td>Reliable tool for assessment of prognosis in palliative care that correlates well with survival time.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Edmonton Functional Assessment<span style=\"white-space: nowrap;\"> Tool<sup>[2]</sup></span></td> <td>First part includes 11 items (communication, mental status, pain, respiratory function, balance [sitting or standing], mobility, walking and wheelchair locomotion, activities of daily living, fatigue, motivation, and performance status) scored on a four point rating scale (0 to 4). The second part is a single overall rating, on a scale of 0 to 3, of patient's functional status.</td> <td>Designed and validated specifically for palliative care populations.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Katz Activity of Daily<span style=\"white-space: nowrap;\"> Living<sup>[3]</sup></span></td> <td>Assesses six domains (bathing, dressing, toileting, transferring, continence, and feeding), which are each rated as dependent (0) or independent (1).</td> <td>Commonly used to assess the functional status of hospice and palliative care patients, despite being originally developed for the chronically ill and aged population.</td> <td>Not validated for palliative care populations.</td> </tr> <tr class=\"divider_bottom\"> <td>Lawton Instrumental Activities of Daily<span style=\"white-space: nowrap;\"> Living<sup>[4]</sup></span></td> <td>Functional assessment tool that assesses eight domains of function (medication management, telephone use, housekeeping, food preparation, laundry, financial management, transportation, and shopping).</td> <td>&nbsp;</td> <td>Neither developed nor validated in palliative care populations.</td> </tr> <tr class=\"divider_bottom\"> <td>Barthel<span style=\"white-space: nowrap;\"> Index<sup>[5]</sup></span></td> <td>Assesses patient's capacity to independently perform 10 tasks (feeding, dressing, personal hygiene, bowel control, bladder control, wheelchair transfer to and from bed, toilet transfer, bathtub transfer, walking on level or being propelled by wheelchair, and ascending and descending stairs).</td> <td>&nbsp;</td> <td>Neither developed nor validated in palliative care populations.</td> </tr> <tr class=\"divider_bottom\"> <td>Functional Independence Measure<span style=\"white-space: nowrap;\"> (FIM)<sup>[6]</sup></span></td> <td>Comprehensive observer-rated scale that assesses domains of self-care, sphincter control, mobility, locomotion, communication, and social cognition.</td> <td>Reliable and valid tool that can be used to measure functional outcomes in patients who can participate in more intensive rehabilitation programs. Global measure of disability, measuring how much assistance individuals need to carry out ADLs.</td> <td>Neither developed nor validated in palliative care populations.</td> </tr> <tr class=\"divider_bottom\"> <td>Berg Balance<span style=\"white-space: nowrap;\"> Scale<sup>[7]</sup></span></td> <td>Observer-rated performance-based instrument that assesses 14 tasks related to changes in position from sitting to standing, transferring, reaching out with outstretched arm, turning, and standing on one foot.</td> <td>Assesses individual risk of falling.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Tinetti Assessment of Balance and<span style=\"white-space: nowrap;\"> Gait<sup>[8]</sup></span></td> <td>Observer-rated performance-based instrument that contains nine items for balance (sitting balance, rising, attempts to rise, immediate standing balance within five seconds, standing balance, being nudged, eyes closed, turning 360 degrees, and sitting down) and seven for gait (initiation of gait, step length and height, step symmetry, step continuity, path walked, trunk, and walking stance).</td> <td>Assesses individual risk of falling.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Timed Up and Go<span style=\"white-space: nowrap;\"> (TUG)<sup>[9]</sup></span></td> <td>Performance-based assessment instrument. Patient asked to stand without using proximal muscles from a sitting position, walk three meters forward and return to a sitting position. The average normal time to complete the task is about 10 seconds. If greater than 20 seconds, patient has a strong likelihood of falling.</td> <td>Assesses risk of falling.</td> <td>Developed for use in older adults. Neither developed nor validated in palliative care populations.</td> </tr> <tr> <td>Six-Minute Walk Test<span style=\"white-space: nowrap;\"> (6MWT)<sup>[10]</sup></span></td> <td>Measure of endurance in which the patient is scored on his or her ability to walk in six minutes.</td> <td>Useful measure of functional capacity and widely used for measuring response to cardiac and pulmonary rehabilitation.</td> <td>Not validated in cancer populations.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADLs: activities of daily living.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Anderson F, Downing GM, Hill J, et al. Palliative performance scale (PPS): a new tool. J Palliat Care 1996; 12:5.</li>&#xD;&#xA;    <li>Kaasa T, Wessel J. The Edmonton Functional Assessment Tool: further development and validation for use in palliative care. J Palliat Care 2001; 17:5.</li>&#xD;&#xA;    <li>Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist 1970; 10:20.</li>&#xD;&#xA;    <li>Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9:179.</li>&#xD;&#xA;    <li>Granger CV, Dewis LS, Peters NC, et al. Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil 1979; 60:14.</li>&#xD;&#xA;    <li>Granger CV, Hamilton BB, Keith RA, et al. Advances in functional assessment for medical rehabilitation. Top Geriatr Rehabil 1986; 1:59.</li>&#xD;&#xA;    <li>Berg KO, Wood-Dauphinee SL, Williams JI, Maki B. Measuring balance in the elderly: validation of an instrument. Can J Public Health 1992; 83 Suppl 2:S7.</li>&#xD;&#xA;    <li>Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 1986; 34:119.</li>&#xD;&#xA;    <li>Podsiadlo D, Richardson S. The timed \"Up &amp; Go\": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39:142.</li>&#xD;&#xA;    <li>Enright PL. The six-minute walk test. Respir Care 2003; 48:783.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 107380 Version 1.0</div></div></div>"},"107383":{"type":"graphic_figure","displayName":"Monogenic disorders of CHI","title":"Monogenic disorders of congenital hyperinsulinism","html":"<div class=\"graphic\"><div style=\"width: 828px\" class=\"figure\"><div class=\"ttl\">Monogenic disorders of congenital hyperinsulinism</div><div class=\"cntnt\"><img style=\"width:808px; height:586px;\" src=\"images/PEDS/107383_Monogenic_disorders_of_CHI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram of &beta;-cell fuel-mediated insulin secretion showing 11 genes currently associated with congenital HI (bold and underlined). Glucose oxidation stimulates insulin secretion via a \"triggering pathway\" by inhibiting ATP-sensitive KATP channels, leading to plasma membrane depolarization, activation of voltage-gated calcium channels, elevation of cytosolic calcium, and release of insulin from stored granules. Insulin secretion is also promoted by various \"amplification pathways\" once cytosolic calcium is elevated, eg, by mitochondria-derived signals or by membrane receptors such as the GLP-1 receptor. Amino acids stimulate insulin secretion through several mechanisms, especially leucine, which allosterically activates GDH enzymatic activity to increase oxidative deamination of glutamate to &alpha;-KG; GDH activity is allosterically inhibited by GTP and by the SCHAD enzyme protein. During glucose-stimulated insulin secretion, the rise in &alpha;-KG increases flux through a gamma amino butyric acid shunt and generates &gamma;-hydroxybutyrate (GHB), which is released as a paracrine inhibitor of glucagon secretion from &alpha;-cells. HI-associated genes include: GCK (glucokinase), HK1 (hexokinase 1), PGM1 (phosphoglucomutase 1), MCT1 (monocarboxylate transporter 1), UCP2 (uncoupling protein 2), SCHAD (short-chain 3-hydroxyacyl-CoA dehydrogenase), GDH (glutamate dehydrogenase), HNF1A (hepatocyte nuclear factor 1A), HNFA (hepatocyte nuclear factor 4A), SUR1 (sulfonylurea receptor 1), Kir6.2 (inwardly rectifying potassium channel 6.2).</div><div class=\"graphic_footnotes\">G-1,6-P: glucose 1,6 diphosphate; G-6-P: glucose 6 phosphate; Ac-CoA: acyl coenzyme A; Pi: inorganic phosphate; PDG: phosphate dependent glutaminase; ADP: adenosine diphosphate; ATP: adenosine triphosphate; GS: glutamine synthetase; GTP: guanosine triphosphate; PCK2: phosphoenolpyruvate carboxykinase 2; PEP: phosphoenolpyruvate; OAA: oxaloacetate; α-KG: alpha-ketoglutarate; GAD: glutamic acid decarboxylase; GABA: gamma-aminobutyrate; GHB: gamma-hydroxybutyrate; SSA: succinic semialdehyde; Ins: insulin; KATP: ATP-dependent potassium (channel); GLP-1: glucagon-like peptide-1; K<SUP>+</SUP>: potassium ion; H<SUP>+</SUP>: hydrogen ion; Ca<SUP innerHtml>++</SUP>: calcium ion. </div><div class=\"graphic_reference\">Republished with permission of The Endocrine Society, from Stanley CA. Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders. J Clin Endocrinol Metab 2016; 101:815. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 107383 Version 1.0</div></div></div>"},"107384":{"type":"graphic_table","displayName":"Disorders causing congenital hyperinsulinism","title":"Disorders causing congenital hyperinsulinism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders causing congenital hyperinsulinism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"6\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Locus</td> <td class=\"subtitle1\">Mode</td> <td class=\"subtitle1\">Triggers</td> <td class=\"subtitle1\">Diazoxide response</td> <td class=\"subtitle1\">&#8593;&nbsp;NH3</td> </tr> <tr> <td colspan=\"7\"><strong>Monogenic hyperinsulinism</strong></td> </tr> <tr> <td class=\"indent1\">KATP-Channel (SUR1/Kir6.2 subunits)</td> <td class=\"centered\">ABCC8/KCNJ11</td> <td class=\"centered\">11p15.1</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Recessive KATP-hyperinsulinism</td> <td class=\"centered\">ABCC8/KCNJ11</td> <td class=\"centered\">11p15.1</td> <td class=\"centered\">Rec</td> <td class=\"centered\">F/P</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Dominant KATP-hyperinsulinism</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Diazoxide-unresponsive</td> <td class=\"centered\">ABCC8 (only?)</td> <td class=\"centered\">11p15.1</td> <td class=\"centered\">Dom</td> <td class=\"centered\">F/P</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent3\">Diazoxide-responsive</td> <td class=\"centered\">ABCC8/KCNJ11</td> <td class=\"centered\">11p15.1</td> <td class=\"centered\">Dom</td> <td class=\"centered\">F/P</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Focal KATP-hyperinsulinism (pat. 11p UPD + pat. rec. KATP mutation)</td> <td class=\"centered\">ABCC8/KCNJ11</td> <td class=\"centered\">11p15.1</td> <td class=\"centered\">Sporadic</td> <td class=\"centered\">F/P</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">GDH</td> <td class=\"centered\">GLUD1</td> <td class=\"centered\">10q23.3</td> <td class=\"centered\">Dom</td> <td class=\"centered\">F/P/Leu</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">GCK</td> <td class=\"centered\">GCK</td> <td class=\"centered\">7p13</td> <td class=\"centered\">Dom</td> <td class=\"centered\">F</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">SCHAD</td> <td class=\"centered\">HADH1</td> <td class=\"centered\">4q25</td> <td class=\"centered\">Rec</td> <td class=\"centered\">F/P/Leu</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">UCP2</td> <td class=\"centered\">UCP2</td> <td class=\"centered\">11q13.4</td> <td class=\"centered\">Dom</td> <td class=\"centered\">F/Glu</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">HNF4A</td> <td class=\"centered\">HNF4A</td> <td class=\"centered\">20q13.12</td> <td class=\"centered\">Dom</td> <td class=\"centered\">F</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">HNF1A</td> <td class=\"centered\">HNF1A</td> <td class=\"centered\">12q24.31</td> <td class=\"centered\">Dom</td> <td class=\"centered\">F</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Pyruvate transporter (MCT1)</td> <td class=\"centered\">SLC16A1</td> <td class=\"centered\">1p13.2</td> <td class=\"centered\">Dom</td> <td class=\"centered\">Exercise</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">HK1</td> <td class=\"centered\">HK1</td> <td class=\"centered\">10q22.1</td> <td class=\"centered\">Dom</td> <td class=\"centered\">F/Glu</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">PGM1</td> <td class=\"centered\">PGM1</td> <td class=\"centered\">1p31.3</td> <td class=\"centered\">Rec</td> <td class=\"centered\">Glu</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"7\"><strong>Syndromic forms of hyperinsulinism*</strong></td> </tr> <tr> <td class=\"indent1\">BWS (pat. 11p UPD)</td> <td class=\"centered\">IGF2/H19/CDKN1C/KCNQ1</td> <td class=\"centered\">11p15.4</td> <td class=\"centered\">Sporadic</td> <td class=\"centered\">F</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Kabuki (mosaic)</td> <td class=\"centered\">KMT2D/KDM6A</td> <td class=\"centered\">12q13.12/Xp11.3</td> <td class=\"centered\">Sporadic</td> <td class=\"centered\">F</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Turner (mosaic X loss)</td> <td class=\"centered\">?</td> <td class=\"centered\">X</td> <td class=\"centered\">Sporadic</td> <td class=\"centered\">F</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Congenital disorders of glycosylation</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Rec</td> <td class=\"centered\">F</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">CDG1a</td> <td class=\"centered\">PMM2</td> <td class=\"centered\">16p13.2</td> <td class=\"centered\">Rec</td> <td class=\"centered\">F</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">CDG1b</td> <td class=\"centered\">MPI</td> <td class=\"centered\">15q24.1</td> <td class=\"centered\">Rec</td> <td class=\"centered\">F</td> <td class=\"centered\">?</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">CDG1t (refer to PGM1 above)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"7\"><strong>Congenital hyperinsulinism-mimickers</strong></td> </tr> <tr> <td class=\"indent1\">Autoimmune hypoglycemia (anti-insulin or anti-insulin receptor antibodies)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Acquired</td> <td class=\"centered\">F/Glu</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">AKT2 (mosaic)</td> <td class=\"centered\">AKT2</td> <td class=\"centered\">19q13.2</td> <td class=\"centered\">Sporadic</td> <td class=\"centered\">F</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">ACT3 (mosaic)</td> <td class=\"centered\">AKT3</td> <td class=\"centered\">1q43-q44</td> <td class=\"centered\">Sporadic</td> <td class=\"centered\">F</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Insulin receptor inactivation</td> <td class=\"centered\">INSR</td> <td class=\"centered\">19p13.2</td> <td class=\"centered\">Dom</td> <td class=\"centered\">Glu</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"7\"><strong>Neonatal hyperinsulinism</strong></td> </tr> <tr> <td class=\"indent1\">Transitional hyperinsulinism in normal newborns</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">All newborns</td> <td class=\"centered\">F</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Perinatal-stress hyperinsulinism (mostly high-risk neonates, but some without apparent stress)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Transient</td> <td class=\"centered\">F</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UPD: uniparental isodisomy; Pat: paternal; Rec: recessive; F: fasting; P: protein; Dom: dominant; Leu: leucine; Glu: glucose.<br />* Partial list. Refer to Alkhayyat 2006<SUP>[1]</SUP> for other syndromic forms of hyperinsulinism.</div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>Alkhayyat H, Christesen HB, Steer J, Stewart H, Brusgaard K, Hussain K. Mosaic Turner syndrome and hyperinsulinaemic hypoglycaemia. J Pediatr Endocrinol Metab 2006; 19:1451.</LI></OL>Republished with permission of The Endocrine Society, from Stanley CA. Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders. J Clin Endocrinol Metab 2016; 101:815. Copyright © 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 107384 Version 1.0</div></div></div>"},"107386":{"type":"graphic_table","displayName":"Contrast allergies","title":"Contrast allergies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contrast allergies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"18%\"></colgroup><colgroup width=\"46%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Incidence</td> <td class=\"subtitle1\">Management</td> <td class=\"subtitle1\">Symptoms</td> </tr> <tr class=\"divider_bottom\"> <td>Mild</td> <td class=\"centered\">3%</td> <td>Self-limited</td> <td>Pruritus, urticaria, nausea, vomiting, flushing, headache</td> </tr> <tr class=\"divider_bottom\"> <td>Moderate</td> <td class=\"centered\">0.2 to 0.4%</td> <td>Treatment required</td> <td>Symptoms in mild category requiring therapy, laryngeal edema, dyspnea</td> </tr> <tr> <td>Severe</td> <td class=\"centered\">0.04%</td> <td>Hospitalization required</td> <td>Cardiac arrhythmia or arrest, circulatory collapse, seizures, unconsciousness</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Morcos SK, Thomsen HS. Adverse reactions to iodinated contrast media. Eur Radiol 2001; 11:1267.</li>&#xD;&#xA;    <li>Thomsen HS, Bush WH Jr. Adverse effects of contrast media: Incidence, prevention and management. Drug Saf 1998; 19:313.</li>&#xD;&#xA;    <li>Thomsen HS, Dorph S. High-osmolar and low-osmolar contrast media. An update on frequency of adverse drug reactions. Acta Radiol 1993; 34:205.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 107386 Version 1.0</div></div></div>"},"107388":{"type":"graphic_diagnosticimage","displayName":"Categories of breast density on mammography","title":"Categories of breast density on mammography","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Categories of breast density on mammography</div><div class=\"cntnt\"><img style=\"width:724px; height:286px;\" src=\"images/PC/107388_Ctgr_brst_dnsty_mmmgr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Almost entirely fatty.<br />(B) Scattered areas of fibroglandular tissue.<br />(C) Heterogeneously dense.<br />(D) Extremely dense.<br />These categories correspond to the four-point scale as defined by the Breast Imaging Reporting and Data System, 5th edition (BI-RADS).</div><div class=\"graphic_reference\">Courtesy of Phoebe Freer, MD and Priscilla Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 107388 Version 1.0</div></div></div>"},"107389":{"type":"graphic_diagnosticimage","displayName":"Breast cancer on mammography","title":"Breast cancer on mammography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breast cancer on mammography</div><div class=\"cntnt\"><img style=\"width:261px; height:449px;\" src=\"images/PC/107389_Brst_cncr_mmmgrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrow identifies a suspicious mass in the left inner upper breast in a 54-year-old woman with heterogeneously dense breast tissue. Biopsy revealed invasive carcinoma.</div><div class=\"graphic_reference\">Courtesy of Phoebe Freer, MD and Priscilla Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 107389 Version 1.0</div></div></div>"},"107393":{"type":"graphic_algorithm","displayName":"Screening for HSG contraindications","title":"Screening for contraindications to hysterosalpingogram (HSG)","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Screening for contraindications to hysterosalpingogram (HSG)</div><div class=\"cntnt\"><img style=\"width:600px; height:412px;\" src=\"images/OBGYN/107393_Screening_HSG_contraindctns.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Severe contrast reaction:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Cardiac arrhythmia or arrest</li>&#xD;&#xA;    <li>Circulatory collapse</li>&#xD;&#xA;    <li>Seizures</li>&#xD;&#xA;    <li>Unconsciousness</li>&#xD;&#xA;    <li>Anaphylaxis</li>&#xD;&#xA;    <li>Hospitalization required</li>&#xD;&#xA;</ul>&#xD;&#xA;&para; HSG premedication for mild contrast reaction:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Prednisone 50 mg orally, given 13, 7, and 1 hour prior to contrast</li>&#xD;&#xA;    <li>Diphenhydramine 50 mg orally, given 1 hour prior to contrast</li>&#xD;&#xA;    <li>Additional measures for the prevention of contrast reactions are reviewed elsewhere; refer to separate topic reviews available in UpToDate (eg, immediate hypersensitivity reactions to radiocontrast media, section on prevention of recurrent reactions, or topic review of prevention of contrast-induced nephropathy)</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Data from: American College of Radiology (ACR). ACR practice parameter for the performance of hysterosalpingography. Amended 2014 (Resolution 39).</div><div id=\"graphicVersion\">Graphic 107393 Version 1.0</div></div></div>"},"107394":{"type":"graphic_table","displayName":"Premedication for contrast allergies","title":"Oral premedication for adults at risk for contrast hypersensitivity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral premedication for adults at risk for contrast hypersensitivity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup width=\"55%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Timing</td> </tr> <tr> <td>Prednisone</td> <td>50 mg</td> <td>Oral</td> <td>13 hours, 7 hours, and 1 hour prior to contrast administration</td> </tr> <tr> <td>Diphenhydramine</td> <td>50 mg</td> <td>Oral</td> <td>1 hour prior to contrast administration</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Emergency treatment for a recurrent hypersensitivity reaction should be available. For additional options, refer to separate topic review of immediate hypersensitivity reactions to radiocontrast media, prevention of recurrent reactions, available in UpToDate.</div><div class=\"graphic_reference\"><a href=\"http://www.acr.org/~/media/37D84428BF1D4E1B9A3A2918DA9E27A3.pdf\"></a>Source: American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media, Version 10.1, 2015. Available at: <a href=\"http://www.acr.org/~/media/37D84428BF1D4E1B9A3A2918DA9E27A3.pdf\" spellcheck=\"true\" target=\"_blank\">http://www.acr.org/~/media/37D84428BF1D4E1B9A3A2918DA9E27A3.pdf</a> (Accessed on May 4, 2016).</div><div id=\"graphicVersion\">Graphic 107394 Version 1.0</div></div></div>"},"107400":{"type":"graphic_table","displayName":"Consent for hysterosalpingography (HSG)","title":"Consent for hysterosalpingography (HSG)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Consent for hysterosalpingography (HSG)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Risks of hysterosalpingography include:</td> </tr> <tr> <td> <ol> <li>Crampy menstrual-like pain during and periodically a day after the procedure. Recommendation: NSAID over-the-counter, as needed, such as ibuprofen. </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>Vaginal bleeding or spotting periodically for a day after the procedure. Recommendation: Patient provided with sanitary pad. </li> </ol> </td> </tr> <tr> <td> <ol start=\"3\"> <li>Small (&#60;1 in 100) chance of infection. Recommendation: If symptoms of fever, pelvic pain, and discharge occur, seek medical attention, as you will need antibiotic therapy. </li> </ol> </td> </tr> <tr> <td> <ol start=\"4\"> <li>Small (&#60;1 in 50) chance of contrast allergy. Vast majority are self-limited. Recommendation: Operating clinician will treat reaction, if necessary. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This text is added to the standard procedure consent form. These complications represent the most common complications and are not an exhaustive list.</div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drug.</div><div id=\"graphicVersion\">Graphic 107400 Version 1.0</div></div></div>"},"107405":{"type":"graphic_diagnosticimage","displayName":"HRCT of chronic HP","title":"High resolution computed tomography of chronic hypersensitivity pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">High resolution computed tomography of chronic hypersensitivity pneumonitis</div><div class=\"cntnt\"><img style=\"width:725px; height:272px;\" src=\"images/PULM/107405_HRCT_chrnc_HP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution computed tomography (HRCT) from a patient with chronic hypersensitivity pneumonitis. Image A from the upper lung zone shows a bronchocentric pattern of reticular opacities and traction bronchiectasis. Vaguely centrilobular ground-glass opacities are also present. Image B from a lower lung zone shows a peripheral, predominantly reticular pattern with traction bronchiectasis and honeycombing.</div><div id=\"graphicVersion\">Graphic 107405 Version 1.0</div></div></div>"},"107406":{"type":"graphic_diagnosticimage","displayName":"Honeycomb change","title":"Chest HRCT showing honeycomb change","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Chest HRCT showing honeycomb change</div><div class=\"cntnt\"><img style=\"width:715px; height:590px;\" src=\"images/PULM/107406_Hnycmb_chng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HRCT showing increased reticular opacities and patchy, subpleural areas of honeycomb change in a patient with idiopathic pulmonary fibrosis. Honeycomb change refers to clusters of cystic airspaces approximately 3 to 10 mm in diameter, usually in a subpleural location. Areas of honeycomb change are indicated by the ovals.</div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography.</div><div id=\"graphicVersion\">Graphic 107406 Version 1.0</div></div></div>"},"107407":{"type":"graphic_table","displayName":"HRCT criteria for UIP","title":"High resolution computed tomography criteria for UIP pattern","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">High resolution computed tomography criteria for UIP pattern</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">UIP pattern<br /> (all four features)</td> <td class=\"subtitle1\">Possible UIP pattern<br /> (all three features)</td> <td class=\"subtitle1\">Inconsistent with UIP pattern<br /> (any of the seven features)</td> </tr> <tr> <td> <ul> <li>Subpleural, basal predominance</li> <li>Reticular abnormality</li> <li>Honeycombing with or without traction bronchiectasis</li> <li>Absence of features listed as inconsistent with UIP pattern (see third column)</li> </ul> </td> <td> <ul> <li>Subpleural, basal predominance</li> <li>Reticular abnormality</li> <li>Absence of features listed as inconsistent with UIP pattern (see third column)</li> </ul> </td> <td> <ul> <li>Upper or mid-lung predominance</li> <li>Peribronchovascular predominance</li> <li>Extensive ground glass abnormality (extent &#62; reticular abnormality)</li> <li>Profuse micronodules (bilateral, predominantly upper lobes)</li> <li>Discrete cysts (multiple, bilateral, away from areas of honeycombing)</li> <li>Diffuse mosaic attenuation/air-trapping (bilateral, in three or more lobes)</li> <li>Consolidation in bronchopulmonary segment(s)/lobe(s)</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UIP: usual interstitial pneumonia.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2011 American Thoracic Society. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183(6):788-824. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 107407 Version 1.0</div></div></div>"},"107408":{"type":"graphic_table","displayName":"Diagnosis of IPF: Combination of HRCT and lung biopsy findings","title":"Diagnosis of IPF based on the combination of high resolution computed tomography and surgical lung biopsy (requires multidisciplinary discussion)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnosis of IPF based on the combination of high resolution computed tomography and surgical lung biopsy (requires multidisciplinary discussion)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Histopathological critera for UIP pattern</td> </tr> <tr> <td class=\"subtitle2\">UIP pattern<br /> (all four criteria)</td> <td class=\"subtitle2\">Probable UIP pattern</td> <td class=\"subtitle2\">Possible UIP pattern<br /> (all three criteria)</td> <td class=\"subtitle2\">Not UIP pattern<br /> (any of the six criteria)</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Evidence of marked fibrosis/architectural distortion, &#177; honeycombing in a predominantly subpleural/paraseptal distribution </li> <li>Presence of patchy involvement of lung parenchyma by fibrosis </li> <li>Presence of fibroblast foci </li> <li>Absence of features against a diagnosis of UIP suggesting an alternate diagnosis (refer to the \"Not UIP pattern\" column) </li> </ul> </td> <td> <ul> <li>Evidence of marked fibrosis/architectural distortion, &#177; honeycombing </li> <li>Absence of either patchy involvement or fibroblastic foci, but not both </li> <li>Absence of features against a diagnosis of UIP suggesting an alternate diagnosis (refer to the \"Not UIP pattern\" column) </li> </ul> <p class=\"indent1\">OR</p> <ul> <li>Honeycomb changes only* </li> </ul> </td> <td> <ul> <li>Patchy or diffuse involvement of lung parenchyma by fibrosis, with or without interstitial inflammation </li> <li>Absence of other criteria for UIP (refer to \"UIP pattern\" column) </li> <li>Absence of features against a diagnosis of UIP suggesting an alternate diagnosis (refer to the \"Not UIP pattern\" column) </li> </ul> </td> <td> <ul> <li>Hyaline membranes<sup>&#182;</sup> </li> <li>Organizing pneumonia<sup>&#182;</sup><sup>&#916;</sup> </li> <li>Granulomas<sup>&#916;</sup> </li> <li>Marked interstitial inflammatory cell infiltrate away from honeycombing </li> <li>Predominant airway centered changes </li> <li>Other features suggestive of an alternate diagnosis </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\" colspan=\"4\">Combination of&nbsp;HRCT and surgical lung biopsy for the diagnosis of IPF<br /> (requires multidisciplinary discussion)</td> </tr> <tr> <td class=\"subtitle2\">HRCT pattern<sup>&#9674;</sup></td> <td class=\"subtitle2\" colspan=\"2\">Surgical lung biopsy pattern<sup>&#9674;</sup> (when performed)</td> <td class=\"subtitle2\">Diagnosis of IPF?<sup>&#167;</sup></td> </tr> <tr> <td class=\"divider_bottom highlight_blue_text\" rowspan=\"2\">UIP</td> <td class=\"highlight_blue_text\" colspan=\"2\"> <p>UIP</p> <p>Probable UIP</p> <p>Possible UIP</p> Nonclassifiable fibrosis<sup>&#165;</sup></td> <td class=\"highlight_blue_text\">YES</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Not UIP</td> <td>No</td> </tr> <tr> <td class=\"divider_bottom highlight_blue_text\" rowspan=\"3\">Possible UIP</td> <td class=\"highlight_blue_text\" colspan=\"2\"> <p>UIP</p> Probable UIP</td> <td class=\"highlight_blue_text\">YES</td> </tr> <tr> <td colspan=\"2\"> <p>Possible UIP</p> Nonclassifiable fibrosis</td> <td>Probable<sup>&#135;</sup></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Not UIP</td> <td>No</td> </tr> <tr> <td rowspan=\"2\">Inconsistent with UIP</td> <td colspan=\"2\">UIP</td> <td>Possible<sup>&#135;</sup></td> </tr> <tr> <td colspan=\"2\"> <p>Probable UIP</p> <p>Possible UIP</p> <p>Nonclassifiable fibrosis</p> Not UIP</td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The shaded cells indicate combinations of HRCT and surgical lung biopsy patterns that correspond with a diagnosis of IPF (a YES in the far right column). The combination of UIP HRCT and probable UIP or possible UIP or nonclassifiable fibrosis (surgical lung biopsy patterns, for example) equals a diagnosis of IPF; the combination of UIP HRCT and not UIP (surgical lung biopsy pattern) does not make the diagnosis of IPF.</div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography; IPF: idiopathic pulmonary fibrosis; UIP: usual interstitial pneumonia.<br />* This scenario usually represents end-stage fibrotic lung disease where honeycombed segments have been sampled but where a UIP pattern might be present in other areas. Such areas are usually represented by overt honeycombing on HRCT and can be avoided by preoperative targeting of biopsy sites away from these areas using HRCT.<br />¶ Can be associated with acute exacerbation of idiopathic pulmonary fibrosis.<br />Δ An isolated or occasional granuloma and/or a mild component of organizing pneumonia pattern may rarely be coexisting in lung biopsies with an otherwise UIP pattern.<br /><FONT class=lozenge>◊</FONT> Patterns as described in the \"Histopathological critera for UIP pattern\" section of the table.<br />§ The accuracy of the diagnosis of IPF increases with multidisciplinary discussion (MDD). This is particularly relevant in cases in which the radiologic and histopathologic patterns are discordant (eg, HRCT is inconsistent with UIP and histopathology is UIP). There are data to suggest that the accuracy of diagnosis is improved with MDD among interstitial lung disease experts compared to clinician-specialists in the community setting; timely referral to interstitial lung disease experts is encouraged (refer to UpToDate text on the diagnosis of IPF).<br />¥ Nonclassifiable fibrosis: Some biopsies may reveal a pattern of fibrosis that does not meet the above criteria for UIP pattern and the other idiopathic interstitial pneumonias (refer to UpToDate text on the classification of idiopathic interstitial pneumonias). These biopsies may be termed \"nonclassifiable fibrosis.\"<br />‡&nbsp;MDD should include discussions of the potential for sampling error and a re-evaluation of adequacy of technique of HRCT. NOTE: In cases with an \"inconsistent with UIP\" HRCT pattern and a \"UIP\" surgical biopsy pattern, the possibility of a diagnosis of IPF still exists and clarification by MDD among interstitial lung disease experts is indicated.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright © 2016 American Thoracic Society. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183(6):788-824. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 107408 Version 1.0</div></div></div>"},"107411":{"type":"graphic_figure","displayName":"FDA: Essure micro-insert and HSG image","title":"US Food and Drug Administration package insert: Essure micro-insert and hysterosalpingogram (HSG)","html":"<div class=\"graphic\"><div style=\"width: 814px\" class=\"figure\"><div class=\"ttl\">US Food and Drug Administration package insert: Essure micro-insert and hysterosalpingogram (HSG)</div><div class=\"cntnt\"><img style=\"width:794px; height:676px;\" src=\"images/OBGYN/107411_FDA_essure_micro_insert_HSG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Drawing of contraceptive micro-insert and appearance on radiograph.<br />(B, C) Images are hysterosalpingograms following device insertion.</div><div class=\"graphic_reference\">Image Copyright &copy; 2016 Bayer. Used with permission.</div><div id=\"graphicVersion\">Graphic 107411 Version 1.0</div></div></div>"},"107414":{"type":"graphic_table","displayName":"Diagnostic criteria for persistent localized Q fever infection","title":"Diagnostic criteria for persistent localized Q fever infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for persistent localized Q fever infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Endocarditis*</td> <td class=\"subtitle1\">Prosthetic joint arthritis*</td> <td class=\"subtitle1\">Vascular infection*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Definite (Positive culture, PCR, or immunohistochemistry of the following specimens)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cardiac valve</td> <td> <ul> <li>Periprosthetic biopsy OR </li> <li>Joint aspirate </li> </ul> </td> <td> <ul> <li>Arterial sample (prosthesis or aneurysm) OR </li> <li>Periarterial abscess OR </li> <li>Spondylodiscitis linked to aorta </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Major</td> </tr> <tr> <td class=\"subtitle3_single\" colspan=\"3\">Microbiology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Positive culture or PCR of the blood or an emboli OR </li> <li>Positive serology with IgGI antibodies &#8805;6400 </li> </ul> </td> <td> <ul> <li>Positive culture or PCR of the blood OR </li> <li>Positive serology with IgGI antibodies &#8805;6400 </li> </ul> </td> <td> <ul> <li>Positive culture or PCR of the blood or emboli OR </li> <li>Positive serology with IgGI antibodies &#8805;6400 </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_single\" colspan=\"3\">Evidence of end-organ involvement</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Echocardiogram positive for infective endocarditis<sup>&#182;</sup> </li> <li>PET scan showing a specific valve fixation and/or mycotic aneurysm </li> </ul> </td> <td> <ul> <li>CT scan or MRI consistent with prosthetic infection<sup>&#916;</sup> </li> <li>PET scan or leukocyte indium scan consistent with infection (eg, specific prosthetic hyperfixation) </li> </ul> </td> <td> <ul> <li>CT scan: aneurysm or vascular prosthesis, periarterial abscess, fistula, or spondylodiscitis </li> <li>PET scan with specific fixation on an aneurysm or vascular prosthesis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Minor</td> </tr> <tr> <td class=\"indent1\">Temperature &#62;38&#176;C</td> <td>Temperature &#62;38&#176;C</td> <td>Temperature &#62;38&#176;C</td> </tr> <tr> <td class=\"indent1\"><em>C. burnetii</em> serology with IgGI antibodies &#8805;800 and &#60;6400</td> <td><em>C. burnetii</em> serology with IgGI antibodies &#8805;800 and &#60;6400</td> <td><em>C. burnetii</em> serology with IgGI antibodies &#8805;800 and &#60;6400</td> </tr> <tr> <td class=\"indent1\">Predisposing heart condition<sup>&#182;</sup></td> <td>Presence of a joint prosthesis</td> <td>Predisposing vascular condition; aneurysm or vascular prosthesis</td> </tr> <tr> <td class=\"indent1\">Vascular phenomena<sup>&#182;</sup> (eg, major arterial emboli, septic pulmonary infarcts, conjunctival hemorrhages)</td> <td>Joint pain</td> <td>Emboli</td> </tr> <tr> <td class=\"indent1\">Immunologic phenomena<sup>&#182;</sup> (eg, glomerulonephritis, Osler's nodes)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">​C. burnetii: Coxiella burnetii; CT: computed tomography; MRI: magnetic resonance imaging; PCR: polymerase chain reaction; PET: positron emission tomography.<br /><STRONG>* Definite diagnosis of persistent Q fever infection</STRONG><br />Definite criteria (positive culture, PCR, or immunohistochemistry of the specimens described above):<br />OR<br />Clinical criteria using:<br /><UL>&#xD;&#xA;<LI>2 major criteria.</LI>&#xD;&#xA;<LI>1 major criteria and 3 minor criteria (including one piece of microbiology evidence and the presence of a cardiac predisposition, joint prosthesis, or vascular predisposition).</LI></UL><STRONG>Possible diagnosis of persistent Q fever infection</STRONG><br /><EM>Endocarditis</EM>:<br /><UL>&#xD;&#xA;<LI>1 major criteria and 2 minor criteria (including one piece of microbiology evidence and the presence of a cardiac predisposition).</LI>&#xD;&#xA;<LI>3 minor criteria (including positive serology and the presence of a cardiac predisposition).</LI></UL><EM>Prosthetic joint infection</EM>:<br /><UL>&#xD;&#xA;<LI>1 major criteria and 2 minor criteria (including one piece of microbiology evidence and the presence of a joint prosthesis).</LI>&#xD;&#xA;<LI>3 minor criteria (including positive serology and the presence of a joint prosthesis).</LI></UL><EM>Vascular infection</EM>: Vascular predisposition, serologic evidence, and fever or emboli.<br />¶ Refer to the topic that discusses chronic Q fever endocarditis for a more detailed discussion of these criteria.<br />Δ Refer to the topic that discusses the diagnosis of prosthetic joint infections.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Million M, Bellevegue L, Labussiere AS, et al. Culture-negative prosthetic joint arthritis related to Coxiella burnetii. Am J Med 2014; 127:786.e7. </LI>&#xD;&#xA;<LI>Million M, Raoult D. Recent advances in the study of Q fever epidemiology, diagnosis and management. J Infect 2015; 71 Suppl 1:S2. </LI>&#xD;&#xA;<LI>Raoult D. Chronic Q fever: expert opinion versus literature analysis and consensus. J Infect 2012; 65:102.</LI></OL></div><div id=\"graphicVersion\">Graphic 107414 Version 1.0</div></div></div>"},"107415":{"type":"graphic_diagnosticimage","displayName":"Normal hysterosalpingogram","title":"Normal hysterosalpingogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal hysterosalpingogram</div><div class=\"cntnt\"><img style=\"width:366px; height:653px;\" src=\"images/OBGYN/107415_Nrml_hstrslpnggrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal hysterosalpingogram of a woman with infertility. Anteroposterior (A) and oblique (B) views demonstrate a normal uterus (asterisk). Both fallopian tubes (arrows) are normal in caliber and there was free flow of contrast bilaterally (arrowheads) into the peritoneal cavity.</div><div id=\"graphicVersion\">Graphic 107415 Version 1.0</div></div></div>"},"107416":{"type":"graphic_diagnosticimage","displayName":"Hysterosalpingogram of normal tubal micro-insert (Essure)","title":"Hysterosalpingogram of normal tubal micro-insert (Essure)","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram of normal tubal micro-insert (Essure)</div><div class=\"cntnt\"><img style=\"width:711px; height:527px;\" src=\"images/OBGYN/107416_Hstrslp_nrml_tbl_insrt_essr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram of a woman three months post-fallopian tube micro-insert (Essure) placement for contraception. The uterine cavity is filled adequately, indicated by corneal distention (asterisks). The Essure inserts are appropriately placed in the fallopian tubes with four radio-opaque markers (arrows) allowing for assessment of correct device location.</div><div id=\"graphicVersion\">Graphic 107416 Version 1.0</div></div></div>"},"107417":{"type":"graphic_diagnosticimage","displayName":"HSG of tubal occlusion","title":"Hysterosalpingogram of tubal occlusion","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram of tubal occlusion</div><div class=\"cntnt\"><img style=\"width:530px; height:742px;\" src=\"images/OBGYN/107417_HSG_tbl_occl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram of 48-year-old woman with infertility. Bilateral oblique views (A and B) demonstrate a normal uterus and right fallopian tube (arrow) with free spill of contrast from the right. The left fallopian tube is occluded (arrowhead), with the tube filling with contrast only to the proximal isthmus.</div><div id=\"graphicVersion\">Graphic 107417 Version 2.0</div></div></div>"},"107418":{"type":"graphic_diagnosticimage","displayName":"HSG of cornual spasm","title":"Hysterosalpingogram of cornual spasm","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram of cornual spasm</div><div class=\"cntnt\"><img style=\"width:711px; height:547px;\" src=\"images/OBGYN/107418_HSG_crnl_spsm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram of 42-year-old woman with infertility. The uterus and right fallopian tube are normal. The left fallopian tube does not opacify (arrow). This could represent occlusion or spasm. A repeat examination one month later demonstrated a normal left fallopian tube.</div><div id=\"graphicVersion\">Graphic 107418 Version 2.0</div></div></div>"},"107419":{"type":"graphic_diagnosticimage","displayName":"HSG of hydrosalpinx and unicornuate uterus","title":"Hysterosalpingogram of hydrosalpinx and unicornuate uterus","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram of hydrosalpinx and unicornuate uterus</div><div class=\"cntnt\"><img style=\"width:712px; height:712px;\" src=\"images/OBGYN/107419_HSG_hdrspnx_uncrn_utrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram of a 29-year-old woman with infertility. There is a single left uterine cavity (asterisk) and a left fallopian tube with a hydrosalpinx (arrow).</div><div id=\"graphicVersion\">Graphic 107419 Version 2.0</div></div></div>"},"107420":{"type":"graphic_diagnosticimage","displayName":"HSG of peritubal adhesions","title":"Hysterosalpingogram of peritubal adhesions and contained spill","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram of peritubal adhesions and contained spill</div><div class=\"cntnt\"><img style=\"width:711px; height:618px;\" src=\"images/OBGYN/107420_HSG_prtbl_adhs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram of woman with infertility. Both fallopian tubes (arrows) are patent and mildly dilated. Contrast spills bilaterally into the periampullary loculated spaces (asterisks), indicating pelvic adhesions.</div><div id=\"graphicVersion\">Graphic 107420 Version 2.0</div></div></div>"},"107421":{"type":"graphic_diagnosticimage","displayName":"Hysterosalpingogram of salpingitis isthmica nodosa","title":"Hysterosalpingogram of salpingitis isthmica nodosum","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram of salpingitis isthmica nodosum</div><div class=\"cntnt\"><img style=\"width:711px; height:585px;\" src=\"images/OBGYN/107421_Hystrslpg_slpng_isthmc_nds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram of a woman with infertility. Outpouchings of contrast (arrows) fill diverticuli of the isthmic portions of the fallopian tubes bilaterally.</div><div id=\"graphicVersion\">Graphic 107421 Version 2.0</div></div></div>"},"107422":{"type":"graphic_diagnosticimage","displayName":"Hysterosalpingogram of incomplete Essure tubal occlusion","title":"Hysterosalpingogram of incomplete Essure tubal occlusion","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram of incomplete Essure tubal occlusion</div><div class=\"cntnt\"><img style=\"width:711px; height:615px;\" src=\"images/OBGYN/107422_Hystrslpg_incmpl_essr_tbl_occl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram of a woman three months after Essure tubal micro-insert placement. Markers indicated devices are positioned correctly. The right tube is occluded but the left tube partially fills (arrow). The patient remained on alternative contraception and was asked to return after three additional months for a repeat examination.</div><div id=\"graphicVersion\">Graphic 107422 Version 1.0</div></div></div>"},"107423":{"type":"graphic_diagnosticimage","displayName":"Hysterosalpingogram of submucosal fibroid and filling defect","title":"Hysterosalpingogram (HSG) of submucosal fibroid and filling defect","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram (HSG) of submucosal fibroid and filling defect</div><div class=\"cntnt\"><img style=\"width:710px; height:597px;\" src=\"images/OBGYN/107423_Hstrs_sbmc_fbrd_fll_dfct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram of a woman with infertility. A persistent, smooth, ovoid filling defect (asterisk) is seen in the left fundal portion of the cavity corresponding to a submucosal fibroid.</div><div id=\"graphicVersion\">Graphic 107423 Version 1.0</div></div></div>"},"107424":{"type":"graphic_diagnosticimage","displayName":"Hysterosalpingogram of uterine synechiae","title":"Hysterosalpingogram (HSG) of uterine synechiae","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram (HSG) of uterine synechiae</div><div class=\"cntnt\"><img style=\"width:713px; height:505px;\" src=\"images/OBGYN/107424_Hstrslpg_utr_snch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram of woman with infertility. A persistent linear filling defect (asterisk) is seen in the uterine cavity indicating luminal adhesions.</div><div id=\"graphicVersion\">Graphic 107424 Version 1.0</div></div></div>"},"107430":{"type":"graphic_diagnosticimage","displayName":"Hysterosalpingogram of uterine adenomyosis","title":"Hysterosalpingogram (HSG) of uterine adenomyosis","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram (HSG) of uterine adenomyosis</div><div class=\"cntnt\"><img style=\"width:712px; height:593px;\" src=\"images/OBGYN/107430_Hstrslpg_utrn_adnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram of woman with infertility. The uterine contour is diffusely irregular with multiple outpouchings of contrast (arrows).</div><div id=\"graphicVersion\">Graphic 107430 Version 1.0</div></div></div>"},"107431":{"type":"graphic_diagnosticimage","displayName":"Hysterosalpingogram of septate uterus","title":"Hysterosalpingogram (HSG) of septate uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram (HSG) of septate uterus</div><div class=\"cntnt\"><img style=\"width:395px; height:722px;\" src=\"images/OBGYN/107431_Hstrslpgr_spt_utr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HSG and magnetic resonance images (MRI) of a 29-year-old woman with infertility from a septate uterus (A and B). HSG (A) shows two uterine cavities (asterisks) originating from a single cervix. MRI fast spin echo T2-weighted image (B) shows normal fundal myometrial contour (arrow).</div><div id=\"graphicVersion\">Graphic 107431 Version 1.0</div></div></div>"},"107432":{"type":"graphic_diagnosticimage","displayName":"Hysterosalpingogram of diethylstilbestrol uterus","title":"Hysterosalpingogram (HSG) of diethylstilbestrol (DES) uterus","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram (HSG) of diethylstilbestrol (DES) uterus</div><div class=\"cntnt\"><img style=\"width:712px; height:513px;\" src=\"images/OBGYN/107432_Hstrs_dthyl_utrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram of woman with history of in-utero diethylstilbestrol exposure. Uterine cavity is small and &nbsp;box-shaped and has cornual rings (arrows).</div><div id=\"graphicVersion\">Graphic 107432 Version 3.0</div></div></div>"},"107437":{"type":"graphic_table","displayName":"Clinical trials of ACTs","title":"Selected trials evaluating efficacy of artemisinin combination therapies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected trials evaluating efficacy of artemisinin combination therapies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Reference</td> <td class=\"subtitle1\">Drug regimen</td> <td class=\"subtitle1\">Result</td> <td class=\"subtitle1\">Number patients</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Year</td> </tr> <tr> <td>Ngasala BE et al<sup>[1]</sup></td> <td>Artemether-lumefantrine</td> <td>High efficacy</td> <td>359</td> <td>Children</td> <td>Tanzania</td> <td>2011</td> </tr> <tr> <td>Achan J et al<sup>[2]</sup></td> <td>Artemether-lumefantrine versus quinine</td> <td>Artemether-lumefantrine superior</td> <td>175</td> <td>Children</td> <td>Uganda</td> <td>2009</td> </tr> <tr> <td>Dorsey G et al<sup>[3]</sup></td> <td>Artemether-lumefantrine verus artesunate-amodiaquine versus amodiaquine- sulfadoxine-pyrimethamine</td> <td>Artemether-lumefantrine superior</td> <td>601</td> <td>Children</td> <td>Uganda</td> <td>2007</td> </tr> <tr> <td>Zwang J et al<sup>[4]</sup></td> <td>Artemether-lumefantrine versus artesunate-amodiaquine</td> <td>Artesunate-amodiaquine was followed by fewer recurrences</td> <td>602</td> <td>Children</td> <td>Uganda</td> <td>2016</td> </tr> <tr> <td>Toure O et al<sup>[5]</sup></td> <td>Artemether-lumefantrine versus arterolane maleate-piperaquine phosphate</td> <td>Comparable efficacy and safety</td> <td>859</td> <td>Children</td> <td>Africa and India</td> <td>2017</td> </tr> <tr> <td>Thriemer K et al<sup>[6]</sup></td> <td>Artemether-lumefantrine versus artesunate-azithromycin</td> <td>Equivalent cure rates</td> <td>228</td> <td>Adults and children</td> <td>Bangladesh</td> <td>2010</td> </tr> <tr> <td>Zwang J et al<sup>[7]</sup></td> <td>Artesunate-amodiaquine versus non-ACT therapy</td> <td>Artesunate-amodiaquine superior to non-ACT therapy</td> <td>11,700</td> <td>Adults and children</td> <td>Multi-country</td> <td>2009</td> </tr> <tr> <td>Tahar R et al<sup>[8]</sup></td> <td>Artesunate-amodiaquine versus atovaquone-proguanil versus artesunate-atovaquone-proguanil</td> <td>Equivalent efficacies by PCR; slower clearance with atovaquone-proguanil arm versus artesunate-atovaquone-proguanil</td> <td>338</td> <td>Children</td> <td>Cameroon</td> <td>2014</td> </tr> <tr> <td>Sirima S et al<sup>[9]</sup></td> <td>Artesunate-mefloquine versus artemether-lumefantrine </td> <td>Comparable efficacy with similar rates of adverse events</td> <td>945</td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Children</span></td> <td>Burkina Faso, Kenya, and Tanzania </td> <td>2016</td> </tr> <tr> <td>Smithuis F et al<sup>[10]</sup></td> <td>Artesunate-mefloquine versus artesunate-amodiaquine versus dihydroartemisinin-piperaquine versus artemether-lumefantrine</td> <td>Artesunate-mefloquine greatest posttreatment suppression</td> <td>808</td> <td>Adults and children</td> <td>Myanmar</td> <td>2010</td> </tr> <tr> <td>Rueangweerayut R et al<sup>[11]</sup></td> <td>Artesunate-mefloquine versus pyronaridine-artesunate</td> <td>Similar efficacies; longer parasite clearance times with pyronaridine-artesunate</td> <td>1271</td> <td>Adults and children</td> <td>Multi-country</td> <td>2012</td> </tr> <tr> <td>Zani B et al<sup>[12]</sup></td> <td>Dihydroartemisinin-piperaquine versus other ACTs</td> <td> <p>In Africa: DP reduces treatment failure compared with artemether-lumefantrine, (though both with PCR-adjusted failure rates &#60;5%).</p> In Asia: DP as effective as artesunate-mefloquine</td> <td>16,382</td> <td>Adults and children</td> <td>Multi-country</td> <td>2014</td> </tr> <tr> <td>Wanzira H et al<sup>[13]</sup></td> <td>Dihydroartemisinin-piperaquine versus artemether-lumefantrine</td> <td>Dihydroartemisinin-piperaquine superior</td> <td>312</td> <td>Children</td> <td>Uganda</td> <td>2014</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACT: artemisinin combination therapy; PCR: polymerase chain reaction; DP: dihydroartemisinin-piperaquine.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Ngasala BE, Malmberg M, Carlsson AM, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children &lt;5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis 2011; 52:873.</LI>&#xD;&#xA;<LI>Achan J, Tibenderana JK, Kyabayinze D, et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 2009; 339:b2763.</LI>&#xD;&#xA;<LI>Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297:2210. </LI>&#xD;&#xA;<LI>Yeka A, Kigozi R, Conrad MD, et al. Artesunate/amodiaquine versus artemether/lumefantrine for the treatment of uncomplicated malaria in Uganda: A randomized trial. J Infect Dis 2016; 213:1134. </LI>&#xD;&#xA;<LI>Toure OA, Mwapasa V, Sagara I, et al. Assessment of efficacy and safety of arterolane maleate-piperaquine phosphate dispersible tablets in comparison with artemether-lumefantrine dispersible tablets in pediatric patients with acute uncomplicated Plasmodium falciparum malaria: A phase 3, randomized, multicenter trial in India and Africa. Clin Infect Dis 2017; 65:1711.</LI>&#xD;&#xA;<LI>Thriemer K, Starzengruber P, Khan WA, et al. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial. J Infect Dis 2010; 202:392. </LI>&#xD;&#xA;<LI>Zwang J, Olliaro P, Barennes H, et al. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J 2009; 8:203. </LI>&#xD;&#xA;<LI>Tahar R, Almelli T, Debue C, et al. Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children. J Infect Dis 2014; 210:1962.&nbsp;</LI>&#xD;&#xA;<LI>Sirima SB, Ogutu B, Lusingu JPA, et al. Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet 2016; 16:1123.</LI>&#xD;&#xA;<LI>Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010; 10:673. </LI>&#xD;&#xA;<LI>Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Eng J Med 2012; 366:1298. </LI>&#xD;&#xA;<LI>Zani B, Gathu M, Donegan S, et al. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2014; 1:CD010927. </LI>&#xD;&#xA;<LI>Wanzira H, Kakuru A, Arinaitwe E, et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. Clin Infect Dis 2014; 59:509.</LI></OL></div><div id=\"graphicVersion\">Graphic 107437 Version 4.0</div></div></div>"},"107438":{"type":"graphic_table","displayName":"ACT regimens uncomplicated falciparum malaria","title":"Artemisinin combination therapy (ACT) regimens for treatment of uncomplicated <EM>Plasmodium falciparum</EM> malaria in nonpregnant adults and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Artemisinin combination therapy (ACT) regimens for treatment of uncomplicated <EM>Plasmodium falciparum</EM> malaria in nonpregnant adults and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Formulations available</td> <td class=\"subtitle1\">Body weight (kg)</td> <td class=\"subtitle1\" colspan=\"2\">Dose*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Artemether-lumefantrine<sup>&#182;</sup></strong></td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Available as tablets containing</p> <p>20 + 120 mg or</p> <p>40 + 240 mg</p> <p>of artemether and lumefantrine, respectively;</p> <p>an orally disintegrating flavored tablet is available in some areas</p> </td> <td>&nbsp;</td> <td colspan=\"2\">Dose administered orally twice daily for three days:</td> </tr> <tr> <td>5 to &#60;15</td> <td colspan=\"2\">20 + 120 mg</td> </tr> <tr> <td>15 to &#60;25</td> <td colspan=\"2\">40 + 240 mg</td> </tr> <tr> <td>25 to &#60;35</td> <td colspan=\"2\">60 + 360 mg</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;35</td> <td colspan=\"2\">80 + 480 mg</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Artesunate-amodiaquine</strong></td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Available as tablets containing</p> <p>25 + 67.5 mg,</p> <p>50 + 135 mg, or</p> <p>100 + 270 mg</p> of artesunate and amodiaquine, respectively</td> <td>&nbsp;</td> <td colspan=\"2\">Dose administered orally once daily for three days:</td> </tr> <tr> <td>4.5 to &#60;9</td> <td colspan=\"2\">25 + 67.5 mg</td> </tr> <tr> <td>9 to &#60;18</td> <td colspan=\"2\">50 + 135 mg</td> </tr> <tr> <td>18 to &#60;36</td> <td colspan=\"2\">100 + 270 mg</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;36</td> <td colspan=\"2\">200 + 540 mg</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Artesunate-mefloquine</strong></td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Available as tablets containing</p> <p>25 + 55 mg or</p> <p>100 + 220 mg</p> of artesunate and mefloquine hydrochloride, respectively<sup>&#916;</sup></td> <td>&nbsp;</td> <td colspan=\"2\">Dose administered orally once daily for three days:</td> </tr> <tr> <td>5 to &#60;9</td> <td colspan=\"2\">25 + 55 mg</td> </tr> <tr> <td>9 to &#60;18</td> <td colspan=\"2\">50 + 110 mg</td> </tr> <tr> <td>18 to &#60;30</td> <td colspan=\"2\">100 + 220 mg</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;30</td> <td colspan=\"2\">200 + 440 mg</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Artesunate-sulfadoxine-pyrimethamine<sup>&#9674;</sup></strong></td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Not available as a fixed-dose combination; available as artesunate tablets (50 mg) and SP tablets (500 mg sulfadoxine and 25 mg pyrimethamine)</p> <p>Available as co-packaged scored tablets</p> </td> <td>&nbsp;</td> <td>Artesunate (orally once daily for three days)</td> <td>SP (single dose orally on day 1)</td> </tr> <tr> <td>5 to &#60;10</td> <td>25 mg</td> <td>250/12.5</td> </tr> <tr> <td>10 to &#60;25</td> <td>50 mg</td> <td>500/25</td> </tr> <tr> <td>25 to &#60;50</td> <td>100 mg</td> <td>1000/50</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;50</td> <td>200 mg</td> <td>1500/75</td> </tr> <tr> <td rowspan=\"9\"><strong>Dihydroartemisinin-piperaquine<sup>&#167;</sup></strong></td> <td rowspan=\"9\"> <p>Available as tablets containing</p> <p>20 + 160 or</p> <p>40 + 320 of</p> dihydroartemisinin and piperaquine, respectively</td> <td>&nbsp;</td> <td colspan=\"2\">Dose administered orally once daily for three days:</td> </tr> <tr> <td>5 to &#60;8</td> <td colspan=\"2\">20 +160</td> </tr> <tr> <td>8 to &#60;11</td> <td colspan=\"2\">30 + 240</td> </tr> <tr> <td>11 to &#60;17</td> <td colspan=\"2\">40 + 320</td> </tr> <tr> <td>17 to &#60;25</td> <td colspan=\"2\">60 + 480</td> </tr> <tr> <td>25 to &#60;36</td> <td colspan=\"2\">80 + 640</td> </tr> <tr> <td>36 to &#60;60</td> <td colspan=\"2\">120 + 960</td> </tr> <tr> <td>60 to &#60;80</td> <td colspan=\"2\">160 + 1280</td> </tr> <tr> <td>&#8805;80</td> <td colspan=\"2\">200 + 1600</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The dosing regimens listed in this table are consistent with the World Health Organization 2015 guidelines for the treatment of uncomplicated <EM>Plasmodium falciparum </EM>malaria and may differ from dosing recommended in approved product information. Product availability varies by locality.</div><div class=\"graphic_footnotes\">SP: sulfadoxine-pyrimethamine; DP: dihydroartemisinin + piperaquine.<br />* In general, the course of ACT is administered for three days. In areas of artemisinin resistance, a six-day course of treatment is warranted.<br />¶ Take after a full meal or whole milk. If patient vomits within 30 minutes of taking a dose, then they should repeat the dose. Ideally, the first two doses should be taken 8 hours apart.<br />Δ Mefloquine hydrochloride (55 mg) is equivalent to mefloquine base (50 mg); mefloquine hydrochloride (220 mg) is equivalent to mefloquine base (200 mg).<br /><FONT class=lozenge>◊</FONT> Sulfadoxine-pyrimethamine should be avoided in the first weeks of life because it could aggravate neonatal hyperbilirubinemia.<br />§ Piperaquine prolongs the QT interval by approximately the same amount as chloroquine but by less than quinine. DP should not be used in patients with congenital QT prolongation or who are on medications that prolong the QT interval.&nbsp;DP may be taken with food but should not be taken with a high-fat meal.</div><div class=\"graphic_reference\">Adapted from: World Health Organization. Guidelines for the treatment of malaria, 3rd ed. WHO: Geneva 2015. Available at: <A spellcheck=true href=\"http://www.who.int/malaria/publications/atoz/9789241549127/en/\" target=_blank>http://www.who.int/malaria/publications/atoz/9789241549127/en/</A> (Accessed on March 22, 2016).</div><div id=\"graphicVersion\">Graphic 107438 Version 2.0</div></div></div>"},"107439":{"type":"graphic_table","displayName":"Criteria severe falciparum malaria","title":"Definition of severe falciparum malaria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of severe falciparum malaria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Manifestations</td> <td class=\"subtitle1_left\">Definitions</td> </tr> <tr class=\"divider_top\"> <td>Impaired consciousness</td> <td>Glasgow coma score &#60;11 in adults or Blantyre coma score &#60;3 in children</td> </tr> <tr> <td>Prostration</td> <td>Generalized weakness so that a person is unable to sit, stand, or walk without assistance</td> </tr> <tr> <td>Multiple convulsions</td> <td>More than two episodes within 24 hours</td> </tr> <tr> <td>Acidosis</td> <td>A base deficit of &#62;8 mEq/L, a plasma bicarbonate level of &#60;15 mmol/L, or venous plasma lactate &#8805;5 mmol/L. Clinical indicators of acidosis include rapid, deep, labored breathing.</td> </tr> <tr> <td>Hypoglycemia</td> <td>Blood or plasma glucose &#60;40 mg/dL (&#60;2.2 mmol/L) for children &#8805;5 years and adults; blood or plasma glucose &#60;54 mg/dL (&#60;3 mmol/L) for children &#60;5 years</td> </tr> <tr> <td>Severe anemia</td> <td>Hemoglobin concentration &#8804;5 g/dL or hematocrit &#8804;15 percent in children &#60;12 years of age (&#60;7 g/dL and &#60;20 percent, respectively, in adults) with parasite count &#62;10,000/mcL (0.2 percent parasitemia)</td> </tr> <tr> <td>Renal impairment</td> <td>Plasma or serum creatinine &#62;3 mg/dL (265 mcmol/L) or blood urea &#62;20 mmol/L</td> </tr> <tr> <td>Jaundice</td> <td>Plasma or serum bilirubin &#62;50 mcmol/L (3 mg/dL) with a parasite count &#62;100,000/mcL&nbsp;(0.2 percent parasitemia)</td> </tr> <tr> <td>Pulmonary edema</td> <td>Radiographically confirmed or oxygen saturation &#60;92 percent on room air with respiratory rate &#62;30/minutes, often with chest indrawing and crepitation on auscultation</td> </tr> <tr> <td>Significant bleeding</td> <td>Including recurrent or prolonged bleeding (from the nose, gums, or venipuncture sites), hematemesis, or melena</td> </tr> <tr> <td>Shock</td> <td>Compensated shock is defined as capillary refill &#8805;3 seconds or temperature gradient on leg (mid to proximal limb), but no hypotension. Decompensated shock is defined as systolic blood pressure &#60;70 mmHg in children or &#60;80 mmHg in adults, with evidence of impaired perfusion (cool peripheries or prolonged capillary refill).</td> </tr> <tr> <td>Hyperparasitemia</td> <td><em>P. falciparum</em> parasitemia &#62;10 percent (&#62;500,000/mcL)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Severe malaria is defined as one or more of the above occurring in the absence of an identified alternative cause and in the presence of <em>Plasmodium falciparum</em> parasitemia.</div><div class=\"graphic_reference\">Source: World Health Organization. Guidelines for the treatment of malaria, 3rd ed. WHO: Geneva 2015. Available at: <a href=\"http://www.who.int/malaria/publications/atoz/9789241549127/en/\" target=\"_blank\">http://www.who.int/malaria/publications/atoz/9789241549127/en/</a> (Accessed on March 22, 2016).</div><div id=\"graphicVersion\">Graphic 107439 Version 3.0</div></div></div>"},"107442":{"type":"graphic_figure","displayName":"Hirschsprung disease baby PI","title":"Hirschsprung disease","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Hirschsprung disease</div><div class=\"cntnt\"><img style=\"width:536px; height:497px;\" src=\"images/PI/107442_Hirschsprung_disease_baby_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the lower digestive system in a baby with Hirschsprung disease (HD). In HD, a problem with the nerve cells in the colon or rectum causes a blockage. The colon and rectum are the lower part of the bowels (also called the large intestine). Because of the blockage, waste builds up in the bowels, and the person cannot have normal bowel movements.</div><div id=\"graphicVersion\">Graphic 107442 Version 1.0</div></div></div>"},"107466":{"type":"graphic_picture","displayName":"Orbital mucormycosis","title":"Orbital mucormycosis in a diabetic following an automobile accident","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Orbital mucormycosis in a diabetic following an automobile accident</div><div class=\"cntnt\"><img style=\"width:756px; height:511px;\" src=\"images/ID/107466_Orbital_mucormycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mucormycosis involving medial canthus and orbit in a 60-year-old woman with diabetes who had multiple injuries from an automobile accident.</div><div class=\"graphic_reference\">Reproduced with permission from: Shields JA, Shields CL. Eyelid, Conjunctival, and Orbital Tumors: An Atlas and Textbook, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2016. Copyright © 2016 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 107466 Version 1.0</div></div></div>"},"107467":{"type":"graphic_picture","displayName":"Rhino-orbital-cerebral mucormycosis","title":"Rhino-orbital-cerebral mucormycosis in a patient with diabetic ketoacidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rhino-orbital-cerebral mucormycosis in a patient with diabetic ketoacidosis</div><div class=\"cntnt\"><img style=\"width:393px; height:373px;\" src=\"images/ID/107467_Rhinocerebral_mucormycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Kauffman CA. Opportunistic fungal infections. In: Schaechter's Mechanisms of Microbial Disease, 5th ed, Engleberg NC, DiRita VJ, Dermody TS, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 107467 Version 1.0</div></div></div>"},"107472":{"type":"graphic_table","displayName":"Management of childhood lead exposure and poisoning","title":"Recommendations on medical management of childhood lead exposure and poisoning","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations on medical management of childhood lead exposure and poisoning</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"2\">No level of lead in the blood is safe. In 2012, the CDC established a new \"reference value\" for blood lead levels (5 mcg/dL [0.24 micromol/L), thereby lowering the level at which evaluation and intervention are recommended.</td> </tr> <tr> <td class=\"subtitle1\">Lead level</td> <td class=\"subtitle1\">Recommendation*</td> </tr> <tr class=\"divider_bottom\"> <td>&#60;5 mcg/dL</td> <td> <ol class=\"numbers_to_nine\"> <li>Review lab results with family. For reference, the geometric mean blood lead level (BLL) for children 1-5 years old is less than 2 mcg/dL. </li> <li>Repeat the BLL in 6-12 months if the child is at high risk or risk changes during the time frame. Ensure levels are done at 1 and 2 years of age. </li> <li>For children screened at age &#60;12 months, consider retesting in 3-6 months&nbsp;because lead exposure may increase as mobility increases. </li> <li>Perform routine health maintenance including assessment of nutrition, physical and mental development, as well as iron deficiency risk factors. </li> <li>Provide anticipatory guidance on common sources of environmental lead exposure: paint in homes built prior to 1978, soil near roadways or other sources of lead, take-home exposures related to adult occupations, imported spices, cosmetics, folk remedies, and cookware. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>5-14 mcg/dL</td> <td> <ol class=\"numbers_to_nine\"> <li>Perform steps as described above for levels &#60;5 mcg/dL (0.24 micromol/L). </li> <li>Re-test venous BLL within 1-3 months to ensure the lead level is not rising. If it is stable or decreasing, retest the BLL in 3 months. Refer patient to local health authorities if such resources are available. In the United States, most jurisdictions require elevated BLLs be reported to the state health department. Contact the CDC at <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">800-CDC-INFO<a href=\"#\" title=\"Call: 800-CDC-INFO\"><img alt=\"\" title=\"Call: 800-CDC-INFO\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> (<span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">800-232-4636<a href=\"#\" title=\"Call: 800-232-4636\"><img alt=\"\" title=\"Call: 800-232-4636\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span>) or the National Lead Information Center at <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">800-424-LEAD<a href=\"#\" title=\"Call: 800-424-LEAD\"><img alt=\"\" title=\"Call: 800-424-LEAD\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> (5323) for resources regarding lead poisoning prevention and local childhood lead poisoning prevention programs. </li> <li>Take a careful environmental history to identify potential sources of exposures (see #5 above) and provide preliminary advice about reducing/eliminating exposures. Take care to consider other children who may be exposed. </li> <li>Provide nutritional counseling related to calcium and iron. In addition, recommend having a fruit at every meal as iron absorption quadruples when taken with Vitamin C-containing foods. Encourage the consumption of iron-enriched foods (eg, cereals, meats). Some children may be eligible for Special Supplemental Nutrition Program for Women, Infants and Child (WIC) or other nutritional counseling. </li> <li>Ensure iron sufficiency with adequate laboratory testing (CBC, Ferritin, CRP) and treatment per AAP guidelines. </li> <li>Perform structured developmental screening evaluations at child health maintenance visits, as lead's effect on development may manifest over years. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>15-44 mcg/dL</td> <td> <ol class=\"numbers_to_nine\"> <li>Perform steps as described above for levels 5-14 mcg/dL (0.24-0.68 micromol/L). </li> <li>Confirm the BLL with repeat venous sample within 1-4 weeks. </li> <li>Additional, specific evaluation of the child, such as a plain abdominal&nbsp;radiograph should be considered based on the environmental investigation and history (eg, pica for paint chips, mouthing behaviors). Gut decontamination using whole bowel irrigation is suggested if leaded foreign bodies are visualized.&nbsp;Any treatment for BLLs in this range should be done in consultation with an expert. Contact local PEHSU or PCC for guidance. </li> </ol> </td> </tr> <tr> <td>&#62;44 mcg/dL</td> <td> <ol class=\"numbers_to_nine\"> <li>Follow guidance for BLL 15-44 mcg/dL (0.72-2.13 micromol/L)&nbsp;as listed above. </li> <li>Confirm the BLL with repeat venous lead level. Timing of repeat BLL&nbsp;is determined by whether symptoms of lead poisoning&nbsp;are present&nbsp;and the height of the initial BLL. &nbsp; </li> <li>Perform&nbsp;chelation therapy (managed with the assistance of an experienced provider). Hospitalize patients in whom lead safe housing cannot be assured and all patients with BLL &#62;69 mcg/dL (3.33 micromol/L). Safety of the home with respect to lead hazards, isolation of the lead source, family social situation, and chronicity of the exposure are factors that may influence management. Contact your regional PEHSU or PCC for assistance. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CDC: Center for Disease Control&nbsp; and Prevention; CBC: complete blood count; CRP: C-reactive protein; AAP: American Academy of Pediatrics; BLL: blood lead level; PEHSU: Pediatric Environmental Health Specialty Unit; PCC: poison control center.<br />*For additional discussion, refer to UpToDate topics on the management of childhood lead poisoning. </div><div class=\"graphic_reference\">Reproduced with permission from: Newman N, Binns HJ, Karwowski M, Lowry J, and the Pediatric Environmental Health Specialty Unit (PEHSU) Lead working group. Recommendations on Medical Management of Childhood Lead Exposure and Poisoning. PEHSU and American Academy of Pediatrics. June, 2013. Available <A spellcheck=true href=\"http://www.pehsu.net/_Library/facts/medical-mgmnt-childhood-lead-exposure-June-2013.pdf\" target=_blank>here</A> (Accessed on May 18, 2016).</div><div id=\"graphicVersion\">Graphic 107472 Version 2.0</div></div></div>"},"107489":{"type":"graphic_table","displayName":"Allergens in wheat flour","title":"Allergens in wheat flour","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Allergens in wheat flour</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Allergen name</td> <td class=\"subtitle1\">Allergen abbreviation</td> </tr> <tr> <td>Alpha-amylase-trypsin inhibitor</td> <td>Tri a 28 and Tri a 29.01</td> </tr> <tr> <td>Alpha-purothionin</td> <td>Tri a 37</td> </tr> <tr> <td>Gliadin</td> <td>Omega-5-gliadin</td> </tr> <tr> <td>I-cys-peroxiredoxin</td> <td>Tri a 32</td> </tr> <tr> <td>Lipid protein transfer</td> <td>Tri a 14</td> </tr> <tr> <td>Peroxidase</td> <td>Tri a Bd36 kd</td> </tr> <tr> <td>Serine protease-like inhibitor</td> <td>Tri a 39</td> </tr> <tr> <td>Serine proteinase inhibitor</td> <td>Tri a 29</td> </tr> <tr> <td>Thaumatin-like protein (TLP)</td> <td>&nbsp;</td> </tr> <tr> <td>Thiol reductase</td> <td>Tri a 27</td> </tr> <tr> <td>Thioredoxin</td> <td>Tri a 25</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Cianferoni A. Wheat allergy: Diagnosis. J Asthma Allergy 2016; 9:13.</div><div id=\"graphicVersion\">Graphic 107489 Version 1.0</div></div></div>"},"107494":{"type":"graphic_figure","displayName":"Simplified risk score for PDNV in adults","title":"Simplified risk score for PDNV in adults","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Simplified risk score for PDNV in adults</div><div class=\"cntnt\"><img style=\"width:340px; height:474px;\" src=\"images/ANEST/107494_Simplified_risk_PDNV_adults.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When 0, 1, 2, 3, 4, and 5 risk factors are present, the corresponding risk for PDNV is approximately 10%, 20%, 30%, 50%, 60%, and 80%, respectively.</div><div class=\"graphic_footnotes\">PDNV: post-discharge nausea and vomiting; PONV: postoperative nausea and vomiting; PACU: post-anesthesia care unit.</div><div class=\"graphic_reference\">From: Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014; 118:85. DOI: <a href=\"http://journals.lww.com/anesthesia-analgesia/pages/articleviewer.aspx?year=2014&amp;issue=01000&amp;article=00013&amp;type=abstract\" target=\"_blank\">10.1213/ANE.0000000000000002</a>. Copyright &copy; 2014 International Anesthesia Research Society. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 107494 Version 1.0</div></div></div>"},"107496":{"type":"graphic_algorithm","displayName":"Urgent evaluation of severe headache in adults","title":"Approach to the urgent evaluation of headache in an adult","html":"<div class=\"graphic\"><div style=\"width: 1328px\" class=\"figure\"><div class=\"ttl\">Approach to the urgent evaluation of headache in an adult</div><div class=\"cntnt\"><img style=\"width:1308px; height:844px;\" src=\"images/NEURO/107496_Urgent_eval_severe_headache.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an overview of our approach to the urgent evaluation of headache in an adult. It should be used in conjunction with other UpToDate content on headache.</div><div class=\"graphic_footnotes\">CO-Hgb: carboxyhemoglobin; CO: carbon monoxide; CT: computed tomography; HA: headache; CNS: central nervous system; MRA: magnetic resonance angiography; MRI: magnetic resonance imaging; MRV: magnetic resonance venography; LP: lumbar puncture; SAH: subarachnoid hemorrhage; c/w: consistent with.<br />* All patients with acute or subacute head trauma should have head CT scan; pregnant women &gt;20 weeks gestation or women in early postpartum should be evaluated for preeclampsia.<br />¶ The main clinical features of these conditions are listed below:<br /><UL>&#xD;&#xA;<LI><STRONG>Giant cell (temporal) arteritis</STRONG> typically affects people age &gt;50 years and may be associated with systemic manifestations fever, fatigue, weight loss, jaw claudication, visual symptoms, particularly transient monocular visual loss and diplopia, or symptoms of polymyalgia rheumatic.</LI>&#xD;&#xA;<LI><STRONG>Acute angle-closure glaucoma</STRONG> may present with vision loss, headache, severe eye pain, light halos, nausea, and vomiting. Exam reveals a red eye, corneal cloudiness or edema, a shallow anterior chamber, and poorly reactive mid dilated pupil.</LI>&#xD;&#xA;<LI><STRONG>Optic neuritis</STRONG> typically presents with painful, monocular visual loss that evolves over several hours to a few days. One-third of patients have visible optic nerve inflammation (papillitis) on funduscopic examination. MRI of the brain and orbits with gadolinium contrast confirms the diagnosis in most cases.</LI>&#xD;&#xA;<LI><STRONG>Idiopathic intracranial hypertension</STRONG> (pseudotumor cerebri) typically affects obese women of child-bearing age. Characteristic features are headache, papilledema, vision loss or diplopia, elevated lumbar puncture opening pressure with normal cerebrospinal fluid composition. MRI with MR venography is the preferred study to exclude secondary causes of elevated intracranial pressure, particularly cerebral venous thrombosis.</LI>&#xD;&#xA;<LI><STRONG>Pheochromocytoma</STRONG> is a rare condition that may present with episodic headache, sweating, and tachycardia. Sustained or paroxysmal hypertension is the most common sign, but 5 to 15% of patients present with normal blood pressure.</LI>&#xD;&#xA;<LI><STRONG>Acute herpes zoster</STRONG> usually presents with a vesicular rash and acute painful neuritis. Prodromal pain may precede the rash by days to weeks. In unusual cases, pain may be related to herpes zoster without rash (zoster sine herpete).</LI>&#xD;&#xA;<LI><STRONG>Postherpetic neuralgia</STRONG> usually affects the thoracic, cervical, and trigeminal nerves. In most cases, the diagnosis is made when pain persists beyond four months in the same distribution as a preceding documented episode of acute herpes zoster.</LI>&#xD;&#xA;<LI><STRONG>Trigeminal neuralgia</STRONG> is defined by sudden, usually unilateral, severe, brief, stabbing or lancinating, recurrent episodes of pain in the distribution of one or more branches of the fifth cranial (trigeminal) nerve.</LI></UL></div><div id=\"graphicVersion\">Graphic 107496 Version 1.0</div></div></div>"},"107499":{"type":"graphic_figure","displayName":"Light exposure timing for westward travel","title":"Light exposure timing for westward travel","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Light exposure timing for westward travel</div><div class=\"cntnt\"><img style=\"width:592px; height:535px;\" src=\"images/SLEEP/107499_Lght_expsr_tim_wst_trvl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship of estimated endogenous circadian rhythm in relation to habitual sleep bout at location of origin (Eastern Standard Time [EST]) and desired sleep bout at destination (Hawaiian Aleutian Standard Time [HAST]). Light exposure/avoidance is timed strategically at the destination to produce phase delay such that the endogenous circadian rhythm aligns with local time.</div><div class=\"graphic_footnotes\">DLMO: dim light melatonin onset; CBT<sub>min</sub>: core body temperature minimum.</div><div id=\"graphicVersion\">Graphic 107499 Version 1.0</div></div></div>"},"107500":{"type":"graphic_figure","displayName":"Light exposure timing for eastward travel","title":"Light exposure timing for eastward travel","html":"<div class=\"graphic\"><div style=\"width: 643px\" class=\"figure\"><div class=\"ttl\">Light exposure timing for eastward travel</div><div class=\"cntnt\"><img style=\"width:623px; height:516px;\" src=\"images/SLEEP/107500_Lght_expsr_tim_east_trvl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship of estimated endogenous circadian rhythm in relation to habitual sleep bout at location of origin (Eastern Standard Time [EST]) and desired sleep bout at destination (Greenwich Mean Time [GMT]). Melatonin and light avoidance/exposure is timed strategically at the destination to produce phase advance such that the endogenous circadian rhythm aligns with local time.</div><div class=\"graphic_footnotes\">DLMO: dim light melatonin onset; CBT<sub>min</sub>: core body temperature minimum.</div><div id=\"graphicVersion\">Graphic 107500 Version 1.0</div></div></div>"},"107502":{"type":"graphic_table","displayName":"Rh haplotype frequencies by ethnicity (United States)","title":"Frequency of Rh haplotype frequencies by ethnicity in a United States population","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of Rh haplotype frequencies by ethnicity in a United States population</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Haplotype</td> <td class=\"subtitle1\">Caucasians</td> <td class=\"subtitle1\">Blacks</td> <td class=\"subtitle1\">Native Americans</td> <td class=\"subtitle1\">Asian</td> </tr> <tr class=\"centered\"> <td>DCe</td> <td>42%</td> <td>17%</td> <td>44%</td> <td>70%</td> </tr> <tr class=\"centered\"> <td>DcE</td> <td>14%</td> <td>11%</td> <td>34%</td> <td>21%</td> </tr> <tr class=\"centered\"> <td>Dce</td> <td>4%</td> <td>44%</td> <td>2%</td> <td>3%</td> </tr> <tr class=\"centered\"> <td>DCE</td> <td>0%</td> <td>0%</td> <td>6%</td> <td>1%</td> </tr> <tr class=\"centered\"> <td>Ce</td> <td>2%</td> <td>2%</td> <td>2%</td> <td>2%</td> </tr> <tr class=\"centered\"> <td>cE</td> <td>1%</td> <td>0%</td> <td>6%</td> <td>0%</td> </tr> <tr class=\"centered\"> <td>ce</td> <td>37%</td> <td>26%</td> <td>6%</td> <td>3%</td> </tr> <tr class=\"centered\"> <td>CE</td> <td>0%</td> <td>0%</td> <td>0%</td> <td>0%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Reid ME, Lomas-Francis C. The Blood Group Antigen FactsBook, 2nd ed, Academic Press: Elsevier, 2003. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107502 Version 1.0</div></div></div>"},"107503":{"type":"graphic_picture","displayName":"Paravertebral block ultrasound probe placement","title":"Paravertebral block ultrasound probe placement","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Paravertebral block ultrasound probe placement</div><div class=\"cntnt\"><img style=\"width:714px; height:535px;\" src=\"images/ANEST/107503_Prvrvrl_blck_ultrs_prb_plc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For thoracic paravertebral block, the patient may be positioned prone, with one arm hanging over the side of the bed. The probe is placed approximately 2 cm lateral to the midline at the chosen spinal level, and is rotated to achieve the optimal ultrasound image.</div><div id=\"graphicVersion\">Graphic 107503 Version 1.0</div></div></div>"},"107505":{"type":"graphic_figure","displayName":"CLC-5 in proximal tubular cells and endosomes","title":"CLC-5 in proximal tubular cells and trafficking of endosomal membranes","html":"<div class=\"graphic\"><div style=\"width: 980px\" class=\"figure\"><div class=\"ttl\">CLC-5 in proximal tubular cells and trafficking of endosomal membranes</div><div class=\"cntnt\"><img style=\"width:960px; height:428px;\" src=\"images/NEPH/107505_CLC5_prox_tublr_cell_endsms.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>CLC-5 in proximal tubular cells, and trafficking of endosomal membranes. In proximal tubular epithelial cells, CLC-5 is expressed in subapical endosomes in which the V-type H<sup>+</sup>-ATPase is responsible for electrogenic transport of protons into the endosomal lumen. Filtered proteins bind to receptors such as megalin at the luminal surface of the cell, from which endosomes bud off. Acidification of the endosomal lumen is required for proteins to be freed from the receptor for subsequent lysosomal degradation and return of small peptides and amino acids to the bloodstream. Megalin and other receptor proteins are recycled back to the apical surface.</li>&#xD;&#xA;    <li>CLC-5 facilitates endosomal acidification by acting as a Cl<sup>&ndash;</sup>/H<sup>+</sup> exchanger. In the presence of an active H<sup>+</sup>-ATPase (left panel), the proton gradient would drive exit of H<sup>+</sup> coupled with entry of Cl<sup>&ndash;</sup>, and this would effectively dissipate the interior positive charge. In the nascent endosome (right panel), an initially high luminal Cl<sup>&ndash;</sup> concentration would drive exit of Cl<sup>&ndash;</sup> coupled with entry of H<sup>+</sup> and thereby achieve acidification in the absence of a proton pump, assuming a mechanism to shunt the inside-positive charge generated by the antiporter.</li>&#xD;&#xA;</ul></div><div id=\"graphicVersion\">Graphic 107505 Version 1.0</div></div></div>"},"107524":{"type":"graphic_table","displayName":"Differences in traditional medical consultation and comanagement","title":"Differences between traditional medical consultation and comanagement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differences between traditional medical consultation and comanagement</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Traditional medical consultation</td> <td class=\"subtitle1\">Comanagement</td> </tr> <tr> <td><strong>Relationship between comanaging physician and surgeon</strong></td> <td><em>Ad hoc</em>, informal</td> <td>Formal, previously negotiated</td> </tr> <tr> <td><strong>Patient selection process</strong></td> <td>Only through referral by surgeon</td> <td>Predetermined selection criteria</td> </tr> <tr> <td><strong>Comanaging physician's focus</strong></td> <td>Confined to issues identified by surgeon</td> <td>Comanaging physician's discretion or based on previously negotiated agreement</td> </tr> <tr> <td><strong>Comanaging physician's scope of practice</strong></td> <td>Makes recommendations; limited order writing privileges</td> <td>Broad scope of practice; can write most orders</td> </tr> <tr> <td><strong>Communication protocols</strong></td> <td>All communication routed through surgeon</td> <td>Comanaging physician may directly communicate with patient and other providers</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Hugo Cheng, MD and Kevin Bozic, MD, MBA.</div><div id=\"graphicVersion\">Graphic 107524 Version 1.0</div></div></div>"},"107527":{"type":"graphic_table","displayName":"Possible contraindications to anticoagulation","title":"Possible contraindications to anticoagulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible contraindications to anticoagulation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Possible contraindication</td> <td class=\"subtitle1\">Factors to consider</td> </tr> <tr> <td>Active, clinically significant bleeding</td> <td>Site and degree of bleeding (eg, nosebleeds and menses generally are not a contraindication; active intracerebral bleeding is almost always an absolute&nbsp;contraindication); interval since bleeding stopped<br /> </td> </tr> <tr> <td>Severe bleeding diathesis</td> <td>Nature, severity, and reversibility&nbsp;of bleeding diathesis</td> </tr> <tr> <td>Severe thrombocytopenia (platelet count &#60;50,000/microL)</td> <td>Absolute platelet count, platelet count trend,&nbsp;and platelet function (eg, some individuals with ITP and a platelet count in the range of 30,000 to 50,000 may tolerate anticoagulation if needed)<br /> </td> </tr> <tr> <td>Major trauma&nbsp;</td> <td>Site and extent of trauma, time interval since event&nbsp;(eg, for a patient with a mechanical heart valve it may be appropriate to anticoagulate sooner after trauma than a patient with a lesser indication)</td> </tr> <tr> <td>Invasive procedure or obstetric delivery (recent, emergent, or planned)&nbsp;</td> <td>Type of procedure and associated bleeding risk, interval between procedure and anticoagulation</td> </tr> <tr> <td>Previous intracranial hemorrhage</td> <td>Time interval since hemorrhage and underlying cause (eg, trauma or uncontrolled hypertension)</td> </tr> <tr> <td>Intracranial or spinal tumor&nbsp;</td> <td>Site and type of tumor, other comorbidities</td> </tr> <tr> <td>Neuraxial anesthesia&nbsp;</td> <td>Interval since spinal/epidural puncture or catheter removal,&nbsp;other alternatives for anesthesia. Traumatic procedures are more concerning.</td> </tr> <tr> <td>Severe, uncontrolled hypertension&nbsp;</td> <td>Absolute blood pressure and blood pressure trend</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This list does not take the place of clinical judgment in deciding whether or not&nbsp;to administer an anticoagulant. In any patient, the risk of bleeding from an anticoagulant must be weighed against the risk of thrombosis and its consequences. The greater the thromboembolic risk, the greater the tolerance for the possibility of bleeding and for shortening the time interval between an episode of bleeding and anticoagulant initiation. Refer to UpToDate topics on the specific indication for the anticoagulant and the specific possible contraindication for discussions of these risks.</div><div class=\"graphic_footnotes\">ITP: immune thrombocytopenia. </div><div id=\"graphicVersion\">Graphic 107527 Version 2.0</div></div></div>"},"107528":{"type":"graphic_figure","displayName":"Estimation of parathyroid gland weight","title":"Estimation of parathyroid gland weight","html":"<div class=\"graphic\"><div style=\"width: 717px\" class=\"figure\"><div class=\"ttl\">Estimation of parathyroid gland weight</div><div class=\"cntnt\"><img style=\"width:697px; height:499px;\" src=\"images/SURG/107528_Estmt_prthyrd_glnd_wght.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The weight of a parathyroid gland in milligrams is approximately the same as its volume in cubic millimeters calculated as a prolate ellipsoid. Measurements are demonstrated on an excised parathyroid but can also be performed in situ.</div><div class=\"graphic_reference\">Courtesy of Mira Milas, MD.</div><div id=\"graphicVersion\">Graphic 107528 Version 1.0</div></div></div>"},"107529":{"type":"graphic_figure","displayName":"Parathyroidectomy techniques for ESRD patients","title":"Parathyroidectomy techniques for ESRD patients","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Parathyroidectomy techniques for ESRD patients</div><div class=\"cntnt\"><img style=\"width:730px; height:510px;\" src=\"images/SURG/107529_Parathyroidectomy_tech_ESRD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Commonly used surgical techniques for treating hyperparathyroidism in ESRD patients include subtotal/near-total parathyroidectomy and total parathyroidectomy with or without autotransplantation. The choice of techniques is dictated by whether or not the patient is a candidate for a renal transplant. Whenever feasible, a thymectomy and parathyroid tissue cryopreservation should be performed with the primary procedure.</div><div class=\"graphic_footnotes\">ESRD: end-stage renal disease.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography © 2016. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 107529 Version 1.0</div></div></div>"},"107531":{"type":"graphic_picture","displayName":"Parathyroid tissue processing for cryopreservation","title":"Parathyroid tissue processing for cryopreservation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parathyroid tissue processing for cryopreservation</div><div class=\"cntnt\"><img style=\"width:354px; height:764px;\" src=\"images/SURG/107531_Prthyrd_tiss_prcsg_cryopres.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the operating room, the parathyroid tissue to be cryopreserved is cut into 30 to 40 pieces of 2 × 2 mm with a scalpel (panel A). The fragments are suspended in ice-chilled saline solution (panel B) and drawn up in 1-mL tuberculin syringes (panel C), which are capped and labeled to identify the patient. The samples are then further processed in the laboratory before they are cryopreserved in the freezing media.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography © 2016. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 107531 Version 1.0</div></div></div>"},"107532":{"type":"graphic_picture","displayName":"Parathyroid autotransplantation to forearm muscle","title":"Parathyroid autotransplantation to forearm muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parathyroid autotransplantation to forearm muscle</div><div class=\"cntnt\"><img style=\"width:306px; height:733px;\" src=\"images/SURG/107532_Parathyrd_autotranspln_mscl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Parathyroid fragments on tip of scalpel to be inserted into muscle pocket held open by fine dissecting clamps.<br />(B) Placement of graft into brachioradialis muscle in nondominant forearm, preferably without dialysis graft in the vicinity.<br />(C) In a different patient, example of enlarged autograft (arrow) prior to excision for recurrent secondary hyperparathyroidism.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography © 2016. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 107532 Version 1.0</div></div></div>"},"107533":{"type":"graphic_picture","displayName":"Basic instruments for parathyroidectomy","title":"Basic instruments for parathyroidectomy","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Basic instruments for parathyroidectomy</div><div class=\"cntnt\"><img style=\"width:508px; height:378px;\" src=\"images/SURG/107533_Bsc_instrmnt_prthrdc.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mira Milas, MD.</div><div id=\"graphicVersion\">Graphic 107533 Version 1.0</div></div></div>"},"107534":{"type":"graphic_table","displayName":"Genetic risk evaluation for breast and/or ovarian cancer","title":"Criteria for genetic risk evaluation and possible testing for breast and/or ovarian cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for genetic risk evaluation and possible testing for breast and/or ovarian cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>A. An individual with breast cancer (including invasive and ductal carcinoma) with any of the following:</strong> <ul class=\"decimal_heading\"> <li>A known mutation in the family of a gene that increases cancer susceptibility </li> <li>Breast cancer diagnosed &#8804;50 years </li> <li>Triple-negative breast cancer diagnosed &#8804;60 years </li> <li>Two breast cancers* (in a single patient) </li> <li>Breast cancer diagnosed at any age, in addition to one of the following: <ul> <li>&#8805;1 close blood relative<sup>&#182;</sup> with breast cancer diagnosed &#8804;50 years, or </li> <li>&#8805;1 close blood relative<sup>&#182;</sup> with ovarian, fallopian tube, or primary peritoneal cancer diagnosed at any age, or </li> <li>&#8805;2 close blood relatives<sup>&#182;</sup> with breast , pancreatic, and/or prostate cancer (Gleason score &#8805;7) diagnosed at any age, or </li> <li>From a population at increased risk<sup>&#916;</sup> </li> </ul> </li> <li>Male gender </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>B. A patient of Ashkenazi Jewish descent with breast, ovarian, or pancreatic cancer diagnosed at any age</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>C. Personal and/or family history of three or more of the following:</strong> <ul class=\"decimal_heading\"> <li>Breast, pancreatic, prostate (Gleason score &#8805;7), diffuse gastric<sup>&#9674;</sup>, colon, endometrial, thyroid, or kidney cancer, melanoma, sarcoma, adrenocortical carcinoma, brain tumors, or leukemia, particularly early onset (and can include multiple primary cancers in the same individual) and/or </li> <li>Dermatologic manifestations consistent with Cowden syndrome (refer to UpToDate topics on PTEN hamartoma tumor syndrome, including Cowden syndrome)<sup>&#167;</sup> and/or </li> <li>Macrocephaly, hamartomatous polyps of gastrointestinal (GI) tract<sup>&#167;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>D. Personal history of ovarian cancer</strong></td> </tr> <tr> <td><strong>E. An individual with no personal history of cancer but with:</strong> <ul class=\"decimal_heading\"> <li>A close relative with any of the following:<sup>&#182;</sup><sup>&#916;</sup> <ul> <li>A known mutation within the family of a gene that increases susceptibility to cancer </li> <li>&#8805;2 breast cancers in a single individual </li> <li>&#8805;2 individuals with breast cancers on the same side of family with at least one diagnosed &#8804;50 years </li> <li>Ovarian cancer </li> <li>Male breast cancer </li> </ul> </li> <li>First- or second-degree relative with breast cancer diagnosed &#8804;45 years </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Two breast cancers indicates either bilateral disease or at least two separate ipsilateral primary tumors (that may have occurred at the same time or at different times).<br />&para; Close blood relatives are first-, second-, and third-degree relatives on the same side of the family. Maternal and paternal sides should be considered independently.<br />&Delta; For populations with founder mutations, requirements for inclusion may be modified.<br /><span class=\"lozenge\">&loz;</span> For lobular breast cancer with a family history of diffuse gastric cancer, <em>CDH1</em> gene testing may be informative.<br />&sect; For hamartomatous colon polyps in conjunction with breast cancer and hyperpigmented macules of the lips and oral mucosa, <em>STK11</em> testing may be informative. Refer to UpToDate topics on Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis.</div><div class=\"graphic_reference\">National Comprehensive Cancer Network, v2.2016 (<a href=\"http://www.nccn.org/\" target=\"_blank\">www.nccn.org</a>).</div><div id=\"graphicVersion\">Graphic 107534 Version 2.0</div></div></div>"},"107536":{"type":"graphic_table","displayName":"Types of CAH with atypical genitalia","title":"Characteristics of different forms of congenital adrenal hyperplasia that may present with atypical genitalia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of different forms of congenital adrenal hyperplasia that may present with atypical genitalia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">21-hydroxylase deficiency</td> <td class=\"subtitle1\">11-beta-hydroxylase deficiency</td> <td class=\"subtitle1\">P450 oxidoreductase deficiency</td> <td class=\"subtitle1\">3-beta-hydroxysteroid dehydrogenase deficiency</td> <td class=\"subtitle1\">17-alpha-hydroxylase deficiency</td> <td class=\"subtitle1\">Lipoid hyperplasia</td> </tr> <tr class=\"divider_bottom\"> <td>Defective gene</td> <td>CYP21A2 (P450c21)</td> <td>CYP11B1 (P450c11)</td> <td>Co-factor for enzymes CYP17A1, CYP21A2 and CYP19A1 (aromatase)</td> <td>HSD3B2 (3-Beta-HSD)</td> <td>CYP17 (P450c17)</td> <td>StAR (steroid acute regulatory protein)</td> </tr> <tr> <td colspan=\"7\">Atypical genitalia</td> </tr> <tr> <td class=\"indent1\">46,XX (virilization)</td> <td>+</td> <td>+</td> <td>+</td> <td>+ (mild or absent)</td> <td>Typical female genitalia, but no puberty</td> <td>Typical female genitalia, but no puberty</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">46,XY (undervirilization)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>+ (typical female external genitalia)</td> </tr> <tr class=\"divider_bottom\"> <td>Adrenal crisis</td> <td>+</td> <td>Rare</td> <td>+</td> <td>+</td> <td>No</td> <td>+</td> </tr> <tr class=\"divider_bottom\"> <td>Incidence (general population)</td> <td>1:11,000 &ndash; 23,000</td> <td>1:100,000</td> <td>Very rare</td> <td>Rare</td> <td>Rare</td> <td>Very rare</td> </tr> <tr> <td>Elevated steroid metabolites</td> <td>17-OHP</td> <td>DOC; 11-deoxycortisol</td> <td>Urinary metabolites of 17-OHP, progesterone, and pregnenolone&nbsp;</td> <td>DHEA, 17&#916;5Preg</td> <td>DOC; corticosterone</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">17-OHP: 17-hydroxyprogesterone; DOC: deoxycorticosterone; DHEA: dehydroepiandrosterone; 17&Delta;5Preg: 17-delta-5-hydroxypregnenolone.</div><div id=\"graphicVersion\">Graphic 107536 Version 2.0</div></div></div>"},"107541":{"type":"graphic_table","displayName":"Anticoagulant agent selection","title":"Factors that influence agent selection for anticoagulation in patients with acute venous thromboembolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that influence agent selection for anticoagulation in patients with acute venous thromboembolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factor</td> <td class=\"subtitle1\">Preferred anticoagulant</td> <td class=\"subtitle1\">Qualifying remarks</td> </tr> <tr class=\"divider_bottom\"> <td>Cancer</td> <td>LMWH</td> <td>More so if: Just diagnosed, extensive VTE, metastatic cancer, very symptomatic; vomiting; on cancer chemotherapy.</td> </tr> <tr class=\"divider_bottom\"> <td>Parenteral therapy to be avoided</td> <td>Rivaroxaban; apixaban</td> <td>VKA, dabigatran, and edoxaban require initial parenteral therapy.</td> </tr> <tr class=\"divider_bottom\"> <td>Once daily oral therapy preferred</td> <td>Rivaroxaban; edoxaban; VKA</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Liver disease and coagulopathy</td> <td>LMWH</td> <td>DOAs contraindicated if INR raised because of liver disease; VKA difficult to control and INR may not reflect antithrombotic effect.</td> </tr> <tr class=\"divider_bottom\"> <td>Renal disease and creatinine clearance &#60;30 mL/min</td> <td>VKA</td> <td>DOAs and LMWH contraindicated with severe renal impairment. Dosing of DOAs with levels of renal impairment differ with the DOA and among jurisdictions.</td> </tr> <tr class=\"divider_bottom\"> <td>Coronary artery disease</td> <td>VKA, rivaroxaban, apixaban, edoxaban</td> <td>Coronary artery events appear to occur more often with dabigatran than with VKA. This has not been seen with the other DOAs, and they have demonstrated efficacy for coronary artery disease. Antiplatelet therapy should be avoided if possible in patients on anticoagulants because of increased bleeding.</td> </tr> <tr class=\"divider_bottom\"> <td>Dyspepsia or history of GI bleeding</td> <td>VKA, apixaban</td> <td>Dabigatran increased dyspepsia. Dabigatran, rivaroxaban, and edoxaban may be associated with more GI bleeding than VKA.</td> </tr> <tr class=\"divider_bottom\"> <td>Poor compliance</td> <td>VKA</td> <td>INR monitoring can help to detect problems. However, some patients may be more compliant with a DOA because it is less complex.</td> </tr> <tr class=\"divider_bottom\"> <td>Thrombolytic therapy use</td> <td>UFH infusion</td> <td>Greater experience with its use in patients treated with thrombolytic therapy.</td> </tr> <tr class=\"divider_bottom\"> <td>Reversal agent needed</td> <td>VKA, UFH, dabigatran</td> <td>Reversal agents for dabigatran may not be universally readily available.</td> </tr> <tr class=\"divider_bottom\"> <td>Pregnancy or pregnancy risk</td> <td>LMWH</td> <td>Potential for other agents to cross the placenta.</td> </tr> <tr> <td>Cost, coverage, licensing</td> <td>Varies among regions and with individual circumstances</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LMWH: low molecular weight heparin; VTE: venous thromboembolism; VKA: vitamin K-dependent antagonist; DOAs: direct oral anticoagulants; INR: international normalized ratio; GI: gastrointestinal; UFH: unfractionated heparin.</div><div class=\"graphic_reference\">Original figure modified for this publication. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149:315. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107541 Version 2.0</div></div></div>"},"107542":{"type":"graphic_table","displayName":"Risk of VTE recurrence","title":"Rate of venous thromboembolism (VTE) recurrence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rate of venous thromboembolism (VTE) recurrence</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">VTE type</td> <td class=\"subtitle1\">First year</td> <td class=\"subtitle1\">Annual rate after first year</td> </tr> <tr> <td>First episode of unprovoked VTE</td> <td>10 percent</td> <td>5 percent</td> </tr> <tr> <td>Second episode of unprovoked VTE</td> <td>15 percent</td> <td>7.5 percent</td> </tr> <tr> <td>First VTE provoked by surgery</td> <td>1 percent</td> <td>0.5 percent</td> </tr> <tr> <td>First VTE provoked by non-surgical factor</td> <td>5 percent</td> <td>2.5 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.</div><div id=\"graphicVersion\">Graphic 107542 Version 1.0</div></div></div>"},"107543":{"type":"graphic_table","displayName":"Bleeding risk with anticoagulation in VTE","title":"Rate of bleeding stratified by risk in patients with venous thromboembolism (VTE) on anticoagulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rate of bleeding stratified by risk in patients with venous thromboembolism (VTE) on anticoagulation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Bleeding risk</td> <td class=\"subtitle1\">First 3 months</td> <td class=\"subtitle1\">Annual rate after first 3 months</td> </tr> <tr> <td>Low risk (no risk factors present)</td> <td>1.6 percent</td> <td>0.8 percent</td> </tr> <tr> <td>Intermediate risk (one risk factor present)</td> <td>3.2 percent</td> <td>1.3 percent</td> </tr> <tr> <td>High risk (two or more risk factors present)</td> <td>12.8 percent</td> <td>&#8805;6.5 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.</div><div id=\"graphicVersion\">Graphic 107543 Version 1.0</div></div></div>"},"107545":{"type":"graphic_picture","displayName":"Oximetry probes","title":"Types of pulse oximetry probes","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Types of pulse oximetry probes</div><div class=\"cntnt\"><img style=\"width:764px; height:250px;\" src=\"images/PULM/107545_Oximetry_probes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Graphic showing several types of oximetry probes; shown from left to right are a (A) finger, (B) ear lobe, and (C) forehead probe.</div><div class=\"graphic_reference\">Courtesy of Nonin Medical, Inc. Reproduced with permission. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 107545 Version 1.0</div></div></div>"},"107546":{"type":"graphic_table","displayName":"Causes and trouble shooting erroneous pulse oximetry readings","title":"Causes and trouble shooting erroneous pulse oximetry readings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes and trouble shooting erroneous pulse oximetry readings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Problem and potential errors</td> <td class=\"subtitle1\">Solution</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Inadequate waveform</td> </tr> <tr> <td class=\"indent1\">Malposition of probe</td> <td>Reposition probe, alternate site</td> </tr> <tr> <td class=\"indent1\">Motion artifact</td> <td>Reposition probe, alternate site</td> </tr> <tr> <td class=\"indent1\">Hypoperfusion</td> <td>Reposition probe, alternate site, warming</td> </tr> <tr> <td class=\"indent1\">Hypothermia</td> <td>Use ear or forehead probe, warming</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Skin pigment</td> <td>Measure arterial blood gas</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Falsely normal or elevated oximetry reading</td> </tr> <tr> <td class=\"indent1\">Carboxyhemoglobin (eg, carbon monoxide poisoning)</td> <td>Co-oximetry</td> </tr> <tr> <td class=\"indent1\">High levels of glycohemoglobin A1c</td> <td>Measure arterial blood gas</td> </tr> <tr> <td class=\"indent1\">Methemoglobin, sulfhemoglobin*</td> <td>Multiwavelength co-oximetry (metHb); biochemical analysis (sulfHb)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ambient light</td> <td>Remove ambient light source</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Falsely low oximetry reading</td> </tr> <tr> <td class=\"indent1\">Inadequate waveform</td> <td>Reposition probe, alternate site</td> </tr> <tr> <td class=\"indent1\">Methemoglobin*</td> <td>Multiwavelength co-oximetry</td> </tr> <tr> <td class=\"indent1\">Sulfhemoglobin*</td> <td>Biochemical analysis</td> </tr> <tr> <td class=\"indent1\">Sickle hemoglobin and inherited forms of abnormal hemoglobin</td> <td>Measure HbS and abnormal Hb levels</td> </tr> <tr> <td class=\"indent1\">Severe anemia</td> <td>Measure arterial blood gas</td> </tr> <tr> <td class=\"indent1\">Venous pulsations or congestion</td> <td>Loosen probe, reposition patient or probe, measure arterial blood gas</td> </tr> <tr> <td class=\"indent1\">Skin pigment</td> <td>Measure arterial blood gas</td> </tr> <tr> <td class=\"indent1\">Ambient light</td> <td>Remove ambient light source</td> </tr> <tr> <td class=\"indent1\">Nail polish</td> <td>Remove polish or change site</td> </tr> <tr> <td class=\"indent1\">Vital dyes</td> <td>Usually transient, measure arterial blood gas</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In these conditions, peripheral arterial oxygen saturation (SpO<SUB>2</SUB>) is low; when levels of methemoglobin (MetHb) or sulfhemoglobin (SulfHb) are mildly elevated, SpO<SUB>2</SUB> underestimates the true arterial oxygen saturation (SaO<SUB>2</SUB>) but when levels are high, the SpO<SUB>2</SUB> automatically trends towards 85 percent such that pulse oximetry can overestimate SaO<SUB>2</SUB>.</div><div class=\"graphic_reference\">Adapted from: Chan ED, Chan MM, Chan MM. Pulse oximetry: understanding its basic principles facilitates appreciation of its limitations. Respir Med 2013; 107:789.</div><div id=\"graphicVersion\">Graphic 107546 Version 1.0</div></div></div>"},"107547":{"type":"graphic_figure","displayName":"Pulse oximeter waveform","title":"Pulse oximeter waveform","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Pulse oximeter waveform</div><div class=\"cntnt\"><img style=\"width:466px; height:446px;\" src=\"images/PULM/107547_Pulse_oximeter_waveform.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common pulsatile signals on a pulse oximeter.<br />(A) Normal signal showing the sharp waveform with a clear dicrotic notch.<br />(B) Pulsatile signal during low perfusion showing a typical sine wave.<br />(C) Pulsatile signal with superimposed noise artifact giving a jagged appearance.<br />(D) Pulsatile signal during motion artifact showing an erratic waveform.</div><div class=\"graphic_reference\">From: Jubran A. Pulse oximetry. Crit Care 2015; 19:272. Copyright &copy; Jubran 2015. Reproduced under the terms of the Creative Commons Attribution License (<a href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">CC BY 4.0</a>). Available at: <a href=\"http://ccforum.biomedcentral.com/articles/10.1186/s13054-015-0984-8\" target=\"_blank\">http://ccforum.biomedcentral.com/articles/10.1186/s13054-015-0984-8</a> (Accessed on May 17, 2016).</div><div id=\"graphicVersion\">Graphic 107547 Version 1.0</div></div></div>"},"107549":{"type":"graphic_table","displayName":"Advantages and disadvantages for APACHE-IV, MPM0-III and SAPS 3","title":"Main advantages and disadvantages for the Acute Physiology and Chronic Health Evaluation-IV, MPM0-III and Simplified Acute Physiology Score 3 scores","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Main advantages and disadvantages for the Acute Physiology and Chronic Health Evaluation-IV, MPM0-III and Simplified Acute Physiology Score 3 scores</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Scoring system</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td>APACHE-IV<sup>[1]</sup></td> <td> <ul> <li>Coefficients regularly updated </li> <li>Provides algorithms for LOS prediction </li> <li>Specific algorithm to predict mortality in CABG surgery patients </li> <li>Less prone to be affected by the case-mix </li> </ul> </td> <td> <ul> <li>Developmental sample restricted to one country </li> <li>More complex data collection </li> <li>High abstraction burden </li> <li>Proprietary scoring system* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>MPM<sub>0</sub>-III<sup>[2]</sup></td> <td> <ul> <li>Low abstraction burden </li> <li>Less prone to interobserver variability </li> <li>By using less physiologic data, may be preferred when laboratory resources are constrained </li> </ul> </td> <td> <ul> <li>Developmental sample mostly restricted to one country </li> <li>More susceptible to case-mix effects </li> </ul> </td> </tr> <tr> <td>SAPS 3<sup>[3,4]</sup></td> <td> <ul> <li>Lowest abstraction burden </li> <li>Less prone to interobserver variability </li> <li>Developmental sample from 35 countries in five continents </li> <li>Customized equations to predict hospital mortality according to seven different geographic regions </li> <li>Potential use for international benchmarking </li> </ul> </td> <td> <ul> <li>Does not provide estimation for LOS </li> <li>Some regional equations were developed using relatively low sample size </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">APACHE: acute physiology and chronic health evaluation; LOS: length of stay; CABG: coronary artery bypass graft; MPM: mortality probability model; SAPS: simplified acute physiology score.<br />* Cerner Corporation has made the score algorithms publicly available.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. Crit Care Med 2006; 34:1297.</li>&#xD;&#xA;    <li>Higgins TL, Teres D, Copes WS, et al. Assessing contemporary intensive care unit outcome: an updated Mortality Probability Admission Model (MPM0-III). Crit Care Med 2007; 35:827.</li>&#xD;&#xA;    <li>Moreno RP, Metnitz PGH, Almeida E, et al. SAPS 3&ndash;from evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med 2005; 31:1345.</li>&#xD;&#xA;    <li>Metnitz PGH, Moreno RP, Almeida E, et al. SAPS 3&ndash;from evaluation of the patient to evaluation of the intensive care unit. Part 1: objectives, methods and cohort description. Intensive Care Med 2005; 31:1336.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Salluh JI, Soares M. ICU severity of illness scores: APACHE, SAPS and MPM. Curr Opin Crit Care 2014; 20:557. DOI: <a href=\"http://journals.lww.com/co-criticalcare/pages/articleviewer.aspx?year=2014&amp;issue=10000&amp;article=00015&amp;type=abstract\" target=\"_blank\">10.1097/MCC.0000000000000135</a>. Copyright &copy; 2014. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 107549 Version 1.0</div></div></div>"},"107550":{"type":"graphic_table","displayName":"Guidelines for endoscopic management of a malignant polyp","title":"Guidelines for endoscopic management of a malignant polyp from the American College of Gastroenterology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for endoscopic management of a malignant polyp from the American College of Gastroenterology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Polypectomy alone is adequate treatment for colorectal polyps with early invasive cancer if specific histologic criteria are met:</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>The polyp is considered to be completely excised by the endoscopist and is submitted in toto for pathological examination. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>The polyp is fixed and sectioned so that it is possible to accurately determine the depth of invasion, grade of differentiation, and completeness of excision of the carcinoma. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>The cancer is not poorly differentiated. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>There is no vascular or lymphatic involvement. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>The margin of the excision is not involved. Invasion of the stalk of pedunculated polyp, by itself, is not an unfavorable prognostic finding, as long as the cancer does not extend to the margin of stalk resection. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Not a sessile polyp. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>No extension beyond the submucosa. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Local staging (MRI, ultrasound) reveals no suspicion for deeper invasion or positive lymph nodes. </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>In addition, appropriate patients for endoscopic management of large (&#8805;2 cm) pedunculated polyps include those in whom the concern for invasive cancer is low, and the size and location of the polyp are amenable to endoscopic resection with a relatively low risk of complications. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Bond, JH. Polyp guideline: Diagnosis, treatment and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterology 2000; 95:3053.</div><div id=\"graphicVersion\">Graphic 107550 Version 1.0</div></div></div>"},"107556":{"type":"graphic_algorithm","displayName":"Surgical approaches to groin hernia repair","title":"Choosing a surgical approach (open versus laparoscopic) for groin hernia repair","html":"<div class=\"graphic\"><div style=\"width: 694px\" class=\"figure\"><div class=\"ttl\">Choosing a surgical approach (open versus laparoscopic) for groin hernia repair</div><div class=\"cntnt\"><img style=\"width:674px; height:748px;\" src=\"images/SURG/107556_Surg_appr_groin_hernia_repr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Hernias with active infection or contamination require an open repair without the use of mesh; a tension-free mesh repair is recommended for all other hernias.</div><div id=\"graphicVersion\">Graphic 107556 Version 2.0</div></div></div>"},"107582":{"type":"graphic_figure","displayName":"Aedes distribution worldwide","title":"Global distribution of <em>Aedes aegypti</em> and <em>Aedes albopictus</em>","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">Global distribution of <em>Aedes aegypti</em> and <em>Aedes albopictus</em></div><div class=\"cntnt\"><img style=\"width:792px; height:438px;\" src=\"images/ID/107582_Aedes_distribution_worldwid.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev 2016; 29(3):487-524. DOI: 10.1128/CMR.00072-15. Reproduced with permission from American Society for Microbiology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 107582 Version 1.0</div></div></div>"},"107583":{"type":"graphic_algorithm","displayName":"Risk assessment of ACS in ED","title":"Assessment of low/intermediate-risk acute coronary syndrome in the emergency department","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Assessment of low/intermediate-risk acute coronary syndrome in the emergency department</div><div class=\"cntnt\"><img style=\"width:468px; height:592px;\" src=\"images/CARD/107583_Risk_assessment_ACS_ED.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overview of approach to the management of patients in the emergency department who are felt to be at low or moderate (not high) risk of ACS. This algorithm should be used in conjunction with other content. It does not apply to patients at very low risk of an ACS, such as those with atypical chest pain, stable vital signs, and a normal electrocardiogram.</div><div class=\"graphic_footnotes\">ACS: acute coronary syndrome.<br />* After initial history, physical examination, and electrocardiogram.<br />&para; Recurrent or ongoing angina (chest pain), unstable vital signs, ischemia on repeat electrocardiogram or monitoring.<br />&Delta; Refer to topic for details.<br /><span class=\"lozenge\">&loz;</span> We generally instruct patients to confer with their primary care physician within 48 hours of discharge.</div><div id=\"graphicVersion\">Graphic 107583 Version 1.0</div></div></div>"},"107586":{"type":"graphic_table","displayName":"Diagnostic evaluation for functional impairment","title":"Diagnostic evaluation for functional impairment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic evaluation for functional impairment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Order of assessment</td> <td class=\"subtitle1\">Focus of evaluation</td> <td class=\"subtitle1\">Diagnostic focus</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Characterize the disability</td> <td class=\"divider_bottom\" rowspan=\"5\">Whole person</td> <td> <ul> <li>Time course (eg, insidious versus rapid) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Associated symptoms (eg, associated pain and its location, shortness of breath, fatigue) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Specific activities affected (eg, walking, bathing, toileting) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Compensatory strategies in use (eg, assistive devices, human help, reducing frequency, spiritual/cognitive strategies) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Define severity/extent of disability (eg, physical performance test, self-report ADL/IADL function) </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Identify contributing impairments</td> <td class=\"divider_bottom\" rowspan=\"5\">Organ system</td> <td> <ul> <li>Sensory impairment (eg, vision, tactile, vestibular) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Nutrition (eg, weight change, temporal wasting) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Cardiopulmonary (eg, shortness of breath, chest pain) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Musculoskeletal (eg, strength, flexibility, balance) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Cognitive disorders (eg, dementia, mild cognitive impairment) </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\">Identify underlying conditions</td> <td class=\"divider_bottom\" rowspan=\"8\">Pathophysiology</td> <td> <ul> <li>Mood disorders (eg, depression, delirium) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Neurologic conditions (eg, neuropathy, stroke, parkinsonism) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Musculoskeletal conditions (eg, osteoarthritis, osteoporosis) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Endocrine conditions (eg, thyroid, diabetes) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Eye diseases (eg, cataracts, macular degeneration) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Medication adverse effects (eg, orthostatic hypotension) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Miscellaneous conditions (eg, anemia, frailty/sarcopenia)</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Social support (eg, availability/involvement of caregiver) </li> </ul> </td> </tr> <tr> <td rowspan=\"3\">Identify contextual factors</td> <td rowspan=\"3\">Personal and environmental context</td> <td> <ul> <li>Financial (eg, insurance, veteran benefits, personal finances) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Physical environment (eg, weather, terrain, steps/doorways) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Personal (eg, personality traits, education, attitude, spiritual) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADL: activities of daily living; IADL: instrumental activities of daily living.</div><div class=\"graphic_reference\">Adapted from: Col&oacute;n-Emeric CS, Whitson HE, Pavon J, Hoenig H. Functional decline in older adults. Am Fam Physician 2013; 88:388.</div><div id=\"graphicVersion\">Graphic 107586 Version 1.0</div></div></div>"},"107588":{"type":"graphic_table","displayName":"Strategies for disability intervention","title":"Strategies for disability intervention","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies for disability intervention</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Increase capacity</td> <td class=\"subtitle1\">Reduce demand</td> </tr> <tr class=\"divider_bottom\"> <td>Medication (eg, oxygen, pain medications, medications to improve cardiac function, antidepressants, thyroid medication)</td> <td>Environmental modification (eg, ramp, railings, wide doorways, bathtub bench, high contrast/low glare lighting)</td> </tr> <tr class=\"divider_bottom\"> <td>Surgery (eg, hip replacement, cataract excision)</td> <td>Assistive device (eg, walker, raised toilet seat, bathtub bench, closed-circuit television)</td> </tr> <tr class=\"divider_bottom\"> <td>Nutrition (eg, weight loss, protein/calorie supplementation)</td> <td>Human help (eg, home health aide, caregiver training, assisted living)</td> </tr> <tr class=\"divider_bottom\"> <td>Exercise (eg, increase strength for balance problems, improve biomechanical integrity by increasing strength and flexibility for arthritic problems and overuse syndromes)</td> <td>Adaptive techniques (eg, energy conservation, joint protection, low vision rehabilitative training)</td> </tr> <tr> <td>Prosthetics (eg, artificial limb, hearing aid)</td> <td>Avoidance (eg, changing jobs, assisted living)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Col&oacute;n-Emeric CS, Whitson HE, Pavon J, Hoenig H. Functional decline in older adults. Am Fam Physician 2013; 88:388.</div><div id=\"graphicVersion\">Graphic 107588 Version 2.0</div></div></div>"},"107589":{"type":"graphic_table","displayName":"Rehabilitation components according to condition","title":"Rehabilitation components according to condition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rehabilitation components according to condition</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"12%\"></colgroup><colgroup width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Disciplines</td> <td class=\"subtitle1\" colspan=\"4\">Interventions</td> <td class=\"subtitle1\" rowspan=\"2\">Typical frequency/duration</td> <td class=\"subtitle1\" rowspan=\"2\">Typical location</td> </tr> <tr> <td class=\"subtitle2\">PT</td> <td class=\"subtitle2\">OT</td> <td class=\"subtitle2\">SLP</td> <td class=\"subtitle2\">Other</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Stroke</strong></td> <td> <ul> <li>Strength </li> <li>Range of motion </li> <li>Balance </li> <li>Mobility </li> </ul> </td> <td> <ul> <li>Self-care (assessment, training and equipment needs) </li> <li>Arm/hand function </li> <li>Cognition </li> </ul> </td> <td> <ul> <li>Swallowing </li> <li>Aphasia </li> <li>Cognition </li> </ul> </td> <td> <ul> <li>Nursing </li> <li>Rehabilitation RN </li> <li>Rehabilitation MD </li> <li>Neuropsychology </li> <li>Social work </li> </ul> </td> <td> <ul> <li>3 to 7 days per week (tapered frequency) </li> <li>2 to 12+ weeks </li> </ul> </td> <td> <ul> <li>Intensive care, through acute care, then: <ul> <li>Intense inpatient rehabilitation </li> <li>Skilled nursing home </li> <li>Home health or </li> <li>Outpatient </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Other neurologic</strong><br /> (parkinsonism, MS, TBI)</td> <td> <ul> <li>Strength </li> <li>Range of motion </li> <li>Balance </li> <li>Mobility </li> </ul> </td> <td> <ul> <li>Self-care (assessment, training and equipment needs) </li> <li>Cognition </li> </ul> </td> <td> <ul> <li>Swallowing </li> <li>Aphasia </li> <li>Cognition </li> </ul> </td> <td> <ul> <li>Geriatric MD&nbsp; </li> <li>Rehabilitation MD </li> </ul> </td> <td> <ul> <li>3 to 5 days per week (tapered frequency) </li> <li>2 to 12+ weeks </li> </ul> </td> <td> <ul> <li>Intensive care, through acute care (TBI), then: <ul> <li>Intense inpatient rehab (TBI) </li> <li>Skilled nursing home </li> <li>Home health or </li> <li>Outpatient </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hip fracture</strong></td> <td> <ul> <li>Strength </li> <li>Range of motion </li> <li>Mobility </li> </ul> </td> <td> <ul> <li>Self-care (assessment, training and equipment needs) </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>Nursing </li> <li>Orthopedic MD </li> <li>Social work </li> </ul> </td> <td> <ul> <li>1 to 6 days per week (tapered frequency) </li> <li>2 to 12+ weeks, (mostly PT, little OT) </li> </ul> </td> <td> <ul> <li>Acute care, then: <ul> <li>Intense inpatient rehab </li> <li>Skilled nursing home </li> <li>Home health or </li> <li>Outpatient </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Total joint replacement</strong></td> <td> <ul> <li>Strength </li> <li>Range of motion </li> <li>Mobility </li> </ul> </td> <td> <ul> <li>Self-care (assessment, training and equipment needs) </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>Nursing </li> <li>Orthopedic MD </li> <li>Social work </li> </ul> </td> <td> <ul> <li>1 to 6 days per week (tapered frequency) </li> <li>2 to 12+ weeks, (mostly PT, little OT) </li> </ul> </td> <td> <ul> <li>Acute care, then: <ul> <li>Skilled nursing home </li> <li>Home health or </li> <li>Outpatient </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Frailty and multimorbidity</strong></td> <td> <ul> <li>Strength </li> <li>Endurance </li> <li>Range of motion </li> <li>Balance </li> <li>Mobility </li> </ul> </td> <td> <ul> <li>Self-care (assessment, training and equipment needs) </li> <li>Cognition </li> </ul> </td> <td> <ul> <li>Rarely needed </li> </ul> </td> <td> <ul> <li>Nursing </li> <li>Geriatric MD </li> <li>Social work </li> </ul> </td> <td> <ul> <li>1 to 3 days per week </li> <li>1 to 6+ weeks </li> </ul> </td> <td> <ul> <li>Skilled nursing home </li> <li>Home health or </li> <li>Outpatient </li> </ul> </td> </tr> <tr> <td><strong>Musculoskeletal</strong><br /> (&#8805;1 joint)</td> <td> <ul> <li>Strength </li> <li>Range of motion </li> <li>Soft tissue </li> <li>Pain control </li> </ul> </td> <td> <ul> <li>Self-care (assessment, training and equipment needs) </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>Geriatric MD </li> <li>Orthopedic MD </li> <li>Rehabilitation MD </li> </ul> </td> <td> <ul> <li>2 to 12+ visits </li> <li>1 to 6 weeks </li> </ul> </td> <td> <ul> <li>Home health or </li> <li>Outpatient </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PT: physical therapy; OT: occupational therapy; SLP: speech-language pathology; RN: registered nurse; MD: medical doctor; MS: multiple sclerosis; TBI: traumatic brain injury.</div><div class=\"graphic_reference\">Courtesy of Helen Hoenig, MD, MPH and Cathleen Colón-Emeric, MD.</div><div id=\"graphicVersion\">Graphic 107589 Version 2.0</div></div></div>"},"107594":{"type":"graphic_table","displayName":"Risk engines for prediction of CVD in patients with diabetes","title":"Risk engines for prediction of atherosclerotic cardiovascular disease (CVD) events in patients with type 1 and 2 diabetes mellitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk engines for prediction of atherosclerotic cardiovascular disease (CVD) events in patients with type 1 and 2 diabetes mellitus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk engine</td> <td class=\"subtitle1\">Patients</td> <td class=\"subtitle1\">Variables</td> </tr> <tr class=\"divider_bottom\"> <td><strong>UKPDS</strong></td> <td>Type 2 diabetes</td> <td> <ul> <li>Age at diagnosis of diabetes </li> <li>Sex </li> <li>Afro-Caribbean ethnicity </li> <li>Smoking </li> <li>HbA1c </li> <li>Systolic blood pressure </li> <li>Total cholesterol/HDL cholesterol ratio </li> <li>Diabetes duration </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Swedish NDR</strong></td> <td>Type 1 diabetes</td> <td> <ul> <li>Age at diagnosis of diabetes </li> <li>Smoking </li> <li>HbA1c </li> <li>Systolic blood pressure </li> <li>Total cholesterol/HDL cholesterol ratio </li> <li>Diabetes duration </li> <li>Macroalbuminuria </li> <li>Previous cardiovascular disease </li> </ul> </td> </tr> <tr> <td><strong>Steno Risk Engine</strong></td> <td>Type 1 diabetes</td> <td> <ul> <li>Age </li> <li>Sex </li> <li>Smoking </li> <li>HbA1c </li> <li>Systolic blood pressure </li> <li>LDL cholesterol </li> <li>Diabetes duration </li> <li>Albuminuria </li> <li>Glomerular filtration rate </li> <li>Exercise </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HDL: high density lipoprotein; LDL: low density lipoprotein; NDR: national diabetes registry; UKPDS: UK Prospective Diabetes Study.</div><div id=\"graphicVersion\">Graphic 107594 Version 1.0</div></div></div>"},"107597":{"type":"graphic_algorithm","displayName":"Unanticipated difficult airway cesarean delivery algorithm","title":"Unanticipated difficult airway cesarean delivery algorithm","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Unanticipated difficult airway cesarean delivery algorithm</div><div class=\"cntnt\"><img style=\"width:544px; height:492px;\" src=\"images/ANEST/107597_Unant_diff_arwy_cesarean_RO.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For further details refer to UpToDate topic on airway management&nbsp;of the pregnant patient at delivery.&nbsp;</div><div class=\"graphic_footnotes\">SGA: supraglottic airway FSI: flexible scope intubation.<br />* Change technique: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Optimize head position</LI>&#xD;&#xA;<LI>Different laryngoscope blade</LI>&#xD;&#xA;<LI>Alternate technique (eg, video laryngoscope, light wand, bougie)</LI>&#xD;&#xA;<LI>More experienced clinician</LI></UL>¶ Repeated attempts at laryngoscopy may result in difficult mask ventilation.<br />Δ Consider SGA placement.<br /><FONT class=lozenge>◊</FONT> Invasive airway techniques include surgical tracheotomy, cricothyrotomy, retrograde intubation, and transtracheal ventilation.<br />§ Examples of unstable maternal condition: Maternal hemorrhage, cardiac arrest, amniotic fluid embolism.<br />¥ Refer to UpToDate content on Anticipated difficult airway for cesarean delivery.</div><div id=\"graphicVersion\">Graphic 107597 Version 2.0</div></div></div>"},"107598":{"type":"graphic_algorithm","displayName":"Anticipated difficult airway cesarean delivery algorithm","title":"Anticipated difficult airway cesarean delivery algorithm","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Anticipated difficult airway cesarean delivery algorithm</div><div class=\"cntnt\"><img style=\"width:468px; height:294px;\" src=\"images/ANEST/107598_Antic_diff_arwy_cesarean_RO.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For further details, refer to the UpToDate topic on airway management of the pregnant patient at delivery.</div><div class=\"graphic_footnotes\">CSE: combined spinal–epidural; SGA: supraglottic airway; ILMA: intubating laryngeal mask airway.<br />* Awake intubation requires patient cooperation, an experienced clinician, and available equipment, and may not be possible in emergent situations because it takes time.<br />¶ Flexible scope intubation, less commonly videolaryngoscopy, SGA, ILMA, lighted stylet, retrograde intubation.<br />Δ Tracheotomy, retrograde wire intubation, cricothyrotomy.</div><div id=\"graphicVersion\">Graphic 107598 Version 1.0</div></div></div>"},"107599":{"type":"graphic_table","displayName":"Intraoperative autonomic dysreflexia - Rapid overview","title":"Intraoperative autonomic dysreflexia: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intraoperative autonomic dysreflexia: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Risk factors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Spinal cord injury above T6 </li> <li>History of AD </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Clinical signs and symptoms*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Sudden hypertension; systolic blood pressure may be &#62;200 mmHg </li> <li>Dysrhythmias: Bradycardia, tachycardia, heart block, sinus arrest all possible </li> <li>Vasoconstriction below spinal lesion, vasodilation above the lesion </li> <li>Facial flushing </li> <li>Headache, in awake patients </li> <li>Nasal congestion, in awake patients </li> <li>Acute left heart failure </li> <li>Myocardial infarction </li> <li>Intracranial hemorrhage </li> <li>Seizures </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Remove inciting stimulus <ul> <li>Stop surgery </li> <li>Empty bladder </li> <li>Look for distention of viscus </li> </ul> </li> <li>Deepen anesthesia if under general anesthesia <ul> <li>Administer propofol bolus </li> <li>Increase inhalation agent </li> </ul> </li> <li>Position head-up to take advantage of orthostatic blood pressure drop </li> <li>Administer 100% oxygen </li> <li>Administer short-acting vasodilator: <ul> <li>Nicardipine bolus (0.2 to 0.5 mg IV) and infusion (2.5 to 25 mg/hour IV, titrated to effect), or </li> <li>Nitroglycerin infusion (5 to 500 mcg/minute IV)<sup>&#182;</sup>, or </li> <li>For severe hypertension, nitroprusside infusion<sup>&#182;</sup> (0.2 to 10 mcg/kg/minute IV) </li> </ul> </li> <li>If longer-acting vasodilator is required<sup>&#916;</sup> <ul> <li>Hydralazine (5 mg IV every 10 minutes titrated to effect, up to 20 mg total dose) </li> <li>Labetolol (5 mg IV every 5 minutes titrated to effect, up to 25 mg total dose)<sup>&#9674;</sup> </li> </ul> </li> <li>Treat arrhythmias as necessary </li> <li>Treat myocardial ischemia (ie, ST changes on electrocardiogram) as necessary </li> <li>Place intraarterial catheter for blood pressure monitoring if resolution does not occur quickly </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: autonomic dysreflexia; IV: intravenous.<br />* Not all signs and symptoms occur in each patient. Severity of signs and symptoms may vary, and depend on success of treatment and underlying comorbidities.<br />¶ Hypotensive effect of nitrates may be exaggerated in patients using sildenafil for erectile dysfunction.<br />Δ When longer-acting vasodilators/beta blockers are administered, hypotension is possible after AD episode resolves.<br />◊ Beta blockers can exacerbate AD-related bradycardia.</div><div id=\"graphicVersion\">Graphic 107599 Version 1.0</div></div></div>"},"107600":{"type":"graphic_figure","displayName":"SEER new cases, deaths, and survival","title":"SEER: New cases, deaths, and 5-year relative survival","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">SEER: New cases, deaths, and 5-year relative survival</div><div class=\"cntnt\"><img style=\"width:715px; height:328px;\" src=\"images/ENDO/107600_SEER_nw_css_dth_srvvl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">SEER 9 incidence and United States mortality from 1975 to 2012, all races, both sexes. Rates are age-adjusted.</div><div class=\"graphic_footnotes\">SEER: Surveillance, Epidemiology, and End Results.</div><div class=\"graphic_reference\">Reproduced from: SEER Cancer Statistics Factsheets: Thyroid Cancer. National Cancer Institute, Bethesda, MD. Available at: <a href=\"http://seer.cancer.gov/statfacts/html/thyro.html\" spellcheck=\"true\" target=\"_blank\">http://seer.cancer.gov/statfacts/html/thyro.html</a> (Accessed on April 4, 2016).</div><div id=\"graphicVersion\">Graphic 107600 Version 1.0</div></div></div>"},"107601":{"type":"graphic_figure","displayName":"SEER data thyroid cancer by race and sex","title":"SEER observed incidence, SEER delay adjusted incidence, and United States death rates*: Cancers of the thyroid, by race and sex","html":"<div class=\"graphic\"><div style=\"width: 767px\" class=\"figure\"><div class=\"ttl\">SEER observed incidence, SEER delay adjusted incidence, and United States death rates*: Cancers of the thyroid, by race and sex</div><div class=\"cntnt\"><img style=\"width:747px; height:456px;\" src=\"images/ENDO/107601_SEER_dt_thrd_cncr_rc_sex.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Regression lines and APCs are calculated using the Joinpoint Regression Program version 4.1.0, April 2014, National Cancer Institute. The APC is the annual percent change for the regression line segments. The APC shown on the graph is for the most recent trend.</div><div class=\"graphic_footnotes\">APC: annual percent change; SEER: Surveillance, Epidemiology, and End Results.<br />* Rates are age-adjusted to the 2000 United States standard population (19 age groups - census P25-1103).<br />&para; The APC is significantly different from zero (p&lt;0.05).</div><div class=\"graphic_reference\">Reproduced from: Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012. National Cancer Institute, Bethesda, MD. Available at: <a href=\"http://seer.cancer.gov/csr/1975_2012/\" spellcheck=\"true\" target=\"_blank\">http://seer.cancer.gov/csr/1975_2012/</a> (Accessed on April 4, 2016).</div><div id=\"graphicVersion\">Graphic 107601 Version 1.0</div></div></div>"},"107602":{"type":"graphic_picture","displayName":"US transducer position for rectus femoris tendon long axis","title":"US transducer position to view rectus femoris tendon in long axis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US transducer position to view rectus femoris tendon in long axis</div><div class=\"cntnt\"><img style=\"width:328px; height:712px;\" src=\"images/SM/107602_US_trnsdcr_pst_rct_fmr_tnd_la.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the positions of the ultrasound transducer and patient for obtaining images of the direct (A) and indirect (B) heads of the rectus femoris tendon at their&nbsp;origins in a long-axis view.</div><div class=\"graphic_reference\">Courtesy of Mederic M Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 107602 Version 1.0</div></div></div>"},"107603":{"type":"graphic_figure","displayName":"SEER data thyroid cancer by race","title":"SEER incidence and US death rates* for cancer of the thyroid, both sexes: Joinpoint analyses for whites and blacks from 1972-2012 and for Asian/Pacific Islanders, American Indians/Alaska Natives, and Hispanics from 1992-2012","html":"<div class=\"graphic\"><div style=\"width: 639px\" class=\"figure\"><div class=\"ttl\">SEER incidence and US death rates* for cancer of the thyroid, both sexes: Joinpoint analyses for whites and blacks from 1972-2012 and for Asian/Pacific Islanders, American Indians/Alaska Natives, and Hispanics from 1992-2012</div><div class=\"cntnt\"><img style=\"width:619px; height:414px;\" src=\"images/ENDO/107603_SEER_dt_thrd_cncr_rc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Regression lines are calculated using the Joinpoint Regression Program version 4.1.0, April 2014, National Cancer Institute. Joinpoint analyses for whites and blacks during the 1975 to 2012 period allow a maximum of five joinpoints. Analyses for other ethnic groups during the period 1992 to 2012 allow a maximum of three joinpoints.</div><div class=\"graphic_footnotes\">AI/AN: American Indian/Alaska Native; API: Asian/Pacific Islander; CHSDA: Contract Health Service Delivery Area; NHIA: NAACCR Hispanic Identification Algorithm; SEER: Surveillance, Epidemiology, and End Results.<br />* Rates are age-adjusted to the 2000 United States standard population (19 age groups - census P25-1103).<br />¶ Rates for American Indian/Alaska Native are based on the CHSDA counties.<br />Δ Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from New Hampshire and Oklahoma.</div><div class=\"graphic_reference\">Reproduced from: Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012. National Cancer Institute, Bethesda, MD. Available at: <a href=\"http://seer.cancer.gov/csr/1975_2012/\" spellcheck=\"true\" target=\"_blank\">http://seer.cancer.gov/csr/1975_2012/</a> (Accessed on April 4, 2016).</div><div id=\"graphicVersion\">Graphic 107603 Version 1.0</div></div></div>"},"107604":{"type":"graphic_diagnosticimage","displayName":"US iliotibial band origin long axis view","title":"US iliotibial band origin long axis view","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">US iliotibial band origin long axis view</div><div class=\"cntnt\"><img style=\"width:781px; height:441px;\" src=\"images/SM/107604_US_iltbl_bnd_org_lng_ax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the origin of the iliotibial band origin at the ilium in a long-axis view.</div><div class=\"graphic_footnotes\">Arrows: iliotibial band origin.<br />Left of the screen: proximal; right of the screen: distal.</div><div class=\"graphic_reference\">Courtesy of Mederic M Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 107604 Version 1.0</div></div></div>"},"107606":{"type":"graphic_figure","displayName":"Physiologic effects of n-3 PUFA","title":"Physiologic effects of n-3 PUFA","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Physiologic effects of n-3 PUFA</div><div class=\"cntnt\"><img style=\"width:716px; height:896px;\" src=\"images/PC/107606_Physiologic_effects_n3_PUFA.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011; 58:2047. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107606 Version 1.0</div></div></div>"},"107607":{"type":"graphic_figure","displayName":"Pathways affected by n-3 PUFA","title":"Pathways affected by n-3 PUFA","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Pathways affected by n-3 PUFA</div><div class=\"cntnt\"><img style=\"width:730px; height:733px;\" src=\"images/PC/107607_Pathways_affected_n_3_PUFA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">n-3 polyunsaturated fatty acids (n-3 PUFA) modulate multiple molecular pathways that together contribute to their physiological effects. First, the physicochemical properties of cellular and organelle membranes are influenced by their lipid composition <STRONG>(center)</STRONG>. Incorporation of n-3 PUFA into these membranes alters membrane fluidity and biophysics of lipid rafts that modulate protein function and signaling events. For example, enrichment of cellular membranes with n-3 PUFA disrupts dimerization and recruitment of toll-like receptor-4, which might contribute to anti-inflammatory effects by down-regulation of nuclear factor-kappaB (NF-kB) activation. Ion channels such as sodium (Na<SUP>+</SUP>), L-type calcium (Ca<SUP>2+</SUP>), and Na<SUP>+</SUP>– Ca<SUP>2+</SUP> exchangers might be similarly modulated by n-3 PUFA incorporation into lipid membranes. Second, n-3 PUFA seem to directly interact with membrane channels and proteins <STRONG>(center)</STRONG>. For example, direct modulation of ion channels or G-protein-coupled receptor 120 (GPR 120) might contribute to anti-arrhythmic or anti-inflammatory effects, respectively. Third, n-3 PUFA directly regulate gene expression via nuclear receptors and transcription factors <STRONG>(lower right)</STRONG>. n-3 PUFA are natural ligands of many key nuclear receptors in multiple tissues, including peroxisome proliferator-activated receptors (PPAR; -alpha, -beta, -delta, and -gamma), hepatic nuclear factors (HNF-4; -alpha and -gamma), retinoid X receptors (RXR), and liver X receptors (alpha and beta). Interactions between n-3 PUFA and nuclear receptors are modulated by cytoplasmic lipid binding proteins (eg, fatty acid [FA] binding proteins) that transport the FAs into the nucleus. n-3 PUFA also alter function of transcription factors such as sterol regulatory element binding protein-1c (SREBP-1c). Such genetic regulation contributes to observed effects of n-3 PUFA on lipid metabolism and inflammatory pathways. Fourth, after release from phospholipids by cytosolic phospholipase A<SUB>2</SUB> (cPLA<SUB>2</SUB>), PUFA including n-3 PUFA are converted to eicosanoids by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450) enzymes <STRONG>(lower left)</STRONG>. n-3 PUFA displace arachidonic acid (AA) in membrane phospholipids, reducing the production of AA-derived eicosanoids (eg, prostaglandin E<SUB>2</SUB> [PGE<SUB>2</SUB>]) while increasing those generated from n-3 PUFA. This altered eicosanoid profile might influence inflammation, thrombosis, and vascular function. Fifth, emerging evidence suggests that n-3 PUFA play an important role in inflammation resolution via specialized pro-resolving mediators (SPMs), including resolvins or protectins that are n-3 PUFA metabolites derived from actions of COX and LOX <STRONG>(top)</STRONG>. Biosynthesis of SPMs seems to require involvement of two or more cell types (\"transcellular biosynthesis\"), with one cell type converting the n-3 fatty acid to metabolic intermediates, and the second cell type converting these intermediates into the SPMs. n-3 PUFA-derived SPMs seem to be key drivers of inflammation resolution programs that reduce chronic inflammation in a wide range of animal models. The roles of each of these molecular pathways in the cardiovascular protection of n-3 PUFA represent promising areas for future investigation.</div><div class=\"graphic_footnotes\">PMN: polymorphonuclear leukocyte; DHA: docosahexaenoic acid; LTB: leukotriene B; ERK: extracellular signal-regulated kinase; mRNA: messenger ribonucleic acid; DNA: deoxyribonucleic acid.</div><div class=\"graphic_reference\">Reproduced from: Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011; 58:2047. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107607 Version 1.0</div></div></div>"},"107608":{"type":"graphic_table","displayName":"Neuraminidase mutations","title":"Clinically important neuraminidase mutations conferring resistance to neuraminidase inhibitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinically important neuraminidase mutations conferring resistance to neuraminidase inhibitors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Influenza type (subtype)</td> <td class=\"subtitle1\" rowspan=\"2\">NA mutation*</td> <td class=\"subtitle1\" colspan=\"3\">Susceptibility levels<sup>&#182;</sup> to:</td> </tr> <tr> <td class=\"subtitle2\">Oseltamivir</td> <td class=\"subtitle2\">Zanamivir</td> <td class=\"subtitle2\">Peramivir</td> </tr> <tr class=\"centered\"> <td class=\"divider_bottom\" rowspan=\"6\"><strong>A (H1N1)</strong></td> <td>E119D</td> <td>RI</td> <td>HRI</td> <td>HRI</td> </tr> <tr class=\"centered\"> <td>E119G</td> <td>S</td> <td>HRI</td> <td>RI</td> </tr> <tr class=\"centered\"> <td>I223R</td> <td>RI</td> <td>RI</td> <td>S (7-fold)</td> </tr> <tr class=\"centered\"> <td>I223V</td> <td>S (6-fold)</td> <td>S (2-fold)</td> <td>S (2-fold)</td> </tr> <tr class=\"centered\"> <td>S247N</td> <td>S (6-fold)</td> <td>S (3-fold)</td> <td>S (1-fold)</td> </tr> <tr class=\"divider_bottom centered\"> <td>H275Y</td> <td>HRI</td> <td>S</td> <td>HRI</td> </tr> <tr class=\"centered\"> <td class=\"divider_bottom\" rowspan=\"4\"><strong>A (H3N2)</strong></td> <td>E119V</td> <td>HRI</td> <td>S</td> <td>S</td> </tr> <tr class=\"centered\"> <td>I222V</td> <td>RI</td> <td>RI</td> <td>S</td> </tr> <tr class=\"centered\"> <td>Del245-248</td> <td>HRI</td> <td>RI</td> <td>S</td> </tr> <tr class=\"divider_bottom centered\"> <td>R292K</td> <td>HRI</td> <td>RI</td> <td>S</td> </tr> <tr class=\"centered\"> <td rowspan=\"6\"><strong>B</strong></td> <td>R150K</td> <td>HRI</td> <td>RI</td> <td>HRI</td> </tr> <tr class=\"centered\"> <td>D197N</td> <td>HRI</td> <td>RI</td> <td>S</td> </tr> <tr class=\"centered\"> <td>I221V</td> <td>RI</td> <td>S</td> <td>RI</td> </tr> <tr class=\"centered\"> <td>H273Y</td> <td>RI</td> <td>S</td> <td>RI</td> </tr> <tr class=\"centered\"> <td>N294S</td> <td>RI</td> <td>S</td> <td>RI</td> </tr> <tr class=\"centered\"> <td>R374K</td> <td>HRI</td> <td>RI</td> <td>--</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: neuraminidase.<br />* Numbers indicate the position of the substituted residue according to specific viral subtype sequence.<br />&para; World Health Organization susceptibility categories: <strong>S:</strong> susceptibility or normal inhibition (&lt;10-fold increase in inhibition for influenza A; &le;5-fold increase in inhibition for influenza B); <strong>RI:</strong> reduced inhibition (between 10- and 100-fold increase in inhibition for influenza A; between 5- and 50-fold increase in inhibition for influenza B); <strong>HRI:</strong> highly reduced inhibition (&gt;100-fold increase in inhibition for influenza A; &gt;50-fold increase in inhibition for influenza B).</div><div id=\"graphicVersion\">Graphic 107608 Version 2.0</div></div></div>"},"107609":{"type":"graphic_picture","displayName":"Modified Schober test","title":"Modified Schober test","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Modified Schober test</div><div class=\"cntnt\"><img style=\"width:539px; height:466px;\" src=\"images/ALLRG/107609_Modified_Schober_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This test measures lumbar flexion and is used to diagnose ankylosing spondylitis. Have the patient stand upright and place&nbsp;marks at the level of the sacral dimples on both sides (the lumbosacral junction). A horizontal line is drawn connecting these two points (iliac crest line). Marks are then placed midline (over the spine) 5 cm below and 10 cm above the ileac crest line. Have the patient bend forward as far as possible without bending at the knees (maximum lumbar flexion) and measure the distance between the top and bottom point. The distance between these two marks should increase from 15 cm standing to at least 20 cm with maximum flexion. A distance &lt;20 cm is abnormal.</div><div id=\"graphicVersion\">Graphic 107609 Version 1.0</div></div></div>"},"107610":{"type":"graphic_table","displayName":"Screening tests to idenitfy disability impairments","title":"Screening tests to identify impairments and factors contributing to disability","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening tests to identify impairments and factors contributing to disability</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Measure/maneuver</td> <td class=\"subtitle1\">Organ system and impairment assessed</td> <td class=\"subtitle1\">Associated functional limitations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Neuromusculoskeletal impairments</td> </tr> <tr> <td class=\"indent1\">Clasp hands behind head and behind back</td> <td>Internal and external rotation and abduction of the shoulder, elbow flexion</td> <td>Dressing (especially upper body), grooming, bathing, and housework</td> </tr> <tr> <td class=\"indent1\">Place ankle on opposite knee</td> <td>External rotation of the hip, hip flexion, and knee flexion</td> <td>Dressing lower body, bathing, toileting</td> </tr> <tr> <td class=\"indent1\">Pick up a penny from the floor <ul class=\"decimal_heading\"> <li><em>To isolate hand function from sitting balance and vision, place penny on table or opposite hand</em></li> </ul> </td> <td>Pinch strength, sensation and fine motor coordination, sitting balance, vision</td> <td>Cooking, feeding self, grooming, dressing, housework</td> </tr> <tr> <td class=\"indent1\">Chair Rise test <ul class=\"decimal_heading\"> <li><em>Rise from straight chair without using arms. Assess qualitatively and/or time five consecutive chair rises</em></li> </ul> </td> <td>Lower extremity strength (especially hip and knee)</td> <td>Bathing safety, toilet transfers, falls</td> </tr> <tr> <td class=\"indent1\">Rise on tip toes <ul class=\"decimal_heading\"> <li><em>Test single heel rise in healthy adults, bilateral heel rise in frail older adults</em></li> </ul> </td> <td>Lower extremity strength (especially ankle strength), balance</td> <td>Stair climbing, housework, bathing safety, falls</td> </tr> <tr> <td class=\"indent1\">Gentle nudge to the sternum</td> <td>Ankle, hip, and trunk strength; balance</td> <td>Housework, bathing safety, falls</td> </tr> <tr> <td class=\"indent1\">Timed Up and Go test <ul class=\"decimal_heading\"> <li><em>Rise and stand from a chair without using arms, walk across room (10 feet), return, sit down</em></li> </ul> </td> <td>Lower extremity strength (especially hip and knee); balance; gross motor coordination</td> <td>Mobility, bathing safety, toilet transfers, housework</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Two-minute walk test <ul class=\"decimal_heading\"> <li><em>Walk at usual pace for&nbsp;two minutes, measure distance</em></li> </ul> </td> <td>Endurance</td> <td>Community mobility, shopping</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Sensory and cognitive impairments</td> </tr> <tr> <td class=\"indent1\">Whisper test</td> <td>High frequency hearing</td> <td>Short-term memory, social function, telephone use</td> </tr> <tr> <td class=\"indent1\">Read a line of 11- to 12-point font</td> <td>Near vision loss</td> <td>Medication management, reading</td> </tr> <tr> <td class=\"indent1\">Snellen chart</td> <td>Distance vision loss</td> <td>Driving</td> </tr> <tr> <td class=\"indent1\">Geriatric depression screen</td> <td>Mood disorders</td> <td>Short-term memory, social function</td> </tr> <tr> <td class=\"indent1\">Time and Change Test <ul class=\"decimal_heading\"> <li><em>Tell the time from a clock face set at 11:10, make USD $1 in change from three quarters, seven dimes, and seven nickels</em></li> </ul> </td> <td>Cognitive impairment</td> <td>Instrumental activities of daily living</td> </tr> <tr> <td class=\"indent1\">Clock Drawing Test <ul class=\"decimal_heading\"> <li><em>Patient draws a clock face and sets hands to 11:10</em> </li> </ul> </td> <td>Executive dysfunction</td> <td>Medication management, financial management, social function</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">STOPP criteria</td> <td>Potentially inappropriate medications</td> <td>Short-term memory, balance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Contextual factors</td> </tr> <tr> <td class=\"indent1\">Ask \"Do you have trouble with stairs inside or outside of your home?\"</td> <td>Physical environment and home safety</td> <td>Falls, social function</td> </tr> <tr> <td class=\"indent1\">Ask \"How confident are you that you can take a bath or shower or get on and off the toilet without falling?\" <ul class=\"decimal_heading\"> <li>Scale: <ul> <li>0 = Not confident at all</li> <li>10 = Completely confident</li> </ul> </li> </ul> </td> <td>Physical environment and home safety</td> <td>Falls, hygiene</td> </tr> <tr> <td class=\"indent1\">Ask \"Who would be able to help you in case of illness or emergency?\"</td> <td>Social support</td> <td>Weight loss, medication management, financial management, social function</td> </tr> <tr> <td class=\"indent1\">Caregiver Burden Scale</td> <td>Caregiver stress</td> <td>Social function</td> </tr> <tr> <td class=\"indent1\">Mini Nutritional Assessment short form</td> <td>Malnutrition</td> <td>Weight loss, physical performance</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">STOPP: screening tool of older persons' potentially inappropriate prescriptions criteria.</div><div class=\"graphic_reference\">Reproduced with permission from: Col&oacute;n-Emeric CS, Whitson HE, Pavon J, Hoenig H. Functional decline in older adults. Am Fam Physician. 2013 Sep 15;88(6):388-94. Copyright &copy; 2013 American Academy of Family Physicians.</div><div id=\"graphicVersion\">Graphic 107610 Version 1.0</div></div></div>"},"107613":{"type":"graphic_algorithm","displayName":"Evaluation of fetal hydronephrosis","title":"Overview evaluation of fetal hydronephrosis","html":"<div class=\"graphic\"><div style=\"width: 762px\" class=\"figure\"><div class=\"ttl\">Overview evaluation of fetal hydronephrosis</div><div class=\"cntnt\"><img style=\"width:742px; height:542px;\" src=\"images/PEDS/107613_Eval_fetal_hydronephrosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm demonstrating an overview of the evaluation and management of fetal hydronephrosis detected in the second trimester of pregnancy.</div><div class=\"graphic_footnotes\">RPD: renal pelvic diameter.<br />* Refer to algorithm \"Postnatal evaluation of unilateral hydronephrosis.\"<br />&para; Refer to algorithm \"Postnatal evaluation of bilateral hydronephrosis.\"</div><div id=\"graphicVersion\">Graphic 107613 Version 1.0</div></div></div>"},"107614":{"type":"graphic_table","displayName":"Genetic defects causing CVID phenotypes","title":"Disorders causing common variable immunodeficiency (CVID) phenotypes (ie, severe reductions in at least two serum immunoglobulin isotypes with normal or low number of B cells)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders causing common variable immunodeficiency (CVID) phenotypes (ie, severe reductions in at least two serum immunoglobulin isotypes with normal or low number of B cells)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Mutated gene</td> <td class=\"subtitle1\">Presumed pathogenesis</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Serum immunoglobulin abnormalities</td> <td class=\"subtitle1\">Associated features</td> </tr> <tr class=\"divider_bottom\"> <td>CVID disorders</td> <td>Unknown (majority of patients)</td> <td>Unknown (majority of patients)</td> <td>Variable</td> <td>Low IgG and IgA and/or IgM</td> <td>Clinical phenotypes vary. Most have recurrent infections. Some have polyclonal lymphoproliferation, autoimmune cytopenias, and/or granulomatous disease.</td> </tr> <tr class=\"divider_bottom\"> <td>ICOS deficiency</td> <td><em>ICOS</em></td> <td>A costimulatory molecule expressed on T cells</td> <td>AR</td> <td>Low IgG and IgA and/or IgM</td> <td>Recurrent infections, autoimmunity, gastroenteritis, and&nbsp;granuloma in some.</td> </tr> <tr class=\"divider_bottom\"> <td>CD19 deficiency</td> <td><em>CD19</em></td> <td>Transmembrane protein that amplifies signal through BCR</td> <td>AR</td> <td>Low IgG and IgA and/or IgM</td> <td>Recurrent infections. May have glomerulonephritis.</td> </tr> <tr class=\"divider_bottom\"> <td>CD81 deficiency</td> <td><em>CD81</em></td> <td>Transmembrane protein that amplifies signal through BCR</td> <td>AR</td> <td>Low IgG, low or normal IgA, and IgM</td> <td>Recurrent infections. May have glomerulonephritis.</td> </tr> <tr class=\"divider_bottom\"> <td>CD20 deficiency</td> <td><em>CD20</em></td> <td>A B cell surface receptor involved in B cell development and plasma cell differentiation</td> <td>AR</td> <td>Low IgG, normal or elevated IgM, and IgA</td> <td>Recurrent infections.</td> </tr> <tr class=\"divider_bottom\"> <td>CD21 deficiency</td> <td><em>CD21</em></td> <td>Also known as complement receptor 2 and forms part of the CD19 complex</td> <td>AR</td> <td>Low IgG; impaired antipneumococcal response</td> <td>Recurrent infections.</td> </tr> <tr class=\"divider_bottom\"> <td>TACI deficiency</td> <td><em>TNFRSF13B</em></td> <td>Encodes TACI; a TNF-receptor family member found on B cells and is a receptor for BAFF and APRIL</td> <td>AD or AR or complex</td> <td>Low IgG and IgA and/or IgM</td> <td>Variable clinical expression.</td> </tr> <tr class=\"divider_bottom\"> <td>BAFF-receptor deficiency</td> <td><em>TNFRSF13C</em></td> <td>Encodes BAFF-R; a TNF-receptor family member found on B cells that is a receptor for BAFF</td> <td>AR</td> <td>Low IgG and IgM</td> <td>Variable clinical expression.</td> </tr> <tr class=\"divider_bottom\"> <td>TWEAK deficiency</td> <td><em>TWEAK</em></td> <td>Encodes TNF-related weak inducer of apoptosis</td> <td>AD</td> <td>Low IgM and IgA; lack of antipneumococcal antibody</td> <td>Pneumonia, bacterial infections, warts; thrombocytopenia; neutropenia.</td> </tr> <tr class=\"divider_bottom\"> <td>NF-kappa-B2 deficiency</td> <td><em>NFKB2</em></td> <td>Encodes an essential component of the noncanonical NF-kappa-B pathway</td> <td>AD</td> <td>Low IgG and IgA and IgM; very low B cells in some</td> <td>Recurrent infections; adrenal insufficiency; ACTH deficiency; alopecia.</td> </tr> <tr class=\"divider_bottom\"> <td>NF-kappa-B1 deficiency</td> <td><em>NFKB1</em></td> <td>Encodes an essential component of the noncanonical NF-kappa-B pathway</td> <td>AD</td> <td>Low IgG and IgA and IgM; low B cells in some</td> <td>Recurrent infections.</td> </tr> <tr> <td>IKAROS</td> <td><em>IKZF1</em></td> <td>Encodes transcription factor IKAROS</td> <td>AD</td> <td>Low IgG and IgA and IgM, very low B cells</td> <td>Recurrent infections, childhood B cell ALL.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M; ICOS: inducible T cell costimulator; AR: autosomal recessive; BCR: B cell receptor; TACI: transmembrane activator and calcium-modulator and cyclophilin ligand (CAML) interactor; TNFRSF: tumor necrosis factor-receptor superfamily; TNF: tumor necrosis factor; BAFF: B cell-activating factor of the&nbsp;TNF family; APRIL: a proliferation-inducing ligand; AD: autosomal dominant; TWEAK: TNF-related weak inducer of apoptosis; NFKB: NF-kappa-B; ACTH: adrenocorticotropic hormone; <EM>IKZF1</EM>: the gene&nbsp;encoding IKAROS; ALL: acute lymphoblastic leukemia.</div><div class=\"graphic_reference\">Data from: Picard C, Al-Herz W, Bousfiha A, et al. Primary immunodeficiency diseases: An update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency 2015. J Clin Immunol 2015; 35:696.</div><div id=\"graphicVersion\">Graphic 107614 Version 4.0</div></div></div>"},"107618":{"type":"graphic_diagnosticimage","displayName":"HSG image of pelvic tuberculosis","title":"Hysterosalpingography (HSG) image of pelvic tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingography (HSG) image of pelvic tuberculosis</div><div class=\"cntnt\"><img style=\"width:712px; height:664px;\" src=\"images/OBGYN/107618_HSG_img_plvc_tbrcls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HSG image of a woman with infertility. The distal ampullary and infundibular portions of the tubes demonstrate dilated caliber (arrows) as well as filling defects and diverticulae (arrowheads) bilaterally. Lack of free spillage into the peritoneal cavity indicates bilateral tubal occlusion.</div><div id=\"graphicVersion\">Graphic 107618 Version 1.0</div></div></div>"},"107619":{"type":"graphic_table","displayName":"Lidocaine dosing for neonatal seizures","title":"Lidocaine dosing for neonatal seizures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lidocaine dosing for neonatal seizures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"6\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Weight</td> <td class=\"subtitle1\">Bolus (mg/kg)<br /> given over 10 minutes</td> <td class=\"subtitle1\">1st infusion</td> <td class=\"subtitle1\">2nd infusion</td> <td class=\"subtitle1\">3rd infusion</td> <td class=\"subtitle1\">Total infusion duration<br /> (hours)</td> <td class=\"subtitle1\">Total dose<br /> (mg/kg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Normothermia</td> </tr> <tr> <td class=\"indent1\">&#60;2.5 kg</td> <td>2</td> <td>6 mg/kg/h x 4 hours</td> <td>3 mg/kg/h x 12 hours</td> <td>1.5 mg/kg/h x 12 hours</td> <td>28</td> <td>80</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;2.5 kg</td> <td>2</td> <td>7 mg/kg/h x 4 hours</td> <td>3.5 mg/kg/h x 12 hours</td> <td>1.75 mg/kg/h x 12 hours</td> <td>28</td> <td>93</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Therapeutic hypothermia</td> </tr> <tr> <td class=\"indent1\">&#60;2.5 kg</td> <td>2</td> <td>6 mg/kg/h x 3.5 hours</td> <td>3 mg/kg/h x 12 hours</td> <td>1.5 mg/kg/h x 12 hours</td> <td>27.5</td> <td>77</td> </tr> <tr> <td class=\"indent1\">&#8805;2.5 kg</td> <td>2</td> <td>7 mg/kg/h x 3.5 hours</td> <td>3.5 mg/kg/h x 12 hours</td> <td>1.75 mg/kg/h x 12 hours</td> <td>27.5</td> <td>89.5</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table is provided as an example of a lidocaine dosing protocol that includes dose adjustments for infants with low body weight and those&nbsp;undergoing therapeutic hypothermia who are at increased risk of drug accumulation; it was used in a cohort of infants who received lidocaine as a second- or third-line antiseizure drug for neonatal seizures unresponsive to first-line therapy (eg, phenobarbital).<br /><br />The optimal dosing regimen in these infants is unknown. Intravenous lidocaine administration may be arrhythmogenic and requires continuous noninvasive monitoring of ECG, heart rate, and blood pressure; it is contraindicated in congenital heart disease or in infants pretreated with phenytoin/fosphenytoin. </div><div class=\"graphic_footnotes\">ECG: electrocardiography.</div><div class=\"graphic_reference\">From: Weeke LC, Toet MC, van Rooij LGM, et al. Lidocaine response rate in aEEG-confirmed neonatal seizures: Retrospective study of 413 full-term and preterm infants. Epilepsia 2016; 57:233. <A href=\"http://onlinelibrary.wiley.com/doi/10.1111/epi.13286/abstract\" target=_blank>http://onlinelibrary.wiley.com/doi/10.1111/epi.13286/abstract</A>. Copyright © 2016 International League Against Epilepsy. Reproduced with permission of Blackwell Publishing Ltd. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 107619 Version 3.0</div></div></div>"},"107620":{"type":"graphic_diagnosticimage","displayName":"Hysterosalpingogram and MRI images of a bicornuate uterus","title":"Bicornuate uterus: Hysterosalpingogram and magnetic resonance images","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">Bicornuate uterus: Hysterosalpingogram and magnetic resonance images</div><div class=\"cntnt\"><img style=\"width:787px; height:437px;\" src=\"images/OBGYN/107620_Hstrslpgrm_MRI_bcrnt_utr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram (HSG) and magnetic resonance images (MRI) from a 30-year-old woman with infertility and bicornuate uterus (A and B). HSG (A) shows two uterine cavities (asterisks) originating from a single cervix. MRI fast spin echo T2-weighted image (B) shows a cleft (arrow) in the fundal myometrial contour (arrow).</div><div id=\"graphicVersion\">Graphic 107620 Version 1.0</div></div></div>"},"107622":{"type":"graphic_picture","displayName":"Chemical leukoderma","title":"Chemical leukoderma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Chemical leukoderma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/107622_Chemical_leukoderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White macules mimicking vitiligo on the hands of a patient with chemical leukoderma.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107622 Version 1.0</div></div></div>"},"107623":{"type":"graphic_picture","displayName":"Mild glanular hypospadias","title":"Examples of mild glanular hypospadias in four male infants","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Examples of mild glanular hypospadias in four male infants</div><div class=\"cntnt\"><img style=\"width:560px; height:727px;\" src=\"images/PEDS/107623_Mldglndlrhypspds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forme fruste (incomplete or partial hypospadias) with clinically insignificant (mild)&nbsp;hypospadias. The black arrows point to the slightly ventral but functional meatus.&nbsp;The white arrowheads point to the blind urethral pit. Forme fruste of hypospadias typically presents without penile curvature or any difficulties with urination or future fertility problems.</div><div id=\"graphicVersion\">Graphic 107623 Version 4.0</div></div></div>"},"107624":{"type":"graphic_table","displayName":"Candida and Aspergillus echinocandin susceptibility","title":"Antifungal activity of echinocandins against <em>Candida</em> and <em>Aspergillus</em> spp","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antifungal activity of echinocandins against <em>Candida</em> and <em>Aspergillus</em> spp</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Species (number of isolates tested)</td> <td class=\"subtitle1\" rowspan=\"2\">Antifungal agent</td> <td class=\"subtitle1\">MIC/MEC (mcg/mL)</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Percent susceptible*</td> </tr> <tr> <td class=\"subtitle2\">Range</td> <td class=\"subtitle2\">50%</td> <td class=\"subtitle2\">90%</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><em>Candida albicans</em> (621)</td> <td>Micafungin</td> <td>&#8804;0.008-0.06</td> <td>0.015</td> <td>0.03</td> <td>100</td> </tr> <tr> <td>Anidulafungin</td> <td>&#8804;0.008-0.12</td> <td>0.015</td> <td>0.06</td> <td>100</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>&#8804;0.008-0.25 </td> <td>0.03</td> <td>0.03</td> <td>100</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><em>C. glabrata</em> (235)</td> <td>Micafungin</td> <td>&#8804;0.008-1</td> <td>0.015</td> <td>0.03</td> <td>98.3</td> </tr> <tr> <td>Anidulafungin</td> <td>0.015-2</td> <td>0.06</td> <td>0.12</td> <td>96.6</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>0.015-1</td> <td>0.03</td> <td>0.06</td> <td>97.9</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><em>C. parapsilosis</em> (197)</td> <td>Micafungin</td> <td>0.12-2</td> <td>1</td> <td>2</td> <td>100</td> </tr> <tr> <td>Anidulafungin</td> <td>0.25-4</td> <td>2</td> <td>2</td> <td>93.4</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>0.06-1</td> <td>0.25</td> <td>0.5</td> <td>100</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><em>C. tropicalis</em> (110)</td> <td>Micafungin</td> <td>&#8804;0.008-1</td> <td>0.03</td> <td>0.06</td> <td>98.2</td> </tr> <tr> <td>Anidulafungin</td> <td>&#8804;0.008-2</td> <td>0.015</td> <td>0.03</td> <td>98.2</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>0.015-2</td> <td>0.03</td> <td>0.06</td> <td>98.2</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><em>C. krusei</em> (37)</td> <td>Micafungin</td> <td>0.06-0.12</td> <td>0.12</td> <td>0.12</td> <td>100</td> </tr> <tr> <td>Anidulafungin</td> <td>0.03-0.06</td> <td>0.06</td> <td>0.06</td> <td>100</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>0.06-0.25</td> <td>0.12</td> <td>0.25</td> <td>100</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><em>C. lusitaniae</em> (33)</td> <td>Micafungin</td> <td>0.03-0.5</td> <td>0.25</td> <td>0.25</td> <td>&nbsp;</td> </tr> <tr> <td>Anidulafungin</td> <td>0.03-1</td> <td>0.5</td> <td>0.5</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>0.03-0.5</td> <td>0.25</td> <td>0.5</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><em>C. dubliniensis</em> (31)</td> <td>Micafungin</td> <td>&#8804;0.008-0.12</td> <td>0.03</td> <td>0.06</td> <td>&nbsp;</td> </tr> <tr> <td>Anidulafungin</td> <td>0.015-0.12</td> <td>0.03</td> <td>0.06</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>0.015-0.12</td> <td>0.06</td> <td>0.12</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><em>C. guilliermondii</em> (15)</td> <td>Micafungin</td> <td>0.5-2</td> <td>1</td> <td>2</td> <td>100</td> </tr> <tr> <td>Anidulafungin</td> <td>1-4</td> <td>2</td> <td>4</td> <td>80</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>0.25-1</td> <td>0.5</td> <td>1</td> <td>100</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><em>C. orthopsilosis</em> (10)</td> <td>Micafungin</td> <td>0.06-1</td> <td>0.5</td> <td>1</td> <td>&nbsp;</td> </tr> <tr> <td>Anidulafungin</td> <td>0.12-1</td> <td>0.5</td> <td>1</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>0.03-0.5</td> <td>0.12</td> <td>0.25</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><em>Aspergillus fumigatus</em> (120)</td> <td>Micafungin</td> <td>&#8804;0.008-0.03</td> <td>&#8804;0.008</td> <td>0.015</td> <td>&nbsp;</td> </tr> <tr> <td>Anidulafungin</td> <td>&#8804;0.008-0.06</td> <td>&#8804;0.008</td> <td>0.03</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Caspofungin</td> <td>&#8804;0.008-0.06</td> <td>0.03</td> <td>0.03</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"3\"><em>A. ﬂavus</em> (13)</td> <td>Micafungin</td> <td>&#8804;0.008-0.03</td> <td>&#8804;0.008</td> <td>&#8804;0.015</td> <td>&nbsp;</td> </tr> <tr> <td>Anidulafungin</td> <td>&#8804;0.008</td> <td>&#8804;0.008</td> <td>&#8804;0.008</td> <td>&nbsp;</td> </tr> <tr> <td>Caspofungin</td> <td>&#8804;0.015-0.03</td> <td>0.015</td> <td>0.015</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration; MEC: minimum effective concentration.<br />* Interpretative categories recommended by the Clinical and Laboratory Standards Institute (CLSI).</div><div class=\"graphic_reference\">Data from: Pfaller MA, Rhomberg PR, Messer SA, et al. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis 2015; 82:303.</div><div id=\"graphicVersion\">Graphic 107624 Version 1.0</div></div></div>"},"107625":{"type":"graphic_picture","displayName":"Localized vitiligo neck","title":"Localized vitiligo with depigmented patches of the neck","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Localized vitiligo with depigmented patches of the neck</div><div class=\"cntnt\"><img style=\"width:712px; height:471px;\" src=\"images/DERM/107625_Lclz_vtlg_nck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Localized vitiligo, depigmented patches of the neck, sparing other body parts.</div><div class=\"graphic_reference\">Courtesy of Pearl E Grimes, MD.</div><div id=\"graphicVersion\">Graphic 107625 Version 1.0</div></div></div>"},"107626":{"type":"graphic_picture","displayName":"Progressive macular hypomelanosis back","title":"Progressive macular hypomelanosis of the back","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Progressive macular hypomelanosis of the back</div><div class=\"cntnt\"><img style=\"width:470px; height:710px;\" src=\"images/DERM/107626_Prgrssvmclrhpmlnsbck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Progressive macular hypomelanosis showing hypopigmented areas of the back.</div><div class=\"graphic_reference\">Courtesy of Pearl E Grimes, MD.</div><div id=\"graphicVersion\">Graphic 107626 Version 2.0</div></div></div>"},"107627":{"type":"graphic_picture","displayName":"Vititligo follicular repigmentation","title":"Vitiligo repigmentation","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Vitiligo repigmentation</div><div class=\"cntnt\"><img style=\"width:468px; height:712px;\" src=\"images/DERM/107627_Fllclr_area_erly_rpgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follicular areas of repigmentation are early signs of response to narrowband UVB phototherapy.</div><div class=\"graphic_footnotes\">UVB: ultraviolet B.</div><div class=\"graphic_reference\">Courtesy of Pearl E Grimes, MD.</div><div id=\"graphicVersion\">Graphic 107627 Version 2.0</div></div></div>"},"107628":{"type":"graphic_picture","displayName":"Vitiligo NB-UVB","title":"Repigmentation of vitiligo with narrowband UVB phototherapy","html":"<div class=\"graphic\"><div style=\"width: 653px\" class=\"figure\"><div class=\"ttl\">Repigmentation of vitiligo with narrowband UVB phototherapy</div><div class=\"cntnt\"><img style=\"width:633px; height:680px;\" src=\"images/DERM/107628_Nrrw_bnd_UVB_phtthrpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A and B) Before and (C and D) after narrowband UVB phototherapy, 68 treatments.</div><div class=\"graphic_footnotes\">UVB: ultraviolet B.</div><div class=\"graphic_reference\">Courtesy of Pearl E Grimes, MD.</div><div id=\"graphicVersion\">Graphic 107628 Version 2.0</div></div></div>"},"107629":{"type":"graphic_picture","displayName":"Vitiligo excimer laser phototherapy","title":"Repigmentation of localized vitiligo with excimer laser phototherapy","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Repigmentation of localized vitiligo with excimer laser phototherapy</div><div class=\"cntnt\"><img style=\"width:574px; height:719px;\" src=\"images/DERM/107629_Vtlg_excmr_lsr_phtthrp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Before and (B) after excimer laser phototherapy.</div><div class=\"graphic_reference\">Courtesy of Pearl E Grimes, MD.</div><div id=\"graphicVersion\">Graphic 107629 Version 1.0</div></div></div>"},"107640":{"type":"graphic_table","displayName":"Risk of late pulmonary toxicity after four courses of BEP","title":"Risk* of late pulmonary toxicity other than pulmonary embolus after four courses of BEP in the Danish Testicular Cancer Registry series","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk* of late pulmonary toxicity other than pulmonary embolus after four courses of BEP in the Danish Testicular Cancer Registry series</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"33.3%\"></colgroup><colgroup width=\"33.3%\"></colgroup><colgroup width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Toxicity</td> <td class=\"subtitle1\">BEP (n = 565)</td> <td class=\"subtitle1\">No BEP (n = 2548)</td> </tr> <tr> <td>Pulmonary fibrosis</td> <td class=\"centered\">3 (0.4%)</td> <td class=\"centered\">5 (0.2%)</td> </tr> <tr> <td>Obstructive pulmonary disease</td> <td class=\"centered\">15 (3.3%)</td> <td class=\"centered\">72 (2.8%)</td> </tr> <tr> <td>Pneumonia</td> <td class=\"centered\">15 (2.6%)</td> <td class=\"centered\">103 (3.3%)</td> </tr> <tr> <td>Pneumothorax</td> <td class=\"centered\">2 (0.3%)</td> <td class=\"centered\">6 (0.4%)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BEP: bleomycin, etoposide, cisplatin.<br />* 15-year cumulative risk, with time at risk calculated one year from the treatment start.</div><div class=\"graphic_reference\">From: Lauritsen J, Kier MG, Bandak M, et al. Pulmonary function in patients with germ cell cancer treated With Bleomycin, Etoposide, and Cisplatin. J Clin Oncol 2016; 34(13):1492-9. Reprinted with permission. Copyright &copy; 2016 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107640 Version 1.0</div></div></div>"},"107641":{"type":"graphic_table","displayName":"Postoperative radioiodine risk stratification and staging","title":"Characteristics according to the ATA risk stratification system and AJCC/TNM staging system that may impact postoperative radioiodine decision-making","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics according to the ATA risk stratification system and AJCC/TNM staging system that may impact postoperative radioiodine decision-making</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">ATA risk staging (TNM)</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Body of evidence suggests RAI improves disease specific survival?</td> <td class=\"subtitle1\">Body of evidence suggests RAI improves disease free survival?</td> <td class=\"subtitle1\">Postsurgical RAI indicated?</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>ATA low risk </li> <li>T1a </li> <li>N0, Nx </li> <li>M0, Mx </li> </ul> </td> <td>Tumor size &#8804;1 cm (uni- or multifocal)</td> <td>No</td> <td>No</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>ATA low risk </li> <li>T1b, T2 </li> <li>N0, Nx </li> <li>M0, Mx </li> </ul> </td> <td>Tumor size &#62;1 to 4 cm</td> <td>No</td> <td>Conflicting observational data</td> <td>Not routine* &#8212; May be considered for patients with aggressive histology or vascular invasion (ATA intermediate risk).</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>ATA low to intermediate risk </li> <li>T3 </li> <li>N0, Nx </li> <li>M0, Mx </li> </ul> </td> <td>Tumor size &#62;4 cm</td> <td>Conflicting data</td> <td>Conflicting observational data</td> <td>Consider* &#8212; Need to consider presence of other adverse features. Advancing age may favor RAI use in some cases, but specific age and tumor size cutoffs subject to some uncertainty.<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>ATA low to intermediate risk </li> <li>T3 </li> <li>N0, Nx </li> <li>M0, Mx </li> </ul> </td> <td>Microscopic ETE, any tumor size</td> <td>No</td> <td>Conflicting observational data</td> <td>Consider* &#8212; Generally favored based on risk of recurrent disease. Smaller tumors with microscopic ETE may not require RAI.</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>ATA low to intermediate risk </li> <li>T1-3 </li> <li>N1a </li> <li>M0, Mx </li> </ul> </td> <td>Central compartment neck lymph node metastases</td> <td>No, except possibly in subgroup of patients &#8805;45 years of age (NTCTCSG Stage III)</td> <td>Conflicting observational data</td> <td>Consider* &#8212; Generally favored, due to somewhat higher risk of persistent or recurrent disease, especially with increasing number of large (&#62;2 to 3 cm) or clinically evident lymph nodes or presence of extranodal extension. Advancing age may also favor RAI use.<sup>&#182;</sup> However, there is insufficient data to mandate RAI use in patients with few (&#60;5) microscopic nodal metastases in central compartment in absence of other adverse features.</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>ATA low to intermediate risk </li> <li>T1-3 </li> <li>N1b </li> <li>M0, Mx </li> </ul> </td> <td>Lateral neck or mediastinal lymph node metastases</td> <td>No, except possibly in subgroup of patients &#8805;45 years of age</td> <td>Conflicting observational data</td> <td>Consider* &#8212; Generally favored, due to higher risk of persistent or recurrent disease, especially with increasing number of macroscopic or clinically evident lymph nodes or presence of extranodal extension. Advancing age may also favor RAI use.<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>ATA high risk </li> <li>T4 </li> <li>Any N </li> <li>Any M </li> </ul> </td> <td>Any size, gross ETE</td> <td>Yes, observational data</td> <td>Yes, observational data</td> <td>Yes</td> </tr> <tr> <td> <ul> <li>ATA high risk </li> <li>M1 </li> <li>Any T </li> <li>Any N </li> </ul> </td> <td>Distant metastases</td> <td>Yes, observational data</td> <td>Yes, observational data</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AJCC: American Joint Committee on Cancer; ATA: American Thyroid Association; ETE: extrathyroidal extension; NTCTCSG: National Thyroid Cancer Treatment Cooperative Study Group; RAI: radioiodine; Tg: thyroglobulin; US: ultrasound.<br />* In addition to standard clinicopathologic features, local factors such as the quality of preoperative and postoperative US evaluations, availability and quality of Tg measurements, experience of the operating surgeon, and clinical concerns of the local disease management team may also be considerations in postoperative RAI decision-making.<br />&para; Recent data from the NTCTCSG have suggested that a more appropriate prognostic age cutoff for their and other classification systems could be 55 years, rather than 45 years, particularly for women.</div><div class=\"graphic_reference\">Reproduced with permission from: Bryan RH, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1. Copyright &copy; 2016 Mary Ann Liebert, Inc. Publishers. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107641 Version 1.0</div></div></div>"},"107642":{"type":"graphic_figure","displayName":"Techniques of pylorus-preserving total pancreatectomy","title":"Techniques of pylorus-preserving total pancreatectomy","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Techniques of pylorus-preserving total pancreatectomy</div><div class=\"cntnt\"><img style=\"width:541px; height:642px;\" src=\"images/SURG/107642_Techniques_of_total_pancreatectomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 107642 Version 1.0</div></div></div>"},"107646":{"type":"graphic_table","displayName":"AFI 14 to 20 weeks of gestation","title":"Amniotic fluid index (AFI) from 14 to 20 weeks of gestation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Amniotic fluid index (AFI) from 14 to 20 weeks of gestation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Weeks of gestation</td> <td class=\"subtitle1\">5<sup>th</sup> percentile</td> <td class=\"subtitle1\">10<sup>th</sup> percentile</td> <td class=\"subtitle1\">50<sup>th</sup> percentile</td> <td class=\"subtitle1\">90<sup>th</sup> percentile</td> <td class=\"subtitle1\">95<sup>th</sup> percentile</td> </tr> <tr class=\"centered\"> <td>14</td> <td>2.8</td> <td>3.1</td> <td>5.0</td> <td>8.0</td> <td>8.6</td> </tr> <tr class=\"centered\"> <td>15</td> <td>3.2</td> <td>3.6</td> <td>5.4</td> <td>8.2</td> <td>9.1</td> </tr> <tr class=\"centered\"> <td>16</td> <td>3.6</td> <td>4.1</td> <td>5.8</td> <td>8.5</td> <td>9.6</td> </tr> <tr class=\"centered\"> <td>17</td> <td>4.1</td> <td>4.0</td> <td>6.3</td> <td>9.0</td> <td>10.3</td> </tr> <tr class=\"centered\"> <td>18</td> <td>4.6</td> <td>5.1</td> <td>6.8</td> <td>9.7</td> <td>11.1</td> </tr> <tr class=\"centered\"> <td>19</td> <td>5.1</td> <td>5.6</td> <td>7.4</td> <td>10.4</td> <td>12.0</td> </tr> <tr class=\"centered\"> <td>20</td> <td>5.5</td> <td>6.1</td> <td>8.0</td> <td>11.3</td> <td>12.9</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These values are based on findings in singleton pregnancies with reliable gestational age assessment, no known fetal anomalies, and no medical or obstetric complications. At each gestational age, 50 patients were recruited, and only one examination was used per pregnancy.</div><div class=\"graphic_reference\">Data from: Magann EF, Sanderson M, Martin JN, Chauhan S. The amniotic fluid index, single deepest pocket, and two-diameter pocket in normal human pregnancy. Am J Obstet Gynecol 2000; 182:1581.</div><div id=\"graphicVersion\">Graphic 107646 Version 2.0</div></div></div>"},"107647":{"type":"graphic_table","displayName":"SDP 14 to 20 weeks of gestation","title":"Single deepest pocket (SDP) at 14 to 20 weeks of gestation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Single deepest pocket (SDP) at 14 to 20 weeks of gestation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Weeks of gestation</td> <td class=\"subtitle1\">5<sup>th</sup> percentile</td> <td class=\"subtitle1\">10<sup>th</sup> percentile</td> <td class=\"subtitle1\">50<sup>th</sup> percentile</td> <td class=\"subtitle1\">90<sup>th</sup> percentile</td> <td class=\"subtitle1\">95<sup>th</sup> percentile</td> </tr> <tr class=\"centered\"> <td>14</td> <td>1.7</td> <td>1.9</td> <td>2.9</td> <td>4.7</td> <td>5.0</td> </tr> <tr class=\"centered\"> <td>15</td> <td>2.0</td> <td>2.2</td> <td>3.4</td> <td>5.1</td> <td>5.5</td> </tr> <tr class=\"centered\"> <td>16</td> <td>2.3</td> <td>2.5</td> <td>3.6</td> <td>5.4</td> <td>5.9</td> </tr> <tr class=\"centered\"> <td>17</td> <td>2.5</td> <td>2.7</td> <td>3.9</td> <td>5.7</td> <td>6.2</td> </tr> <tr class=\"centered\"> <td>18</td> <td>2.7</td> <td>2.9</td> <td>4.1</td> <td>5.9</td> <td>6.4</td> </tr> <tr class=\"centered\"> <td>19</td> <td>2.8</td> <td>3.1</td> <td>4.3</td> <td>6.1</td> <td>6.6</td> </tr> <tr class=\"centered\"> <td>20</td> <td>2.9</td> <td>3.2</td> <td>4.4</td> <td>6.2</td> <td>6.7</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These values are based on findings in singleton pregnancies with reliable gestational age assessment, no known fetal anomalies, and no medical or obstetric complications. At each gestational age, 50 patients were recruited, and only one examination was used per pregnancy.</div><div class=\"graphic_reference\">Data from: Magann EF, Sanderson M, Martin JN, Chauhan S. The amniotic fluid index, single deepest pocket, and two-diameter pocket in normal human pregnancy. Am J Obstet Gynecol 2000; 182:1581.</div><div id=\"graphicVersion\">Graphic 107647 Version 2.0</div></div></div>"},"107648":{"type":"graphic_table","displayName":"Two-dimensional pocket 14 to 20 weeks of gestation","title":"Two-dimensional pocket at 14 to 20 weeks of gestation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Two-dimensional pocket at 14 to 20 weeks of gestation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Weeks of gestation</td> <td class=\"subtitle1\">5<sup>th</sup> percentile</td> <td class=\"subtitle1\">10<sup>th</sup> percentile</td> <td class=\"subtitle1\">50<sup>th</sup> percentile</td> <td class=\"subtitle1\">90<sup>th</sup> percentile</td> <td class=\"subtitle1\">95<sup>th</sup> percentile</td> </tr> <tr class=\"centered\"> <td>14</td> <td>4.3</td> <td>4.7</td> <td>9.5</td> <td>18.3</td> <td>22.6</td> </tr> <tr class=\"centered\"> <td>15</td> <td>5.8</td> <td>6.4</td> <td>13.0</td> <td>23.8</td> <td>28.3</td> </tr> <tr class=\"centered\"> <td>16</td> <td>7.3</td> <td>8.1</td> <td>16.6</td> <td>29.2</td> <td>33.7</td> </tr> <tr class=\"centered\"> <td>17</td> <td>8.7</td> <td>9.6</td> <td>19.8</td> <td>33.8</td> <td>38.5</td> </tr> <tr class=\"centered\"> <td>18</td> <td>9.8</td> <td>10.9</td> <td>22.5</td> <td>37.6</td> <td>42.4</td> </tr> <tr class=\"centered\"> <td>19</td> <td>10.6</td> <td>11.9</td> <td>24.3</td> <td>40.3</td> <td>45.3</td> </tr> <tr class=\"centered\"> <td>20</td> <td>11.0</td> <td>12.6</td> <td>25.4</td> <td>42.0</td> <td>47.4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These values are based on findings in singleton pregnancies with reliable gestational age assessment, no known fetal anomalies, and no medical or obstetric complications. At each gestational age, 50 patients were recruited, and only one examination was used per pregnancy.</div><div class=\"graphic_reference\">Data from: Magann EF, Sanderson M, Martin JN, Chauhan S. The amniotic fluid index, single deepest pocket, and two-diameter pocket in normal human pregnancy. Am J Obstet Gynecol 2000; 182:1581.</div><div id=\"graphicVersion\">Graphic 107648 Version 2.0</div></div></div>"},"107649":{"type":"graphic_table","displayName":"Medication effects on sleep architecture","title":"Medication effects on sleep architecture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medication effects on sleep architecture</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication/medication class</td> <td class=\"subtitle1\">SL</td> <td class=\"subtitle1\">SE</td> <td class=\"subtitle1\">TST</td> <td class=\"subtitle1\">N2</td> <td class=\"subtitle1\">N3</td> <td class=\"subtitle1\">REM</td> </tr> <tr> <td>Vasopressors</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595;</td> </tr> <tr> <td>Beta blockers</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8595;</td> </tr> <tr> <td>Benzodiazepines</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595;</td> </tr> <tr> <td>Propofol</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8595;</td> </tr> <tr> <td>Dexmedetomidine</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8595;&ndash;&#8593;</td> <td class=\"centered\">&#8595;</td> </tr> <tr> <td>Opioids</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595;</td> </tr> <tr> <td>Steroids</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595;</td> </tr> <tr> <td>Beta agonists</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8595;&ndash;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Theophylline</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593;&ndash;</td> <td class=\"centered\">&#8595;&ndash;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SL: sleep latency; SE: sleep efficiency; TST: total sleep time; N2: stage 2 non-rapid eye movement (NREM) sleep; N3: stage 3 NREM sleep; REM: rapid eye movement sleep.</div><div id=\"graphicVersion\">Graphic 107649 Version 1.0</div></div></div>"},"107650":{"type":"graphic_table","displayName":"Inpatient groups with an increased prevalence of OSA","title":"Inpatient groups with an increased prevalence of obstructive sleep apnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inpatient groups with an increased prevalence of obstructive sleep apnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Acute stroke</td> </tr> <tr> <td>Acute decompensated heart failure</td> </tr> <tr> <td>Acute coronary syndrome</td> </tr> <tr> <td>Atrial fibrillation</td> </tr> <tr> <td>Elective surgery</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 107650 Version 1.0</div></div></div>"},"107655":{"type":"graphic_table","displayName":"Classes of hemorrhage in trauma","title":"Classes of hemorrhage in trauma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classes of hemorrhage in trauma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;Clinical feature</td> <td class=\"subtitle1\">Class I</td> <td class=\"subtitle1\">Class II</td> <td class=\"subtitle1\">Class III</td> <td class=\"subtitle1\">Class IV</td> </tr> <tr> <td><strong>Blood loss (mL)</strong></td> <td class=\"centered\">Up to 750</td> <td class=\"centered\">750 to 1500</td> <td class=\"centered\">1500 to 2000</td> <td class=\"centered\">&#62;2000</td> </tr> <tr> <td><strong>Blood loss (percent blood volume)</strong></td> <td class=\"centered\">Up to 15 percent</td> <td class=\"centered\">15 to 30 percent</td> <td class=\"centered\">30 to 40 percent</td> <td class=\"centered\">&#62;40 percent</td> </tr> <tr> <td><strong>Pulse rate (beats/minute)</strong></td> <td class=\"centered\">&#60;100</td> <td class=\"centered\">100 to 120</td> <td class=\"centered\">120 to 140</td> <td class=\"centered\">&#62;140</td> </tr> <tr> <td><strong>Systolic blood pressure</strong></td> <td class=\"centered\">Normal</td> <td class=\"centered\">Normal</td> <td class=\"centered\">Decreased</td> <td class=\"centered\">Decreased</td> </tr> <tr> <td><strong>Pulse pressure (mmHg)</strong></td> <td class=\"centered\">Normal or increased</td> <td class=\"centered\">Decreased</td> <td class=\"centered\">Decreased</td> <td class=\"centered\">Decreased</td> </tr> <tr> <td><strong>Respiratory rate (breaths/minute)</strong></td> <td class=\"centered\">14 to 20</td> <td class=\"centered\">20 to 30</td> <td class=\"centered\">30 to 40</td> <td class=\"centered\">&#62;35</td> </tr> <tr> <td><strong>Urine output (mL/hour)</strong></td> <td class=\"centered\">&#62;30</td> <td class=\"centered\">20 to 30</td> <td class=\"centered\">5 to 15</td> <td class=\"centered\">Negligible</td> </tr> <tr> <td><strong>Mental status</strong></td> <td class=\"centered\">Slightly anxious</td> <td class=\"centered\">Mildly anxious</td> <td class=\"centered\">Anxious, confused</td> <td class=\"centered\">Confused, lethargic</td> </tr> <tr> <td><strong>Initial fluid replacement</strong></td> <td class=\"centered\">Crystalloid</td> <td class=\"centered\">Crystalloid</td> <td class=\"centered\">Crystalloid and blood</td> <td class=\"centered\">Crystalloid and blood</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table shows the&nbsp;estimated&nbsp;blood loss&nbsp;(for a 70 kg man)&nbsp;based on initial&nbsp;presentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Advanced trauma life support student course manual (9th ed), chapter 3, page 69, Table 3.1; Blood Loss Table; Published by: American College of Surgeons (Corporate Author) 2012. Copyright &copy; American College of Surgeons. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 107655 Version 2.0</div></div></div>"},"107658":{"type":"graphic_table","displayName":"Maximum permissible residual disinfectant levels","title":"Maximum permissible residual disinfectant levels in drinking water and water used in the preparation of dialysis fluid","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maximum permissible residual disinfectant levels in drinking water and water used in the preparation of dialysis fluid</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"24%\"></colgroup><colgroup span=\"2\" width=\"38%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Maximum permitted level in drinking water (mg/L)</td> <td class=\"subtitle1\">Maximum permitted level in water used for the preparation of dialysis fluid (mg/L)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Disinfectant</td> </tr> <tr> <td class=\"indent1\">Chlorine</td> <td>4 (as Cl<sub>2</sub>)</td> <td>0.1*</td> </tr> <tr> <td class=\"indent1\">Chloramine</td> <td>4 (as Cl<sub>2</sub>)</td> <td>See footnote*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chlorine dioxide</td> <td>0.8 (as ClO<sub>2</sub>)</td> <td>See footnote<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Disinfectant by-products</td> </tr> <tr> <td class=\"indent1\">Total trihalomethanes (TTHM)<sup>&#916;</sup></td> <td>0.08</td> <td>Not specified</td> </tr> <tr> <td class=\"indent1\">Haloacetic acids (HAA5)<sup>&#9674;</sup></td> <td>0.06</td> <td>Not specified</td> </tr> <tr> <td class=\"indent1\">Chlorite</td> <td>1</td> <td>Not specified</td> </tr> <tr> <td class=\"indent1\">Bromate</td> <td>0.01</td> <td>Not specified</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Total chlorine is defined as the sum free chlorine and combined chlorine. There is no direct method for the measurement of chloramine. It is generally established by measuring total and free chlorine concentrations and calculating the difference. When total chlorine tests are used as a single analysis, the maximum level for both chlorine and chloramine should not exceed 0.1 mg/L. Since there is no distinction between chlorine and chloramine, this safely assumes that all chlorine present is chloramine.<br />¶ There is little information about the potential toxicity of chlorine dioxide and its daughter products to hemodialysis patients. A review of the literature yielded a single, historic report of 17 dialysis patients treated with water containing 0.02 to 0.08 mg/L of chlorite ions and no detectable chlorate ions, in whom hematologic changes were noted.<SUP>[1]</SUP><br />Δ Total trihalomethanes are the sum of the concentrations of chloroform, bromodichloromethane, dibromochloromethane, and bromoform.<br /><FONT class=lozenge>◊</FONT> Haloacetic acids (five) are the sum of the concentrations of mono-, di-, and trichloroacetic acids and mono- and dibromoacetic acids.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ames RG, Stratton JW. Effect of chlorine dioxide water disinfection on hematologic and serum parameters of renal dialysis patients. Arch Environ Health 1987, 42:280.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 107658 Version 2.0</div></div></div>"},"107660":{"type":"graphic_picture","displayName":"Paratubal cysts","title":"Paratubal cysts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paratubal cysts</div><div class=\"cntnt\"><img style=\"width:401px; height:284px;\" src=\"images/OBGYN/107660_Paratubal_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A hydatid cyst of Morgagni dangles from its stalk near the fimbriated end of this formalin-fixed fallopian tube.<br />(B) A paratubal cyst bulges from one aspect of the fallopian tube in this fresh specimen. A portion of the fimbriated end of the tube is at top.</div><div class=\"graphic_reference\">Reproduced with permission from: Reichert RA. Diagnostic Gynecologic and Obstetric Pathology: An Atlas and Text, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 107660 Version 1.0</div></div></div>"},"107661":{"type":"graphic_figure","displayName":"Paratubal paraovarian cysts","title":"Anatomic locations of paratubal and paraovarian cysts","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Anatomic locations of paratubal and paraovarian cysts</div><div class=\"cntnt\"><img style=\"width:526px; height:344px;\" src=\"images/OBGYN/107661_Paratubalparaovariancysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(1) A hydatid cyst of Morgagni arises from the hydatid of Morgagni, which is a remnant of the paramesonephric duct.<br />(2) A Kobelt cyst arises from the appendix vesiculosa, which is a remnant of&nbsp;the mesonephric duct.<br />(3) A cyst of the epoophoron arises from the epoophoron, which is a remnant of the mesonephric tubules.<br />(4) A cyst of the paroophoron arises from the paroophoron, which is a remnant of the mesonephric tubules.<br />(5) A Gartner duct cyst arises from the duct of Gartner, which is a remnant of the mesonephric duct.</div><div class=\"graphic_reference\">Modified from: Janovski NA, Paramanandhan TL. Ovarian Tumors: Major Problems in Obstetrics and Gynecology, WB Saunders, Philadelphia 1973.</div><div id=\"graphicVersion\">Graphic 107661 Version 1.0</div></div></div>"},"107670":{"type":"graphic_table","displayName":"Classification of triple I","title":"Classification of triple I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of triple I</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Features of isolated maternal fever and triple I* with classification<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2\">Terminology</td> <td class=\"subtitle2\">Features and comments</td> </tr> <tr> <td>Isolated maternal fever (\"documented\" fever)</td> <td>Maternal oral temperature &#8805;39.0&#176;C (102.2&#176;F) on any one occasion is documented fever. If the oral temperature is 38.0&#176;C (100.4&#176;F)&nbsp;to 38.9&#176;C (102.02&#176;F), repeat the measurement in 30 minutes; if the repeat value remains at least 38.0&#176;C (100.4&#176;F), it is documented fever.</td> </tr> <tr> <td>Suspected triple I</td> <td>Fever without a clear source plus any of the following: <ol> <li>Baseline fetal tachycardia (greater than 160 beats per min for 10 min or longer, excluding accelerations, decelerations, and periods of marked variability) </li> <li>Maternal white blood cell count greater than 15,000 per mm<sup>3</sup> in the absence of corticosteroids </li> <li>Definite purulent fluid from the cervical os </li> </ol> </td> </tr> <tr> <td>Confirmed triple I</td> <td>All of the above plus objective laboratory findings of infection, such as<sup>&#916;</sup>: <ol> <li>Positive amniotic fluid Gram stain for bacteria, low amniotic fluid glucose (eg, &#8804;14 mg/dL), high amniotic fluid white cell count in the absence of a bloody tap (eg, &#62;30 cells/mm<sup>3</sup>), or positive amniotic fluid culture results, or </li> <li>Histopathologic evidence of infection or inflammation or both in the placenta, fetal membranes, or the umbilical cord vessels (funisitis) </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">min: minutes; mm: millimeters.<br />*&nbsp;Triple I refers to intrauterine inflammation or infection or both.<br />¶&nbsp;Discontinue the use of the term \"chorioamnionitis.\" Refer to UpToDate text for discussion.<br />Δ&nbsp;Laboratory studies on amniotic fluid should be performed on fluid obtained by amniocentesis. Placental histopathology is obtained after delivery.</div><div class=\"graphic_reference\">Adapted from: Higgins RD, Saade G, Polin RA, et al. Evaluation and management of women and newborns with a maternal diagnosis of chorioamnionitis: Summary of a workshop. Obstet Gynecol 2016; 127:426. DOI: <A href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2016&amp;issue=03000&amp;article=00002&amp;type=abstract\" target=_blank>10.1097/AOG.0000000000001246</A>. Copyright © 2016 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 107670 Version 4.0</div></div></div>"},"107671":{"type":"graphic_figure","displayName":"Debranching and hybrid repair of Type I arch","title":"Debranching and hybrid repair of Type I arch","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Debranching and hybrid repair of Type I arch</div><div class=\"cntnt\"><img style=\"width:504px; height:597px;\" src=\"images/SURG/107671_Debranching_and_hybrid_repair_of_Type_I_arch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For a Type I arch repair, the arch vessels are debranched, which provides&nbsp;adequate tissue for a stent-graft&nbsp;landing zone in the proximal ascending aorta.</div><div id=\"graphicVersion\">Graphic 107671 Version 1.0</div></div></div>"},"107672":{"type":"graphic_figure","displayName":"Total arch set-up","title":"Total arch set-up","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Total arch set-up</div><div class=\"cntnt\"><img style=\"width:535px; height:356px;\" src=\"images/SURG/107672_Total_arch_set-up.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic of the cardiopulmonary bypass set-up used for total arch replacement. Optimal exposure is achieved by keeping cannulas low profile and tucked out of the operative field. Central arterial cannulation with bi-caval venous cannulation is preferred. An&nbsp;LV vent is placed in the superior pulmonary vein, antegrade cardioplegia is given via the aorta, and retrograde cardioplegia is given via the coronary sinus.</div><div class=\"graphic_footnotes\">IVC: inferior vena cava; LV: left ventricle; SVC: superior vena cava.</div><div id=\"graphicVersion\">Graphic 107672 Version 2.0</div></div></div>"},"107674":{"type":"graphic_table","displayName":"Rx suspected S. aureus and streptococcal SSTI neonates","title":"Doses for antibiotics suggested in the treatment of suspected staphylococcal or streptococcal skin and soft tissue infections in neonates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doses for antibiotics suggested in the treatment of suspected staphylococcal or streptococcal skin and soft tissue infections in neonates</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Parenteral antibiotics</td> <td class=\"subtitle1\" colspan=\"2\">Infants &#8804;7 days of age</td> <td class=\"subtitle1\" colspan=\"3\">Infants 8 to 28 days of age</td> </tr> <tr> <td class=\"subtitle2\">BW &#8804;2 kg</td> <td class=\"subtitle2\">BW &#62;2 kg</td> <td class=\"subtitle2\">BW &#8804;2 kg</td> <td class=\"subtitle2\" colspan=\"2\">BW &#62;2 kg</td> </tr> <tr> <td>Cefazolin</td> <td>15 mg/kg IV every 12 hours</td> <td>25 mg/kg IV every 12 hours&nbsp;</td> <td>15 mg/kg IV every 12 hours</td> <td colspan=\"2\">25 mg/kg IV every 8 hours</td> </tr> <tr> <td>Cefotaxime</td> <td>50 mg/kg IV every 12 hours</td> <td> <p>50 mg/kg IV every 12 hours</p> </td> <td>50 mg/kg IV every 8 to 12 hours</td> <td colspan=\"2\">50 mg/kg IV every 8 hours</td> </tr> <tr> <td>Ceftazidime</td> <td>50 mg/kg IV every 12 hours</td> <td>50 mg/kg IV every 12 hours</td> <td>50 mg/kg IV every 8 to 12 hours</td> <td colspan=\"2\">50 mg/kg IV every 8 hours</td> </tr> <tr> <td>Ceftriaxone*</td> <td>50 mg/kg IV every 24 hours</td> <td> <p>50 mg/kg IV</p> <p>every&nbsp;24 hours</p> </td> <td>50 mg/kg IV every 24 hours</td> <td colspan=\"2\">50 mg/kg IV every 24 hours</td> </tr> <tr> <td>Clindamycin<sup>&#182;</sup></td> <td>5 mg/kg IV every 12 hours</td> <td>5 mg/kg IV every 8 hours</td> <td>5 mg/kg IV every 8 hours</td> <td colspan=\"2\">5 mg/kg IV every 6 hours</td> </tr> <tr> <td>Gentamicin<sup>&#916;</sup></td> <td>5 mg/kg IV every 48 hours</td> <td>4 mg/kg IV every 24 hours</td> <td>5 mg/kg IV every 36 hours</td> <td colspan=\"2\">4 to 5 mg/kg IV every 24 hours</td> </tr> <tr> <td>Linezolid</td> <td>10 mg/kg IV every 12 hours</td> <td>10 mg/kg IV every 8 hours</td> <td>10 mg/kg IV every 8 hours</td> <td colspan=\"2\">10 mg/kg IV every 8 hours</td> </tr> <tr> <td>Nafcillin</td> <td>25 mg/kg IV every 12 hours</td> <td>25 mg/kg every 8 hours</td> <td>25 mg/kg IV every 8 hours</td> <td colspan=\"2\">25 mg/kg IV every 6 hours</td> </tr> <tr> <td>Oxacillin</td> <td class=\"divider_bottom\">25 mg/kg IV every 12 hours</td> <td class=\"divider_bottom\">25 mg/kg every 8 hours</td> <td class=\"divider_bottom\">25 mg/kg IV every 8 hours</td> <td class=\"divider_bottom\" colspan=\"2\">25 mg/kg IV every 6 hours</td> </tr> <tr> <td>Piperacillin-tazobactam<sup>&#9674;</sup></td> <td class=\"divider_bottom\">100 mg/kg piperacillin component IV every 12 hours</td> <td class=\"divider_bottom\">100 mg/kg piperacillin component IV every 12 hours</td> <td class=\"divider_bottom\">100 mg/kg piperacillin component IV every 8 hours</td> <td class=\"divider_bottom\" colspan=\"2\">100 mg/kg piperacillin component IV every 8 hours</td> </tr> <tr> <td rowspan=\"4\">Vancomycin<sup>&#167;</sup></td> <td class=\"subtitle2\" colspan=\"5\">Dosed according to serum creatinine concentration as indicated below</td> </tr> <tr> <td class=\"subtitle3\" colspan=\"5\">Serum creatinine concentration (mg/dL)</td> </tr> <tr> <td class=\"subtitle3\">&#60;0.7</td> <td class=\"subtitle3\">0.7 to 0.9</td> <td class=\"subtitle3\">1.0 to 1.2</td> <td class=\"subtitle3\">1.3 to 1.6</td> <td class=\"subtitle3\">&#62;1.6</td> </tr> <tr> <td>15 mg/kg IV every 12 hours</td> <td>20 mg/kg IV every 24 hours</td> <td>15 mg/kg IV every 24 hours</td> <td>10 mg/kg IV every 24 hours</td> <td>15 mg/kg IV every 48 hours</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">Oral antibiotics for completion of therapy<sup>&#165;</sup></td> <td class=\"subtitle1\" colspan=\"2\">Infants &#8804;7 days of age</td> <td class=\"subtitle1\" colspan=\"3\">Infants 8 to 28 days of age</td> </tr> <tr> <td class=\"subtitle2\">BW &#8804;2 kg</td> <td class=\"subtitle2\">BW &#62;2 kg</td> <td class=\"subtitle2\">BW &#60;2 kg</td> <td class=\"subtitle2\" colspan=\"2\">BW &#62;2 kg</td> </tr> <tr> <td>Cephalexin</td> <td colspan=\"2\">Oral therapy not appropriate</td> <td colspan=\"3\">6.25 to 12.5 mg/kg orally every 6 hours</td> </tr> <tr> <td>Clindamycin<sup>&#182;</sup></td> <td>5 mg/kg orally every 12 hours</td> <td>5 mg/kg orally every 8 hours</td> <td>5 mg/kg orally every 8 hours</td> <td colspan=\"2\">5 mg/kg orally every 6 hours</td> </tr> <tr> <td>Linezolid<sup>&#135;</sup></td> <td colspan=\"2\">Oral therapy not appropriate</td> <td>10 mg/kg orally every 8 hours</td> <td colspan=\"2\">10 mg/kg orally every 8 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table provides the doses of antibiotics that may be used in the treatment of staphylococcal or streptococcal SSTIs in neonates. Refer to UpToDate content on SSTIs in neonates for details regarding the choice of antimicrobial therapy.</div><div class=\"graphic_footnotes\">SSTI: skin and soft tissue infection; BW: body weight; IV: intravenously; MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>; MSSA: methicillin-susceptible <EM>S. aureus</EM>.<br />* Ceftriaxone should not be administered to neonates&nbsp;if they are also receiving intravenous calcium in any form.<br />¶ Monitor carefully when used if more than 15% of local community-associated <EM>S. aureus</EM> isolates are resistant to clindamycin.<br />Δ Gentamicin is necessary to provide coverage for possible gram-negative pathogens. The optimal, individualized dose should be based on determination of serum concentrations. Doses may differ from those recommended by the package insert.<br />◊ If there is another indication for piperacillin-tazobactam (eg, <EM>Pseudomonas</EM> infection).<br />§&nbsp;Dosing algorithm for vancomycin based upon serum creatinine concentration in neonates born at gestational age &gt;28 weeks. Serum creatinine concentration will take approximately 5 to 7 days after birth to reasonably reflect neonatal renal function. Cautious use of creatinine-based dosing strategy with frequent assessment of renal function and vancomycin serum concentrations are recommended in neonates ≤7 days old<SUP>[1]</SUP>. A vancomycin dosing method based upon postnatal age and weight is provided as an alternative to the serum creatinine-based method listed above and may be useful in some clinical situations. This particular algorithm was provided in the 2009 edition of the Red Book<SUP>[2]</SUP>.<br />Postnatal age &lt;7 days: &#xD;&#xA;<UL>&#xD;&#xA;<LI>&lt;1200 g: 15 mg/kg IV every 24 hours</LI> &#xD;&#xA;<LI>1200 to 2000 g: 10 to 15 mg/kg IV every 12 or 18 hours</LI> &#xD;&#xA;<LI>&gt;2000 g: 10 to 15 mg/kg IV every 8 or 12 hours</LI></UL>Postnatal age ≥7 days:  &#xD;&#xA;<UL>&#xD;&#xA;<LI>&lt;1200 g: 15 mg/kg IV every 24 hours</LI> &#xD;&#xA;<LI>1200 to 2000 g: 10 to 15 mg/kg IV every 8 or 12 hours</LI> &#xD;&#xA;<LI>&gt;2000 g: 10 to 15 mg/kg IV every 6 or 8 hours</LI></UL>¥ Oral therapy should be directed by results of antibiotic susceptibility testing. If no pathogen is identified, we provide coverage for both MRSA and MSSA (eg, clindamycin).<br />‡&nbsp;Oral linezolid is reserved for isolates resistant to other agents; consultation with an expert in infectious diseases is suggested to ensure that it is the only oral option.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Nelson's Pediatric Antimicrobial Therapy, 21<SUP>st</SUP> ed, Bradley JS, Nelson JD, Cantey JB, et al (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.36.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Antibacterial drugs for newborn infants: Dose and frequency of administration. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28<EM>th</EM> ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.745.</LI></OL>Data adapted from: American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<EM>th</EM> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.</div><div id=\"graphicVersion\">Graphic 107674 Version 4.0</div></div></div>"},"107675":{"type":"graphic_figure","displayName":"Felt and bioglue repair of aortic dissection","title":"Felt and bioglue repair of aortic dissection","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Felt and bioglue repair of aortic dissection</div><div class=\"cntnt\"><img style=\"width:516px; height:423px;\" src=\"images/SURG/107675_Felt_and_bioglue_for_dissections.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During repair aortic dissection, a technique to eliminate the false lumen uses felt and fibrin glue.</div><div id=\"graphicVersion\">Graphic 107675 Version 1.0</div></div></div>"},"107676":{"type":"graphic_figure","displayName":"Aortic root involvement","title":"Aortic root involvement","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Aortic root involvement</div><div class=\"cntnt\"><img style=\"width:506px; height:353px;\" src=\"images/SURG/107676_Aortic_root_involvement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ascending aortic aneurysm with aortic root dilatation affecting the valve (A) necessitates replacement of the aortic root and aortic valve using a valved conduit (B). The coronary arteries are reimplanted.</div><div id=\"graphicVersion\">Graphic 107676 Version 1.0</div></div></div>"},"107677":{"type":"graphic_figure","displayName":"Valve sparing aortic root","title":"Valve sparing aortic root","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Valve sparing aortic root</div><div class=\"cntnt\"><img style=\"width:511px; height:343px;\" src=\"images/SURG/107677_Valve_sparing_aortic_root.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figures shows a close-up view of a valve-sparing aortic root replacement showing excision of the affected tissue down to the annulus (A), and reconstruction with a tube graft and coronary artery reimplantation (B).</div><div id=\"graphicVersion\">Graphic 107677 Version 1.0</div></div></div>"},"107678":{"type":"graphic_figure","displayName":"Valve-sparing aortic root replacement ","title":"Valve-sparing aortic root replacement ","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Valve-sparing aortic root replacement </div><div class=\"cntnt\"><img style=\"width:524px; height:333px;\" src=\"images/SURG/107678_David_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ascending aortic aneurysm without dilation of the aortic root can be repaired with&nbsp;a valve-sparing aortic root replacement (ie, T. David procedure). The ascending aorta is resected sparing&nbsp;the aortic annulus and valve leaflets (A),&nbsp;and replaced with a tube graft (B,C)&nbsp;that is sutured&nbsp;to the&nbsp;annulus and resuspending the valves. The coronary arteries are reimplanted (C).</div><div id=\"graphicVersion\">Graphic 107678 Version 1.0</div></div></div>"},"107679":{"type":"graphic_figure","displayName":"Hemi-arch peninsula","title":"Hemi-arch peninsula","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Hemi-arch peninsula</div><div class=\"cntnt\"><img style=\"width:516px; height:365px;\" src=\"images/SURG/107679_Hemi-arch_peninsula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the arch vessels (brachiocephalic, carotid, left subclavian) are not involved by dissection or aneurysm but the lesser curve of the arch needs to be covered, a hemi-arch repair can be performed. </div><div id=\"graphicVersion\">Graphic 107679 Version 1.0</div></div></div>"},"107680":{"type":"graphic_figure","displayName":"Crawford extent I aortic repair","title":"Crawford extent I aortic repair","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Crawford extent I aortic repair</div><div class=\"cntnt\"><img style=\"width:505px; height:597px;\" src=\"images/SURG/107680_Crawford_extent_I_descending_thoracic_aorta_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Crawford extent I thoracoabdominal aortic repair extends from the just distal to the&nbsp;left subclavian artery to the renal arteries.</div><div id=\"graphicVersion\">Graphic 107680 Version 1.0</div></div></div>"},"107681":{"type":"graphic_figure","displayName":"Thoracic aortic replacement for connective tissue disease","title":"Descending thoracic aortic replacement CTD","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Descending thoracic aortic replacement CTD</div><div class=\"cntnt\"><img style=\"width:504px; height:597px;\" src=\"images/SURG/107681_Descending_thoracic_aortic_replacement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repair of a Crawford extent II thoracoabdominal aortic aneurysm with individual anastomosis&nbsp;to&nbsp;each of the&nbsp;visceral vessels. This type of repair is often used in patients with connective tissue disorders to prevent visceral artery aneurysmal dilation in the future.</div><div id=\"graphicVersion\">Graphic 107681 Version 1.0</div></div></div>"},"107683":{"type":"graphic_algorithm","displayName":"Treatment algorithm for post-herniorrhaphy groin pain","title":"Treatment algorithm for post-herniorrhaphy groin pain","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for post-herniorrhaphy groin pain</div><div class=\"cntnt\"><img style=\"width:554px; height:1204px;\" src=\"images/SURG/107683_Tx_algo_pst_hrnrrhph_grn_pn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">US: ultrasound; CT: computed tomography; MRI: magnetic resonance imaging; NSAIDs: nonsteroidal anti-inflammatory drugs.<br />* Standard postoperative pain management includes administration of NSAIDs and/or narcotic medications, as well as nonpharmacologic measures such as rest and icing of the groin area.<br />¶ Medical pain management includes anti-epileptics (eg, gabapentin or progabalin), or antidepressants (eg, duloxetine).</div><div id=\"graphicVersion\">Graphic 107683 Version 1.0</div></div></div>"},"107686":{"type":"graphic_diagnosticimage","displayName":"Adult with chronic osteomyelitis","title":"Adult with chronic osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Adult with chronic osteomyelitis</div><div class=\"cntnt\"><img style=\"width:564px; height:764px;\" src=\"images/ID/107686_Adult_chronic_osteomyelitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">39-year-old man with chronic osteomyelitis of the tibia and a draining wound. Plain films (A and B) demonstrate a sclerotic sequestrum in the defect of the tibia (arrow). Magnetic resonance imaging axial T1 &amp; T2 images (C and D) show the sequestrum (arrow) in the intraosseous abscess. The abscess/sinus tract can be seen extending to the skin on the T2 image (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Charles Spritzer, MD.</div><div id=\"graphicVersion\">Graphic 107686 Version 1.0</div></div></div>"},"107687":{"type":"graphic_diagnosticimage","displayName":"Child with chronic osteomyelitis","title":"Child with chronic osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Child with chronic osteomyelitis</div><div class=\"cntnt\"><img style=\"width:271px; height:328px;\" src=\"images/ID/107687_Child_chronic_osteomyelitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four-year-old boy with chronic osteomyelitis. Radiographs of the femur demonstrate pathologic fracture and involucrum (arrow).</div><div class=\"graphic_reference\">Courtesy of Charles Spritzer, MD.</div><div id=\"graphicVersion\">Graphic 107687 Version 1.0</div></div></div>"},"107688":{"type":"graphic_figure","displayName":"Total thoracoabdominal aortic replacement","title":"Total thoracoabdominal aortic replacement","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Total thoracoabdominal aortic replacement</div><div class=\"cntnt\"><img style=\"width:504px; height:597px;\" src=\"images/SURG/107688_Thoracoabdominal_aortic_replacement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Open total thoracoabdominal aneurysm replacement. The left subclavian and left carotid artery have been debranched (re-routed) and the descending abdominal aorta is completely replaced with the intercostal (above)&nbsp;and visceral (below) vessels preserved and reimplanted as island patches.</div><div id=\"graphicVersion\">Graphic 107688 Version 1.0</div></div></div>"},"107689":{"type":"graphic_diagnosticimage","displayName":"RAI uptake after total thyroidectomy","title":"Radioactive iodine uptake in thyroid bed after total thyroidectomy","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Radioactive iodine uptake in thyroid bed after total thyroidectomy</div><div class=\"cntnt\"><img style=\"width:764px; height:606px;\" src=\"images/ENDO/107689_RAI_uptake_after_total.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Total thyroidectomy seldom results in removal of all thyroid tissue. Post RAI ablation scanning with SPECT/CT most commonly localized the specific uptake areas within the thyroid bed in the regions of Berry's ligament, lobar region, pyramidal lobe, and superior poles. Although this uptake probably represents residual normal thyroid tissue, in some cases the uptake could also be caused by persistent thyroid cancer in the thyroid bed.</div><div class=\"graphic_footnotes\">CT: computed tomography; RAI: radioactive iodine; SPECT: single-photon emission computed tomography.</div><div class=\"graphic_reference\">From: Zeuren R, Biagini A, Grewal RK, Ret al. RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system. Laryngoscope 2015; 125(10):2417-24. <a href=\"http://onlinelibrary.wiley.com/doi/10.1002/lary.25295/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1002/lary.25295/abstract</a>. Copyright &copy; 2015 The American Laryngological, Rhinological and Otological Society, Inc. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 107689 Version 1.0</div></div></div>"},"107690":{"type":"graphic_table","displayName":"Medical cadmium removal triggered by medical surveillance","title":"Medical cadmium removal actions triggered by initial medical surveillance*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical cadmium removal actions triggered by initial medical surveillance*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Biological measurement</td> <td class=\"subtitle1\">Normal levels</td> <td class=\"subtitle1\">Elevated levels, non-mandatory removal</td> <td class=\"subtitle1\">Highly elevated levels, non-mandatory removal</td> <td class=\"subtitle1\">Highly elevated levels, mandatory removal</td> </tr> <tr class=\"divider_bottom\"> <td>Cadmium in urine (CdU)<sup>&#182;</sup></td> <td>&#8804;3</td> <td>&#62;3 and &#8804;7</td> <td>&#62;7</td> <td>&#62;7</td> </tr> <tr class=\"divider_bottom\"> <td>Cadmium in blood (CdB)<sup>&#916;</sup></td> <td>&#8804;5</td> <td>&#62;5 and &#8804;10</td> <td>&#62;10</td> <td>&#62;10</td> </tr> <tr class=\"divider_bottom\"> <td>Beta-2 (beta2MU)<sup>&#9674;</sup></td> <td>&#8804;300</td> <td>&#62;300 and &#8804;750</td> <td>&#62;750</td> <td>&#62;750</td> </tr> <tr class=\"divider_bottom\"> <td>Trigger level</td> <td>All three measurements at normal levels.</td> <td>Any one measurement at an elevated level.</td> <td>Any one measurement at a highly elevated level.</td> <td>After confirmed follow-up testing within 90 days, either CdU or CdB remains at a highly elevated level, or beta2MU remains at a highly elevated level and either CdU or CdB is at an elevated level.</td> </tr> <tr class=\"divider_bottom\"> <td>Risk at this level</td> <td>Negligible or relatively low risk of renal tubular proteinuria (ie, consistent with the background rate among the general population).</td> <td>Elevated risk of renal tubular proteinuria (ie, above the background level experienced by the general population).</td> <td> <p>Elevated, and perhaps highly elevated, risk of renal tubular proteinuria (ie, above the background level experienced by the general population).</p> Risk may not be abnormal if beta2MU is highly elevated and CdU and CdB are at normal levels.<sup>&#167;</sup></td> <td>Highly elevated risk of renal tubular proteinuria.</td> </tr> <tr> <td>Actions</td> <td>Provide annual biological monitoring and biennial medical examinations.</td> <td>Provide semiannual biological monitoring and annual medical examinations until all measurements return to normal levels.</td> <td> <p>If medically removed from job: Provide quarterly biological monitoring and semiannual medical examinations until clinician decides to return employee to job or permanently remove the employee from job.</p> If not medically removed from job: Provide quarterly biological monitoring and semiannual medical examinations until all measurements return to normal levels.</td> <td>Mandatory medical removal required. Provide quarterly biological monitoring and semiannual medical examinations until clinician decides to return employee to job or permanently remove the employee from job.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CdU: cadmium in urine; CdB: cadmium in blood; beta2MU: beta-2 microglobulin in urine.<br />* This table only addresses those actions designed to decrease cadmium; other requirements may apply based on the results of the other medical examinations.<br />¶ CdU = CdU mcg per gram of creatinine in urine.<br />Δ beta2MU = beta2MU mcg per gram of creatinine in urine<br /><FONT class=lozenge>◊</FONT> CdB = CdB mcg per liter of whole blood.<br />§ In cases in which the beta2MU is highly elevated and CdU and CdB are at normal levels, the clinician should check to determine that the beta2MU levels accurately reflect the true beta2MU levels. If they do, then the clinician must determine the cause of the highly elevated levels of proteins in urine (eg, presence of end-stage renal disease or immune-deficiency diseases).</div><div class=\"graphic_reference\">Reproduced from: OSHA Brief. Medical evaluation of renal effects of cadmium exposure. Available at: <a href=\"https://www.osha.gov/Publications/OSHA_3675.pdf\" spellcheck=\"true\" target=\"_blank\">https://www.osha.gov/Publications/OSHA_3675.pdf</a> (Accessed on April 13, 2016).</div><div id=\"graphicVersion\">Graphic 107690 Version 1.0</div></div></div>"},"107691":{"type":"graphic_table","displayName":"Vitiligo therapies","title":"Therapies for stabilization and repigmentation of vitiligo","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapies for stabilization and repigmentation of vitiligo</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stabilization</td> <td class=\"subtitle1\">Repigmentation</td> </tr> <tr> <td>Oral corticosteroids</td> <td>Topical corticosteroids</td> </tr> <tr> <td>NB-UVB phototherapy</td> <td>Calcineurin inhibitors</td> </tr> <tr> <td>Minocycline</td> <td>Vitamin D analogues</td> </tr> <tr> <td>Methotrexate</td> <td>NB-UVB phototherapy</td> </tr> <tr> <td>Vitamin supplementation</td> <td>Psoralen photochemotherapy</td> </tr> <tr> <td>&nbsp;</td> <td>Targeted phototherapy</td> </tr> <tr> <td>&nbsp;</td> <td> <p>Experimental agents</p> <p class=\"indent1\"><span class=\"indent2\"></span><span class=\"indent1\"></span><span class=\"indent1\"></span>Afamelanotide</p> <p class=\"indent1\">Prostaglandin F2-alpha analogues</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NB-UVB: narrowband ultraviolet B.</div><div id=\"graphicVersion\">Graphic 107691 Version 4.0</div></div></div>"},"107698":{"type":"graphic_table","displayName":"Microbiology amniotic fluid in preterm labor or chorioamnionitis","title":"Microbiology of amniotic fluid in women with spontaneous preterm labor or clinical chorioamnionitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Microbiology of amniotic fluid in women with spontaneous preterm labor or clinical chorioamnionitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><em>Fusobacterium</em> species</td> </tr> <tr> <td><em>Ureaplasma</em> species</td> </tr> <tr> <td><em>Sneathia</em></td> </tr> <tr> <td><em>Gardnerella vaginalis</em></td> </tr> <tr> <td><em>Mycoplasma hominis</em></td> </tr> <tr> <td><em>Streptococcus</em> species</td> </tr> <tr> <td><em>Lactobacillus</em> species</td> </tr> <tr> <td><em>Peptostreptococcus</em> species</td> </tr> <tr> <td><em>Bacteroides</em> species</td> </tr> <tr> <td><em>Leptotrichia amnionii</em></td> </tr> <tr> <td><em>Acinetobacter</em> species</td> </tr> <tr> <td><em>Porphyromonas</em> species</td> </tr> <tr> <td><em>Bacillus</em> species</td> </tr> <tr> <td><em>Veillonella</em> species</td> </tr> <tr> <td><em>Staphylococcus</em> species</td> </tr> <tr> <td><em>Prevotella</em> species</td> </tr> <tr> <td><em>Escherichia coli</em></td> </tr> <tr> <td><em>Delftia acidovorans</em></td> </tr> <tr> <td><em>Neisseria cinerea</em></td> </tr> <tr> <td><em>Pseudomonas aeruginosa</em></td> </tr> <tr> <td><em>Eubacterium</em> species</td> </tr> <tr> <td><em>Enterococcus</em> species</td> </tr> <tr> <td><em>Candida</em> species</td> </tr> <tr> <td><em>Abiotrophia defectiva</em></td> </tr> <tr> <td><em>Micrococcus luteus</em></td> </tr> <tr> <td>Firmicutes</td> </tr> <tr> <td><em>Cutibacterium </em>(formerly<em> Propionibacterium</em>)<em> acnes</em></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Organisms were detected using cultivation and molecular microbiologic techniques.</div><div class=\"graphic_reference\">Data from: Kim CJ, Romero R, Chaemsaithong P, et al. Acute inflammatory lesions of the placenta. Am J Obstet Gynecol 2015; 213:S29.</div><div id=\"graphicVersion\">Graphic 107698 Version 2.0</div></div></div>"},"107699":{"type":"graphic_algorithm","displayName":"Staging and management of Merkel cell carcinoma","title":"Staging and management of Merkel cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Staging and management of Merkel cell carcinoma</div><div class=\"cntnt\"><img style=\"width:662px; height:424px;\" src=\"images/ONC/107699_Staging_management_Merkel.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RT: radiation therapy.<br />* Initial evaluation based upon symptoms and physical findings, including imaging of the lung to exclude primary small cell carcinoma of the lung.<br />&para; Sentinel lymph node biopsy may be performed before wide local excision, although the latter can be done right after sentinel lymph node biopsy in the same anesthetic setting.<br />&Delta; The role of sentinel lymph node biopsy is less well established in MCC of the head and neck because of variable lymphatic drainage patterns.<br /><span class=\"lozenge\">&loz;</span> Fine needle aspiration (FNA), core needle biopsy, or open biopsy.<br />&sect; Surgery for the primary tumor is preferred; if this is not technically feasible or if the patient is not a surgical candidate, definitive RT is an alternative.<br />&yen; Adjuvant RT to the primary is indicated if any high-risk features are present. High-risk features include the presence of a primary tumor &gt;1 cm, positive surgical margins or limited surgical resection margins, lymphovascular invasion, or immunocompromised host. Adjuvant nodal RT is indicated if there is a higher risk of anatomic, technical, or histologic failure (previous wide local excision, immunohistochemistry not performed, or immunocompromised host).<br />&Dagger; Adjuvant immunotherapy with checkpoint inhibitors limited to formal clinical trial setting.<br />&dagger; Definitive treatment of regional lymph nodes includes regional lymph node dissection and/or RT.<br />** Enrollment in clinical trial of checkpoint inhibition immunotherapy, if available, or systemic chemotherapy as indicated for small cell carcinoma of the lung.</div><div id=\"graphicVersion\">Graphic 107699 Version 1.0</div></div></div>"},"107703":{"type":"graphic_picture","displayName":"Lichen sclerosus wrists","title":"Extragenital lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Extragenital lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:550px; height:756px;\" src=\"images/DERM/107703_Lichen_sclerosus_wrists.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Porcelain-white plaques on the wrists of a 63-year-old woman.</div><div class=\"graphic_reference\">Copyright &copy; Diepgen TL, Yihune G et al. Dermatology Online Atlas (<a href=\"http://www.dermis.net/\" target=\"_blank\">www.dermis.net</a>). Reprinted with permission.</div><div id=\"graphicVersion\">Graphic 107703 Version 1.0</div></div></div>"},"107705":{"type":"graphic_picture","displayName":"Discoid lupus dark skin","title":"Discoid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Discoid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/107705_Discoid_lupus_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White atrophic lesions are present in this patient with discoid lupus erythematosus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107705 Version 1.0</div></div></div>"},"107708":{"type":"graphic_table","displayName":"Quintero stages for classification of TTTS","title":"Quintero stages for classification of twin-twin transfusion syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Quintero stages for classification of twin-twin transfusion syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td>Stage I</td> <td>Oligohydramnios and polyhydramnios sequence*, and the bladder of the donor twin is visible. Dopplers in both twins are normal.</td> </tr> <tr class=\"divider_bottom\"> <td>Stage II</td> <td>Oligohydramnios and polyhydramnios sequence, but the bladder of the donor is not visualized. Dopplers in both twins are normal.</td> </tr> <tr class=\"divider_bottom\"> <td>Stage III</td> <td>Oligohydramnios and polyhydramnios sequence, nonvisualized bladder, and abnormal Dopplers. There is absent/reversed end diastolic velocity in the umbilical artery, reversed flow in a-wave of the ductus venosus, or pulsatile flow in the umbilical vein in either fetus.</td> </tr> <tr class=\"divider_bottom\"> <td>Stage IV</td> <td>One or both fetuses show signs of hydrops.</td> </tr> <tr> <td>Stage V</td> <td>One or both fetuses have died.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Although Quintero staging represents one method of standardization, there are several important limitations. Atypical presentations can occur; for example, the donor twin may have both a persistent bladder and abnormal umbilical Doppler flow. In addition, although higher stages are generally associated with a worsening perinatal prognosis, the clinical presentation of a particular case does not always follow an orderly progression of stages. For example, a stage I case may progress rapidly in several days to stage III and regression of disease can occur in as many as 15 percent of stage I cases and 60 percent of stage II disease.</div><div class=\"graphic_footnotes\">* Before 20 weeks of gestation, the maximum vertical amniotic fluid pockets for oligohydramnios and polyhydramnios are usually defined as &lt;2 cm and &gt;8 cm, respectively. After 20 weeks, the maximum vertical pocket for polyhydramnios is defined as &gt;10 cm.</div><div class=\"graphic_reference\">Data from: Quintero RA, Morales WJ, Allen MH, et al. Staging of twin-twin transfusion syndrome. J Perinatol 1999; 19:550.</div><div id=\"graphicVersion\">Graphic 107708 Version 4.0</div></div></div>"},"107711":{"type":"graphic_table","displayName":"Classification of HDL by physical properties","title":"Classification of HDL by physical properties","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of HDL by physical properties</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Method</td> <td class=\"subtitle1\" colspan=\"5\">HDL classification</td> </tr> <tr> <td class=\"subtitle2\">Very large (HDL-VL)</td> <td class=\"subtitle2\">Large (HDL-L)</td> <td class=\"subtitle2\">Medium (HDL-M)</td> <td class=\"subtitle2\">Small (HDL-S)</td> <td class=\"subtitle2\">Very small (HDL-VS)</td> </tr> <tr> <td>Analytical ultracentrifugation</td> <td class=\"centered\">1.063 to 1.087</td> <td class=\"centered\">1.088 to 1.110</td> <td class=\"centered\">1.110 to 1.129</td> <td class=\"centered\">1.129 to 1.154</td> <td class=\"centered\">1.154 to 1.21</td> </tr> <tr> <td>Size range (nm)</td> <td class=\"centered\">12.9 to 9.7</td> <td class=\"centered\">9.7 to 8.8</td> <td class=\"centered\">8.8 to 8.2</td> <td class=\"centered\">8.2 to 7.8</td> <td class=\"centered\">7.8 to 7.2</td> </tr> <tr> <td>Density gradient ultracentrifugation</td> <td class=\"centered\">HDL 2b</td> <td class=\"centered\">HDL 2a</td> <td class=\"centered\">HDL 3a</td> <td class=\"centered\">HDL 3b</td> <td class=\"centered\">HDL 3c</td> </tr> <tr> <td>Density range (g/mL)</td> <td class=\"centered\">1.063 to 1.087</td> <td class=\"centered\">1.088 to 1.110</td> <td class=\"centered\">1.110 to 1.129</td> <td class=\"centered\">1.129 to 1.154</td> <td class=\"centered\">1.154 to 1.170</td> </tr> <tr> <td>Gradient gel electrophoresis</td> <td class=\"centered\">HDL 2b</td> <td class=\"centered\">HDL 2a</td> <td class=\"centered\">HDL 3a</td> <td class=\"centered\">HDL 3b</td> <td class=\"centered\">HDL 3c</td> </tr> <tr> <td>2D gel electrophoresis</td> <td class=\"centered\">Alpha-1</td> <td class=\"centered\">Alpha-2</td> <td class=\"centered\">Alpha-3</td> <td class=\"centered\">Alpha-4</td> <td class=\"centered\">Pre-beta-1 HDL</td> </tr> <tr> <td>Size range (nm)</td> <td class=\"centered\">11.2 to 10.8</td> <td class=\"centered\">9.4 to 9.0</td> <td class=\"centered\">8.5 to 7.5</td> <td class=\"centered\">7.5 to 7.0</td> <td class=\"centered\">6.0 to 5.0</td> </tr> <tr> <td>Nuclear magnetic resonance spectroscopy</td> <td class=\"centered\">Large HDL-P</td> <td class=\"centered\" colspan=\"2\">Medium HDL-P</td> <td class=\"centered\" colspan=\"2\">Small HDL-P</td> </tr> <tr> <td>Size range (nm)</td> <td class=\"centered\">12.9 to 9.7</td> <td class=\"centered\">9.7 to 8.8</td> <td class=\"centered\">8.8 to 8.2</td> <td class=\"centered\">8.2 to 7.8</td> <td class=\"centered\">7.8 to 7.2</td> </tr> <tr> <td>Ion mobility</td> <td class=\"centered\">HDL 2b</td> <td class=\"centered\" colspan=\"4\">HDL 2a + 3</td> </tr> <tr> <td>Size range (nm)</td> <td class=\"centered\">14.5 to 10.5</td> <td class=\"centered\" colspan=\"4\">10.5 to 7.65</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HDL: high density lipoprotein; HDL-P: HDL particle concentration.</div><div class=\"graphic_reference\">Adapted with permission of the American Association For Clinical Chemistry, from: Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL Measures, HDL Particle Heterogeneity, Proposed HDL Nomenclature and Relation to Atherosclerotic Cardiovascular Events. Clin Chem 2011; 57:392; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 107711 Version 1.0</div></div></div>"},"107713":{"type":"graphic_table","displayName":"Differential diagnosis adnexal mass","title":"Differential diagnosis of an adnexal mass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of an adnexal mass</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gynecologic: Ovarian</td> <td class=\"subtitle1\">Gynecologic: Tubal</td> <td class=\"subtitle1\">Gynecologic: Extraovarian and extratubal</td> <td class=\"subtitle1\">Nongynecologic</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Benign</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Functional (physiologic) cyst </li> <li>Corpus luteal cyst </li> <li>Luteoma of pregnancy </li> <li>Theca lutein cyst </li> <li>Polycystic ovaries </li> <li>Endometrioma </li> <li>Cystadenoma </li> <li>Benign ovarian germ cell tumor (eg, mature teratoma) </li> <li>Benign sex cord-stromal tumor </li> </ul> </td> <td> <ul> <li>Ectopic pregnancy </li> <li>Hydrosalpinx </li> </ul> </td> <td> <ul> <li>Paraovarian cyst </li> <li>Paratubal cyst </li> <li>Uterine leiomyoma (pedunculated or cervical) </li> <li>Tubo-ovarian abscess </li> </ul> </td> <td> <ul> <li>Constipation </li> <li>Appendiceal abscess </li> <li>Diverticular abscess </li> <li>Pelvic abscess </li> <li>Bladder diverticulum </li> <li>Ureteral diverticulum </li> <li>Pelvic kidney </li> <li>Peritoneal cyst </li> <li>Nerve sheath tumor </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Malignant or borderline</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Epithelial carcinoma </li> <li>Epithelial borderline neoplasm </li> <li>Malignant ovarian germ cell tumor </li> <li>Malignant sex cord-stromal tumor </li> </ul> </td> <td> <ul> <li>Epithelial carcinoma </li> <li>Serous tubal intraepithelial neoplasia </li> </ul> </td> <td> <ul> <li>Metastatic endometrial carcinoma </li> </ul> </td> <td> <ul> <li>Appendiceal neoplasm </li> <li>Bowel neoplasm </li> <li>Metastasis (eg, breast, colon, lymphoma) </li> <li>Retroperitoneal sarcoma </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Rauh-Hain JA, Melamed A, Buskwofie A, Schorge JO. Adnexal mass in the postmenopausal patient. Clin Obstet Gynecol 2015; 58:53.</div><div id=\"graphicVersion\">Graphic 107713 Version 4.0</div></div></div>"},"107719":{"type":"graphic_table","displayName":"Rx uncomplicated non-falciparum malaria pregnancy","title":"Treatment of uncomplicated non-falciparum malaria in pregnant women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of uncomplicated non-falciparum malaria in pregnant women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;Type of infection</td> <td class=\"subtitle1\">Trimester</td> <td class=\"subtitle1\">Drug and dose</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"><strong>Chloroquine-sensitive infection</strong></td> <td>First trimester</td> <td><strong>Chloroquine:</strong> 600 mg base (= 1000 mg salt) orally immediately, followed by 300 mg base (= 500 mg salt) orally at 6, 24, and 48 hours. Total dose: 1500 mg base (=2500 mg salt).*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Second or third trimester</td> <td><strong>Chloroquine:</strong> Dosing as above.</td> </tr> <tr> <td class=\"indent1\"><strong>OR</strong></td> </tr> <tr> <td><strong>Artemisinin combination therapy: </strong>One of the following:</td> </tr> <tr> <td class=\"indent1\"><strong>Dihydroartemisinin-piperaquine:<sup>&#182;</sup></strong> 1 tablet = 40 mg of dihydroartemisinin and 320 mg of piperaquine phosphate. Dosing for patients 36 to &#60;60 kg consists of 3 tablets orally per day for three days. Dosing for patients 60 to &#60;80 kg consists of 4 tablets per day orally for three days.</td> </tr> <tr> <td class=\"indent1\"><strong>Artesunate-mefloquine:</strong> 1 tablet = 100 mg artesunate and 220 mg mefloquine hydrochloride per tablet. Dosing for patients &#8805;30 kg consists of 2 tablets per day orally for three days.</td> </tr> <tr> <td class=\"indent1\"><strong>Artemether-lumefantrine:</strong> 1 tablet = 20 mg artemether and 120 mg lumefantrine. A three-day treatment schedule with a total of six oral doses is recommended based on weight (25 to 34 kg: 3 tablets per dose; &#8805;35 kg: 4 tablets per dose). The patient should receive the initial dose, followed by the second dose eight hours later, then one dose orally twice daily for the following two days. Take after a full meal or whole milk.</td> </tr> <tr> <td class=\"indent1 divider_bottom\"><strong>Artesunate-amodiaquine:</strong> 1 tablet = 100 mg artesunate and 270 mg amodiaquine. Dosing for patients &#8805;36 kg consists of 2 tablets per day orally for three days.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Chloroquine-resistant infection</strong></td> <td>First trimester</td> <td><strong>Quinine sulfate:<sup>&#916;</sup></strong> 542 mg base (= 650 mg salt) orally three times daily for three&nbsp;or seven days.</td> </tr> <tr class=\"divider_bottom\"> <td>Second or third trimester</td> <td><strong>Artemisinin combination therapy:</strong> Dosing as above.</td> </tr> <tr> <td rowspan=\"2\"><strong>Anti-relapse therapy<sup>&#9674;</sup></strong></td> <td>During pregnancy and breastfeeding infants less than six months.</td> <td><strong>Chloroquine prophylaxis:</strong> 300 mg base (= 500 mg salt) orally once weekly for the duration of the pregnancy; to be initiated following completion of antimalarial therapy.</td> </tr> <tr> <td>After delivery (or after breastfeeding infants are older than six months) and both mother and baby are confirmed to be G6PD normal</td> <td> <p><strong>Primaquine:</strong></p> <p>Tropical areas: 0.5 mg base/kg, maximum 30 mg base (= 0.9 mg salt/kg, maximum 52.6 mg salt) orally per day for 14 days.</p> <p>Temperate areas: 0.25 mg base/kg, maximum 15 mg base (= 0.45 mg salt/kg, maximum 26.3 mg salt) orally per day for 14 days.</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The dosing regimens listed in this table are generally consistent with the World Health Organization 2015 guidelines (3rd edition) for the treatment of malaria and United States Centers for Disease Control and Prevention guidelines for the treatment of uncomplicated malaria in the United States (as revised July 2013) and may differ from dosing recommended in approved product information. Product availability varies by locality.</div><div class=\"graphic_footnotes\">G6PD: glucose-6-phosphate-dehydrogenase.<br />* The dosing for chloroquine summarized in the table is based on the recommendations of the United States Centers for Disease Control and Prevention. The dosing for chloroquine recommended by the World Health Organization consists of the following: Total dose: 25 mg base/kg, administered as 10 mg base/kg orally on day 1 followed by 10 mg/kg orally on day 2, and 5 mg/kg base on day 3.<br />¶&nbsp;Piperaquine component prolongs the QT interval by approximately the same amount as chloroquine but by less than quinine; avoid use in patients with congenital QT prolongation or who are on medications that prolong the QT interval. Dihydroartemisinin-piperaquine may be taken with food but should not be taken with a high-fat meal.<br />​Δ&nbsp;For infections acquired in Southeast Asia, quinine treatment should continue for seven days. For infections acquired in Africa and South America, quinine treatment should continue for three days. In the United States, quinine is encapsulated in a 324 mg (sulfate salt)&nbsp;dose; therefore, for adult dosing, two capsules are sufficient.<br />◊&nbsp;For infections with <EM>P. vivax</EM> or <EM>P. ovale</EM>.<br /></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>United States Centers for Disease Control guidelines for treatment of malaria http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf. (Accessed on March 23, 2016.)</LI>&#xD;&#xA;<LI>World Health Organization. Guidelines for the treatment of malaria, 3rd ed. WHO, Geneva 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/ (Accessed on March 23, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 107719 Version 3.0</div></div></div>"},"107720":{"type":"graphic_table","displayName":"Log for breast pumping","title":"Example of a log for monitoring breast pumping frequency and output","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of a log for monitoring breast pumping frequency and output</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"12\" width=\"7.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"13\">Day 2: 24 to 48 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\"> <p>Circle the closest hour to the beginning of each pumping session</p> Record how much milk you pump from both breasts in the space below the time</td> <td class=\"subtitle2_left\" style=\"text-align: right;\" colspan=\"2\"><strong>Today's date:</strong></td> <td class=\"subtitle2_left\" colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text centered\" style=\"vertical-align: middle;\" rowspan=\"2\"><strong>AM</strong></td> <td class=\"highlight_gray_text centered\"><strong>12</strong></td> <td class=\"highlight_gray_text centered\"><strong>1</strong></td> <td class=\"highlight_gray_text centered\"><strong>2</strong></td> <td class=\"highlight_gray_text centered\"><strong>3</strong></td> <td class=\"highlight_gray_text centered\"><strong>4</strong></td> <td class=\"highlight_gray_text centered\"><strong>5</strong></td> <td class=\"highlight_gray_text centered\"><strong>6</strong></td> <td class=\"highlight_gray_text centered\"><strong>7</strong></td> <td class=\"highlight_gray_text centered\"><strong>8</strong></td> <td class=\"highlight_gray_text centered\"><strong>9</strong></td> <td class=\"highlight_gray_text centered\"><strong>10</strong></td> <td class=\"highlight_gray_text centered\"><strong>11</strong></td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text centered\" style=\"vertical-align: middle;\" rowspan=\"2\"><strong>PM</strong></td> <td class=\"highlight_gray_text centered\"><strong>12</strong></td> <td class=\"highlight_gray_text centered\"><strong>1</strong></td> <td class=\"highlight_gray_text centered\"><strong>2</strong></td> <td class=\"highlight_gray_text centered\"><strong>3</strong></td> <td class=\"highlight_gray_text centered\"><strong>4</strong></td> <td class=\"highlight_gray_text centered\"><strong>5</strong></td> <td class=\"highlight_gray_text centered\"><strong>6</strong></td> <td class=\"highlight_gray_text centered\"><strong>7</strong></td> <td class=\"highlight_gray_text centered\"><strong>8</strong></td> <td class=\"highlight_gray_text centered\"><strong>9</strong></td> <td class=\"highlight_gray_text centered\"><strong>10</strong></td> <td class=\"highlight_gray_text centered\"><strong>11</strong></td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"13\"><strong>Goals/tips:</strong> <ul class=\"decimal_heading\"> <li>Hand express colostrum and save every drop for your baby </li> <li>Continue to pump often, every 2 to 3 hours, even during the night </li> <li>Ask your nurse or lactation staff for help with hand expression and pumping </li> <li>Ask the lactation team about where you can get a hospital grade pump for home use </li> </ul> <strong>Did you know?</strong><br /> The nurse can use your colostrum to give your baby mouth care</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Example of pumping log for mothers to use to track daily milk volume.</div><div class=\"graphic_reference\">Courtesy of Nancy Hurst, PhD, RN, IBCLC, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 107720 Version 1.0</div></div></div>"},"107721":{"type":"graphic_figure","displayName":"Fitting breast shield for pumping","title":"Proper fit of a breast shield for pumping breast milk","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proper fit of a breast shield for pumping breast milk</div><div class=\"cntnt\"><img style=\"width:445px; height:634px;\" src=\"images/PEDS/107721_Fitting_breast_shield_for_pumping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the appropriate fit of a breast shield for pumping breast milk. The nipple should be centered and move easily within the tunnel of the shield without rubbing against the sides. If a breast shield is too small, the nipple will rub against the sides of the tunnel causing discomfort and possible trauma, resulting in milk ejection inhibition and poor milk flow. If a breast shield is too large, a loss or reduction in suction will occur due to air leakage, resulting in ineffective stimulation, milk ejection, and milk flow.</div><div id=\"graphicVersion\">Graphic 107721 Version 2.0</div></div></div>"},"107722":{"type":"graphic_figure","displayName":"Adolescent BMI and cardiovascular mortality","title":"BMI in adolescence predicts adult cardiovascular mortality","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">BMI in adolescence predicts adult cardiovascular mortality</div><div class=\"cntnt\"><img style=\"width:573px; height:384px;\" src=\"images/PEDS/107722_AdlscBMIcrdvsmrtl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These data are from a large population study from Israel and show that BMI during late adolescence was associated with cardiovascular mortality in mid-adulthood. The hazard ratio for death is compared with the reference group with BMI between the 5th and 24th percentiles.</div><div class=\"graphic_footnotes\">BMI: body mass index.</div><div class=\"graphic_reference\">Data from: Twig G, Yaniv G, Levine H, et al. Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood. N Engl J Med 2016; 374:2430.</div><div id=\"graphicVersion\">Graphic 107722 Version 3.0</div></div></div>"},"107727":{"type":"graphic_figure","displayName":"Thoracic aorta stent zones of attachment","title":"Thoracic aorta stent proximal zones of attachment","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Thoracic aorta stent proximal zones of attachment</div><div class=\"cntnt\"><img style=\"width:499px; height:617px;\" src=\"images/SURG/107727_Thoracic_aorta_stent_zones_of_attachment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure depicts the possible proximal landing zones for a thoracic aortic stent-graft. the proximal edge of the covered endograft is:<br /><br />Zone 0: proximal to the innominate artery origin<br />Zone 1: distal to the innominate but proximal to the left common carotid artery origin<br />Zone 2: distal to the &nbsp;left common carotid artery but proximal to the subclavian artery<br />Zone 3: ≥2 cm of the left subclavian artery without covering it<br />Zone 4: 2 cm distal to the left subclavian artery and ends within the proximal half of the descending thoracic aorta (T6 approximating the midpoint of the descending thoracic aorta)<br />Zone 5: starts in the distal half of the descending thoracic aorta but proximal to the celiac artery<br />Zone 6: celiac origin to the top of the superior mesenteric artery<br />Zone 7: SMA origin, suprarenal aorta</div><div class=\"graphic_reference\">Fillinger MG, Greenberg RK, McKinsey JF, et al. Reporting standards for thoracic endovascular aortic repair (TEVAR). J Vasc Surg 2010; 52:1022.</div><div id=\"graphicVersion\">Graphic 107727 Version 1.0</div></div></div>"},"107731":{"type":"graphic_table","displayName":"Parasomnias and sleep-related movement disorders in children","title":"Parasomnias and sleep-related movement disorders in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parasomnias and sleep-related movement disorders in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Transition from wakefulness into sleep</td> <td class=\"subtitle1\">NREM sleep</td> <td class=\"subtitle1\">REM sleep</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Parasomnias</td> </tr> <tr> <td class=\"indent1\">Confusional arousals</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X*</td> <td class=\"centered\">&nbsp;</td> <td rowspan=\"3\">Very common in young children and usually resolve by late childhood. Refer to UpToDate topic on parasomnias in children.</td> </tr> <tr> <td class=\"indent1\">Sleepwalking</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X*</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sleep terrors</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X*</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Nightmares</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td>Most common in children; persist into adulthood in 2 to 8% of the population.</td> </tr> <tr> <td class=\"indent1\">Sleep paralysis</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td>Onset usually in adolescence.</td> </tr> <tr> <td class=\"indent1\">Sleep enuresis</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td>Defined as age &#62;5 years and two or more episodes/week.</td> </tr> <tr> <td class=\"indent1\">REM sleep behavior disorder</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td>Seen primarily in adult males; occasionally emerges in children. Often associated with an underlying neurological disorder, eg, <span style=\"color: black;\">Parkinson's disease and other alpha synucleinopathies</span><span style=\"color: black;\">, </span>narcolepsy, brainstem tumors, or antidepressant medications.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Parasomnia overlap disorder</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td>REM sleep behavior disorder combined with another parasomnia.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Sleep-related movement disorders</td> </tr> <tr> <td class=\"indent1\">Restless legs syndrome (RLS)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Urge to move legs occurs at rest while awake. Often associated with iron deficiency; refer to UpToDate topic on RLS in children.</td> </tr> <tr> <td class=\"indent1\">Periodic limb movement disorder (PLMD)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td>Often associated with iron deficiency and RLS.</td> </tr> <tr> <td class=\"indent1\">Sleep-related leg cramps</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>May be idiopathic or secondary to other medical conditions. In children these are typically benign and self-limited. The frequency tends to increase with advancing age.</td> </tr> <tr> <td class=\"indent1\">Bruxism</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Rhythmic movement disorder (RMD)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\"><span style=\"color: black;\">(X)</span><span style=\"color: black;\">&nbsp;</span></td> <td><span style=\"color: black;\">Rhythmic movements at sleep onset are common and benign in infants and toddlers. This is termed rhythmic movement <em>disorder </em>if there is associated self-injury, interference with sleep, or effects on daytime function. The exclusively REM-related rhythmic movements occur more frequently in adults.</span></td> </tr> <tr> <td class=\"indent1\">Benign sleep myoclonus of infancy</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Occurs in neurologically normal infants younger than six months of age.</td> </tr> <tr> <td class=\"indent1\">Isolated symptoms and normal variants</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Sleep starts (hypnic jerks) </li> </ul> </td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Common at all ages; occurs at sleep onset.</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Hypnagogic foot tremor </li> </ul> </td> <td class=\"centered\">X</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Common at all ages; typically near sleep onset.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Catathrenia (sleep-related groaning) </li> </ul> </td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td>Catathrenia is usually categorized with sleep-related breathing disorders because it appears to be associated with prolonged expiration.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Sleep-related medical and neurological disorders</td> </tr> <tr> <td class=\"indent1\">Sleep-related epilepsy</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X*</td> <td class=\"centered\">&nbsp;</td> <td>Episodes tend to be brief, stereotyped, and occur in clusters, randomly through the night.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NREM: non-rapid eye movement; REM: rapid eye movement; RLS: restless legs syndrome; PLMD: periodic limb movement disorder; RMD: rhythmic movement disorder.<br />* Confusional arousals, sleepwalking and night terrors arise during stage N3 of NREM sleep, which tends to occur during the first third of the night. Sleep-related epilepsy tends to occur during stage N1 or N2 of NREM sleep, and is more likely to occur in clusters and randomly through the night.</div><div class=\"graphic_reference\">Courtesy of Dr. Suresh Kotagal.</div><div id=\"graphicVersion\">Graphic 107731 Version 1.0</div></div></div>"},"107732":{"type":"graphic_diagnosticimage","displayName":"Radiograph of lower extremity in CHH demonstrating bowing","title":"Anteroposterior radiograph of the lower extremity in cartilage hair hypoplasia demonstrating bowing","html":"<div class=\"graphic\"><div style=\"width: 759px\" class=\"figure\"><div class=\"ttl\">Anteroposterior radiograph of the lower extremity in cartilage hair hypoplasia demonstrating bowing</div><div class=\"cntnt\"><img style=\"width:739px; height:907px;\" src=\"images/ALLRG/107732_Lower_extremity_CHH_bowing.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Riley P Jr, Weiner DS, Leighley B, et al. Cartilage hair hypoplasia: Characteristics and orthopaedic manifestations. J Child Orthop 2015; 9:145. Reproduced under the terms of the Creative Commons Attribution License.</div><div id=\"graphicVersion\">Graphic 107732 Version 1.0</div></div></div>"},"107745":{"type":"graphic_figure","displayName":"Biologic therapies and mycobacterial infections","title":"Postmarketing observational studies reporting incidence of mycobacterial infections in patients receiving biologic therapies in Europe, North America, and Asia","html":"<div class=\"graphic\"><div style=\"width: 822px\" class=\"figure\"><div class=\"ttl\">Postmarketing observational studies reporting incidence of mycobacterial infections in patients receiving biologic therapies in Europe, North America, and Asia</div><div class=\"cntnt\"><img style=\"width:802px; height:316px;\" src=\"images/ID/107745_Bilgc_thrps_mycbctrl_infect.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>TB incidence (patient-years) in biologic-treated patients (incidence reflects combined outcome for anti-TNF therapy unless otherwise indicated): Arkema 2015 21.6/100,000 (anti-TNF, abatacept, anakinra, rituximab, tocilizumab); Abreu 2013 405/100,000 for etanercept (not pictured 792/100,000 for adalimumab and 1337/100,000 for infliximab); Baddley 2014 40/100,000; Sanchez-Moya 2013 146/100,000 (anti-TNF, ustekinumab, efalizumab); Winthrop 2013 49/100,000; Dixon 2010 95/100,000; Favalli 2009 212/100,000; Tubach 2009 116.7/100,000; Rybar 2008 237/100,000; Gomez-Reino 2007 172/100,000; Brassard 2006 257/100,000; Dixon 2006 150/100,000 for infliximab (not pictured 50/100,000 for etanercept and 90/100,000 for adalimumab); Sichletidis 2006 449/100,000; Askling 2005 118/100,000; Carmona 2005 117/100,000; Listing 2005 310/100,000 for infliximab; Wolfe 2004 52.5/100,000 for infliximab; Gomez-Reino 2003 1113/100,000 for infliximab; Yoo 2014 1700/100,000; Ke 2013 954.5/100,000; Lee 2013 519/100,000; Mok 2014 930/100,000 (anti-TNF, rituximab, tocilizumab); Kim 2011 561/100,000; Seong 2007 2558/100,000 for infliximab (not pictured 0/100,000 for etanercept).<SUP>[1-24]</SUP></LI>&#xD;&#xA;<LI>NTM incidence (patient-years) in biologic-treated patients: Baddley 2014 40/100,000; Winthrop 2013 74/100,000; Lee 2013 230.7/100,000.<SUP>[3,5,21]</SUP></LI></UL></div><div class=\"graphic_footnotes\">TB: tuberculosis; NTM: non-tuberculous mycobacteria; TNF: tumor necrosis factor.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Arkema EV, Jonsson J, Baecklund E, et al. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis 2015; 74:1212.</LI>&#xD;&#xA;<LI>Abreu C, Magro F, Santos-Antunes J, et al. Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohns Colitis 2013; 7:e486.</LI>&#xD;&#xA;<LI>Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in newusers of tumour necrosis factor inhibitor therapy: Results of the SAfety Assessment of Biologic ThERapy (SABER) Study. Ann Rheum Dis 2014; 73:1942.</LI>&#xD;&#xA;<LI>Sanchez-Moya AI, Garcia-Doval I, Carretero G, et al. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. J Eur Acad Dermatol Venereol 2013; 27:1366.</LI>&#xD;&#xA;<LI>Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72:37.</LI>&#xD;&#xA;<LI>Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522.</LI>&#xD;&#xA;<LI>Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNF alpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009; 8:266.</LI>&#xD;&#xA;<LI>Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60:1884.</LI>&#xD;&#xA;<LI>Rybar I, Rozborilova E, Zanova E, et al. The effectiveness for prevention of tuberculosis in patients with inflammatory rheumatic diseases treated with TNF inhibitors. Bratisl Lek Listy 2008; 109:164.</LI>&#xD;&#xA;<LI>Gomez-Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis inpatients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57:756.</LI>&#xD;&#xA;<LI>Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43:717.</LI>&#xD;&#xA;<LI>Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54:2368.</LI>&#xD;&#xA;<LI>Sichletidis L, Settas L, Spyratos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10:1127.</LI>&#xD;&#xA;<LI>Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52:1986.</LI>&#xD;&#xA;<LI>Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766.</LI>&#xD;&#xA;<LI>Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403.</LI>&#xD;&#xA;<LI>Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50:372.</LI>&#xD;&#xA;<LI>Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48:2122.</LI>&#xD;&#xA;<LI>Yoo IK, Choung RS, Hyun JJ, et al. Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-alpha therapy. Yonsei Med J 2014; 55:442.</LI>&#xD;&#xA;<LI>Ke WM, Chen LS, Parng IM, et al. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. Int J Tuberc Lung Dis 2013; 17:1590.</LI>&#xD;&#xA;<LI>Lee SK, Kim SY, Kim EY, et al. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. Lung 2013; 191:565.</LI>&#xD;&#xA;<LI>Mok CC, Chan KY, Lee KL, et al. Factors associated with withdrawal of the anti-TNF alpha biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry. Int J Rheum Dis 2014; 17:1.</LI>&#xD;&#xA;<LI>Kim EM, Uhm WS, Bae SC, et al. Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 2011; 38:2218.</LI>&#xD;&#xA;<LI>Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007; 34:706.</LI></OL>Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 2015; 74:2107. Reproduced with permission from BMJ Publishing Group, Ltd. Copyright © 2015.</div><div id=\"graphicVersion\">Graphic 107745 Version 1.0</div></div></div>"},"107747":{"type":"graphic_picture","displayName":"Bronchoscope types","title":"Types of bronchoscopes","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Types of bronchoscopes</div><div class=\"cntnt\"><img style=\"width:756px; height:330px;\" src=\"images/PULM/107747_Bronchscope_types.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopes in increasing size are displayed. An ultrathin bronchoscope is shown on the left while an endobronchial ultrasound (EBUS) scope is shown on the right. The remaining pieces of equipment are routine bronchoscopes of two different sizes. The ultrathin and routine bronchoscopes have a light source, a camera, and a suction port seen at the tip.</div><div class=\"graphic_reference\">Image courtesy of Olympus America Inc. Copyright &copy; 2016. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107747 Version 2.0</div></div></div>"},"107748":{"type":"graphic_picture","displayName":"Dorsiflexion external rotation test for syndesmotic ankle injury","title":"Dorsiflexion external rotation test for syndesmotic ankle injury","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Dorsiflexion external rotation test for syndesmotic ankle injury</div><div class=\"cntnt\"><img style=\"width:531px; height:712px;\" src=\"images/SM/107748_Drsflx_ext_rtt_tst_sndsmtc_ankl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dorsiflexion external rotation test is used to help diagnose a syndesmotic ankle injury. To perfrom the test, the injured leg is stabilized by grasping the upper calf or front of the knee with one hand. The other hand grasps the foot, dorsiflexes the ankle to its endpoint, and then gently but firmly externally rotates the foot.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD, FAAFP, FACSM.</div><div id=\"graphicVersion\">Graphic 107748 Version 1.0</div></div></div>"},"107749":{"type":"graphic_picture","displayName":"Pulmonary tumor embolism histology","title":"Pulmonary tumor embolism histology","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Pulmonary tumor embolism histology</div><div class=\"cntnt\"><img style=\"width:764px; height:630px;\" src=\"images/PULM/107749_Pulm_tumor_embolism_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histology of the lung (A, B, and C) and lymph node of lung hilum (D).<br />(A) Cross section of bronchus showing a number of carcinoma emboli in lymphatic vessels on its wall (some indicated by arrows).<br />(B) Lung on honeycomb tissue area displaying multiple neoplastic emboli in lymph vessels (some indicated by arrows), which is a diffusely found aspect.<br />(C) Lung in peripheral area showing pleural lymphatic vessels filled with tumor emboli (arrowheads).<br />(D) Lymph node with metastatic renal cell carcinoma represented by various carcinomatous emboli (some indicated by asterisks) [Hematoxilin &amp; eosin; 2.5X, 10X, 5X, and 10X objectives, respectively].</div><div class=\"graphic_reference\">Reproduced with permission from: Ara&uacute;jo J&uacute;nior AC, Furtado RH, Castelli JB. Case 6/2010 - 70-year-old hypertensive and diabetic female patient with interstitial and bilateral pulmonary alveolar infiltrate, dry cough, dyspnea, loss of appetite and no fever. Arq Bras Cardiol 2010; 95:e139. Copyright &copy; 2010 Sociedade Brasileira de Cardiologia. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107749 Version 1.0</div></div></div>"},"107751":{"type":"graphic_figure","displayName":"Electromagnetic navigational biopsy techniques","title":"Electromagnetic navigational bronchoscopic and transthoracic biopsy","html":"<div class=\"graphic\"><div style=\"width: 699px\" class=\"figure\"><div class=\"ttl\">Electromagnetic navigational bronchoscopic and transthoracic biopsy</div><div class=\"cntnt\"><img style=\"width:679px; height:747px;\" src=\"images/PULM/107751_Elctrmgntc_nvgtnl_bpsy_tchn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows concurrent computed tomographic and virtual images displayed to the bronchoscopist during electromagnetic navigational bronchoscopy. Real-time images and virtual images together guide the bronchoscopist to the peripheral target lesion for biopsy. Panel B shows similar computed tomographic images during navigation of a transthoracic needle to biopsy a target peripheral nodule. The biopsy needle is directed so that it is present in the lesion in the axial, coronal, and&nbsp;oblique CT views to ensure the best yield.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 Veran Medical Technologies. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107751 Version 1.0</div></div></div>"},"107752":{"type":"graphic_table","displayName":"Complications common fractures not involving nerves or arteries","title":"Potential non-neurologic non-arterial complications associated with some common fractures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential non-neurologic non-arterial complications&nbsp;associated with&nbsp;some common fractures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Osteomyelitis</td> <td class=\"subtitle1\">Non-union</td> <td class=\"subtitle1\">Acute compartment syndrome</td> <td class=\"subtitle1\">Complex regional pain syndrome</td> <td class=\"subtitle1\">Deep vein thrombosis (DVT)</td> <td class=\"subtitle1\">Other important complications</td> </tr> <tr> <td><strong>Open fractures</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Rib</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X*</td> </tr> <tr> <td><strong>Humerus, supracondylar elbow</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Forearm</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Distal radius</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Scaphoid</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Hamate</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Hip/pelvis</strong></td> <td class=\"centered\">X<sup>&#182;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Femur</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X<sup>&#916;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X<sup>&#916;</sup></td> </tr> <tr> <td><strong>Tibia</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Talus</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X<sup>&#9674;</sup></td> </tr> <tr> <td><strong>Proximal fifth metatarsal</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X<sup>&#167;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Depending on number and severity, rib fractures are associated with risk of pulmonary. contusion, pneumothorax, hemothorax, liver or spleen laceration, and other injuries.<br />&para; Elevated risk of osteomyelitis if open fracture.<br />&Delta; Femoral neck fractures are at risk of non-union and avascular necrosis.<br /><span class=\"lozenge\">&loz;</span> Talus fractures are at risk for avascular necrosis.<br />&sect; Except styloid fractures, which are not at increased risk.</div><div id=\"graphicVersion\">Graphic 107752 Version 2.0</div></div></div>"},"107753":{"type":"graphic_figure","displayName":"Radial EBUS","title":"Radial endobronchial ultrasound of a peripheral pulmonary lesion","html":"<div class=\"graphic\"><div style=\"width: 1092px\" class=\"figure\"><div class=\"ttl\">Radial endobronchial ultrasound of a peripheral pulmonary lesion</div><div class=\"cntnt\"><img style=\"width:1072px; height:368px;\" src=\"images/PULM/107753_Radial_EBUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows a representative image of a bronchoscope with a radial endobronchial ultrasound probe (left) and sheath (right). Panels B and C show a computed tomographic (B) and corresponding radial ultrasound (C) image of a peripheral pulmonary lesion. The radial ultrasound image demonstrates a fairly well circumscribed echoic lesion with the hyper echoic (brighter white) boundary between the aerated lung and the lesion.</div><div class=\"graphic_reference\">Image courtesy of Olympus America Inc. Copyright &copy; 2016. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107753 Version 1.0</div></div></div>"},"107754":{"type":"graphic_figure","displayName":"Planning electromagnetic navigation","title":"Pre-procedure planning view of electromagnetic navigation system","html":"<div class=\"graphic\"><div style=\"width: 1028px\" class=\"figure\"><div class=\"ttl\">Pre-procedure planning view of electromagnetic navigation system</div><div class=\"cntnt\"><img style=\"width:1008px; height:565px;\" src=\"images/PULM/107754_Planning_electromagnet_nav.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic shows axial, saggital, and coronal computed tomographic (CT) views generated using a specific CT protocol prior to the procedure. It also shows a three dimensional (3D map) virtual bronchoscopic image of the tracheobronchial tree that the bronchoscopist can use to gain closest access to a target lesion. The bronchoscopist can, in real-time, follow where they are as they proceed through the patient's bronchi towards a nodule.</div><div class=\"graphic_reference\">All rights reserved. Used with the permission of Medtronic.</div><div id=\"graphicVersion\">Graphic 107754 Version 1.0</div></div></div>"},"107755":{"type":"graphic_figure","displayName":"Planning virtual bronchoscopy","title":"Planning and procedural views for virtual bronchoscopic navigation","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Planning and procedural views for virtual bronchoscopic navigation</div><div class=\"cntnt\"><img style=\"width:710px; height:581px;\" src=\"images/PULM/107755_Planning_virtual_bronchscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows axial, coronal, and saggital images generated using a specific protocol with target selected by placing the red cross hairs on the lesion in all three planes. Major blood vessels are highlighted in red and blue. Panel B shows the virtual bronchoscopic view and pathway used during the procedure to navigate to the lesion.</div><div class=\"graphic_footnotes\">A: anterior; P: posterior; R: right; L: left; LLB/LB6: LLB and LB6 indicate segments of the left bronchial tree.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 Broncus. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107755 Version 1.0</div></div></div>"},"107756":{"type":"graphic_picture","displayName":"Leprosy hypopigmented dark skin","title":"Hypopigmented indeterminate leprosy","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Hypopigmented indeterminate leprosy</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/107756_Leprosy_hyppigmnt_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical hypopigmented lesions in a patient with indeterminate leprosy.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107756 Version 1.0</div></div></div>"},"107757":{"type":"graphic_picture","displayName":"Leprosy hypopigmented light skin","title":"Hypopigmented indeterminate leprosy","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Hypopigmented indeterminate leprosy</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/107757_Leprosy_hypopigmnt_lght_skn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large hypopigmented patch is present on the abdomen of a patient with early leprosy.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107757 Version 1.0</div></div></div>"},"107761":{"type":"graphic_picture","displayName":"Onchocerciasis skin","title":"Onchocerciasis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Onchocerciasis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/107761_Onchocerciasis_skin_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin depigmentation with perifollicular spots of normal pigmentation (\"leopard skin\") on the leg of a patient with onchocerciasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107761 Version 1.0</div></div></div>"},"107762":{"type":"graphic_picture","displayName":"Scleroderma skin pigmentation","title":"Scleroderma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Scleroderma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/107762_Scleroderma_skin_pigment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse hyperpigmentation and depigmentation with sparing of perifollicular skin resulting in a salt-and-pepper appearance of the leg skin in this patient with systemic sclerosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107762 Version 1.0</div></div></div>"},"107763":{"type":"graphic_figure","displayName":"Mycobacterial infections in RA","title":"Tuberculosis and nontuberculous mycobacteria in the general population and in patients with rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculosis and nontuberculous mycobacteria in the general population and in patients with rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:444px; height:504px;\" src=\"images/ID/107763_Mycobacterial_infections_RA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crude incidence rates of TB and NTM disease observed in the general population and in patients with rheumatoid arthritis in a large northern California health maintenance organization 2000 to 2008.<sup>[1]</sup> Patient TB screening results were not reported in this study.</div><div class=\"graphic_footnotes\">RA: rheumatoid arthritis; NTM: nontuberculous mycobacteria; TB: tuberculosis; TNF: tumor necrosis factor.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Winthrop K, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72:37.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Rheumatology. Winthrop KL, Iseman M. Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy. Nat Rev Rheumatol 2013; 9:524. Copyright &copy; 2013. <a href=\"http://www.nature.com/nrrheum\" target=\"_blank\">www.nature.com/nrrheum</a>.</div><div id=\"graphicVersion\">Graphic 107763 Version 1.0</div></div></div>"},"107766":{"type":"graphic_algorithm","displayName":"Overview of management for inherited thrombophilia","title":"Overview of management for patients with inherited thrombophilia","html":"<div class=\"graphic\"><div style=\"width: 1030px\" class=\"figure\"><div class=\"ttl\">Overview of management for patients with inherited thrombophilia</div><div class=\"cntnt\"><img style=\"width:1010px; height:488px;\" src=\"images/HEME/107766_Mgmt_inhrtd_thrombophl_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>This algorithm applies to individuals with known inherited thrombophilia (factor V Leiden&nbsp;or prothrombin G20210A mutation; protein S, protein C, or AT deficiency). It is a general overview of our approach and does not substitute for clinical judgment regarding the risks and benefits of anticoagulation for an individual patient.</LI>&#xD;&#xA;<LI>Individuals with AT deficiency may have heparin resistance, and if they&nbsp;require anticoagulation, use of a non-heparin anticoagulant and/or AT replacement along with appropriate doses of heparin may be necessary. Refer to the UpToDate topic on AT deficiency for details.</LI>&#xD;&#xA;<LI>Routine obstetrical care includes mechanical thromboprophylaxis and/or anticoagulation for women undergoing cesarean delivery. Routine postoperative care includes thromboprophylaxis in most cases; individuals with thrombophilia may require more aggressive prophylaxis than those without. Refer to UpToDate for indications for thrombophilia testing and other aspects of obstetric and postoperative management.</LI></UL></div><div class=\"graphic_footnotes\">VTE: venous thromboembolism; PE: pulmonary embolism; DVT: deep vein thrombosis; FVL: factor V Leiden mutation; PS: protein S; AT: antithrombin.<br />* Atypical site of VTE includes mesenteric, portal, cerebral veins.<br />¶ All individuals with inherited thrombophilia should have education regarding signs and symptoms of VTE; risk assessment for first degree relatives; and, for women, avoidance of hormonal contraceptives if possible.<br />Δ Routine care includes appropriate thromboprophylaxis for surgical procedures based on the procedure-associated risk of VTE.</div><div id=\"graphicVersion\">Graphic 107766 Version 3.0</div></div></div>"},"107768":{"type":"graphic_table","displayName":"Comparison of MHT with bioidentical HT","title":"Comparison of FDA-approved MHT with custom-compounded bioidentical HT","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of FDA-approved MHT with custom-compounded bioidentical HT</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">MHT (FDA approved)</td> <td class=\"subtitle1\">BIH (unregulated)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Goal of intervention</strong></td> <td> <p>Treatment: Clinicians prescribe estrogen to treat symptoms (primarily vasomotor)</p> They add progestin only for women with a uterus to prevent endometrial hyperplasia</td> <td> <p>Replacement: Clinicians prescribe replacing multiple sex steroids with the goal of restoring levels to the premenopausal range</p> Progesterone is often recommended for all women, even those without a uterus</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pretreatment testing</strong></td> <td> <p>No pretreatment testing&nbsp;is required</p> Baseline hormones do not predict dose requirements</td> <td>Extensive salivary or blood testing is required</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Biochemical testing for monitoring</strong></td> <td>This is rarely needed</td> <td>Routine salivary or blood testing to monitor and adjust doses is required</td> </tr> <tr class=\"divider_bottom\"> <td><strong>FDA approval status and concerns</strong></td> <td>FDA-approved estrogens and progestins, including 17-beta estradiol and progesterone, are required to: <ol> <li>Demonstrate sufficient purity, potency, efficacy, and safety for approval </li> <li>Have a failure rate of &#60;2% in quality and potency tests </li> <li>Have indications (hot flashes, vaginal atrophy, prevention of bone loss) </li> <li>Be supported by well-conducted RCTs </li> <li>Have package inserts that provide extensive product information, which may include black box warnings </li> <li>Have all adverse events reported to the FDA both before approval and after marketing </li> <li>E3 not approved </li> </ol> </td> <td>Compounded bioidenticals have: <ol> <li>No requirement to prove efficacy or safety before use </li> <li>No requirement for routine monitoring for purity or potency (sporadic assessments indicate high failure rates) </li> <li>Unsupported claims that the approach is safer and more effective than conventional HT </li> <li>No requirement for package inserts or black box warnings </li> <li>No listed concerns about possible overdosing or underdosing or the risk of higher estrogen/inadequate progesterone exposure </li> <li>No requirement for adverse event reporting </li> <li>E3 is a commonly included agent </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Timing and duration of treatment</strong></td> <td>Perimenopause, ages 50 to 59, or &#60;10 years after menopause is recommended</td> <td>There are no age or duration restrictions</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Evidence for efficacy (relief of symptoms)</strong></td> <td>There is 80 to 90% relief with appropriate estrogen doses</td> <td>There is anecdotal evidence for efficacy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Other benefits</strong></td> <td> <p>Alleviating adverse mood</p> Reduction in fracture</td> <td> <p>Energy</p> <p>Vitality</p> Increased attractiveness (these are only claims and not supported by RCTs)</td> </tr> <tr> <td><strong>Risks</strong></td> <td> <ol class=\"numbers_to_nine\"> <li>Breast cancer: E + P after&nbsp;five years of use </li> <li>CVD: Risk of CHD, stroke, particularly in older women (WHI), safer in younger menopausal women because of very low absolute risk (ages 50 to 59) </li> <li>VTE: Small excess at all ages, but absolute risk small in younger women ages 50 to 59 </li> <li>Gallbladder disease </li> <li>Urinary incontinence </li> </ol> </td> <td>The lack of evidence for harm (due to overall lack of evidence of any sort) is suggested by some of these products as evidence of safety</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MHT: menopausal hormone therapy; FDA: US Food and Drug Administration; BIH: custom-compounded bioidentical hormone therapy; RCT: randomized controlled trial; E3: estriol; HT: hormone therapy; E + P: estrogen plus progestin; CVD: cardiovascular disease;&nbsp;CHD: coronary heart disease; WHI: Women's Health Initiative; VTE: venous thromboembolism.</div><div class=\"graphic_reference\">Republished with permission of The Endocrine Society, from Santoro N, Braunstein GD, Butts CL, et al. Compounded bioidentical hormones in Endocrinology practice: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2016; 101:1318. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 107768 Version 2.0</div></div></div>"},"107769":{"type":"graphic_table","displayName":"Breast cancer cutoffs MHT","title":"Breast cancer cutoffs for counseling before recommending MHT","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Breast cancer cutoffs for counseling before recommending MHT</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk category*</td> <td class=\"subtitle1\">5-year NCI or IBIS breast cancer risk assessment (%)</td> <td class=\"subtitle1\">Suggested approach</td> </tr> <tr> <td>Low</td> <td>&#60;1.67</td> <td>MHT ok</td> </tr> <tr> <td>Intermediate</td> <td>1.67 to 5</td> <td>Caution<sup>&#182;</sup></td> </tr> <tr> <td>High</td> <td>&#62;5</td> <td>Avoid</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MHT: menopausal hormone therapy; NCI: National Cancer Institute; IBIS: International Breast Intervention Study.<br />* Categories here are newly defined for these guidelines and based on recommendations published for use of antiestrogens for breast cancer prevention. The assumption is that candidates for breast cancer prevention with antiestrogens should not be candidates for initiating MHT. Method to calculate risk varies among countries.<br />¶ Caution indicates need for detailed counseling regarding anticipated benefits and risks of MHT with strong consideration of nonhormonal therapies for symptom relief, and possible consideration of chemopreventive strategies for women who meet suggested criteria.</div><div class=\"graphic_reference\">Republished with permission of The Endocrine Society, from Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100:3975. Copyright &copy; 2015; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 107769 Version 1.0</div></div></div>"},"107770":{"type":"graphic_table","displayName":"CVD risk with MHT","title":"Evaluating CVD risk in women contemplating MHT","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluating CVD risk in women contemplating MHT</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">10-year CVD risk</td> <td class=\"subtitle1\" colspan=\"2\">Years since menopause onset</td> </tr> <tr> <td class=\"subtitle2\">&#60;5 years</td> <td class=\"subtitle2\">6 to 10 years</td> </tr> <tr> <td>Low (&#60;5%)</td> <td>MHT ok</td> <td>MHT ok</td> </tr> <tr> <td>Moderate (5 to 10%)</td> <td>MHT ok (choose transdermal)</td> <td>MHT ok (choose transdermal)</td> </tr> <tr> <td>High (&#62;10%)*</td> <td>Avoid MHT</td> <td>Avoid MHT</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CVD risk calculated by ACC/AHA Cardiovascular Risk Calculator. Methods to calculate risk and risk stratification vary among countries.</div><div class=\"graphic_footnotes\">ACC: American College of Cardiology; AHA: American Heart Association; CVD: cardiovascular disease; MHT: menopausal hormone therapy; MI: myocardial infarction.<br />* High risk includes known MI, stroke, peripheral artery disease, etc.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Manson JE. Current recommendations: what is the clinician to do? Fertil Steril 2014; 101:916.</li>&#xD;&#xA;    <li>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100:3975.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 107770 Version 1.0</div></div></div>"},"107772":{"type":"graphic_table","displayName":"Associations of religion/spirituality with health in cancer","title":"Estimated associations between religion/spirituality and health in patients with cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated associations between religion/spirituality and health in patients with cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Physical health</td> <td class=\"subtitle1\" colspan=\"3\">Mental health</td> <td class=\"subtitle1\" colspan=\"3\">Social health</td> </tr> <tr> <td class=\"subtitle2\">R/S dimension</td> <td class=\"subtitle2\">Estimate<br /> (SE)</td> <td class=\"subtitle2\">Number of unique samples<br /> (studies)</td> <td class=\"subtitle2\">Number of reported effect sizes</td> <td class=\"subtitle2\">Estimate<br /> (SE)</td> <td class=\"subtitle2\">Number of unique samples<br /> (studies)</td> <td class=\"subtitle2\">Number of reported effect sizes</td> <td class=\"subtitle2\">Estimate<br /> (SE)</td> <td class=\"subtitle2\">Number of unique samples<br /> (studies)</td> <td class=\"subtitle2\">Number of reported effect sizes</td> </tr> <tr> <td>Overall R/S</td> <td class=\"centered\">0.15 (0.02)*</td> <td class=\"centered\">101</td> <td class=\"centered\">497</td> <td class=\"centered\">0.19 (0.02)*<sup>&#182;</sup></td> <td class=\"centered\">148</td> <td class=\"centered\">617</td> <td class=\"centered\">0.20 (0.02)*</td> <td class=\"centered\">78</td> <td class=\"centered\">227</td> </tr> <tr> <td>Affective<sup>&#916;</sup></td> <td class=\"centered\">0.26 (0.02)*</td> <td class=\"centered\">55</td> <td class=\"centered\">223</td> <td class=\"centered\">0.38 (0.03)*<sup>&#9674;</sup></td> <td class=\"centered\">68</td> <td class=\"centered\">234</td> <td class=\"centered\">0.32 (0.03)*</td> <td class=\"centered\">39</td> <td class=\"centered\">112</td> </tr> <tr> <td>Behavioral<sup>&#167;</sup></td> <td class=\"centered\">0.01 (0.02)</td> <td class=\"centered\">29</td> <td class=\"centered\">96</td> <td class=\"centered\">0.03 (0.03)</td> <td class=\"centered\">43</td> <td class=\"centered\">133</td> <td class=\"centered\">0.08 (0.03)<sup>&#165;</sup></td> <td class=\"centered\">17</td> <td class=\"centered\">38</td> </tr> <tr> <td>Cognitive<sup>&#135;</sup></td> <td class=\"centered\">0.07 (0.02)*</td> <td class=\"centered\">22</td> <td class=\"centered\">90</td> <td class=\"centered\">0.10 (0.02)*</td> <td class=\"centered\">41</td> <td class=\"centered\">160</td> <td class=\"centered\">0.10 (0.03)<sup>&#134;</sup></td> <td class=\"centered\">18</td> <td class=\"centered\">45</td> </tr> <tr> <td>Other**</td> <td class=\"centered\">0.08 (0.03)<sup>&#165;</sup></td> <td class=\"centered\">23</td> <td class=\"centered\">88</td> <td class=\"centered\">0.08 (0.02)<sup>&#134;</sup></td> <td class=\"centered\">43</td> <td class=\"centered\">90</td> <td class=\"centered\">0.13 (0.03)*</td> <td class=\"centered\">22</td> <td class=\"centered\">32</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A positive relation between R/S and health outcomes reflects more R/S and better health. Estimates are z-scale effect sizes.</div><div class=\"graphic_footnotes\">R/S: religion/spirituality; SE: standard error.<br />* p&lt;0.001.<br />¶ After the exclusion of spiritual well-being and on the basis of 108 studies and 433 effect sizes, the estimated association between overall R/S and mental health was 0.09 (0.01).<br />Δ Affective dimension of R/S; these aspects having to do with subjective emotional experience, such as a sense of transcendence, meaning, purpose or connect to a source larger than oneself.<br /><FONT class=lozenge>◊</FONT> After the exclusion of spiritual well-being and on the basis of 20 studies and 50 effect sizes, the estimated association between affective R/S and mental health was 0.29 (0.06).<br />§ Behavioral dimension refers to R/S practices or behaviors.<br />¥ p&lt;0.05.<br />‡ Cognitive refers to the religious or spiritual beliefs.<br />† p&lt;0.01.<br />** Other – not all R/S constructs are easily categorized into these dimensions. This category accounts for the subset of R/S measures that are relatively frequently used (eg, service attendance, prayer) and that may have important relationships with health outcomes but that do not fall squarely into other R/S dimensions.</div><div class=\"graphic_reference\">From: Park CL, Sherman AC, Jim HSL, Salsman JM. Religion/Spirituality and health in the context of cancer: Cross-domain integration, unresolved issues, and future directions. Cancer 2015; 121(21):3789-94. <a href=\"http://onlinelibrary.wiley.com/doi/10.1002/cncr.29351/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1002/cncr.29351/abstract</a>. Copyright &copy; 2016 American Cancer Society. Modified with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 107772 Version 1.0</div></div></div>"},"107781":{"type":"graphic_table","displayName":"Diagnostic guide to midfoot pain","title":"Diagnostic guide to the patient with midfoot pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic guide to the patient with midfoot pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Is there pain over medial arch, navicular prominence, or N-spot?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Is there pain on direct palpation of the N-spot? - Consider navicular stress fracture.</li> <li>Is there pain over the navicular prominence AND pain when testing posterior tibialis? - Consider insertional tendinopathy.</li> <li>Is navicular prominence pronounced? - Consider an accessory navicular with either fibrous separation or stress fracture.</li> <li>Is there pain over medial arch but not directly over the navicular? - Consider longitudinal arch strain.</li> <li>Are there nodules along the plantar surface of midfoot? - Consider planter fibromatosis (Ledderhose disease).</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Is there pain over the navicular prominence along with some unilateral loss of static or dynamic longitudinal arch?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Is there rupture of the \"spring ligament\" (calcaneonavicular ligament)?</li> <li>Is there complete or partial rupture of the posterior tibialis tendon?</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Is there pain over the dorsum of the midfoot?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Is there bony irregularity over the tarso-metatarsal (TMT) articulations? - Consider TMT bossing or generalized arthritis.</li> <li>Is there pain over Lisfranc joint following trauma? - Consider Lisfranc joint sprain or fracture.</li> <li>Is there a soft swollen mass over the dorsal midfoot? - Consider ganglion cyst.</li> <li>Is there generalized swelling along extensor tendons and pain with resisted toe extension? - Consider extensor tendinopathy.</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Is there pain over the lateral midfoot?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Is pain associated with tenderness or increased mobility of cuboid? - Consider cuboid subluxation.</li> <li>Is pain elicited by resisted foot eversion? - Consider fibularis (peroneus) brevis or fibularis (peroneus) longus tendinopathy.</li> <li>Is there pain or swelling at base of the fifth metatarsal? - Consider enthesopathy of fibularis (peroneus) brevis, fibularis tertius,&nbsp;or avulsion fracture.</li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 107781 Version 2.0</div></div></div>"},"107782":{"type":"graphic_table","displayName":"Diagnostic guide to rear foot pain","title":"Diagnostic guide to patient with rear foot pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic guide to patient with rear foot pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Is there pain over the plantar insertion of the plantar fascia into the medial calcaneus?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Is this worse with first steps in the morning and tender to palpation? Consider plantar fasciitis. </li> <li>Is there night pain and diffuse tenderness when calcaneus is squeezed? Consider calcaneal stress fracture. </li> <li>Is tenderness greatest directly over the os calcis and not made worse by extension of the great toe? Consider split fat pad or contusion/minor fracture of os calcis. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Is there pain at the posterior calcaneus with a bony irregularity?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Is there swelling and pain when the distal Achilles tendon is squeezed? Consider enthesopathy. </li> <li>Is there tenderness and/or swelling directly over the bony irregularity? Consider painful Haglund deformity with possible swelling. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Is there a rigid flat foot and some bony irregularity of the rear foot?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Is rear foot motion restricted? Consider tarsal coalition. </li> <li>Is there a discreetly palpable bony irregularity? Consider an accessory ossicle. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Is there pain at the talar dome or lateral talar area?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Is pain made worse by dorsiflexion or plantarflexion of the ankle? Consider anterior impingement syndrome from tibial or talar spurring. </li> <li>Is pain at the lateral talus, and has the patient had a severe or recurrent ankle sprains? Consider osteochondral injury of talus. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Is there pain behind or pain and swelling just anterior to the lateral malleolus?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Does resisted foot eversion make pain worse? Consider fibularis (peroneal) tendinopathy. </li> <li>Is swelling greater anterior to lateral malleolus, and is rear foot pronated? Consider sinus tarsi syndrome. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Is there pain in the rear foot just superior to the calcaneus?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Does pain increase with single or repeated plantar flexion? Consider os trigone or posterior impingement from talar spurring. </li> <li>Is pain made worse by squeezing area deep to the Achilles tendon? Consider retrocalcaneal bursitis. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Is there pain along the plantar surface of the foot but no tenderness?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Is there a positive Tinel's sign at the tarsal tunnel, or marked pronation? Consider tarsal tunnel syndrome. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Are there painless, flesh colored papules along the fat pad and calcaneus?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Is there any reason for increased pressure on heel strike? Consider piezogenic papules. </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 107782 Version 1.0</div></div></div>"},"107783":{"type":"graphic_table","displayName":"Intragastric balloons for weight loss","title":"Intragastric balloons for weight loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intragastric balloons for weight loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Balloon system</td> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Balloon material&nbsp;</td> <td class=\"subtitle1\">Balloon volume when filled&nbsp;</td> <td class=\"subtitle1\">Duration of treatment</td> <td class=\"subtitle1\">Insertion/removal method</td> <td class=\"subtitle1\">US FDA approved</td> <td class=\"subtitle1\">Reported weight loss with balloon treatment</td> </tr> <tr> <td>Orbera</td> <td>Apollo Endosurgery</td> <td>&nbsp;Silicone</td> <td>400 to 700 mL</td> <td>6 months</td> <td>Endoscopy/Endoscopy<br /> </td> <td>Yes</td> <td>&nbsp;32% EWL</td> </tr> <tr> <td>ReShape Integrated Dual Balloon System</td> <td>ReShape Medical</td> <td>&nbsp;Silicone</td> <td>750 to 900 mL</td> <td>6 months</td> <td>Endoscopy/Endoscopy<br /> </td> <td>Yes</td> <td>&nbsp;28% EWL</td> </tr> <tr> <td>Obalon</td> <td>Obalon Therapeutics</td> <td>Nylon/Polyethylene/<br /> Silicone/Titanium<br /> </td> <td>250 mL per balloon, up to 3 balloons</td> <td>6 months</td> <td>Procedureless/<br /> Endoscopy<br /> </td> <td>No&nbsp;</td> <td>&nbsp;6.8% TBWL</td> </tr> <tr> <td>Spatz Adjustable Balloon System</td> <td>Spatz FGIA</td> <td>&nbsp;Silicone</td> <td>Adjustable</td> <td>12 months</td> <td>Endoscopy/Endoscopy<br /> </td> <td>No</td> <td>45 to 49% EWL</td> </tr> <tr> <td>Elipse Gastric Balloon System</td> <td>Allurion Technologies</td> <td>&nbsp;Polyurethane</td> <td>550 mL</td> <td>4 months</td> <td>Procedureless/Procedureless<br /> </td> <td>No</td> <td>&nbsp;37% EWL</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">US FDA: United States Food and Drug Administration; Percent excess weight loss (% EWL):&nbsp;Amount of weight loss/(patient’s initial weight - ideal body weight); Percent total body weight loss (% TBWL): Amount of weight loss/patient's initial weight. </div><div class=\"graphic_reference\">Prepared with data from:<br /><br /><OL>&#xD;&#xA;<LI>​ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, Abu Dayyeh BK, Kumar N, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015; 82:425.</LI>&#xD;&#xA;<LI>Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 2015; 11:874.</LI>&#xD;&#xA;<LI>Brooks J, Srivastava ED, Mathus-Vliegen EM. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg 2014; 24:813.</LI>&#xD;&#xA;<LI>Machytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg 2011; 21:1499.</LI>&#xD;&#xA;<LI>Abstracts of the 13th International Congress on Obesity. Track 3: Determinants, assessments and consequences. Obes Rev 2016; 17:35.</LI>&#xD;&#xA;<LI>Sullivan S, Swain JM, Woodman G, et al. The Obalon swallowable 6-month balloon system is more effective than moderate intensity life-style therapy alone: Results from a 6-month randomized sham controlled trial. Gastroenterology 2016; 150:S126.</LI></OL></div><div id=\"graphicVersion\">Graphic 107783 Version 3.0</div></div></div>"},"107784":{"type":"graphic_figure","displayName":"Total arch repair","title":"Total arch repair","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Total arch repair</div><div class=\"cntnt\"><img style=\"width:516px; height:345px;\" src=\"images/SURG/107784_Total_arch_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aneurysm of the aortic arch (A) requires excision of all the involved arch tissue. Balloon occlusion catheters are used to deliver antegrade cerebral perfusion to the innominate and left carotid arteries (B). Once the proximal and distal graft anastomoses are completed, antegrade flow can be re-established to the rest of the body while the grafts are anastomosed to the head vessels to complete the repair (D). </div><div id=\"graphicVersion\">Graphic 107784 Version 1.0</div></div></div>"},"107785":{"type":"graphic_figure","displayName":"Debranching and hybrid repair of Type II arch","title":"Debranching and hybrid repair of Type II arch","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Debranching and hybrid repair of Type II arch</div><div class=\"cntnt\"><img style=\"width:504px; height:597px;\" src=\"images/SURG/107785_Debranching_and_hybrid_repair_of_Type_II_arch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For a Type II aortic arch repair, the great vessels are debranched and the ascending aorta is replaced. A thoracic stent-graft can then be positioned within the reconstructed ascending aorta, if needed.</div><div id=\"graphicVersion\">Graphic 107785 Version 1.0</div></div></div>"},"107786":{"type":"graphic_figure","displayName":"Debranching and hybrid repair of Type III arch","title":"Debranching and hybrid repair of Type III arch","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Debranching and hybrid repair of Type III arch</div><div class=\"cntnt\"><img style=\"width:504px; height:597px;\" src=\"images/SURG/107786_Debranching_and_hybrid_repair_of_Type_III_arch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For a Type III arch, an open elephant trunk repair is used, in which the ascending aorta and branch vessels are replaced, followed by endovascular stent-graft repair of the descending&nbsp;aorta, if needed.</div><div id=\"graphicVersion\">Graphic 107786 Version 1.0</div></div></div>"},"107787":{"type":"graphic_figure","displayName":"Crawford extent II aortic repair ","title":"Crawford extent II aortic repair ","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Crawford extent II aortic repair </div><div class=\"cntnt\"><img style=\"width:504px; height:597px;\" src=\"images/SURG/107787_Crawford_extent_II_descending_thoracic_aorta_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Crawford extent II thoracoabdominal aortic repair extends from just distal to the left subclavian artery to the aortic bifurcation. This repair has the highest rate of paraplegia given the number of segmental arteries feeding the spinal cord that may need to be covered.</div><div id=\"graphicVersion\">Graphic 107787 Version 1.0</div></div></div>"},"107788":{"type":"graphic_figure","displayName":"Crawford extent III aortic repair","title":"Crawford extent III aortic repair","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Crawford extent III aortic repair</div><div class=\"cntnt\"><img style=\"width:504px; height:597px;\" src=\"images/SURG/107788_Crawford_extent_III_descending_thoracic_aorta_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Crawford extent III thoracoabdominal aortic repair extends from the mid-descending aorta to the aortic bifurcation.</div><div id=\"graphicVersion\">Graphic 107788 Version 2.0</div></div></div>"},"107791":{"type":"graphic_figure","displayName":"Crawford extent IV aortic repair","title":"Crawford extent IV aortic repair","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Crawford extent IV aortic repair</div><div class=\"cntnt\"><img style=\"width:504px; height:597px;\" src=\"images/SURG/107791_Crawford_extent_IV_descending_thoracic_aorta_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates repair of a Crawford extent IV thoracic aortic aneurysm showing replacement of the descending aorta below the diaphragm with the celiac, SMA and right renal artery anastomosed as a patch and the left renal artery replaced with a Dacron tube graft. </div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 107791 Version 2.0</div></div></div>"},"107792":{"type":"graphic_figure","displayName":"Safi modified Crawford extent V aortic repair","title":"Safi modified Crawford extent V aortic repair","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Safi modified Crawford extent V aortic repair</div><div class=\"cntnt\"><img style=\"width:505px; height:597px;\" src=\"images/SURG/107792_Crawford_extent_V_descending_thoracic_aorta_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Safi modified Crawford extent V thoracic aortic aneurysm repair showing reimplanted intercostal arteries and island patch of the celiac artery and SMA. The renal arteries and IMA are not affected. </div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery; IMA: inferior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 107792 Version 2.0</div></div></div>"},"107796":{"type":"graphic_table","displayName":"Stages of anesthetic depth","title":"Stages of anesthetic depth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of anesthetic depth</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td><strong>Stage I</strong></td> <td>Analgesia state: Patient is conscious and rational, with decreased perception of pain.</td> </tr> <tr> <td><strong>Stage II</strong></td> <td>Delirium stage: Patient is unconscious; body responds reflexively; irregular breathing pattern with breathholding.</td> </tr> <tr> <td><strong>Stage III</strong></td> <td>Surgical anesthesia: Increasing degrees of muscle relaxation; unable to protect airway.</td> </tr> <tr> <td><strong>Stage IV</strong></td> <td>Medullary depression: There is depression of cardiovascular and respiratory centers.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Hewer CL. The stages and signs of general anesthesia. Br Med J 1937; 2:274.</div><div id=\"graphicVersion\">Graphic 107796 Version 2.0</div></div></div>"},"107801":{"type":"graphic_figure","displayName":"Bispecific antibody to replace activated factor VIII","title":"Bispecific antibody that could be used to replace the function of FVIIIa","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Bispecific antibody that could be used to replace the function of FVIIIa</div><div class=\"cntnt\"><img style=\"width:754px; height:546px;\" src=\"images/HEME/107801_ACE910_bispecific_antibody.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate content on treatment of hemophilia for further details. <br />(A) In normal hemostasis, FVIIIa (orange) forms a complex with FIXa (red) and&nbsp;promotes interaction between FIXa and&nbsp;FX (blue)&nbsp;by binding to both factors on the phospholipid membrane.<br />(B) A bispecific antibody&nbsp;that can simultaneously bind&nbsp;to FIXa (red)&nbsp;and FX (blue)&nbsp;could mimic the activity of FVIIIa and promote interaction between FIXa and FX on the phospholipid membrane.</div><div class=\"graphic_footnotes\">FVIIIa: activated coagulation factor VIII (eight); FIXa: activated coagulation factor IX (nine); FX: coagulation factor X (ten).</div><div class=\"graphic_reference\">From: Sampei Z, Igawa T, Soeda et al. Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity. PLoS One 2013; 8:e57479. Available at: <A href=\"http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057479\" target=_blank>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057479</A> (Accessed on May 10, 2016). Copyright © 2013 Sampei et al. Reproduced under the terms of the <A href=\"http://creativecommons.org/licenses/by/4.0/\" target=_blank>Creative Commons Attribution License</A>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</div><div id=\"graphicVersion\">Graphic 107801 Version 2.0</div></div></div>"},"107802":{"type":"graphic_picture","displayName":"Retronychia","title":"Retronychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retronychia</div><div class=\"cntnt\"><img style=\"width:246px; height:370px;\" src=\"images/DERM/107802_Retronychia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thick, yellowish, onycholytic nail with whitish maceration proximally. Granulation tissue is seen protruding from under the proximal nail fold.</div><div class=\"graphic_reference\">From: Baumgartner M, Haneke E. Retronychia: Diagnosis and treatment. Dermatol Surg 2010; 36:1610. DOI: <a href=\"http://journals.lww.com/dermatologicsurgery/pages/articleviewer.aspx?year=2010&amp;issue=10000&amp;article=00023&amp;type=abstract\" target=\"_blank\">10.1111/j.1524-4725.2010.01693.x</a>. Copyright &copy; 2010 American Society for Dermatologic Surgery. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 107802 Version 1.0</div></div></div>"},"107803":{"type":"graphic_picture","displayName":"Onychopapilloma 1","title":"Onychopapilloma","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Onychopapilloma</div><div class=\"cntnt\"><img style=\"width:622px; height:701px;\" src=\"images/DERM/107803_Onychopapilloma_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychopapilloma with distal triangular onycholysis and splinter hemorrhage.</div><div class=\"graphic_reference\">From: Jellinek NJ, Lipner SR. Longitudinal erythronychia: Retrospective single-center study evaluating differential diagnosis and the likelihood of malignancy. Dermatol Surg 2016; 42:310. DOI: <A href=\"http://journals.lww.com/dermatologicsurgery/pages/articleviewer.aspx?year=2016&amp;issue=03000&amp;article=00005&amp;type=abstract\" target=_blank>10.1097/DSS.0000000000000594</A>. Copyright © 2016 American Society for Dermatologic Surgery. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 107803 Version 1.0</div></div></div>"},"107804":{"type":"graphic_picture","displayName":"Onychopapilloma 2","title":"Onychopapilloma","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Onychopapilloma</div><div class=\"cntnt\"><img style=\"width:622px; height:667px;\" src=\"images/DERM/107804_Onychopapilloma_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychopapilloma with distal subungual keratosis and&nbsp;splinter hemorrhage.</div><div class=\"graphic_reference\">From: Jellinek NJ, Lipner SR. Longitudinal erythronychia: Retrospective single-center study evaluating differential diagnosis and the likelihood of malignancy. Dermatol Surg 2016; 42:310. DOI: <a href=\"http://journals.lww.com/dermatologicsurgery/pages/articleviewer.aspx?year=2016&amp;issue=03000&amp;article=00005&amp;type=abstract\" target=\"_blank\">10.1097/DSS.0000000000000594</a>. Copyright &copy; 2016 American Society for Dermatologic Surgery. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 107804 Version 1.0</div></div></div>"},"107805":{"type":"graphic_picture","displayName":"Onychopapilloma 3","title":"Onychopapilloma","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Onychopapilloma</div><div class=\"cntnt\"><img style=\"width:622px; height:711px;\" src=\"images/DERM/107805_Onychopapilloma_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychopapilloma with confluent distal hemorrhage resembling melanonychia.</div><div class=\"graphic_reference\">From: Jellinek NJ, Lipner SR. Longitudinal erythronychia: Retrospective single-center study evaluating differential diagnosis and the likelihood of malignancy. Dermatol Surg 2016; 42:310. DOI: <a href=\"http://journals.lww.com/dermatologicsurgery/pages/articleviewer.aspx?year=2016&amp;issue=03000&amp;article=00005&amp;type=abstract\" target=\"_blank\">10.1097/DSS.0000000000000594</a>. Copyright &copy; 2016 American Society for Dermatologic Surgery. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 107805 Version 1.0</div></div></div>"},"107806":{"type":"graphic_picture","displayName":"Onychopapilloma 4","title":"Onychopapilloma","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Onychopapilloma</div><div class=\"cntnt\"><img style=\"width:611px; height:756px;\" src=\"images/DERM/107806_Onychopapilloma_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychopapilloma composed nearly entirely of splinter hemorrhages.</div><div class=\"graphic_reference\">From: Jellinek NJ, Lipner SR. Longitudinal erythronychia: Retrospective single-center study evaluating differential diagnosis and the likelihood of malignancy. Dermatol Surg 2016; 42:310. DOI: <a href=\"http://journals.lww.com/dermatologicsurgery/pages/articleviewer.aspx?year=2016&amp;issue=03000&amp;article=00005&amp;type=abstract\" target=\"_blank\">10.1097/DSS.0000000000000594</a>. Copyright &copy; 2016 American Society for Dermatologic Surgery. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 107806 Version 1.0</div></div></div>"},"107807":{"type":"graphic_diagnosticimage","displayName":"Superficial cervical plexus block ultrasound","title":"Superficial cervical plexus block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Superficial cervical plexus block ultrasound</div><div class=\"cntnt\"><img style=\"width:712px; height:464px;\" src=\"images/ANEST/107807_Sprfc_crvcl_plx_blck_ultrsnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cervical plexus can sometimes be visualized as a collection of hypoechoic ovals, posterior to the posterior fascia of the sternocleidomastoid muscle.&nbsp;The arrow indicates needle insertion. For further details, refer to the&nbsp;UpToDate topic on nerve blocks of the scalp, neck, and&nbsp;trunk.</div><div id=\"graphicVersion\">Graphic 107807 Version 1.0</div></div></div>"},"107808":{"type":"graphic_table","displayName":"Brief dietary assessment questionnaire","title":"Brief dietary assessment questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Brief dietary assessment questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Over the past few months:</td> <td class=\"subtitle1\">0 points</td> <td class=\"subtitle1\">1 point</td> <td class=\"subtitle1\">2 points</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\"> <li>How many times a week do you eat fast food meals or snacks? </li> </ol> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Less than one time</td> <td><span class=\"primarybox_left\">&nbsp;</span>One to three times</td> <td><span class=\"primarybox_left\">&nbsp;</span>Four or more times</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"2\"> <li>How many servings of fruit did you eat each day? </li> </ol> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Five or more</td> <td><span class=\"primarybox_left\">&nbsp;</span>Three to four</td> <td><span class=\"primarybox_left\">&nbsp;</span>Two or less</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"3\"> <li>How many servings of vegetables did you eat each day? </li> </ol> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Five or more</td> <td><span class=\"primarybox_left\">&nbsp;</span>Three to four</td> <td><span class=\"primarybox_left\">&nbsp;</span>Two or less</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"4\"> <li>How many regular sodas or glasses of sweet tea did you drink each day? </li> </ol> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Less than one</td> <td><span class=\"primarybox_left\">&nbsp;</span>One to two</td> <td><span class=\"primarybox_left\">&nbsp;</span>Three or more</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"5\"> <li>How many times a week did you eat beans (like pinto or black beans), chicken, or fish? </li> </ol> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Three or more times</td> <td><span class=\"primarybox_left\">&nbsp;</span>One to two times</td> <td><span class=\"primarybox_left\">&nbsp;</span>Less than one time</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"6\"> <li>How many times a week did you eat regular snack chips or crackers (not low-fat)? </li> </ol> </td> <td><span class=\"primarybox_left\">&nbsp;</span>One time or less</td> <td><span class=\"primarybox_left\">&nbsp;</span>Two to three times</td> <td><span class=\"primarybox_left\">&nbsp;</span>Four or more times</td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"7\"> <li>How many times a week did you eat desserts and other sweets (not the low-fat kind)? </li> </ol> </td> <td><span class=\"primarybox_left\">&nbsp;</span>One time or less</td> <td><span class=\"primarybox_left\">&nbsp;</span>Two to three times</td> <td><span class=\"primarybox_left\">&nbsp;</span>Four or more times</td> </tr> <tr class=\"divider_bottom\"> <td> <ol class=\"numbers_to_nine\" start=\"8\"> <li>How much margarine, butter, or meat fat do you use to season vegetables or put on potatoes, bread, or corn? </li> </ol> </td> <td><span class=\"primarybox_left\">&nbsp;</span>Very little</td> <td><span class=\"primarybox_left\">&nbsp;</span>Some</td> <td><span class=\"primarybox_left\">&nbsp;</span>A lot</td> </tr> <tr class=\"divider_top\"> <td><strong>Summary score (sum of all items) = _____</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Responses in the&nbsp;first points&nbsp;column indicate healthy eating habits (scored 0), responses in the&nbsp;second points&nbsp;column indicate less healthy eating habits (scored 1), and responses in the third points column indicate the least healthy eating habits (scored 2).&nbsp;Summary scores may range from 0 to 16, with lower numbers indicating good dietary habits and higher scores indicating poorer dietary habits.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; Alice Ammerman. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107808 Version 1.0</div></div></div>"},"107810":{"type":"graphic_figure","displayName":"Menticoglou maneuver","title":"Menticoglou maneuver","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Menticoglou maneuver</div><div class=\"cntnt\"><img style=\"width:478px; height:314px;\" src=\"images/OBGYN/107810_Menticogloumaneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After an assistant gently flexes the fetal head toward the anterior shoulder, the obstetrician places his/her right middle finger into the fetus' posterior axilla from the left side of the pelvis and the left middle finger into the posterior axilla from the right side of the pelvis. The two middle fingers in the axilla are then used to pull the posterior shoulder downward along the curve of the sacrum. Once the shoulder has been brought down sufficiently, the posterior arm can be grasped and delivered.</div><div class=\"graphic_reference\">Modified from: Menticoglou SM. A modified technique to deliver the posterior arm in severe shoulder dystocia. Obstet Gynecol 2006; 108:755.</div><div id=\"graphicVersion\">Graphic 107810 Version 2.0</div></div></div>"},"107812":{"type":"graphic_table","displayName":"Approach to shoulder dystocia","title":"Approach to shoulder dystocia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to shoulder dystocia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Notify</strong> nursing, anesthesia, obstetric, and pediatric staff to come to patient's room, if not already available, to provide assistance as needed.</td> </tr> <tr> <td><strong>Stop maternal pushing</strong> while preparations are made and maneuvers are undertaken to reposition the fetus.</td> </tr> <tr> <td><strong>Check for and release</strong> a tight nuchal cord, if present.</td> </tr> <tr> <td><strong>Position the patient</strong> with her buttocks flush with the edge of the bed to provide optimal access for executing maneuvers to affect delivery.</td> </tr> <tr> <td><strong>Consider performing a mediolateral or median&nbsp;third- or fourth-degree episiotomy</strong> to facilitate delivery of the posterior shoulder and other internal procedures. Episiotomy by itself does not help to release the anterior shoulder and increases perineal trauma.</td> </tr> <tr> <td><strong>Drain</strong> a distended bladder, if present.</td> </tr> <tr> <td><strong>Avoid excessive neck rotation, head and neck traction, and fundal pressure</strong> because this combination of maneuvers can stretch and injure the brachial plexus.</td> </tr> <tr> <td> <p><strong>Perform&nbsp;maneuvers sequentially until shoulder dystocia is released. The sequence may be modified based on provider expertise with the various maneuvers.</strong></p> <ul class=\"decimal_heading\"> <li>Perform McRoberts maneuver </li> <li>Perform McRoberts maneuver with suprapubic pressure </li> <li>Deliver the posterior arm or Gaskin all-fours maneuver* </li> <li>If the posterior arm cannot be delivered, deliver the posterior shoulder&nbsp;&nbsp; </li> <li>Rotate the fetus (Rubin or Woods maneuver) </li> <li>Fracture the fetal clavicle </li> </ul> Procedures of&nbsp;last resort: <ul class=\"decimal_heading\"> <li>Gunn-Zavanelli-O'Leary maneuver </li> <li>Abdominal rescue </li> <li>Symphysiotomy (potentially high maternal morbidity) </li> </ul> </td> </tr> <tr> <td><strong>Document</strong> your evaluation, assessment, and management.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Although most obstetricians do not perform the Gaskin all-fours maneuver, this is one of the initial group of maneuvers used my some midwives and other clinicians, particularly for the mother in a birthing bed with no, only local, or pudendal anesthesia. Some providers prefer to use it before attempting to deliver the posterior arm or shoulder since the latter require more technical expertise. The available literature on this maneuver is limited and its role in the management of shoulder dystocia has not been firmly established; however, case reports&nbsp;support both the efficacy and low morbidity of this simple approach. Refer to the UpToDate topic on management of shoulder dystocia for more information.</div><div id=\"graphicVersion\">Graphic 107812 Version 3.0</div></div></div>"},"107815":{"type":"graphic_table","displayName":"HCM phenocopies","title":"Genetic syndromes, metabolic disorders, and neuromuscular diseases associated with hypertrophic cardiomyopathy in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic syndromes, metabolic disorders, and neuromuscular diseases associated with hypertrophic cardiomyopathy in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Multiple congenital anomaly syndromes</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/163950\" target=\"_blank\">Noonan syndrome</a></td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/151100\" target=\"_blank\">LEOPARD syndrome</a></td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/130650\" target=\"_blank\">Beckwith-Wiedemann syndrome</a></td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/115150\" target=\"_blank\">Cardiofacialcutaneous syndrome</a></td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/180849\" target=\"_blank\">Rubinstein-Taybi syndrome</a></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/218040\" target=\"_blank\">Costello syndrome</a></td> </tr> <tr> <td class=\"subtitle1_single\">Inborn errors of metabolism</td> </tr> <tr> <td class=\"indent1\">Glycogen storage diseases:</td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/232300\" target=\"_blank\">Pompe disease</a> (glycogen storage disease type II)</td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/232400\" target=\"_blank\">Forbes disease</a> (glycogen storage disease type III, also known as Cori disease)</td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/261750\" target=\"_blank\">Phosphorylase kinase deficiency</a> (glycogen storage disease type IX)</td> </tr> <tr> <td class=\"indent1\">Carnitine deficiency:</td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/608836\" target=\"_blank\">Carnitine palmitoyltransferase type II deficiency</a></td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/212138\" target=\"_blank\">Carnitine-acylcarnitine translocase deficiency</a></td> </tr> <tr> <td class=\"indent1\">Mucopolysaccharidoses:</td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/607014\" target=\"_blank\">Hurler syndrome</a> (mucopolysaccharidosis type I)</td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/309900\" target=\"_blank\">Hunter syndrome</a> (mucopolysaccharidosis type II)</td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/253000\" target=\"_blank\">Morquio syndrome</a></td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/607016\" target=\"_blank\">Scheie syndrome</a></td> </tr> <tr> <td class=\"indent1\">Other lysosomal diseases:</td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/300257\" target=\"_blank\">Danon disease</a></td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/230000\" target=\"_blank\">Fucosidosis</a></td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/252500\" target=\"_blank\">I-cell disease</a></td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/301500\" target=\"_blank\">Fabry disease</a></td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/248500\" target=\"_blank\">Mannosidosis</a></td> </tr> <tr> <td class=\"indent1\">Organic acidurias:</td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/251000\" target=\"_blank\">Methylmalonic aciduria</a></td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/302060\" target=\"_blank\">Barth syndrome </a>(3-methylglutaconic aciduria, type II)</td> </tr> <tr> <td class=\"indent1\">Glycosylation disorders (eg, <a href=\"http://www.omim.org/entry/212065\" target=\"_blank\">phosphomannomutase 2 deficiency</a>)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/269700\" target=\"_blank\">Congenital generalized lipodystrophy</a></td> </tr> <tr> <td class=\"subtitle1_single\">Mitochondrial disorders</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/540000\" target=\"_blank\">MELAS syndrome</a></td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/256000\" target=\"_blank\">Leigh syndrome</a></td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/252010\" target=\"_blank\">Complex I deficiency</a></td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/212350\" target=\"_blank\">Sengers syndrome</a></td> </tr> <tr> <td class=\"indent1\">Defects of beta-oxidation enzymes:</td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/201475\" target=\"_blank\">Very long chain acyl-CoA dehydrogenase deficiency</a></td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/609016\" target=\"_blank\">Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency</a></td> </tr> <tr> <td class=\"indent2\"><a href=\"http://www.omim.org/entry/231680\" target=\"_blank\">Multiple acyl-COA dehydrogenase deficiency</a></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Combined respiratory chain deficiencies</td> </tr> <tr> <td class=\"subtitle1_single\">Neuromuscular disorders</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/229300\" target=\"_blank\">Friedreich ataxia</a></td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/160900\" target=\"_blank\">Myotonic dystrophy</a></td> </tr> <tr> <td class=\"indent1\"><a href=\"http://www.omim.org/entry/255320\" target=\"_blank\">Minicore (multicore) myopathy</a></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Prepared with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Colan DC. Cardiomyopathies. In: Nadas' Pediatric Cardiology, 2nd ed, Keane JF, Lock JE, Fyler DC. (Eds), Saunders, Philadelphia 2006. p.432.</li>&#xD;&#xA;    <li>Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007; 115:773.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 107815 Version 2.0</div></div></div>"},"107821":{"type":"graphic_figure","displayName":"Ultrasound transducer manipulation","title":"Ultrasound transducer manipulation","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Ultrasound transducer manipulation</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/ANEST/107821_Ultrasound_transducer_manipulation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound transducer can be manipulated through a variety of motions to change the direction and orientation of the ultrasound beam, as shown in this graphic.</div><div id=\"graphicVersion\">Graphic 107821 Version 1.0</div></div></div>"},"107823":{"type":"graphic_table","displayName":"Antibiotic oversight strategies","title":"Antibiotic oversight strategies: Preauthorization versus prospective audit and feedback","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic oversight strategies: Preauthorization versus prospective audit and feedback</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Preauthorization</td> <td class=\"subtitle1\">Prospective audit and feedback</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Advantages</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Reduces initiation of unnecessary/inappropriate antibiotics </li> <li>Optimizes empiric choices and influences downstream use </li> <li>Prompts review of clinical data/prior cultures at the time of initiation of therapy </li> <li>Decreases antibiotic costs, including those due to high-cost agents </li> <li>Provides mechanism for rapid response to antibiotic shortages </li> <li>Direct control over antibiotic use </li> </ul> </td> <td> <ul> <li>Can increase visibility of antimicrobial stewardship program and build collegial relationships </li> <li>More clinical data available for recommendations, enhancing uptake by prescribers </li> <li>Greater flexibility in timing of recommendations </li> <li>Can be done on less than daily basis if resources are limited </li> <li>Provides educational benefit to clinicians </li> <li>Prescriber autonomy maintained </li> <li>Can address de-escalation of antibiotics and duration of therapy </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Disadvantages</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Impacts use of restricted agents only </li> <li>Addresses empiric use to a much greater degree than downstream use </li> <li>Loss of prescriber autonomy </li> <li>May delay therapy well </li> <li>Effectiveness depends on skill of approver </li> <li>Real-time resource intensive </li> <li>Potential for manipulation of system (eg, presenting request in a biased manner to gain approval) </li> <li>May simply shift to other antibiotic agents and select for different antibiotic-resistance patterns </li> </ul> </td> <td> <ul> <li>Compliance voluntary </li> <li>Typically labor-intensive </li> <li>Success depends on delivery method of feedback to prescribers </li> <li>Prescribers may be reluctant to change therapy if patient is doing well </li> <li>Identification of interventions may require information technology support and/or purchase of computerized surveillance systems </li> <li>May take longer to achieve reductions in targeted antibiotic use </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016; 62(10):e51-77, by permission of Oxford University Press on behalf of The Infectious Diseases Society of America. Copyright © 2016 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.idsociety.org/\" target=_blank>www.idsociety.org</A>.</div><div id=\"graphicVersion\">Graphic 107823 Version 5.0</div></div></div>"},"107824":{"type":"graphic_table","displayName":"Medical history that poses nutrition-related risks in pregnancy","title":"Medical history that poses potential nutrition-related risks in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical history that poses potential nutrition-related risks in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medical history or condition</td> <td class=\"subtitle1\">Examples*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Diabetes</td> <td> <ul> <li>Type 1 diabetes </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Type 2 diabetes </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Obstetric history</td> <td> <ul> <li>Previous child with neural tube defect </li> </ul> </td> </tr> <tr> <td> <ul> <li>Gestational diabetes </li> </ul> </td> </tr> <tr> <td> <ul> <li>Hyperemesis gravidarum </li> </ul> </td> </tr> <tr> <td> <ul> <li>Hypertensive disorder of pregnancy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Current multifetal pregnancy </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Inborn metabolic disorders</td> <td> <ul> <li>Phenylketonuria </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Maple syrup urine disease </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Surgical history</td> <td> <ul> <li>Bariatric surgery </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Bowel resection </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Gastrointestinal disease/conditions that cause malabsorption</td> <td> <ul> <li>Crohn disease </li> </ul> </td> </tr> <tr> <td> <ul> <li>Ulcerative colitis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Cystic fibrosis </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Nutrition issues</td> <td> <ul> <li>Obesity </li> </ul> </td> </tr> <tr> <td> <ul> <li>Overweight </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Eating disorder (past or current) </li> </ul> </td> </tr> <tr> <td>Unhealthy behaviors</td> <td> <ul> <li>Use of cigarettes, alcohol, stimulants, illicit drugs </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not an exhaustive list.</div><div id=\"graphicVersion\">Graphic 107824 Version 1.0</div></div></div>"},"107825":{"type":"graphic_table","displayName":"Stewardship program metrics","title":"Metrics for evaluation of stewardship program interventions to improve antibiotic use and clinical outcomes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Metrics for evaluation of stewardship program interventions to improve antibiotic use and clinical outcomes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Process measures</td> <td class=\"subtitle1\">Outcome measures</td> </tr> <tr> <td> <ul> <li>Excess days of therapy (ie, unnecessary days of therapy avoided based on accepted targets and benchmarks)* </li> <li>Duration of therapy </li> <li>Proportion of patients compliant with facility-based guideline or treatment algorithm* </li> <li>Proportion of patients with revision of antibiotics based on microbiology data </li> <li>Proportion of patients converted to oral therapy </li> </ul> </td> <td> <ul> <li>Hospital length of stay </li> <li>30-day mortality </li> <li>Unplanned hospital readmission within 30 days </li> <li>Proportion of patients diagnosed with hospital-acquired <em>Clostridium difficile</em> infection or other adverse event(s) related to antibiotic treatment* </li> <li>Proportion of patients with clinical failure (eg, need to broaden therapy, recurrence of infection) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These metrics are applicable for antibiotic stewardship program interventions to reduce antibiotic treatment of asymptomatic bacteriuria, which, in most cases, should not be treated; therefore, the other metrics do not apply.</div><div class=\"graphic_reference\">Reproduced from: Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016; 62(10):e51-77, by permission of Oxford University Press on behalf of The Infectious Diseases Society of America. Copyright © 2016 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.idsociety.org/\" target=_blank>www.idsociety.org</A>.</div><div id=\"graphicVersion\">Graphic 107825 Version 4.0</div></div></div>"},"107826":{"type":"graphic_table","displayName":"Iron-rich foods","title":"Iron-rich foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Iron-rich foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Amount</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Foods that provide 3 to 12 mg of iron</td> </tr> <tr> <td class=\"indent1\">Clams</td> <td>Four large or nine small</td> </tr> <tr> <td class=\"indent1\">Oysters</td> <td>Six medium</td> </tr> <tr> <td class=\"indent1\">Octopus</td> <td>3 oz cooked</td> </tr> <tr> <td class=\"indent1\">Spinach</td> <td>1/2 cup cooked</td> </tr> <tr> <td class=\"indent1\">Lentils</td> <td>1/2 cup cooked</td> </tr> <tr> <td class=\"indent1\">Pumpkin seeds</td> <td>1 oz roasted</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fortified cereals</td> <td>1 cup</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Foods that provide 1.6 to 3 mg of iron</td> </tr> <tr> <td class=\"indent1\">Sirloin steak</td> <td>3 oz</td> </tr> <tr> <td class=\"indent1\">Roast beef</td> <td>3 oz</td> </tr> <tr> <td class=\"indent1\">Lean hamburger</td> <td>3 oz</td> </tr> <tr> <td class=\"indent1\">Pork</td> <td>3 oz</td> </tr> <tr> <td class=\"indent1\">Lamb</td> <td>3 oz</td> </tr> <tr> <td class=\"indent1\">Salmon</td> <td>3 oz</td> </tr> <tr> <td class=\"indent1\">Tilapia</td> <td>3 oz</td> </tr> <tr> <td class=\"indent1\">Kidney beans</td> <td>1/2 cup cooked</td> </tr> <tr> <td class=\"indent1\">Lima beans</td> <td>1/2 cup cooked</td> </tr> <tr> <td class=\"indent1\">Navy beans</td> <td>1/2 cup cooked</td> </tr> <tr> <td class=\"indent1\">Oatmeal</td> <td>1 cup cooked</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cashew nuts</td> <td>1 oz dry roasted</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Foods that provide 0.5 to 1.5 mg of iron</td> </tr> <tr> <td class=\"indent1\">Chicken</td> <td>3 oz</td> </tr> <tr> <td class=\"indent1\">Eggs</td> <td>One whole</td> </tr> <tr> <td class=\"indent1\">Green peas</td> <td>1/2 cup</td> </tr> <tr> <td class=\"indent1\">Tomato juice</td> <td>6 oz</td> </tr> <tr> <td class=\"indent1\">Broccoli</td> <td>1/2 cup</td> </tr> <tr> <td class=\"indent1\">Brussels sprouts</td> <td>1/2 cup cooked</td> </tr> <tr> <td class=\"indent1\">Almonds</td> <td>1 oz roasted</td> </tr> <tr> <td class=\"indent1\">Peanuts</td> <td>2 oz roasted</td> </tr> <tr> <td class=\"indent1\">Dried apricots</td> <td>Five halves</td> </tr> <tr> <td class=\"indent1\">Raisins</td> <td>1 oz (about 60 raisins)</td> </tr> <tr> <td class=\"indent1\">Raspberries</td> <td>1 cup</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Strawberries</td> <td>1 cup</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Foods high in vitamin C that enhance iron absorption when consumed&nbsp;with iron-containing foods</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Broccoli</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Bell peppers</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Cantaloupe</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Grapefruit and grapefruit juice</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Kiwi</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Orange and orange juice</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Tomatoes and tomato sauces</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Strawberries</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">mg: milligrams; oz: ounces.</div><div id=\"graphicVersion\">Graphic 107826 Version 1.0</div></div></div>"},"107827":{"type":"graphic_table","displayName":"Calcium content of foods","title":"Calcium content of foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Calcium content of foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Amount</td> <td class=\"subtitle1\">Calcium (mg)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Dairy</td> </tr> <tr> <td class=\"indent1\">Milk, sheep's</td> <td>1 cup</td> <td>470</td> </tr> <tr> <td class=\"indent1\">Milk, goat's</td> <td>1 cup</td> <td>325</td> </tr> <tr> <td class=\"indent1\">Milk, cow's</td> <td>1 cup</td> <td>300</td> </tr> <tr> <td class=\"indent1\">Yogurt</td> <td>1 cup (8 oz)</td> <td>400</td> </tr> <tr> <td class=\"indent1\">Greek yogurt</td> <td>&#189; cup (4 oz)</td> <td>120</td> </tr> <tr> <td class=\"indent1\">Cheddar cheese</td> <td>1 oz</td> <td>200</td> </tr> <tr> <td class=\"indent1\">Parmesan cheese</td> <td>1 tbsp</td> <td>45</td> </tr> <tr> <td class=\"indent1\">Ice cream</td> <td>&#189; cup</td> <td>84</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cottage cheese</td> <td>&#189; cup</td> <td>125</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Dairy alternatives</td> </tr> <tr> <td class=\"indent1\">Soy milk, calcium fortified</td> <td>1 cup</td> <td>200 to 400</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Almond milk, calcium fortified</td> <td>1 cup</td> <td>200 to 500</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Legumes</td> </tr> <tr> <td class=\"indent1\">Edamame, cooked</td> <td>&#189; cup</td> <td>50</td> </tr> <tr> <td class=\"indent1\">Garbanzo beans, cooked</td> <td>&#189; cup</td> <td>40</td> </tr> <tr> <td class=\"indent1\">Pinto beans, cooked</td> <td>&#189; cup</td> <td>40</td> </tr> <tr> <td class=\"indent1\">Tofu, firm, calcium-set</td> <td>4 oz</td> <td>300 to 780</td> </tr> <tr> <td class=\"indent1\">Tofu, regular</td> <td>4 oz</td> <td>90 to 170</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">White beans</td> <td>&#189; cup</td> <td>90</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vegetables</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Arugula, raw</td> <td>1 cup</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Bok choy, cooked</td> <td>&#189; cup</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Broccoli, raw</td> <td>1 cup</td> <td>45</td> </tr> <tr> <td class=\"indent1\">Broccoli, cooked</td> <td>&#189; cup</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Chard, cooked</td> <td>&#189; cup</td> <td>50</td> </tr> <tr> <td class=\"indent1\">Kale, raw</td> <td>1 cup</td> <td>25</td> </tr> <tr> <td class=\"indent1\">Kale, cooked</td> <td>&#189; cup</td> <td>50</td> </tr> <tr> <td class=\"indent1\">Spinach, raw</td> <td>1 cup</td> <td>30</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Spinach, cooked</td> <td>&#189; cup</td> <td>120</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Fruits</td> </tr> <tr> <td class=\"indent1\">Figs, raw</td> <td>Two medium</td> <td>35</td> </tr> <tr> <td class=\"indent1\">Figs, dried</td> <td>&#189; cup</td> <td>120</td> </tr> <tr> <td class=\"indent1\">Kiwi, raw</td> <td>&#189; cup</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Orange juice, calcium fortified</td> <td>4 oz</td> <td>175</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Orange juice, regular</td> <td>4 oz</td> <td>15</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Nuts</td> </tr> <tr> <td class=\"indent1\">Almonds, roasted</td> <td>1 oz</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Brazil nuts</td> <td>1 oz</td> <td>45</td> </tr> <tr> <td class=\"indent1\">Chia seeds, dried</td> <td>1 oz</td> <td>180</td> </tr> <tr> <td class=\"indent1\">Sesame seeds, whole toasted</td> <td>1 oz</td> <td>280</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">mg: milligrams; tbsp: tablespoons; oz: ounces.<br />* Adult women (pregnant, lactating, and nonpregnant) require 1000 mg calcium/day. Note that absorption of calcium is best when it is consumed at amounts equal to or less than 500 mg at a time.</div><div class=\"graphic_reference\">Reproduced from: United States Department of Agriculture (USDA) National Agricultural Library. USDA National Nutrient Database for Standard Reference. Available at: <a href=\"https://ndb.nal.usda.gov/\" target=\"_blank\">https://ndb.nal.usda.gov/</a> (Accessed on April 27, 2016).</div><div id=\"graphicVersion\">Graphic 107827 Version 1.0</div></div></div>"},"107829":{"type":"graphic_table","displayName":"Alt rx uncomplicated non-falciparum","title":"Second-line antimalarial regimens for treatment of uncomplicated non-falciparum malaria in nonpregnant adults and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Second-line antimalarial regimens for treatment of uncomplicated non-falciparum malaria in nonpregnant adults and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug&nbsp;</td> <td class=\"subtitle1\">Adults</td> <td class=\"subtitle1\"> <p>Children</p> <p>(pediatric weight-based dose should not exceed standard [non-weight-based] adult dose)</p> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hydroxychloroquine<sup>&#182;</sup></strong></td> <td>620 mg base (= 800 mg salt) orally immediately, followed by 310 mg base (= 400 mg salt) orally at 6, 24, and 48 hours. Total dose: 1550 mg base (= 2000 mg salt)</td> <td>10 mg base/kg orally immediately, followed by 5 mg base/kg orally at 6, 24, and 48 hours. Total dose: 25 mg base/kg. Maximum total dose 1550 mg base ( = 2000 mg salt).</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Atovaquone-proguanil</strong></p> <p>Adult tab = 250 mg atovaquone/100 mg proguanil</p> Pediatric tab = 62.5 mg atovaquone/25 mg proguanil</td> <td>4 adult tabs orally once daily for three days</td> <td> <p>5 to 8 kg: 2 pediatric tabs orally once daily for three days</p> <p>9 to 10 kg: 3&nbsp;pediatric tabs orally once daily for three days</p> <p>11 to 20 kg: 1 adult tab orally once daily for three days</p> <p>21 to 30 kg: 2 adult tabs orally once daily for three days</p> <p>31 to 40 kg: 3 adult tabs orally once daily for three days</p> &#62;40 kg: 4 adult tabs orally once daily for three days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Quinine plus tetracycline or doxycycline<sup>&#916;</sup></strong></td> <td>Quinine sulfate: 542 mg base (= 650 mg salt)<sup>&#9674;</sup> orally three times daily for three or seven days<sup>&#167;</sup></td> <td>Quinine sulfate: 8.3 mg base/kg ( = 10 mg salt/kg) orally three times daily for three or seven days<sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>PLUS</strong> one of the following:</td> <td><strong>PLUS</strong> one of the following:</td> </tr> <tr> <td class=\"indent1\">Doxycycline: 100 mg orally twice daily for seven days</td> <td class=\"indent1\">Doxycycline<sup>&#916;</sup>: 2.2 mg/kg orally every 12 hours for seven days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tetracycline: 250 mg orally four times daily for seven days</td> <td class=\"indent1\">Tetracycline<sup>&#916;</sup>: 6.25 mg/kg orally every 6 hours for seven days</td> </tr> <tr> <td><strong>Mefloquine</strong></td> <td>684 mg base (= 750 mg salt) orally as initial dose, followed by 456 mg base (= 500 mg salt) orally given 6 to 12 hours after initial dose. Total dose = 1250 mg salt</td> <td>13.7 mg base/kg (= 15 mg salt/kg) orally as initial dose, followed by 9.1 mg base/kg (= 10 mg salt/kg) orally given 6 to 12 hours after initial dose. Total dose = 25 mg salt/kg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The approach to antimalarial selection depends on a number of factors including species diagnosis and likelihood of chloroquine resistance. Preferred regimens for treatment of chloroquine-sensitive non-falciparum malaria consist of chloroquine or artemisinin combination therapy (ACT). Preferred regimens for treatment of chloroquine-resistant non-falciparum malaria consist of ACT. Issues related to treatment of non-falciparum malaria are discussed further in the text. (Refer to the UpToDate topic on non-falciparum malaria in nonpregnant adults and children and the separate table on ACT regimens.)<br />The dosing regimens listed in this table are generally consistent with the United States Centers for Disease Control and Prevention&nbsp;guidelines for the treatment of uncomplicated malaria in the United States (as revised July 2013) and may differ from dosing recommended in approved product information. Product availability varies by locality.</div><div class=\"graphic_footnotes\">¶ Hydroxychloroquine is appropriate only for treatment of chloroquine-susceptible infection.<br />Δ Doxycycline and tetracycline are not indicated for use in children less than eight years old. For children less than eight years old with chloroquine-resistant <EM>P. vivax</EM> who cannot take an ACT, mefloquine is the recommended treatment. If mefloquine is not available or tolerated and if the treatment benefits outweigh the risks, atovaquone-proguanil should be used instead.<br /><FONT class=lozenge>◊</FONT> United States–manufactured quinine sulfate capsule is only available in a 324 mg (salt) strength; therefore, two capsules should be sufficient for adult dosing. Pediatric dosing may be difficult due to unavailability of noncapsule forms of quinine in the United States.<br />§ For infections acquired in Southeast Asia, quinine treatment should continue for seven days. For infections acquired elsewhere, quinine treatment should continue for three days.</div><div class=\"graphic_reference\">Adapted from: United States Centers for Disease Control guidelines for treatment of malaria: http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf (Accessed March 22, 2016). CDC Malaria Hotline: <SPAN class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">(770) 488-7788</SPAN> Monday to Friday 8:00 am to 4:30 pm EST; <SPAN class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">(770) 488-7100</SPAN> after hours, weekends, and holiday.</div><div id=\"graphicVersion\">Graphic 107829 Version 1.0</div></div></div>"},"107830":{"type":"graphic_table","displayName":"ACTs for rx non-falciparum malaria","title":"Artemisinin combination therapy (ACT) regimens for treatment of uncomplicated non-falciparum malaria in nonpregnant adults and children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Artemisinin combination therapy (ACT) regimens for treatment of uncomplicated non-falciparum malaria in nonpregnant adults and children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Formulations available</td> <td class=\"subtitle1\">Body weight (kg)</td> <td class=\"subtitle1\">Dose*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\"><strong>Dihydroartemisinin-piperaquine<sup>&#182;</sup></strong></td> <td class=\"divider_bottom\" rowspan=\"9\"> <p>Available as tablets containing</p> <p>20 + 160 or</p> <p>40 + 320 of</p> dihydroartemisinin and piperaquine, respectively</td> <td>&nbsp;</td> <td>Dose administered orally once daily for three days:</td> </tr> <tr> <td>5 to &#60;8</td> <td class=\"indent1\">20 + 160</td> </tr> <tr> <td>8 to &#60;11</td> <td class=\"indent1\">30 + 240</td> </tr> <tr> <td>11 to &#60;17</td> <td class=\"indent1\">40 + 320</td> </tr> <tr> <td>17 to &#60;25</td> <td class=\"indent1\">60 + 480</td> </tr> <tr> <td>25 to &#60;36</td> <td class=\"indent1\">80 + 640</td> </tr> <tr> <td>36 to &#60;60</td> <td class=\"indent1\">120 + 960</td> </tr> <tr> <td>60 to &#60;80</td> <td class=\"indent1\">160 + 1280</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;80</td> <td class=\"indent1\">200 + 1600</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Artesunate-mefloquine</strong></td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Available as tablets containing</p> <p>25 + 55 mg or</p> <p>100 + 220 mg</p> <p>of artesunate and mefloquine hydrochloride, respectively<sup>&#916;</sup></p> </td> <td>&nbsp;</td> <td>Dose administered orally once daily for three days:</td> </tr> <tr> <td>5 to &#60;9</td> <td class=\"indent1\">25 + 55 mg</td> </tr> <tr> <td>9 to &#60;18</td> <td class=\"indent1\">50 + 110 mg</td> </tr> <tr> <td>18 to &#60;30</td> <td class=\"indent1\">100 + 220 mg</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;30</td> <td class=\"indent1\">200 + 440 mg</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Artemether-lumefantrine<sup>&#9674;</sup></strong></td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Available as tablets containing</p> <p>20 + 120 mg or</p> <p>40 + 240 mg</p> <p>of artemether and lumefantrine, respectively.</p> <p>An orally disintegrating flavored tablet is available in some areas.</p> </td> <td>&nbsp;</td> <td>Dose administered orally twice daily for three days:</td> </tr> <tr> <td>5 to &#60;15</td> <td class=\"indent1\">20 + 120 mg</td> </tr> <tr> <td>15 to &#60;25</td> <td class=\"indent1\">40 + 240 mg</td> </tr> <tr> <td>25 to &#60;35</td> <td class=\"indent1\">60 + 360 mg</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;35</td> <td class=\"indent1\">80 + 480 mg</td> </tr> <tr> <td rowspan=\"5\"><strong>Artesunate-amodiaquine</strong></td> <td rowspan=\"5\"> <p>Available as tablets containing</p> <p>25 + 67.5 mg,</p> <p>50 + 135 mg, or</p> <p>100 + 270 mg</p> of artesunate and amodiaquine, respectively</td> <td>&nbsp;</td> <td>Dose administered orally once daily for three days:</td> </tr> <tr> <td>4.5 to &#60;9</td> <td class=\"indent1\">25 + 67.5 mg</td> </tr> <tr> <td>9 to &#60;18</td> <td class=\"indent1\">50 + 135 mg</td> </tr> <tr> <td>18 to &#60;36</td> <td class=\"indent1\">100 + 270 mg</td> </tr> <tr> <td>&#8805;36</td> <td class=\"indent1\">200 + 540 mg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The dosing regimens listed in this table are consistent with the World Health Organization 2015 guidelines for the treatment of malaria and may differ from dosing recommended in approved product information. Product availability varies by locality.</div><div class=\"graphic_footnotes\">DP: Dihydroartemisinin-piperaquine.<br />* In general, the course of ACT is administered for three days. In areas of artemisinin resistance, a six-day course of treatment is warranted.<br />¶ Piperaquine prolongs the QT interval by approximately the same amount as chloroquine but by less than quinine. DP should not be used in patients with congenital QT prolongation or who are on medications that prolong the QT interval. DP may be taken with food but should not be taken with a high-fat meal.<br />Δ&nbsp;Mefloquine hydrochloride (55 mg) is equivalent to mefloquine base (50 mg); mefloquine hydrochloride (220 mg) is equivalent to mefloquine base (200 mg). <br /><FONT class=lozenge>◊</FONT> Take after a full meal or whole milk. If patient vomits within 30 minutes of taking a dose, then they should repeat the dose. Ideally, the first two doses should be taken 8 hours apart.</div><div class=\"graphic_reference\">Data from: World Health Organization. Guidelines for the treatment of malaria, 3rd ed. WHO, Geneva 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/ (Accessed on March 22, 2016).</div><div id=\"graphicVersion\">Graphic 107830 Version 2.0</div></div></div>"},"107831":{"type":"graphic_figure","displayName":"Number of heart transplants by year","title":"Number of heart transplants (all recipient ages) by year (transplants: 1982 to 2013) and geographic region","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">Number of heart transplants (all recipient ages) by year (transplants: 1982 to 2013) and geographic region</div><div class=\"cntnt\"><img style=\"width:792px; height:504px;\" src=\"images/CARD/107831_Number_heart_transplants_yr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">NOTE: This figure includes the heart transplants that are reported to the ISHLT Transplant Registry. As such, the presented data may not mirror the changes in the number of heart transplants performed worldwide.</div><div class=\"graphic_reference\">Reproduced from: Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report&mdash;2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015; 34:1244. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107831 Version 1.0</div></div></div>"},"107832":{"type":"graphic_figure","displayName":"Underlying etiology of heart failure leading to heart transplant","title":"Underlying etiology of heart failure leading to heart transplant (transplants: January 2009 to June 2014)","html":"<div class=\"graphic\"><div style=\"width: 722px\" class=\"figure\"><div class=\"ttl\">Underlying etiology of heart failure leading to heart transplant (transplants: January 2009 to June 2014)</div><div class=\"cntnt\"><img style=\"width:702px; height:744px;\" src=\"images/CARD/107832_Undrlng_etlg_HF_hrt_trnplnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Underlying etiology of heart failure leading to heart transplant (transplants: January 2009 to June 2014). For some retransplants, a diagnosis other than retransplant was reported, and therefore the total percentage of retransplants may be greater.</div><div class=\"graphic_reference\">Reproduced from: Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report&mdash;2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015; 34:1244. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107832 Version 1.0</div></div></div>"},"107833":{"type":"graphic_figure","displayName":"Use of mechanical circulatory support at time of heart transplan","title":"Use of mechanical circulatory support at time of heart transplant by year of transplant","html":"<div class=\"graphic\"><div style=\"width: 814px\" class=\"figure\"><div class=\"ttl\">Use of mechanical circulatory support at time of heart transplant by year of transplant</div><div class=\"cntnt\"><img style=\"width:794px; height:460px;\" src=\"images/CARD/107833_Mechanicl_crcltry_spprt_hrt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECMO: extracorporeal membrane oxygenation; LVAD: left ventricular assist device; RVAD: right ventricular assist device; TAH: total artificial heart.</div><div class=\"graphic_reference\">Reproduced from: Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report&mdash;2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015; 34:1244. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107833 Version 1.0</div></div></div>"},"107834":{"type":"graphic_table","displayName":"Estimated caloric needs per day","title":"Estimated caloric needs per day, by age, sex, and physical activity level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated caloric needs per day, by age, sex, and physical activity level</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Males</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\">Age</td> <td class=\"subtitle2_left\">Sedentary*</td> <td class=\"subtitle2_left\">Moderately active<sup>&#182;</sup></td> <td class=\"subtitle2_left\">Active<sup>&#916;</sup></td> </tr> <tr class=\"divider_top highlight_gray_text\"> <td>2</td> <td>1000</td> <td>1000</td> <td>1000</td> </tr> <tr> <td>3</td> <td>1000</td> <td>1400</td> <td>1400</td> </tr> <tr class=\"highlight_gray_text\"> <td>4</td> <td>1200</td> <td>1400</td> <td>1600</td> </tr> <tr> <td>5</td> <td>1200</td> <td>1400</td> <td>1600</td> </tr> <tr class=\"highlight_gray_text\"> <td>6</td> <td>1400</td> <td>1600</td> <td>1800</td> </tr> <tr> <td>7</td> <td>1400</td> <td>1600</td> <td>1800</td> </tr> <tr class=\"highlight_gray_text\"> <td>8</td> <td>1400</td> <td>1600</td> <td>2000</td> </tr> <tr> <td>9</td> <td>1600</td> <td>1800</td> <td>2000</td> </tr> <tr class=\"highlight_gray_text\"> <td>10</td> <td>1600</td> <td>1800</td> <td>2200</td> </tr> <tr> <td>11</td> <td>1800</td> <td>2000</td> <td>2200</td> </tr> <tr class=\"highlight_gray_text\"> <td>12</td> <td>1800</td> <td>2200</td> <td>2400</td> </tr> <tr> <td>13</td> <td>2000</td> <td>2200</td> <td>2600</td> </tr> <tr class=\"highlight_gray_text\"> <td>14</td> <td>2000</td> <td>2400</td> <td>2800</td> </tr> <tr> <td>15</td> <td>2200</td> <td>2600</td> <td>3000</td> </tr> <tr class=\"highlight_gray_text\"> <td>16</td> <td>2400</td> <td>2800</td> <td>3200</td> </tr> <tr> <td>17</td> <td>2400</td> <td>2800</td> <td>3200</td> </tr> <tr class=\"highlight_gray_text\"> <td>18</td> <td>2400</td> <td>2800</td> <td>3200</td> </tr> <tr> <td>19 to 20</td> <td>2600</td> <td>2800</td> <td>3000</td> </tr> <tr class=\"highlight_gray_text\"> <td>21 to 25</td> <td>2400</td> <td>2800</td> <td>3000</td> </tr> <tr> <td>26 to 30</td> <td>2400</td> <td>2600</td> <td>3000</td> </tr> <tr class=\"highlight_gray_text\"> <td>31 to 35</td> <td>2400</td> <td>2600</td> <td>3000</td> </tr> <tr> <td>36 to 40</td> <td>2400</td> <td>2600</td> <td>2800</td> </tr> <tr class=\"highlight_gray_text\"> <td>41 to 45</td> <td>2200</td> <td>2600</td> <td>2800</td> </tr> <tr> <td>46 to 50</td> <td>2200</td> <td>2400</td> <td>2800</td> </tr> <tr class=\"highlight_gray_text\"> <td>51 to 55</td> <td>2200</td> <td>2400</td> <td>2800</td> </tr> <tr> <td>56 to 60</td> <td>2200</td> <td>2400</td> <td>2600</td> </tr> <tr class=\"highlight_gray_text\"> <td>61 to 65</td> <td>2000</td> <td>2400</td> <td>2600</td> </tr> <tr> <td>66 to 70</td> <td>2000</td> <td>2200</td> <td>2600</td> </tr> <tr class=\"highlight_gray_text\"> <td>71 to 75</td> <td>2000</td> <td>2200</td> <td>2600</td> </tr> <tr> <td>76 and up</td> <td>2000</td> <td>2200</td> <td>2400</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Females<sup>&#9674;</sup></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\">Age</td> <td class=\"subtitle2_left\">Sedentary*</td> <td class=\"subtitle2_left\">Moderately active<sup>&#182;</sup></td> <td class=\"subtitle2_left\">Active<sup>&#916;</sup></td> </tr> <tr class=\"divider_top highlight_gray_text\"> <td>2</td> <td>1000</td> <td>1000</td> <td>1000</td> </tr> <tr> <td>3</td> <td>1000</td> <td>1200</td> <td>1400</td> </tr> <tr class=\"highlight_gray_text\"> <td>4</td> <td>1200</td> <td>1400</td> <td>1400</td> </tr> <tr> <td>5</td> <td>1200</td> <td>1400</td> <td>1600</td> </tr> <tr class=\"highlight_gray_text\"> <td>6</td> <td>1200</td> <td>1400</td> <td>1600</td> </tr> <tr> <td>7</td> <td>1200</td> <td>1600</td> <td>1800</td> </tr> <tr class=\"highlight_gray_text\"> <td>8</td> <td>1400</td> <td>1600</td> <td>1800</td> </tr> <tr> <td>9</td> <td>1400</td> <td>1600</td> <td>1800</td> </tr> <tr class=\"highlight_gray_text\"> <td>10</td> <td>1400</td> <td>1800</td> <td>2000</td> </tr> <tr> <td>11</td> <td>1600</td> <td>1800</td> <td>2000</td> </tr> <tr class=\"highlight_gray_text\"> <td>12</td> <td>1600</td> <td>2000</td> <td>2200</td> </tr> <tr> <td>13</td> <td>1600</td> <td>2000</td> <td>2200</td> </tr> <tr class=\"highlight_gray_text\"> <td>14</td> <td>1800</td> <td>2000</td> <td>2400</td> </tr> <tr> <td>15</td> <td>1800</td> <td>2000</td> <td>2400</td> </tr> <tr class=\"highlight_gray_text\"> <td>16</td> <td>1800</td> <td>2000</td> <td>2400</td> </tr> <tr> <td>17</td> <td>1800</td> <td>2000</td> <td>2400</td> </tr> <tr class=\"highlight_gray_text\"> <td>18</td> <td>1800</td> <td>2000</td> <td>2400</td> </tr> <tr> <td>19 to 20</td> <td>2000</td> <td>2200</td> <td>2400</td> </tr> <tr class=\"highlight_gray_text\"> <td>21 to 25</td> <td>2000</td> <td>2200</td> <td>2400</td> </tr> <tr> <td>26 to 30</td> <td>1800</td> <td>2000</td> <td>2400</td> </tr> <tr class=\"highlight_gray_text\"> <td>31 to 35</td> <td>1800</td> <td>2000</td> <td>2200</td> </tr> <tr> <td>36 to 40</td> <td>1800</td> <td>2000</td> <td>2200</td> </tr> <tr class=\"highlight_gray_text\"> <td>41 to 45</td> <td>1800</td> <td>2000</td> <td>2200</td> </tr> <tr> <td>46 to 50</td> <td>1800</td> <td>2000</td> <td>2200</td> </tr> <tr class=\"highlight_gray_text\"> <td>51 to 55</td> <td>1600</td> <td>1800</td> <td>2200</td> </tr> <tr> <td>56 to 60</td> <td>1600</td> <td>1800</td> <td>2200</td> </tr> <tr class=\"highlight_gray_text\"> <td>61 to 65</td> <td>1600</td> <td>1800</td> <td>2000</td> </tr> <tr> <td>66 to 70</td> <td>1600</td> <td>1800</td> <td>2000</td> </tr> <tr class=\"highlight_gray_text\"> <td>71 to 75</td> <td>1600</td> <td>1800</td> <td>2000</td> </tr> <tr> <td>76 and up</td> <td>1600</td> <td>1800</td> <td>2000</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Sedentary means a lifestyle that includes only the physical activity of independent living.<br />&para; Moderately active means a lifestyle that includes physical activity equivalent to walking about 1.5 to 3 miles per day at 3 to 4 miles per hour, in addition to the activities of independent living.<br />&Delta; Active means a lifestyle that includes physical activity equivalent to walking more than 3 miles per day at 3 to 4 miles per hour, in addition to the activities of independent living.<br /><span class=\"lozenge\">&loz;</span> Estimates for females do not include women who are pregnant or breastfeeding.</div><div class=\"graphic_reference\">Reproduced from: U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015&ndash;2020 Dietary Guidelines for Americans, 8th Edition, December 2015. Available at: <a href=\"http://health.gov/dietaryguidelines/2015/guidelines/\" target=\"_blank\">http://health.gov/dietaryguidelines/2015/guidelines/</a> (Accessed on April 25, 2016).</div><div id=\"graphicVersion\">Graphic 107834 Version 2.0</div></div></div>"},"107836":{"type":"graphic_diagnosticimage","displayName":"CT scan of airway distortion","title":"CT scan of airway distortion","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">CT scan of airway distortion</div><div class=\"cntnt\"><img style=\"width:594px; height:446px;\" src=\"images/SURG/107836_CT_scan_airway_distortion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows airway distortion (arrow) due to an anterior mediastinal mass.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 107836 Version 1.0</div></div></div>"},"107838":{"type":"graphic_picture","displayName":"Connective tissue nevus 1","title":"Connective tissue nevus in Buschke-Ollendorff syndrome","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Connective tissue nevus in Buschke-Ollendorff syndrome</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/107838_Buschke_Ollendorff_syndr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Connective tissue nevus presenting as multiple flesh-colored to yellowish papules, some of which coalescing into plaques, in a child with Buschke-Ollendorff syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107838 Version 2.0</div></div></div>"},"107840":{"type":"graphic_figure","displayName":"Menstrual patterns after menarche","title":"Proportion of menstrual cycles that are ovulatory differs from the proportion that are regular during the early post-menarcheal years","html":"<div class=\"graphic\"><div style=\"width: 816px\" class=\"figure\"><div class=\"ttl\">Proportion of menstrual cycles that are ovulatory differs from the proportion that are regular during the early post-menarcheal years</div><div class=\"cntnt\"><img style=\"width:796px; height:407px;\" src=\"images/PEDS/107840_Mnstrlpttrnaftrmnrch.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of the percent of menstrual cycles that are 21 to 45 days duration (grey) and percent of menstrual cycles that are ovulatory (orange) by post-menarcheal age through young adulthood. Ovulation was determined by normalcy of urinary pregnanediol glucuronide in weekly samples collected during the last 12 days of each menstrual cycle; cycles with clearly detectable but subnormal pregnanediol are here designated as having luteal insufficiency (blue). Pregnanediol is a metabolite of the progesterone secreted by the corpus luteum formed in response to ovulation. Pregnanediol concentrations indicating antecedent attenuated ovulation signify that&nbsp;most of the menstrual cycles that are not ovulatory had sufficient cyclic follicular activity to generate an immature corpus luteum, rather than being truly anovulatory.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol 136, Pages 1154-65, Copyright &copy; 2015 by the AAP.</div><div id=\"graphicVersion\">Graphic 107840 Version 3.0</div></div></div>"},"107841":{"type":"graphic_figure","displayName":"Persistence of anovulation in adolescents","title":"Probability that an adolescent with symptomatic anovulatory symptoms will have ongoing menstrual abnormality","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Probability that an adolescent with symptomatic anovulatory symptoms will have ongoing menstrual abnormality</div><div class=\"cntnt\"><img style=\"width:612px; height:380px;\" src=\"images/PEDS/107841_Prsstncanvladlsc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Probability that an adolescent with symptomatic anovulatory symptoms will have ongoing menstrual abnormality. \"All symptomatic cases\" curve represents the data of Southam, et al (Southam and Richart 1966). \"Hyperandrogenic\" and \"Non-hyperandrogenic\" curves are hypothetical, based on data discussed in the text. Hyperandrogenic cases are predominantly a mix of physiologic anovulation and PCOS, with PCOS persisting. Non-hyperandrogenic cases are a mix of physiologic anovulation and hypogonadal cases (ranging from primary hypogonadism through hypothalamic amenorrhea to hypogonadotropic hypogonadism), with hypogonadal cases persisting.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol 136, Pages 1154-65, Copyright &copy; 2015 by the AAP.</div><div id=\"graphicVersion\">Graphic 107841 Version 3.0</div></div></div>"},"107842":{"type":"graphic_table","displayName":"Diagnostic criteria for PCOS in adolescents","title":"International consensus diagnostic criteria for polycystic ovary syndrome in adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International consensus diagnostic criteria for polycystic ovary syndrome in adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Otherwise unexplained combination of:</td> </tr> <tr> <td class=\"subtitle2_single\">1. Abnormal uterine bleeding pattern</td> </tr> <tr> <td class=\"indent1\">a. Abnormal for age or gynecologic age</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">b. Persistent symptoms for one to two years</td> </tr> <tr> <td class=\"subtitle2_single\">2. Evidence of hyperandrogenism</td> </tr> <tr> <td class=\"indent1\">a. Persistent testosterone elevation above adult norms in a reliable reference laboratory is the best evidence</td> </tr> <tr> <td class=\"indent1\">b. Moderate-severe hirsutism is clinical evidence of hyperandrogenism</td> </tr> <tr> <td class=\"indent1\">c. Moderate-severe inflammatory acne vulgaris is an indication to test for hyperandrogenemia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol 136, Pages 1154-65, Copyright &copy; 2015 by the AAP.</div><div id=\"graphicVersion\">Graphic 107842 Version 4.0</div></div></div>"},"107843":{"type":"graphic_table","displayName":"Acne scoring system for adolescents","title":"An acne scoring system for adolescents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">An acne scoring system for adolescents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Comedonal</td> <td class=\"subtitle1\">Inflammatory</td> </tr> <tr> <td class=\"subtitle2\">Severity</td> <td class=\"subtitle2\">Lesions<sup>&#182;</sup></td> <td class=\"subtitle2\">Lesions<sup>&#916;</sup></td> </tr> <tr> <td>Mild</td> <td class=\"centered\">1-10</td> <td class=\"centered\">1-10</td> </tr> <tr> <td>Moderate</td> <td class=\"centered\">11-25</td> <td class=\"centered\">11-25</td> </tr> <tr> <td>Severe</td> <td class=\"centered\">&#62;25</td> <td class=\"centered\">&#62;25</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Face, chest, shoulders, and back may be graded separately.<br />&para; Open (\"blackheads\") or closed (\"whiteheads\") comedones (&gt;1 mm diameter).<br />&Delta; Pustules, papules (&le;5 mm), and nodules (&gt;5 mm). Scarring should be noted separately.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol 136, Pages 1154-65, Copyright © 2015 by the AAP.</div><div id=\"graphicVersion\">Graphic 107843 Version 3.0</div></div></div>"},"107846":{"type":"graphic_picture","displayName":"LMA Supreme supraglottic airway","title":"LMA Supreme supraglottic airway","html":"<div class=\"graphic\"><div style=\"width: 657px\" class=\"figure\"><div class=\"ttl\">LMA Supreme supraglottic airway</div><div class=\"cntnt\"><img style=\"width:637px; height:720px;\" src=\"images/EM/107846_LMA_supreme_airway.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The LMA Supreme is a single-use&nbsp;laryngeal mask airway&nbsp;with stiffer cuff, integrated bite block, and a port for an&nbsp;orogastric tube.</div><div class=\"graphic_reference\">Property of Teleflex Incorporated. Copyright &copy; 2013 Teleflex Incorporated. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107846 Version 1.0</div></div></div>"},"107851":{"type":"graphic_diagnosticimage","displayName":"CXR (AP view) showing a CIED with RV, RA, and CS leads","title":"Chest radiograph (AP view) showing a CIED with right ventricular, right atrial, and coronary sinus leads","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Chest radiograph (AP view) showing a CIED with right ventricular, right atrial, and coronary sinus leads</div><div class=\"cntnt\"><img style=\"width:714px; height:576px;\" src=\"images/ANEST/107851_CXR_AP_vw_shw_CIED_RV_RA_CS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pulse generator of this CIED has been relocated using lead extenders (which eliminate the need for new lead placement) from the left to the right side to accommodate the patient's radiation therapy for breast cancer. The shock coils (one of which is seen at the tip of the right ventricular lead arrow) identify this system as high-energy capable (implantable cardioverter-defibrillator). The coronary sinus lead is used to pace the left ventricle for cardiac resynchronization therapy.</div><div class=\"graphic_footnotes\">CXR: chest radiograph; AP: anteroposterior; CIED: cardiac implantable electronic device; RV: right ventricular; RA: right atrial; CS: coronary sinus; CRT-D: cardiac resynchronization therapy-defibrillator; LV: left ventricular.</div><div id=\"graphicVersion\">Graphic 107851 Version 1.0</div></div></div>"},"107852":{"type":"graphic_diagnosticimage","displayName":"CXR (lateral view) showing a CIED with RV, RA, and CS leads","title":"Chest radiograph (lateral view) showing a CIED with right ventricular, right atrial, and coronary sinus leads","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Chest radiograph (lateral view) showing a CIED with right ventricular, right atrial, and coronary sinus leads</div><div class=\"cntnt\"><img style=\"width:562px; height:716px;\" src=\"images/ANEST/107852_CXR_ltrl_shw_CIED_RV_RA_CS_ld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph (lateral view) showing a&nbsp;CIED with RV, RA, and CS leads to demonstrate the posterior trajectory of the CS lead.</div><div class=\"graphic_footnotes\">CXR: chest radiograph; CIED: cardiac implantable electronic device; RV: right ventricular; RA: right atrial; CS: coronary sinus; LV: left ventricular.</div><div id=\"graphicVersion\">Graphic 107852 Version 2.0</div></div></div>"},"107853":{"type":"graphic_diagnosticimage","displayName":"CXR showing pacemaker and thalamic stimulator device","title":"Chest radiograph in a patient with a pacemaker and a thalamic stimulator device","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Chest radiograph in a patient with a pacemaker and a thalamic stimulator device</div><div class=\"cntnt\"><img style=\"width:716px; height:689px;\" src=\"images/ANEST/107853_CXR_ptnt_thlmc_stmlt_dvc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph demonstrating typical left-sided placement of a dual-chamber cardiac pacemaker, as well as a thalamic stimulator used to control Parkinson disease in the right chest.</div><div class=\"graphic_footnotes\">CXR: chest radiograph.</div><div id=\"graphicVersion\">Graphic 107853 Version 1.0</div></div></div>"},"107854":{"type":"graphic_diagnosticimage","displayName":"CXR showing CRT: Defibrillator (CRT-D) and incidental CVC","title":"Chest radiograph showing cardiac resynchronization therapy: Defibrillator (CRT-D) and incidental central venous catheter","html":"<div class=\"graphic\"><div style=\"width: 698px\" class=\"figure\"><div class=\"ttl\">Chest radiograph showing cardiac resynchronization therapy: Defibrillator (CRT-D) and incidental central venous catheter</div><div class=\"cntnt\"><img style=\"width:678px; height:714px;\" src=\"images/ANEST/107854_CXR_CRT_dfbrltr_CRTD_incdnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiography (anteroposterior view) showing a CIED with RV, RA, and coronary sinus leads. The shock coils identify this system as high-energy capable (implantable cardioverter-defibrillator). The coronary sinus lead is used to pace the LV for CRT. An incidental&nbsp;CVC is present.</div><div class=\"graphic_footnotes\">CXR: chest radiograph; CIED: cardiac implantable cardioverter-defibrillator device; CRT: cardiac resynchronization therapy; CRT-D: cardiac resynchronization therapy-defibrillator; CVC: central venous catheter; LV: left ventricular/left ventricle; RV: right ventricular; RA: right atrial.</div><div id=\"graphicVersion\">Graphic 107854 Version 3.0</div></div></div>"},"107855":{"type":"graphic_picture","displayName":"i-gel Airway","title":"i-gel Airway","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">i-gel Airway</div><div class=\"cntnt\"><img style=\"width:720px; height:480px;\" src=\"images/EM/107855_i_gel_Airway.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The i-gel is a type of laryngeal mask that uses a non-inflatable cuff and wider tubing for stability. </div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 Intersurgical Incorporated. All rights reserved.​</div><div id=\"graphicVersion\">Graphic 107855 Version 1.0</div></div></div>"},"107856":{"type":"graphic_picture","displayName":"Air-Q Blocker supraglottic airway","title":"Air-Q Blocker supraglottic intubating airway","html":"<div class=\"graphic\"><div style=\"width: 760px\" class=\"figure\"><div class=\"ttl\">Air-Q Blocker supraglottic intubating airway</div><div class=\"cntnt\"><img style=\"width:740px; height:313px;\" src=\"images/EM/107856_Air_Q_Blocker.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Air-Q&nbsp;is a supraglottic airway&nbsp;designed for blind or endoscopically-guided intubation. </div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 Mercury Medical. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107856 Version 1.0</div></div></div>"},"107857":{"type":"graphic_algorithm","displayName":"Evaluation of the adult with asymptomatic hematuria","title":"Evaluation of the adult with asymptomatic hematuria","html":"<div class=\"graphic\"><div style=\"width: 972px\" class=\"figure\"><div class=\"ttl\">Evaluation of the adult with asymptomatic&nbsp;hematuria</div><div class=\"cntnt\"><img style=\"width:952px; height:1776px;\" src=\"images/NEPH/107857_Evaladulthematuriaedit1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RBC: red blood cell; HPF: high-power field; WBC: white blood cell; CT: computed tomography; BPH: benign prostatic hyperplasia.<br />* Abdominopelvic CT without contrast using a low radiation dose is recommended in most patients. For additional recommendations, refer to UpToDate topics on diagnosis of nephrolithiasis.<br />¶ Some patients with gross hematuria cannot empty their bladder due to severe clots and therefore develop urinary retention. Such patients should undergo prompt imaging and urology evaluation.<br />Δ Patients age &lt;35 with noncontrast CT positive for nephrolithiasis may not need postcontrast imaging. For patients with contraindications to iodinated contrast, refer to UpToDate content for imaging options.<br /><FONT class=lozenge>◊</FONT> For a list of potential environmental/workplace exposures that increase risk for bladder cancer, see <A href=\"http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-risk-factors\" target=_blank>http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-risk-factors</A>.</div><div id=\"graphicVersion\">Graphic 107857 Version 4.0</div></div></div>"},"107859":{"type":"graphic_table","displayName":"Complications of short bowel syndrome","title":"Acute and chronic complications of short bowel syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute and chronic complications of short bowel syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Acute complications</td> <td class=\"subtitle1\" colspan=\"3\">Chronic complications</td> </tr> <tr> <td>Watery diarrhea</td> <td>Liver disease</td> <td>Nutritional deficiencies</td> <td>Skin manifestations</td> </tr> <tr> <td>Electrolyte disturbances</td> <td>Central venous catheter-related complications</td> <td>Growth delay</td> <td>Financial hardships</td> </tr> <tr> <td>Dehydration&nbsp;</td> <td>Dysmotility</td> <td>Metabolic bone disease&nbsp;&nbsp;</td> <td>Oral aversion&nbsp;&nbsp;</td> </tr> <tr> <td>Obstruction&nbsp;</td> <td>Diarrhea</td> <td>Enteric hyperoxaluria</td> <td>Oral complications&nbsp;&nbsp;</td> </tr> <tr> <td>Central venous catheter-associated&nbsp;complications</td> <td>Electrolyte disturbances</td> <td>Eosinophilic gastrointestinal disorders</td> <td>Adhesions/obstruction</td> </tr> <tr> <td>Central venous catheter-associated blood stream infections</td> <td>Small intestine bacterial overgrowth</td> <td>Gastrointestinal bleeding</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Christopher Duggan, MD, and Alexandra Carey, MD.&#xD;&#xA;<ol>&#xD;&#xA;    <li>Duro D, Kamin D, Duggan C. Overview of pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr 2008; 47 Suppl 1:S33. </li>&#xD;&#xA;    <li>Youssef NN, Mezoff AG, Carter BA, Cole CR. Medical update and potential advances in the treatment of pediatric intestinal failure. Curr Gastroenterol Rep 2012; 14:243.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 107859 Version 1.0</div></div></div>"},"107860":{"type":"graphic_picture","displayName":"Anastomotic ulceration in SBS","title":"Anastomotic ulceration of the small bowel in a child with short bowel syndrome","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Anastomotic ulceration of the small bowel in a child with short bowel syndrome</div><div class=\"cntnt\"><img style=\"width:452px; height:311px;\" src=\"images/PEDS/107860_Anstmtc_ulcrtn_SBS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multifocal superficial anastomotic ulcerations in the small bowel of a four-year-old female with short bowel syndrome due to necrotizing enterocolitis. The patient has a history of ileal resection and ileo-colonic anastomosis. Her clinical course was complicated by anemia requiring blood transfusion due to anastomotic ulceration and gastrointestinal bleeding. She failed medical therapy (antibiotics, antiinflammatories, and steroids) and ultimately required surgical resection of the affected bowel. </div><div class=\"graphic_reference\">Courtesy of Christopher Duggan, MD, and Alexandra Carey, MD.</div><div id=\"graphicVersion\">Graphic 107860 Version 1.0</div></div></div>"},"107861":{"type":"graphic_table","displayName":"Ultrasound adnexal mass","title":"Sonographic appearance of adnexal masses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sonographic appearance of adnexal masses</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"85%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sonographic appearance and specific etiologies</td> <td class=\"subtitle1\">Malignant?</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Simple cysts</td> </tr> <tr> <td class=\"indent1\">Non-neoplastic physiologic cyst (dominant follicle, arrested follicle, corpus luteum)</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Paraovarian or paratubal cyst</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cystadenoma (ovarian or tubal)</td> <td>No</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Anechoic cysts with thin septations (complete or incomplete)</td> </tr> <tr> <td class=\"indent1\">Two adjacent non-neoplastic physiologic cysts</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Paratubal cyst</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Hydrosalpinx</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Peritoneal inclusion cyst</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Theca lutein cysts</td> <td>No</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cysts with internal echoes, no solid areas</td> </tr> <tr> <td class=\"indent1\">Non-neoplastic physiologic cyst with hemorrhage</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Endometrioma</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Abscess (gynecologic or gastrointestinal)</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Benign ovarian neoplasm (cystadenoma, cystic teratoma)</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Borderline ovarian tumor</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gastrointestinal (duplication cyst, mucocele)</td> <td>Usually not (mucoceles may be malignant)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cysts with solid-appearing areas (including irregularly thick septations and walls or septal/mural nodules)</td> </tr> <tr> <td class=\"indent1\">Corpus luteum</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Mature cystic teratoma</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Cystadenoma (ovarian or tubal)</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Cystadenocarcinoma (ovarian or tubal, including borderline tumors)</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ectopic pregnancy</td> <td>No</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mostly or completely solid mass</td> </tr> <tr> <td class=\"indent1\">Adnexal torsion</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Leiomyoma (pedunculated or broad ligament)</td> <td>No (but rarely may be a sarcoma)</td> </tr> <tr> <td class=\"indent1\">Epithelial ovarian or tubal carcinoma</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Ovarian sex cord-stromal tumors (eg, fibroma, Sertoli-Leydig)</td> <td>May be benign or malignant</td> </tr> <tr> <td class=\"indent1\">Ovarian germ cell tumors (eg, teratocarcinoma, struma ovarii)</td> <td>May be benign or malignant</td> </tr> <tr> <td class=\"indent1\">Metastasis to ovary</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Nongynecologic primary tumor (gastrointestinal, neurogenic)</td> <td>Some</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 107861 Version 1.0</div></div></div>"},"107862":{"type":"graphic_picture","displayName":"Neonatal pustular melanosis","title":"Neonatal pustular melanosis","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Neonatal pustular melanosis</div><div class=\"cntnt\"><img style=\"width:594px; height:411px;\" src=\"images/PEDS/107862_Nntl_pstlr_mlns.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Gerardo Cabrera-Meza.</div><div id=\"graphicVersion\">Graphic 107862 Version 1.0</div></div></div>"},"107863":{"type":"graphic_picture","displayName":"Skin breakdown near ostomy in SBS","title":"Skin breakdown from ostomy leakage in a patient with short bowel syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin breakdown from ostomy leakage in a patient with short bowel syndrome</div><div class=\"cntnt\"><img style=\"width:304px; height:412px;\" src=\"images/PEDS/107863_Skn_brkdwn_ostmy_SBS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peristomal skin breakdown (contact dermatitis) and candida rash from ostomy leakage in a nine-year-old male with short bowel syndrome secondary to jejunal volvulus.&nbsp;A functional ileostomy is seen on the right (medial), and a defunctionalized mucous fistula is on the left (lateral). Treatment options consisted of soaks, antifungal powder, barrier wipes, high absorbency dressings, border dressings, hydrocortisone ointment, and systemic or topical antifungal therapy in collaboration with a specialized wound care team.</div><div class=\"graphic_reference\">Courtesy of Christopher Duggan, MD, and Alexandra Carey, MD.</div><div id=\"graphicVersion\">Graphic 107863 Version 1.0</div></div></div>"},"107864":{"type":"graphic_picture","displayName":"Cauterization of granulation tissue near gastrostomy","title":"Cauterization of granulation tissue near gastrostomy","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">Cauterization of granulation tissue near gastrostomy</div><div class=\"cntnt\"><img style=\"width:630px; height:554px;\" src=\"images/PEDS/107864_Ctrzt_grnlt_tss_gstr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Granulation tissue at the gastrostomy tube site in a patient with short bowel syndrome. The picture shows treatment with topical silver nitrate, for chemical cauterization.</div><div class=\"graphic_reference\">Courtesy of Christopher Duggan, MD, and Alexandra Carey, MD.</div><div id=\"graphicVersion\">Graphic 107864 Version 1.0</div></div></div>"},"107865":{"type":"graphic_picture","displayName":"Tooth discoloration due to prolonged hyperbilirubinemia","title":"Tooth discoloration due to prolonged conjugated hyperbilirubinemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tooth discoloration due to prolonged conjugated hyperbilirubinemia</div><div class=\"cntnt\"><img style=\"width:320px; height:214px;\" src=\"images/PEDS/107865_Tth_dsclr_prlng_hprblrbnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked discoloration of the teeth in a 10-year-old male with short bowel syndrome with prior history of chronic parenteral nutrition dependence and cholestasis. This is most likely caused by prolonged conjugated hyperbilirubinemia during dental development.</div><div class=\"graphic_reference\">Courtesy of Christopher Duggan, MD, and Alexandra Carey, MD.</div><div id=\"graphicVersion\">Graphic 107865 Version 1.0</div></div></div>"},"107883":{"type":"graphic_movie","displayName":"Intubation via LMA Fastrach","title":"Intubation via LMA Fastrach","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Intubation via LMA Fastrach</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/107883_IntubationLMAFastrachvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:612px; height:612px;\" src=\"images/EM/107883_IntubationLMAFastrachimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The LMA Fastrach can be used as a laryngeal mask airway or as a conduit for tracheal intubation, as demonstrated in this video.</div><div class=\"graphic_reference\">Courtesy of Erik G Laurin, MD and Aaron E Bair, MD.</div><div id=\"graphicVersion\">Graphic 107883 Version 3.0</div></div></div>"},"107884":{"type":"graphic_picture","displayName":"Epiglottis elevating bar of LMA Fastrach","title":"Epiglottis elevating bar of LMA Fastrach ","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Epiglottis elevating bar&nbsp;of LMA Fastrach </div><div class=\"cntnt\"><img style=\"width:720px; height:632px;\" src=\"images/EM/107884_Epiglottis_elevating_bar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The LMA Fastrach (pictured on the right) incorporates an epiglottic elevating bar that extends lengthwise over the aperture through which the endotracheal tube exits the LMA. The elevating bar prevents the epiglottis from interfering with passage of the endotracheal tube.</div><div class=\"graphic_reference\">Property of Teleflex Incorporated. Copyright &copy; 2013 Teleflex Incorporated. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107884 Version 1.0</div></div></div>"},"107885":{"type":"graphic_movie","displayName":"Placement of i-gel airway","title":"Placement of i-gel airway","html":"<div class=\"graphic normal\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Placement of i-gel airway</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/107885_Placementigelairwayvid.mp4\" style=\"width:640px;height:368px\"></div><img style=\"width:648px; height:486px;\" src=\"images/EM/107885_Placementigelairwayimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The i-gel is&nbsp;a laryngeal mask that uses a non-inflatable cuff and wider tubing for stability.</div><div class=\"graphic_reference\">Courtesy of Erik G Laurin, MD and Aaron E Bair, MD.</div><div id=\"graphicVersion\">Graphic 107885 Version 2.0</div></div></div>"},"107886":{"type":"graphic_picture","displayName":"Fiberoptic intubation via supraglottic airway: Step 1","title":"Fiberoptic intubation via supraglottic airway: Step 1 - Initial ETT placement","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Fiberoptic intubation via supraglottic airway: Step 1 - Initial ETT placement</div><div class=\"cntnt\"><img style=\"width:587px; height:787px;\" src=\"images/EM/107886_Fbrptc_intb_sprglt_air_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If blind intubation via a supraglottic airway has been unsuccessful and fiberoptic intubation is to be performed, partially withdraw the ETT so the distal portion remains within the supraglottic airway.</div><div class=\"graphic_reference\">Courtesy of Erik G Laurin, MD and Aaron E Bair, MD.</div><div id=\"graphicVersion\">Graphic 107886 Version 1.0</div></div></div>"},"107887":{"type":"graphic_table","displayName":"Local anesthetic systemic toxicity: Rapid overview","title":"Local anesthetic systemic toxicity: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Local anesthetic systemic toxicity: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Etiology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Unintended intravascular injection of LA </li> <li>Systemic absorption of LA </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Risk factors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Extremes of age (ie, &#60;4 months or &#62;79 years) </li> <li>Cardiac conduction disease </li> <li>Ischemic heart disease </li> <li>Renal dysfunction </li> <li>Hepatic dysfunction </li> <li>Pregnancy </li> <li>Carnitine deficiency </li> <li>Highly vascular block site </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Signs and symptoms* <em>LAST can occur &#62;15 minutes after injection of LA</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>CNS:<sup>&#182;</sup> <ul> <li>Tinnitus </li> <li>Circumoral numbness </li> <li>Metallic taste </li> <li>Agitation </li> <li>Dysarthria </li> <li>Seizures </li> <li>Loss of consciousness </li> <li>Respiratory arrest </li> </ul> </li> <li>Cardiovascular:<sup>&#182;</sup> <ul> <li>Hypotension </li> <li>Bradycardia </li> <li>Ventricular arrhythmias </li> <li>Cardiovascular collapse </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Stop injection or infusion </li> <li>Call for help </li> </ul> <ul> <li>Airway management: Prevent hypoxemia, hypercarbia, and acidosis </li> <li>Suppress seizures <ul> <li>Benzodiazepines preferred </li> </ul> </li> <li>Arrange for cardiopulmonary bypass </li> <li>Manage arrhythmias and cardiac arrest per ACLS <ul> <li>Avoid vasopressin, calcium channel blockers, beta blockers, and LA </li> <li>Administer amiodarone as the first line antiarrhythmic </li> <li>Reduce individual epinephrine dose to &#60;1 mcg/kg (10- to 100-mcg bolus doses) </li> </ul> </li> <li>Institute lipid emulsion therapy with 20% lipid emulsion (TPN) <ul> <li>Bolus 1.5 mL/kg IV over 1 minute </li> <li>Continuous infusion 0.25 mL/kg/minute </li> <li>Repeat bolus for persistent cardiovascular collapse </li> <li>Double infusion to 0.5 mL/kg/minute for persistent hypotension </li> <li>Continue infusion for at least 10 minutes after hemodynamic stability is achieved </li> <li>Maximum dose approximately 10 mL/kg lipid emulsion over first 30 minutes </li> <li>Propofol is not a substitute for lipid emulsion </li> </ul> </li> <li>Institute cardiopulmonary bypass for LAST unresponsive to lipid emulsion and ACLS </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For further information, refer to UpToDate content on local anesthetic systemic toxicity.</div><div class=\"graphic_footnotes\">LA: local anesthetic; LAST: local anesthetic systemic toxicity; CNS: central nervous system; TPN: total parenteral nutrition; ACLS: advanced cardiac life support.<br />* Not all signs and symptoms occur in every patient.<br />&para; Cardiovascular collapse may occur without CNS signs or symptoms, especially with rapid intravascular injection.</div><div id=\"graphicVersion\">Graphic 107887 Version 5.0</div></div></div>"},"107888":{"type":"graphic_picture","displayName":"Fiberoptic intubation via supraglottic airway: Step 2","title":"Fiberoptic intubation via supraglottic airway: Step 2 - Inflate cuff of ETT within supraglottic airway","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Fiberoptic intubation via supraglottic airway: Step 2 - Inflate cuff of ETT within supraglottic airway</div><div class=\"cntnt\"><img style=\"width:587px; height:786px;\" src=\"images/EM/107888_Fbrptc_intb_sprglt_air_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once the ETT is partially withdrawn, inflate the cuff of the ETT.</div><div class=\"graphic_reference\">Courtesy of Erik G Laurin, MD and Aaron E Bair, MD.</div><div id=\"graphicVersion\">Graphic 107888 Version 1.0</div></div></div>"},"107890":{"type":"graphic_picture","displayName":"Endoscope intubation supraglottic airway: Advancing to carina","title":"Fiberoptic intubation via a supraglottic airway: Advancing the scope to the carina","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Fiberoptic intubation via a supraglottic airway:&nbsp;Advancing the scope&nbsp;to the carina</div><div class=\"cntnt\"><img style=\"width:764px; height:510px;\" src=\"images/EM/107890_Endscp_intbtn_sprglttc_crn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Once the fiberoptic endoscope is properly placed, it is steadily advanced and guided under direct visualization through the vocal cords (Panel A)&nbsp;and to the carina (Panel B).</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 107890 Version 3.0</div></div></div>"},"107891":{"type":"graphic_movie","displayName":"Placement of King LT airway","title":"Placement of King LT airway","html":"<div class=\"graphic normal\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Placement of King LT airway</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/107891_PlacementKingLTairwyvid.mp4\" style=\"width:640px;height:368px\"></div><img style=\"width:648px; height:487px;\" src=\"images/EM/107891_PlacementKingLTairwyimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The King LT is an example of a laryngeal tube. It has a pharyngeal cuff and an esophageal cuff, with a port between the cuffs at the level of the laryngeal inlet to allow for gas exchange.</div><div class=\"graphic_reference\">Courtesy of Erik G Laurin, MD and Aaron E Bair, MD.</div><div id=\"graphicVersion\">Graphic 107891 Version 1.0</div></div></div>"},"107892":{"type":"graphic_picture","displayName":"Intubation via King LT using disposable fiberoptic scope","title":"Intubation via King LT using disposable fiberoptic endoscope","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Intubation via King LT using disposable fiberoptic endoscope</div><div class=\"cntnt\"><img style=\"width:484px; height:1086px;\" src=\"images/EM/107892_Intb_Kng_LT_dsps_fbrp_scp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When using a single-use&nbsp;fiberoptic endoscope (FE),&nbsp;as shown in the photographs above, the FE can be advanced down the King LT into the trachea&nbsp;(A)&nbsp;and the proximal end of the FE cut with trauma shears (B), leaving the flexible tail of the FE as a “track” from the oropharynx to the trachea (C). Then the King LT can be deflated and removed over the aScope tail (D), and an ETT railroaded over the aScope tail into the trachea (F). </div><div class=\"graphic_reference\">Courtesy of Erik G Laurin, MD and Aaron E Bair, MD.</div><div id=\"graphicVersion\">Graphic 107892 Version 1.0</div></div></div>"},"107894":{"type":"graphic_picture","displayName":"Shagreen patch 2","title":"Tuberous sclerosis complex: Shagreen patch","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tuberous sclerosis complex: Shagreen patch</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/107894_Shagreen_patch_2_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A typical \"shagreen patch\" presenting as a yellowish plaque with an orange-peel-like surface in a patient with tuberous sclerosis complex.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 107894 Version 1.0</div></div></div>"},"107895":{"type":"graphic_table","displayName":"Pancreatic CA predisp syndromes and risk of panc CA","title":"Pancreatic cancer predisposition syndromes and risk of pancreatic cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pancreatic cancer predisposition syndromes and risk of pancreatic cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"35%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Group (mutated gene)</td> <td class=\"subtitle1\">Other characteristics</td> <td class=\"subtitle1\">Relative risk for pancreatic cancer</td> <td class=\"subtitle1\">Lifetime risk for pancreatic cancer by age 70 years (incidence)</td> </tr> <tr> <td>No history</td> <td>&nbsp;</td> <td>1</td> <td>0.5%</td> </tr> <tr> <td>HBOC (<em>BRCA1</em>) </td> <td>Predisposition to breast, ovarian, prostate cancer</td> <td>3</td> <td>1.2%</td> </tr> <tr> <td>HBOC (<em>BRCA2</em>)</td> <td>Predisposition to breast, ovarian, prostate cancer, Jewish ancestry in some (refer for gene testing)</td> <td>3.5 to 10</td> <td>2 to 5%</td> </tr> <tr> <td>Familial PC + 1 FDR affected</td> <td>Pancreatic ductal adenocarcinoma&nbsp;in an individual with one affected FDR (sibling, parent, or child)</td> <td>4.6</td> <td>&nbsp;</td> </tr> <tr> <td>Familial PC+ 2 FDR affected (unknown)</td> <td>Pancreatic ductal adenocarcinoma&nbsp;in an individual with two affected FDRs</td> <td>6.4</td> <td>&nbsp;</td> </tr> <tr> <td>Lynch II syndrome (mismatch repair genes <em>MLH1, MSH2, MSH6</em>)</td> <td>Predisposition to colorectal, endometrial cancer</td> <td>8.6</td> <td>3.7%</td> </tr> <tr> <td>FAMMM (<em>CKDN2A</em>)</td> <td>Predisposition to melanoma, multiple nevi, atypical moles (autosomal dominant)</td> <td>13 to 36</td> <td>10 to 19%</td> </tr> <tr> <td>Familial PC + 3 FDR affected (unknown)</td> <td>Pancreatic ductal adenocarcinoma&nbsp;in an individual with three affected FDRs</td> <td>32</td> <td>&nbsp;</td> </tr> <tr> <td>Hereditary pancreatitis (<em>PRSS1, SPINK1</em>)</td> <td>Young-onset pancreatitis (autosomal dominant)</td> <td>50 to 82</td> <td>25 to 44%</td> </tr> <tr> <td>Peutz-Jeghers syndrome (<em>STK11</em>)</td> <td>&nbsp;</td> <td>132</td> <td>11 to 66%</td> </tr> <tr> <td>HBOC (<em>PALB2</em>)</td> <td>&nbsp;</td> <td>unknown</td> <td>unknown</td> </tr> <tr> <td>Ataxia-telangiectasia (<em>ATM</em>)</td> <td>&nbsp;</td> <td>unknown</td> <td>unknown</td> </tr> <tr> <td>Li-Fraumeni (<em>TP53</em>)</td> <td>&nbsp;</td> <td>unknown</td> <td>unknown</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HBOC: hereditary breast ovarian cancer syndrome; BRCA: breast-related cancer; familial PC: familial pancreatic cancer (pancreatic ductal adenocarcinoma) in the absence of a definable high-risk inherited mutation; FDR: first-degree relative; FAMMM: familial atypical multiple mole melanoma syndrome; CDKN: cyclin-dependent kinase inhibitor.</div><div id=\"graphicVersion\">Graphic 107895 Version 2.0</div></div></div>"},"107897":{"type":"graphic_table","displayName":"Examples of primary and subspecialty palliative care skills","title":"Representative primary and subspecialty palliative care skills in each domain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Representative primary and subspecialty palliative care skills in each domain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Primary palliative care skills</td> <td class=\"subtitle1\">Subspecialty palliative care skills</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Assessment/treatment of physical symptoms</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Basic pain management</li> <li>Basic management of other physical symptoms</li> <li>Basic use of adjuvant pain relievers</li> <li>Equi-analgesic dose conversion</li> </ul> </td> <td> <ul> <li>Management of refractory pain</li> <li>Management of other refractory symptoms</li> <li>Methadone transition when large doses of opioids are being used</li> <li>Patients with addiction problems and serious illness</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Psychological, social, cultural, and&nbsp;spiritual aspects of care</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Basic management of depression/anxiety</li> <li>Exploration of psychosocial suffering</li> <li>Basic exploration of spiritual and religious views</li> <li>Basic exploratory family meeting</li> </ul> </td> <td> <ul> <li>Management of more complex depression, anxiety, grief, and existential distress</li> <li>Severe religious/spiritual suffering</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Serious illness communication issues</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Exploring patient goals in light of circumstances</li> <li>Making recommendations about code status</li> <li>Seeking consensus among treating professionals</li> <li>Seeking consensus among the patient and family</li> </ul> </td> <td> <ul> <li>Dying patients who want \"everything\"</li> <li>Major conflict among family members</li> <li>Major conflict among treating teams</li> <li>Requests about assisted dying</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Care coordination</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Coordinating care among specialists </li> <li>Clearly defining the primary treating team </li> <li>Managing transitions to hospice care </li> <li>Managing transitions out of the hospital</li> </ul> </td> <td> <ul> <li>Transition to hospice with no clear provider</li> <li>Patient/family major resistance to discharge</li> <li>Conflict with the designated outpatient provider</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Quill TE, Abernathy AP. Generalist plus specialist palliative care - creating a more sustainable model. N Engl J Med 2013; 368:1173.</div><div id=\"graphicVersion\">Graphic 107897 Version 2.0</div></div></div>"},"107900":{"type":"graphic_table","displayName":"Fluids for postoperative replacement and maintenance therapy","title":"Fluids for postoperative replacement and maintenance therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fluids for postoperative replacement and maintenance therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Solution<br /> (US trade name)</td> <td class=\"subtitle1\">Sodium<br /> (mEq/L)</td> <td class=\"subtitle1\">Potassium<br /> (mEq/L)</td> <td class=\"subtitle1\">Chloride<br /> (mEq/L)</td> <td class=\"subtitle1\">Lactate<br /> (mEq/L)</td> <td class=\"subtitle1\">Acetate<br /> (mEq/L)</td> <td class=\"subtitle1\">pH</td> <td class=\"subtitle1\">Osmolarity<br /> (mOsm/L)</td> </tr> <tr class=\"divider_bottom\"> <td>0.9% Sodium Chloride</td> <td class=\"centered\">154</td> <td class=\"centered\">0</td> <td class=\"centered\">154</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">5.5</td> <td class=\"centered\">308</td> </tr> <tr class=\"divider_bottom\"> <td>Lactated Ringer's</td> <td class=\"centered\">130</td> <td class=\"centered\">4</td> <td class=\"centered\">109</td> <td class=\"centered\">28</td> <td class=\"centered\">0</td> <td class=\"centered\">6.5</td> <td class=\"centered\">273</td> </tr> <tr class=\"divider_bottom\"> <td>5% Albumin (human)</td> <td class=\"centered\">130 to 160</td> <td class=\"centered\">&#8804;2</td> <td class=\"centered\">Varies</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">6.9 </td> <td class=\"centered\">300</td> </tr> <tr> <td>Plasma-Lyte</td> <td class=\"centered\">140</td> <td class=\"centered\">5</td> <td class=\"centered\">98</td> <td class=\"centered\">0</td> <td class=\"centered\">27</td> <td class=\"centered\">7.4</td> <td class=\"centered\">294</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">US: United States.</div><div id=\"graphicVersion\">Graphic 107900 Version 2.0</div></div></div>"},"107901":{"type":"graphic_table","displayName":"Diagnostic yield of familial panc CA screening/surveillance","title":"Diagnostic yield of familial pancreatic cancer screening and surveillance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic yield of familial pancreatic cancer screening and surveillance</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">High-risk group</td> <td class=\"subtitle1\">Imaging tests</td> <td class=\"subtitle1\">Diagnostic yield*</td> </tr> <tr> <td>Brentnall 1999; n = 14</td> <td>FPC</td> <td>EUS + ERCP + CT</td> <td>7/14 (50%)<sup>&#182;</sup></td> </tr> <tr> <td>Kimmey 2002; n = 46<sup>&#916;</sup></td> <td>FPC</td> <td>EUS; ERCP<sup>&#9674;</sup></td> <td>12/46 (26%)<sup>&#182;</sup></td> </tr> <tr> <td>Canto 2004; n = 38</td> <td>FPC, PJS</td> <td>EUS; ERCP<sup>&#9674;</sup>, EUS-FNA<sup>&#9674;</sup>, CT<sup>&#9674;</sup></td> <td>2/38 (5.3%)<sup>&#182;</sup></td> </tr> <tr> <td>Canto 2006; n = 78</td> <td>FPC, PJS</td> <td>EUS; CT<sup>&#9674;</sup>, EUS-FNA<sup>&#9674;</sup>, ERCP<sup>&#9674;</sup></td> <td>8/78 (10.2%)<sup>&#182;</sup><sup>&#167;</sup></td> </tr> <tr> <td>Poley 2009; n = 44</td> <td>FPC, BRCA, PJS, CDKN2A, p53, hereditary pancreatitis</td> <td>EUS; CT<sup>&#9674;</sup>, MRI<sup>&#9674;</sup></td> <td>10/44 (23%)</td> </tr> <tr> <td>Langer 2009; n = 76</td> <td>FPC, BRCA</td> <td>EUS + MRCP; EUS-FNA<sup>&#9674;</sup></td> <td>1/76 (1.3%)<sup>&#182;</sup><sup>&#167;</sup></td> </tr> <tr> <td>Verna 2010; n = 51</td> <td>FPC, BRCA, CDKN2A</td> <td>EUS and/or MRCP</td> <td>6/51 (12%)<sup>&#182;</sup></td> </tr> <tr> <td>Ludwig 2011; n = 109</td> <td>FPC, BRCA</td> <td>MRCP; EUS<sup>&#9674;</sup>, EUS-FNA<sup>&#9674;</sup></td> <td>9/109 (8.3%)<sup>&#167;</sup></td> </tr> <tr> <td>Vasen 2011; n = 79</td> <td>CDKN2A</td> <td>MRI/MRCP</td> <td>14/79 (18%)<sup>&#182;</sup></td> </tr> <tr> <td>Al-Sukhni 2011; n = 262</td> <td>FPC, BRCA, PJS, CDKN2A, hereditary pancreatitis</td> <td>MRI; CT<sup>&#9674;</sup>, EUS<sup>&#9674;</sup>, ERCP<sup>&#9674;</sup></td> <td>19/262 (7.3)<sup>&#167;</sup></td> </tr> <tr> <td>Schneider 2011<sup>&#165;</sup>; n = 72</td> <td>FPC, BRCA, PALB2</td> <td>EUS+MRCP</td> <td>11/72 (15%)<sup>&#167;</sup></td> </tr> <tr> <td>Canto 2012; n = 216</td> <td>FPC, BRCA, PJS</td> <td>CT, MRI/MRCP, EUS; ERCP<sup>&#9674;</sup></td> <td>5/216 (2.3%)<sup>&#182;</sup> &ndash; 92/216 (42%)</td> </tr> <tr> <td>Harinck 2015; n = 139</td> <td>FPC, BRCA, PJS, CDKN2A</td> <td>MRI, EUS</td> <td>11/139 (8%)<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr> <td>Vasen 2016; n = 411</td> <td>FPC, BRCA, PALB2, CDKN2A</td> <td>MRI, MRCP, EUS</td> <td>32/411 (7.8%)<sup><span style=\"font-size: 13px;\">&#182;</span></sup><sup><span style=\"font-size: 13px;\">&#167; </span></sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FPC: familial pancreatic cancer; EUS: endoscopic ultrasound; ERCP: endoscopic retrograde cholangiopancreatography; CT: computed tomography; PJS: Peutz-Jeghers syndrome; EUS-FNA: endoscopic ultrasound-guided fine needle aspiration; BRCA: breast-related cancer; CDKN2A: cyclin-dependent kinase inhibitor 2A; MRI: magnetic resonance imaging; MRCP: magnetic resonance cholangiopancreatography; IPMN: intraductal papillary mucinous neoplasms.<br />* Yield is defined as the detection of any pathologically proven (pre)malignant lesion (&ge;PanIN2/IPMN and pancreatic adenocarcinoma) and lesions that are morphologically suspicious for branch-duct IPMNs.<br />&para; Includes only pathologically proven pancreatic neoplasms (histology or cytology).<br />&Delta; Continuation of Brentnall 1999, included 14 high-risk individuals from Brentnall 1999.<br /><span class=\"lozenge\">&loz;</span> Test performed only as an&nbsp;additional test for detected abnormalities.<br />&sect; Includes baseline and follow-up.<br />&yen; Continuation of Langer 2009, includes high-risk individuals from this series. ​</div><div id=\"graphicVersion\">Graphic 107901 Version 1.0</div></div></div>"},"107902":{"type":"graphic_table","displayName":"CAPS summit consensus statements about panc CA screening","title":"International Cancer of the Pancreas Screening (CAPS) consortium consensus on screening for pancreatic cancer in patients with increased risk for familial pancreatic cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International Cancer of the Pancreas Screening (CAPS) consortium consensus on screening for pancreatic cancer in patients with increased risk for familial pancreatic cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"8%\"></colgroup><colgroup width=\"92%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">&nbsp;</td> <td class=\"subtitle1_single\">Statement</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Who should be screened?</td> </tr> <tr> <td class=\"centered\">A1</td> <td>Individuals with <strong>three or more</strong> affected <strong>blood</strong> relatives, with at least one affected FDR, should be considered for screening.</td> </tr> <tr> <td class=\"centered\">A2</td> <td>Individuals with <strong>at least two affected FDR</strong> with PC, with at least one affected FDR, should be considered for screening once they reach a certain age.</td> </tr> <tr> <td class=\"centered\">A3</td> <td>Individuals with two or more affected blood relatives with PC, with at least one affected FDR, should be considered for screening.</td> </tr> <tr> <td class=\"centered\">A4</td> <td>All Peutz-Jeghers syndrome patients should be screened, regardless of family history of PC.</td> </tr> <tr> <td class=\"centered\">A5</td> <td>p16 carriers with one affected FDR should be considered for screening.</td> </tr> <tr> <td class=\"centered\">A6</td> <td>BRCA2 mutation carriers with one affected FDR should be considered for screening.</td> </tr> <tr> <td class=\"centered\">A7</td> <td>BRCA2 mutation carriers with two affected family members (no FDR) with PC should be considered for screening.</td> </tr> <tr> <td class=\"centered\">A8</td> <td>PALB2 mutation carriers with one affected FDR should be considered for screening.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">A9</td> <td>Mismatch repair gene mutation carriers (Lynch syndrome) with one affected FDR should be considered for screening.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">How should high-risk individuals be screened?</td> </tr> <tr> <td class=\"centered\">B1</td> <td>Initial screening should include (multiple answers allowed): <ul> <li>EUS 83.7%, MRI/MRCP 73.5%, CT 26.5%, abdominal ultrasound 14.3%, ERCP 2.0%. </li> </ul> </td> </tr> <tr> <td class=\"centered\">B2</td> <td>When previous screening did not detect an abnormality that met criteria for shortening of the interval or surgical resection, follow-up screening should include (multiple answers allowed): <ul> <li>EUS 79.6%, MRI/MRCP 69.4%, CT 22.4%, abdominal ultrasound 4.1%, ERCP 2.0%. </li> </ul> </td> </tr> <tr> <td class=\"centered\">B3</td> <td>Standardized nomenclature should be used to define chronic pancreatitis-like abnormalities.</td> </tr> <tr> <td class=\"centered\">B4</td> <td>Whenever a cystic lesion is detected, an additional ERCP should <strong>not</strong> be performed.</td> </tr> <tr> <td class=\"centered\">B5</td> <td>Patients with a cystic lesion without worrisome features for malignancy should have an imaging test after 6 to 12 months.</td> </tr> <tr> <td class=\"centered\">B6</td> <td>In case of detection of a solid lesion, CT should also be performed.</td> </tr> <tr> <td class=\"centered\">B7</td> <td>In case of detection of a solid lesion, ERCP should <strong>not</strong> be performed.</td> </tr> <tr> <td class=\"centered\">B8</td> <td>In case of detection of a solid lesion <strong>at baseline</strong> with an indeterminate diagnosis and not being referred for immediate surgery, imaging should be repeated after three months.</td> </tr> <tr> <td class=\"centered\">B9</td> <td>In case of detection of a new solid lesion on <strong>follow-up</strong> with an indeterminate diagnosis and not being referred for immediate surgery, imaging should be repeated after three months.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">B10</td> <td>If an indeterminate main pancreatic duct stricture without a mass is detected, repeat imaging should be performed within three months.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">When should surgery be performed?</td> </tr> <tr> <td class=\"centered\">C1</td> <td>Screening should only be offered to individuals who are candidates for surgery.</td> </tr> <tr> <td class=\"centered\">C1</td> <td>Pancreatic resections should be performed at specialty centers (taking into account volume, morbidity and mortality rates, and expertise available).</td> </tr> <tr> <td class=\"centered\">C2</td> <td><em>Intraoperatively,</em> further pancreatectomy (up to a possible total) should be performed in patients with otherwise reasonable life expectancy to achieve R0 resection of cancer.</td> </tr> <tr> <td class=\"centered\">C3</td> <td><em>Intraoperatively,</em> further pancreatectomy (up to a possible total) should <strong>not</strong> be performed in a patient with otherwise reasonable life expectancy and no cancer, but with <strong>unifocal PanIN-2</strong> in the resected specimen but not at the margin.</td> </tr> <tr> <td class=\"centered\">C4</td> <td><em>Postoperatively,</em> further pancreatectomy (up to a possible total) should <strong>not</strong> be performed in patients with otherwise reasonable life expectancy in a patient without cancer in the resected specimen but with <strong>PanIN-2</strong> at margin.</td> </tr> <tr> <td class=\"centered\">C5</td> <td><em>Postoperatively,</em> further pancreatectomy (up to a possible total) should <strong>not</strong> be performed in patients with otherwise reasonable life expectancy in a patient who did not have cancer, but had <strong>unifocal PanIN-2</strong> in the resected specimens but not at the margin.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">C6</td> <td><em>Postoperatively,</em> further pancreatectomy (up to a possible total) should <strong>not</strong> be performed in patients with otherwise reasonable life expectancy in a patient without cancer, but had <strong>multifocal PanIN-2</strong> in the resected specimens but <strong>not</strong> at the margin.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">What are the goals of screening? What outcome(s) would be considered a \"success\"?</td> </tr> <tr> <td class=\"centered\">D1</td> <td>One of the pathologic lesions that is a potential target for early detection and treatment is <strong>resectable carcinoma</strong>.</td> </tr> <tr> <td class=\"centered\">D2</td> <td>One of the pathologic lesions that is a potential target for early detection and treatment is <strong>PanINs</strong>.</td> </tr> <tr> <td class=\"centered\">D3</td> <td>One of the pathologic lesions that is a potential target for early detection and treatment is <strong>IPMNs</strong>.</td> </tr> <tr> <td class=\"centered\">D4</td> <td>Detection and treatment of <strong>multifocal PanIN-3</strong> should be considered a success of a screening/surveillance program.</td> </tr> <tr> <td class=\"centered\">D5</td> <td>Detection and treatment of <strong>IPMN with high-grade dysplasia</strong> should be considered a success of a screening/surveillance program.</td> </tr> <tr> <td class=\"centered\">D6</td> <td>Detection and treatment of invasive cancer-T1N0M0 detected at baseline should be considered a success of a screening program.</td> </tr> <tr> <td class=\"centered\">D7</td> <td>Detection and treatment of invasive cancer-T1N0M0 detected on follow-up should be considered a success of a screening program.</td> </tr> <tr> <td class=\"centered\">D8</td> <td>Detection and treatment of invasive cancer &#62;T1N0M0 resectable with margins negative at baseline, should be considered a success of a screening program.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDR: first-degree relative; PC: pancreatic cancer; BRCA: breast-related cancer; EUS: endoscopic ultrasound; MRI: magnetic resonance imaging; MRCP: magnetic resonance cholangiopancreatography; CT: computed tomography; ERCP: endoscopic retrograde cholangiopancreatography; PanIN: pancreatic intraepithelial neoplasia; IPMN: intraductal papillary mucinous neoplasms.</div><div class=\"graphic_reference\">Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62:339-47. Reproduced with permission from BMJ Publishing Group Ltd. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 107902 Version 1.0</div></div></div>"},"107904":{"type":"graphic_table","displayName":"Baseline studies prior to chelation in lead-poisoned children","title":"Baseline studies in children receiving chelation for lead poisoning","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Baseline studies in children receiving chelation for lead poisoning</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Abdominal radiograph for leaded foreign bodies or flecks in the GI tract </li> </ul> </td> </tr> <tr> <td> <ul> <li>Free erythrocyte protoporphyrin (if not already obtained) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Serum electrolytes </li> </ul> </td> </tr> <tr> <td> <ul> <li>Blood urea nitrogen </li> </ul> </td> </tr> <tr> <td> <ul> <li>Serum creatinine </li> </ul> </td> </tr> <tr> <td> <ul> <li>Serum calcium </li> </ul> </td> </tr> <tr> <td> <ul> <li>Serum magnesium </li> </ul> </td> </tr> <tr> <td> <ul> <li>Serum aspartate aminotransferase and alanine aminotransferase </li> </ul> </td> </tr> <tr> <td> <ul> <li>Urinalysis </li> </ul> </td> </tr> <tr> <td> <ul> <li>Neuroimaging (eg, computed tomography of the brain) in patients with encephalopathy </li> </ul> </td> </tr> <tr> <td> <ul> <li>Screening for G6PD deficiency (eg, fluorescent spot test or methemoglobin reduction test)* </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal; G6PD: glucose-6-phosphate dehydrogenase.<br />* Indicated for patients of an ethnicity with high prevalence for the disease (eg, African-American or Mediterranean descent) who are receiving dimercaprol. However, chelation should not be delayed while awaiting results.</div><div id=\"graphicVersion\">Graphic 107904 Version 1.0</div></div></div>"},"107905":{"type":"graphic_picture","displayName":"Location of pisiform external landmarks","title":"Location of pisiform from external landmarks","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Location&nbsp;of pisiform from external landmarks</div><div class=\"cntnt\"><img style=\"width:530px; height:710px;\" src=\"images/SM/107905_Plptn_psfrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The circle in the photograph above shows the location of the pisiform bone. Focal tenderness at this sport suggests injury to the pisiform.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD.</div><div id=\"graphicVersion\">Graphic 107905 Version 2.0</div></div></div>"},"107906":{"type":"graphic_algorithm","displayName":"Pneumococcal vaccination immunocompromised adults","title":"UpToDate recommendations* for pneumococcal vaccination in immunocompromised<sup>¶</sup> adults (≥19 years) in the United States","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">UpToDate recommendations* for pneumococcal vaccination in immunocompromised<sup>&para;</sup> adults (&ge;19 years) in the United States</div><div class=\"cntnt\"><img style=\"width:466px; height:554px;\" src=\"images/ID/107906_Pneumococcalimmunoasplenc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PCV13: 13-valent pneumococcal conjugate vaccine (Prevnar 13); PPSV23: 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23).<br />* UpToDate's recommendations differ from those of the United States Advisory Committee on Immunization Practices (ACIP). Refer to the UpToDate topic on pneumococcal vaccination in adults for additional information.<br />¶ Immunocompromising conditions that are indications for pneumococcal vaccination are: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Congenital or acquired immunodeficiency (including B or T lymphocyte deficiency, complement deficiencies, and phagocytic disorders excluding chronic granulomatous disease)</LI>&#xD;&#xA;<LI>HIV infection</LI>&#xD;&#xA;<LI>Hematologic malignancy (eg, leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma)</LI>&#xD;&#xA;<LI>Solid organ transplantation</LI>&#xD;&#xA;<LI>Iatrogenic immunosuppression (including long-term systemic glucocorticoids or radiation)</LI>&#xD;&#xA;<LI>Chronic kidney disease</LI>&#xD;&#xA;<LI>Nephrotic syndrome</LI></UL>These recommendations do not apply to hematopoietic cell transplant (HCT) recipients, patients with anatomic or functional asplenia, or patients with a cochlear implant or cerebrospinal fluid (CSF) leak in the absence of an immunocompromising condition. Refer to the relevant UpToDate topics for recommendations regarding these other patient groups.<br />Δ Only a single dose of PCV13 is indicated during adulthood.<br /><FONT class=lozenge>◊</FONT> The ACIP recommends a dose of PPSV23 at or after 65 years of age but does not recommend additional doses of PPSV23 every 10 years thereafter; in contrast, UpToDate recommends such revaccination.</div><div class=\"graphic_reference\">Reference: Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.</div><div id=\"graphicVersion\">Graphic 107906 Version 3.0</div></div></div>"},"107907":{"type":"graphic_algorithm","displayName":"Pneumococcal vaccination adults cochlear implant CSF leak IPD","title":"UpToDate recommendations* for pneumococcal vaccination in adults (≥19 years of age) with a cochlear implant, CSF leak, or history of invasive pneumococcal disease<sup>¶</sup><sup>Δ</sup> in the United States","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">UpToDate recommendations* for pneumococcal vaccination in adults (&ge;19 years of age) with a cochlear implant, CSF leak, or history of invasive pneumococcal disease<sup>&para;</sup><sup>&Delta;</sup> in the United States</div><div class=\"cntnt\"><img style=\"width:422px; height:384px;\" src=\"images/ID/107907_Pneu_cochlr_implnt_CSF_leak.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; PCV13: 13-valent pneumococcal conjugate vaccine (Prevnar 13); PPSV23: 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23).<br />* UpToDate's recommendations differ from those of the United States Advisory Committee on Immunization Practices (ACIP). Refer to the UpToDate topic on pneumococcal vaccination in adults for additional information.<br />¶ This algorithm applies only to immunocompetent patients who have a cochlear implant, CSF leak, or history of invasive pneumococcal disease. Refer to the relevant UpToDate topics for recommendations regarding other patient groups.<br />Δ UpToDate recommends PCV13 and PPSV23 for patients with a history of invasive pneumococcal disease as outlined in this algorithm. In contrast, the ACIP has not issued a recommendation about pneumococcal vaccination of such patients.<br /><FONT class=lozenge>◊</FONT> Only a single dose of PCV13 is indicated during adulthood.<br />§ The ACIP recommends a dose of PPSV23 at or after 65 years of age but does not recommend additional doses of PPSV23 every 10 years thereafter; in contrast, UpToDate recommends such revaccination.</div><div class=\"graphic_reference\">Reference: Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.</div><div id=\"graphicVersion\">Graphic 107907 Version 3.0</div></div></div>"},"107908":{"type":"graphic_algorithm","displayName":"Pneumococcal vaccination immunocompetent 65 years and older","title":"UpToDate recommendations* for pneumococcal vaccination in immunocompetent<sup>¶</sup> adults ≥65 years of age in the United States","html":"<div class=\"graphic\"><div style=\"width: 826px\" class=\"figure\"><div class=\"ttl\">UpToDate recommendations* for pneumococcal vaccination in immunocompetent<sup>&para;</sup> adults &ge;65 years of age in the United States</div><div class=\"cntnt\"><img style=\"width:806px; height:568px;\" src=\"images/ID/107908_Pneu_immunocomp_65yrs_older.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PPSV23: 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23); PCV13: 13-valent pneumococcal conjugate vaccine (Prevnar 13).<br />* UpToDate's recommendations differ from those of the United States Advisory Committee on Immunization Practices (ACIP). Refer to the UpToDate topic on pneumococcal vaccination in adults for additional information.<br />¶ This algorithm applies only to immunocompetent patients ≥65 years of age who do not have anatomic or functional asplenia, a cochlear implant, or a cerebrospinal fluid leak. Refer to the relevant UpToDate topics for recommendations regarding other patient groups.<br />Δ Only a single dose of PCV13 is indicated during adulthood. The ACIP recommends PCV13 for all adults ≥65 years of age, but UpToDate recommends PCV13 only for adults ≥65 of age who have one of the conditions outlined above.<br /><FONT class=lozenge>◊</FONT> The ACIP recommends a dose of PPSV23 at or after 65 years of age but does not recommend additional doses of PPSV23 every 10 years thereafter;&nbsp;by contrast, UpToDate recommends such revaccination.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102.</li>&#xD;&#xA;    <li>Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged &ge;65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 107908 Version 3.0</div></div></div>"},"107909":{"type":"graphic_algorithm","displayName":"Pneumococcal vaccination immunocompetent 19 through 64 years","title":"UpToDate recommendations* for pneumococcal vaccination in immunocompetent adults ≥19 and <65 years of age in the United States","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">UpToDate recommendations* for pneumococcal vaccination in immunocompetent adults &ge;19 and &lt;65 years of age in the United States</div><div class=\"cntnt\"><img style=\"width:554px; height:694px;\" src=\"images/ID/107909_Pneu_vacc_medical_condition.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PPSV23: 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23); PCV13: 13-valent pneumococcal conjugate vaccine (Prevnar 13).<br />* UpToDate's recommendations differ from those of the United States Advisory Committee on Immunization Practices (ACIP). Refer to the UpToDate topic on pneumococcal vaccination in adults for additional information.<br />¶ Only one dose of PCV13 is indicated during adulthood; if PCV13 was already given, an additional dose is not needed.<br />Δ The ACIP recommends a dose of PPSV23 at or after 65 years of age but does not recommend additional doses of PPSV23 every 10 years thereafter; in contrast, UpToDate recommends such revaccination.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102.</li>&#xD;&#xA;    <li>Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged &ge;65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 107909 Version 2.0</div></div></div>"},"107910":{"type":"graphic_table","displayName":"Guiding principles feeding advancement","title":"Guiding principles for advancing feeds during inpatient care of an infant with short bowel syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guiding principles for advancing feeds during inpatient care of an infant with short bowel syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>Principle 1</strong></td> <td>Quantify feeding intolerance primarily by stool or ostomy output, and hydration status.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>Principle 2</strong></td> <td>Tolerance assessed no more than twice per 24 hours; no more than one advancement in feeds per 24-hour period.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>Principle 3</strong></td> <td>Typical enteral feeding goal are 150 to 200 mL/kg/day, and 100 to 140 kcal/kg/day, provided that weight gain is adequate.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>Principle 4</strong></td> <td>If ostomy or stool output precludes advancement at 20 kcal/ounce for 7 days, then the caloric density of the formula may be increased.</td> </tr> <tr> <td class=\"centered\"><strong>Principle 5</strong></td> <td>Isocaloric reductions in parenteral nutrition support should be undertaken simultaneously with feeding advancement, provided that weight gain is adequate.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Brenn M, Gura K, Duggan C. Intestinal failure. In Sonneville K, Duggan C (eds), Manual of Pediatric Nutrition (5th ed.). People's Medical Publishing House &ndash; USA, Shelton, CT, 2013.</div><div id=\"graphicVersion\">Graphic 107910 Version 1.0</div></div></div>"},"107913":{"type":"graphic_picture","displayName":"Transverse intercostal PVB (photo of probe in place)","title":"Transverse intercostal paravertebral block (photo of probe in place)","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Transverse intercostal paravertebral block (photo of probe in place)</div><div class=\"cntnt\"><img style=\"width:553px; height:376px;\" src=\"images/ANEST/107913_Trnsvrs_intrcst_PVB_pht_prb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For thoracic paravertebral block, the transducer can be placed in either a sagittal plane or transverse plane. Transverse placement is shown in this photo, with the needle oriented in plane to the transducer. For further details, refer to the&nbsp;UpToDate topic on nerve blocks of the scalp, neck, and&nbsp;trunk.</div><div class=\"graphic_footnotes\">PVB: paravertebral block.</div><div id=\"graphicVersion\">Graphic 107913 Version 1.0</div></div></div>"},"107914":{"type":"graphic_table","displayName":"Approach to the treatment of acne vulgaris","title":"Treatment of acne vulgaris","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of acne vulgaris</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr class=\"divider_bottom\"> <td><strong>First line treatment</strong></td> <td class=\"centered\"> <p>Benzoyl peroxide (BP) or topical retinoid</p> <p><strong>&ndash; OR &ndash;</strong></p> Topical combination therapy*<br /> BP <strong>+</strong><br /> Antibiotic or retinoid <strong>+</strong><br /> BP or retinoid <strong>+</strong><br /> BP <strong>+</strong><br /> Antibiotic</td> <td class=\"centered\"> <p>Topical combination therapy*<br /> BP <strong>+</strong><br /> Antibiotic or retinoid <strong>+</strong><br /> BP or retinoid <strong>+</strong><br /> BP <strong>+</strong><br /> Antibiotic</p> <p><strong>&ndash; OR &ndash;</strong></p> <p>Oral antibiotic <strong>+</strong><br /> Topical retinoid <strong>+</strong><br /> BP</p> <p><strong>&ndash; OR &ndash;</strong></p> Oral antibiotic <strong>+</strong><br /> Topical retinoid <strong>+</strong><br /> BP <strong>+</strong><br /> Topical antibiotic</td> <td class=\"centered\"> <p>Oral antibiotic <strong>+</strong><br /> Topical combination therapy*<br /> BP <strong>+</strong><br /> Antibiotic or retinoid <strong>+</strong><br /> BP or retinoid <strong>+</strong><br /> BP <strong>+</strong><br /> Antibiotic</p> <p><strong>&ndash; OR &ndash;</strong></p> Oral isotretinoin</td> </tr> <tr> <td><strong>Alternative treatment</strong></td> <td class=\"centered\"> <p>Add topical retinoid or BP (if not on already)</p> <p><strong>&ndash; OR &ndash;</strong></p> <p>Consider alternate retinoid</p> <p><strong>&ndash; OR &ndash;</strong></p> Consider topical dapsone</td> <td class=\"centered\"> <p>Consider alternate combination therapy</p> <p><strong>&ndash; OR &ndash;</strong></p> <p>Consider change in oral antibiotic</p> <p><strong>&ndash; OR &ndash;</strong></p> <p>Add combined oral contraceptive or oral spironolactone (females)</p> <p><strong>&ndash; OR &ndash;</strong></p> Consider oral isotretinoin</td> <td class=\"centered\"> <p>Consider change in oral antibiotic</p> <p><strong>&ndash; OR &ndash;</strong></p> <p>Add combined oral contraceptive or oral spironolactone (females)</p> <p><strong>&ndash; OR &ndash;</strong></p> Consider oral isotretinoin</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Treatment algorithm for the management of acne vulgaris in adolescents and young adults. The <em>asterisks</em> (*) indicate that the drug may be prescribed as a fixed combination product or as separate component.</div><div class=\"graphic_footnotes\">BP: benzoyl peroxide.</div><div class=\"graphic_reference\">Reproduced from: Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016: 74:945. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 107914 Version 1.0</div></div></div>"},"107930":{"type":"graphic_diagnosticimage","displayName":"Subcostal TAP block ultrasound","title":"Subcostal transversus abdominis plane block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Subcostal transversus abdominis plane block ultrasound</div><div class=\"cntnt\"><img style=\"width:712px; height:591px;\" src=\"images/ANEST/107930_Sbcstl_TAP_blck_ultrsnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the subcostal TAP block, local anesthetic is injected between the rectus muscle and the transversus abdominis muscle, in the transversus abdominis plane. For further details, refer to the UpToDate topic on nerve blocks of the neck, scalp, and trunk.</div><div class=\"graphic_footnotes\">TAP: transversus abdominis plane.</div><div id=\"graphicVersion\">Graphic 107930 Version 1.0</div></div></div>"},"107933":{"type":"graphic_table","displayName":"Anaphylaxis - Perioperative setting (adult)","title":"Anaphylaxis - Perioperative setting (adult)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anaphylaxis - Perioperative setting (adult)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Signs (and symptoms, if patient can communicate)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Hypotension/shock. </li> <li>Tachycardia/arrhythmias. </li> <li>Dyspnea/wheezing/high peak inspiratory pressure/bronchospasm. </li> <li>Hypoxemia or decreased O<sub>2</sub> saturation noted on pulse oximetry. </li> <li>Decreased breath sounds. </li> <li>Angioedema (face, lips, laryngeal stridor). </li> <li>Hives/itching. </li> <li>Flushing. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Immediate actions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Call for help. Inform team and surgeon. Get code cart. </li> <li>Check for possible causes: Stop antibiotics, muscle relaxants, IV contrast, blood products, and latex exposure. </li> <li>Administer 100% FiO<sub>2</sub>. </li> <li>Secure or establish airway. </li> <li>For severe hypotension/shock, give epinephrine bolus (may repeat or escalate dose in one to two minutes and titrate to effect). <ul> <li>Dosing 10 to 100 mcg per IV bolus. </li> <li>If no detectable blood pressure, then initiate ACLS protocol and administer fluid bolus (approximately 25 to 50 mL/kg). </li> </ul> </li> <li>For ongoing hypotension, start IV infusion of epinephrine. <ul> <li>Dosing 2 to 10 mcg/minute, titrated to effect. </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Other therapies for anaphylaxis (if signs/symptoms persist)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Albuterol: Four to eight puffs initially for bronchospasm; alternatively, 2.5 mg albuterol in 2.5 mL of saline nebulized for administration via the endotracheal tube. </li> <li>Methylprednisolone: 125 mg IV or hydrocortisone: 100 mg IV. </li> <li>H1 antihistamines: Diphenhydramine: 50 mg IV. </li> <li>H2 antihistamines: Ranitidine: 50 mg IV (or famotidine or cimetidine). </li> <li>Vasopressin for refractory hypotension (1 to 2 units bolus or infusion). </li> <li>Norepinephrine infusion for refractory hypotension as an alternative (2 to 10 mcg/minute titrated to effect). </li> <li>Continue fluid administrations for refractory hypotension up to 50 mL/kg; after the first two liters or fluid resuscitation for refractory shock, further hemodynamic monitoring should be considered. </li> <li>Consider vasopressin or glucagon (1 to 5 mg slow IV bolus over five minutes) for refractory shock if patient has received high-dose beta-blockers. </li> <li>Echocardiography (transthoracic or transesophageal) to diagnose cause of refractory hypotension. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Consider and exclude other causes of signs/symptoms</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Pneumothorax/tension pneumothorax. </li> <li>Pericardial tamponade. </li> <li>Myocardial infarction. </li> <li>Aspiration. </li> <li>Pulmonary edema. </li> <li>Air or pulmonary embolus. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">If patient develops cardiovascular collapse</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Go to ACLS protocols for: <ul> <li>Asystole/PEA. </li> <li>VF/VT. </li> <li>No detectable blood pressure. </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Send serum tryptase </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><span style=\"font-size: 10px;\"></span> <p>Obtain at least&nbsp;1 mL of blood in a red top tube for serum tryptase assay, ideally within&nbsp;1 hour, but may remain elevated up to&nbsp;3 hours&nbsp;from onset of&nbsp;event. Repeat serum tryptase after 24 hours to establish baseline concentration.</p> </td> </tr> <tr> <td class=\"subtitle1_single\">After resuscitation</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Observe patient in the intensive care unit recovery room for 12 to 24 hours. </li> <li>Continue corticosteroids for 24 hours. </li> <li>Refer to allergist. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; FiO<sub>2</sub>: fraction of inspired oxygen; ACLS: advanced cardiac life support; PEA: pulseless electrical activity; VF: ventricular fibrillation; VT: ventricular tachycardia.</div><div id=\"graphicVersion\">Graphic 107933 Version 5.0</div></div></div>"},"107934":{"type":"graphic_picture","displayName":"Lumbar plexus sagittal probe (lateral decubitus position)","title":"Lumbar plexus sagittal probe (lateral decubitus position)","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Lumbar plexus sagittal probe (lateral decubitus position)</div><div class=\"cntnt\"><img style=\"width:712px; height:530px;\" src=\"images/ANEST/107934_Lmbr_plx_sgt_prb_ltrl_dcbt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided lumbar plexus block, the transducer is initially placed longitudinally adjacent to the lumbar spine, as shown in this photo, to image the vertebral transverse processes. For further details, refer to UpToDate content on lumbar plexus block.</div><div id=\"graphicVersion\">Graphic 107934 Version 1.0</div></div></div>"},"107936":{"type":"graphic_picture","displayName":"Lumbar plexus transverse probe (lateral decubitus position)","title":"Lumbar plexus transverse probe (lateral decubitus position)","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Lumbar plexus transverse probe (lateral decubitus position)</div><div class=\"cntnt\"><img style=\"width:710px; height:532px;\" src=\"images/ANEST/107936_Lmb_plx_trnsv_prb_lat_dcbt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided lumbar plexus block, the transducer is initially placed longitudinally to identify the spinous processes and is then turned 90 degrees, as shown in this photo, to obtain a transverse view of the psoas major muscle. For further details, refer to the UpToDate content on lumbar plexus block.</div><div id=\"graphicVersion\">Graphic 107936 Version 1.0</div></div></div>"},"107940":{"type":"graphic_table","displayName":"CHD variants and anatomic features","title":"Congenital heart disease: Variants and anatomic features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Congenital heart disease: Variants and anatomic features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">CHD variants</td> <td class=\"subtitle1\">Anatomic features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Acyanotic conditions</td> </tr> <tr> <td class=\"indent1\">VSD</td> <td>Structural defect in interventricular septum</td> </tr> <tr> <td class=\"indent1\">ASD</td> <td>Structural defect in interatrial septum</td> </tr> <tr> <td class=\"indent1\">PDA defect</td> <td>Persistent communication between pulmonary artery and aorta via ductus arteriosus</td> </tr> <tr> <td class=\"indent1\">Atrioventricular septal defect</td> <td>Endocardial cushion defect resulting in communication between all four chambers</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ebstein anomaly</td> <td>Low-riding tricuspid valve into right ventricle resulting in enlarged right atrium</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cyanotic conditions</td> </tr> <tr> <td class=\"indent1\">Tetralogy of Fallot</td> <td>VSD, right ventricular hypertrophy, pulmonary stenosis, overriding aorta</td> </tr> <tr> <td class=\"indent1\">Total anomalous pulmonary venous connection</td> <td>Abnormal pulmonary vein drainage into right atrium; requires ASD to feed systemic circulation, otherwise fatal</td> </tr> <tr> <td class=\"indent1\">Persistent truncus arteriosus</td> <td>Failure of division of pulmonary arteries and aorta resulting in common venous and arterial trunk</td> </tr> <tr> <td class=\"indent1\">Hypoplastic left heart syndrome</td> <td>Significantly underdeveloped left ventricle; requires PDA for survival otherwise fatal</td> </tr> <tr> <td class=\"indent1\">Eisenmenger syndrome</td> <td>Reversal of left-to-right shunt; accordingly, development of pulmonary hypertension</td> </tr> <tr> <td class=\"indent1\">d-TGA</td> <td>Parallel circulations consisting of aorta arising from right ventricle and pulmonary artery arising from left ventricle without communication; noncompatible with life</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ASD: atrial septal defect; CHD: congenital heart disease; d-TGA: transposition of great arteries; PDA: patent ductus arteriosus; VSD: ventricular septal defect.</div><div class=\"graphic_reference\">From: Attar H, Sachdeva A, Sundararajan S. Cardioembolic stroke in adults with a history of congenital heart disease. Stroke 2016; 47:e79. DOI: <a href=\"http://stroke.ahajournals.org/content/47/5/e79.extract\" target=\"_blank\">10.1161/STROKEAHA.116.012882</a>. Copyright &copy; 2016 American Heart Association. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 107940 Version 1.0</div></div></div>"},"107941":{"type":"graphic_algorithm","displayName":"Mechanisms ischemic stroke in congenital heart disease","title":"Mechanisms of ischemic stroke in acyanotic and cyanotic heart disease","html":"<div class=\"graphic\"><div style=\"width: 684px\" class=\"figure\"><div class=\"ttl\">Mechanisms of ischemic stroke in acyanotic and cyanotic heart disease</div><div class=\"cntnt\"><img style=\"width:664px; height:166px;\" src=\"images/ID/107941_Mchnsms_ischemic_stroke_CHD.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Attar H, Sachdeva A, Sundararajan S. Cardioembolic stroke in adults with a history of congenital heart disease. Stroke 2016; 47:e79. DOI: <a href=\"http://stroke.ahajournals.org/content/47/5/e79.extract\" target=\"_blank\">10.1161/STROKEAHA.116.012882</a>. Copyright &copy; 2016 American Heart Association. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 107941 Version 1.0</div></div></div>"},"107942":{"type":"graphic_figure","displayName":"Dorsal short-arm splint","title":"Dorsal short-arm splint","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Dorsal short-arm splint</div><div class=\"cntnt\"><img style=\"width:490px; height:224px;\" src=\"images/SM/107942_Dorsal_short-arm_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture above shows the general shape and location for a short-arm dorsal splint. For some injuries, the metacarpophalangeal (MCP) joints do not require immobilization, and so&nbsp;the distal end of the splint stops proximal to them.&nbsp;</div><div id=\"graphicVersion\">Graphic 107942 Version 2.0</div></div></div>"},"107944":{"type":"graphic_figure","displayName":"Somersault maneuver","title":"Somersault maneuver for delivery of the fetus with a tight nuchal cord","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Somersault maneuver for delivery of the fetus with a tight nuchal cord</div><div class=\"cntnt\"><img style=\"width:517px; height:689px;\" src=\"images/OBGYN/107944_Somersault_maneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>Queensland Ambulance Service. Obstetrics: Nuchal umbilical cord. Clinical Practice Procedures. Available at: <A spellcheck=true href=\"https://ambulance.qld.gov.au/clinical.html\" target=_blank>https://ambulance.qld.gov.au/clinical.html</A> (Accessed on June 29, 2016).</LI>&#xD;&#xA;<LI>East Carolina University College of Nursing. Somersault maneuver demo. Available at: <A spellcheck=true href=\"https://www.youtube.com/watch?v=WaJ6sZ4nfnQ\" target=_blank>https://www.youtube.com/watch?v=WaJ6sZ4nfnQ</A> (Accessed on June 29, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 107944 Version 1.0</div></div></div>"},"107958":{"type":"graphic_table","displayName":"Specific causes of ID in children","title":"Diagnostic tests for specific causes* of ID in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic tests for specific causes* of ID in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"60%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Testing</td> </tr> <tr class=\"divider_bottom\"> <td>Down syndrome</td> <td> <ul> <li>Characteristic dysmorphic features </li> <li>Wide range of cognitive impairment </li> <li>Cardiac defects and multiple congenital anomalies </li> </ul> </td> <td>G-banded karyotype analysis</td> </tr> <tr class=\"divider_bottom\"> <td>Fragile X<sup>&#182;</sup></td> <td> <ul> <li>Males with moderate to severe ID, macrocephaly, large ears, enlarged testes<span style=\"color: black;\"> after puberty</span><span style=\"color: black;\">, perseverative speech, and poor eye contact </span></li> <li><span style=\"color: black;\">Occurs in males and females </span></li> <li><span style=\"color: black;\">Family history of ID </span></li> </ul> </td> <td><em>FMR1</em> DNA analysis</td> </tr> <tr class=\"divider_bottom\"> <td>Rett syndrome</td> <td> <ul> <li>Females with normal early development followed by regression to moderate or severe ID </li> <li>Stereotypic hand movements </li> </ul> </td> <td><em>MECP2</em> testing</td> </tr> <tr class=\"divider_bottom\"> <td>Klinefelter syndrome</td> <td> <ul> <li>Males with mild to moderate ID, hypogonadism, tall stature, gynecomastia, reduced body hair </li> </ul> </td> <td>G-banded karyotype analysis</td> </tr> <tr class=\"divider_bottom\"> <td>Prader-Willi syndrome</td> <td> <ul> <li>Mild to moderate cognitive impairment, behavior difficulties, food-seeking behavior and obesity, hypogonadism, neonatal hypotonia, delayed motor milestones </li> </ul> </td> <td>Methylation analysis to detect abnormal parent-specific methylation on chromosome 15q11.2-13</td> </tr> <tr class=\"divider_bottom\"> <td>DiGeorge (22q11.2 deletion) syndrome</td> <td> <ul> <li>Mild to moderate ID, multiple congenital anomalies (including cardiac defects, hypoplastic thymus, palatal abnormalities), immunodeficiency </li> </ul> </td> <td>FISH for 22q11.2 deletion</td> </tr> <tr class=\"divider_bottom\"> <td>Metabolic disorders</td> <td> <ul> <li>Severity of ID varies </li> <li>Episodic decompensation (eg, with febrile illnesses or periods of starvation) </li> <li>Family history of metabolic disorders or parental consanguinity </li> <li>Seizures, developmental regression, failure to thrive </li> </ul> </td> <td>Metabolic screening (typically this includes measurement of plasma amino acids, urine organic acids, serum ammonia, and lactate; more selective testing can be performed based on the patient's specific characteristics). Further metabolic testing is guided by a specialist.</td> </tr> <tr class=\"divider_bottom\"> <td>Muscular dystrophy</td> <td> <ul> <li>Mild to moderate ID </li> <li>Proximal muscle weakness </li> </ul> </td> <td>Measure serum creatinine kinase as initial screen; if elevated, perform additional evaluation (refer to UpToDate topics on muscular dystrophy for details).</td> </tr> <tr class=\"divider_bottom\"> <td>Congenital hypothyroidism<sup>&#916;</sup></td> <td> <ul> <li>Decelerating growth velocity/short stature, cold intolerance, feeding problems, puffy facies, macroglossia, large fontanels, hypotonia, dry skin, prolonged jaundice </li> </ul> </td> <td>Thyroid function tests (serum TSH free T4)</td> </tr> <tr> <td>Lead poisoning<sup>&#9674;</sup></td> <td> <ul> <li>Mild to moderate cognitive impairment, language delay, and behavior problems </li> <li>Vomiting, colicky abdominal pain, fatigue, renal insufficiency </li> <li>Exposure history (eg, persistent mouthing behavior, living in a house or child care facility built before 1950, recent immigration or home renovation, folk remedies, and some parental occupations [smelting, soldering, and auto body repair]) </li> </ul> </td> <td>Blood&nbsp;lead level</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMA: chromosomal microarray analysis; CT: computed tomography; DNA: deoxyribonucleic acid; FISH: fluorescence in situ hybridization; <EM>FMR1</EM>: fragile X mental retardation 1 gene; GDD: global developmental delay; ID: intellectual disability; <EM>MECP2</EM>: methyl-CpG-binding protein 2 gene; MRI: magnetic resonance imaging; TSH: thyroid stimulating hormone; T4: thyroxine<br />* Common specific causes of ID are listed here. There are many other causes of ID in children. For more details, refer to UpToDate's topics on ID in children and topics on the specific diseases and conditions listed.<br />¶ Many experts recommend fragile X testing in all children with unexplained ID or autism, since fragile X syndrome often presents with non-specific GDD in young children.<br />Δ Thyroid testing is recommended routinely for infants and children presenting with ID in countries without newborn screening programs for congenital hypothyroidism. In these areas, unrecognized congenital hypothyroidism is a more common cause of ID. In countries where newborn screening for hypothyroidism is routinely performed, congenital hypothyroidism is an uncommon cause of ID and therefore routine thyroid testing is not necessary for children with ID who lack associated signs and symptoms of hypothyroidism.<br /><FONT class=lozenge>◊</FONT> Blood lead testing should also be performed if the child has not had prior lead screening. Lead toxicity is an uncommon cause of ID in the United States; however, case identification is essential to allow for treatment and for evaluation of other children who may have been similarly exposed. Refer to UpToDate content on screening for lead poisoning for further information.</div><div id=\"graphicVersion\">Graphic 107958 Version 3.0</div></div></div>"},"107977":{"type":"graphic_table","displayName":"Menstrual cycle regularity by age","title":"Variation in menstrual cycle by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Variation in menstrual cycle by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Difference between longest and shortest cycles (days)*</td> </tr> <tr> <td>18 to 25</td> <td>&#177;4 days</td> </tr> <tr> <td>26 to 41</td> <td>&#177;4 days</td> </tr> <tr> <td>42 to 45</td> <td>&#177;4 days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* There are slight differences&nbsp;between age strata, but ±4 days is noted for each age range for the sake of simplicity. These slight differences have limited value in clinical situations, but may be useful for the design and interpretation of epidemiological and clinical studies.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Harlow SD, Lin X, Ho MJ. Analysis of menstrual diary data across the reproductive life span applicability of the bipartite model approach and the importance of within-woman variance. J Clin Epidemiol 2000; 53:722.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 107977 Version 1.0</div></div></div>"},"107984":{"type":"graphic_picture","displayName":"Wrist oblique plain radiographs and positioning","title":"Wrist oblique plain radiographs and positioning","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Wrist oblique plain radiographs and positioning</div><div class=\"cntnt\"><img style=\"width:766px; height:829px;\" src=\"images/SM/107984_Wrist_xray_oblique_views.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) External oblique with wrist pronated 45 degrees. Scaphoid and scaphotrapezial joint are seen well.<br />(B) Internal oblique (supinated 45 degrees) shows hamate and pisotriquetral joint.<br />(C) Hand supinated 30 degrees from neutral rotation.<br />(D) Beam is positioned perpendicularly and centered on pisiform.<br />(E) Radiograph of undisplaced pisiform fracture. Joint space is widened (arrow) owing to hemorrhage and swelling.</div><div class=\"graphic_reference\">Reproduced with permission from: Amrami KK, Berger RA. Imaging of the wrist. In: The Wrist: Diagnosis and Operative Treatment, 2nd ed, Cooney III WP (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Mayo Foundation for Medical Education and Research. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 107984 Version 2.0</div></div></div>"},"107988":{"type":"graphic_algorithm","displayName":"Rx uncomplicated malaria nonfalciparum nonpregnant individuals","title":"Treatment of uncomplicated malaria caused by non-falciparum species in nonpregnant individuals","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">Treatment of uncomplicated malaria caused by non-falciparum species in nonpregnant individuals</div><div class=\"cntnt\"><img style=\"width:785px; height:346px;\" src=\"images/ID/107988_Rx_uncomp_malaria_nonflcprm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Uncomplicated non-falciparum malaria refers to malaria infection caused by a non-falciparum species in the absence of hemodynamic instability, pulmonary edema, hemolysis, severe anemia, coagulopathy, hypoglycemia, metabolic acidosis, renal failure, hepatic dysfunction, altered mental status, focal neurological deficits, or seizures.<br />Antimalarial drug dosing is presented separately; refer to related UpToDate text and tables.</div><div class=\"graphic_footnotes\">* Patients with mixed infections that include both non-falciparum and <em>P. falciparum</em> species should be treated as for <em>P. falciparum</em>; refer to related UpToDate text and tables.<br />&para; The species may be determined by microscopy, rapid diagnostic tests, or molecular tools. Refer to the UpToDate topic on diagnosis of malaria for further discussion.<br />&Delta; Refer to the UpToDate text for further discussion regarding areas with chloroquine-resistant <em>P. vivax</em>. If chloroquine susceptibility is uncertain, chloroquine resistance may be assumed for purposes of selecting an antimalarial regimen for treatment of <em>P. vivax</em> infection. Additional information regarding malaria endemic countries with evidence of reduced chloroquine efficacy may be found at: http://www.wwarn.org/vivax/surveyor/.<br /><span class=\"lozenge\">&loz;</span> The choice between chloroquine and artemisinin combination therapy should be made based on drug availability and local treatment guidelines. In some regions, a universal policy of treatment with artemisinin combination therapy for all species of malaria is favored. Use of artemisinin combination therapy should be implemented in areas where the chloroquine treatment failure rate at day 28 is &gt;10 percent.<br />&sect; The life cycles of <em>P. vivax</em> and <em>P. ovale</em> include a hypnozoite liver stage, which is a dormant stage that can reactivate weeks, months, or years after the initial infection, causing relapse. Therefore, presumptive anti-relapse therapy with primaquine is required to eradicate the hypnozoites of these species. Primaquine is contraindicated for patients deficient in glucose-6-phosphate dehydrogenase (G6PD), as well as pregnant women, infants less than six months old, and women breastfeeding infants less than six months old. Refer to the UpToDate text for discussion of issues related to preventing relapse in patients who are unable to take primaquine.<br />&yen; Treatment of <em>P. knowlesi</em> infection with artemisinin combination therapy may be associated with faster parasite clearance than chloroquine; refer to the UpToDate text for further discussion.</div><div id=\"graphicVersion\">Graphic 107988 Version 1.0</div></div></div>"},"107989":{"type":"graphic_algorithm","displayName":"Management of acute colonic diverticulitis","title":"Management of acute colonic diverticulitis","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Management of acute colonic diverticulitis</div><div class=\"cntnt\"><img style=\"width:688px; height:1296px;\" src=\"images/SURG/107989_Mngmnt_acute_colnc_dvrtclts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* Criteria for inpatient management (only need to meet one): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Complicated diverticulitis (refer to the ¶ footnote below)</LI>&#xD;&#xA;<LI>Immunosuppression</LI>&#xD;&#xA;<LI>High fever</LI>&#xD;&#xA;<LI>Significant leukocytosis</LI>&#xD;&#xA;<LI>Severe abdominal pain</LI>&#xD;&#xA;<LI>Advanced age</LI>&#xD;&#xA;<LI>Significant comorbidities</LI>&#xD;&#xA;<LI>Intolerance of oral intake</LI>&#xD;&#xA;<LI>Noncompliance/unrealibility for return visits/lack of support system</LI>&#xD;&#xA;<LI>Failure of outpatient treatment</LI></UL>¶ Complications of acute diverticulitis: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Perforation</LI>&#xD;&#xA;<LI>Abscess</LI>&#xD;&#xA;<LI>Obstruction</LI>&#xD;&#xA;<LI>Fistulization</LI></UL>Δ Criteria for discharge (all must be met): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Normalization of vital signs</LI>&#xD;&#xA;<LI>Resolution of severe abdominal pain</LI>&#xD;&#xA;<LI>Resolution of significant leukocytosis</LI>&#xD;&#xA;<LI>Tolerance of oral diet</LI></UL></div><div id=\"graphicVersion\">Graphic 107989 Version 2.0</div></div></div>"},"107990":{"type":"graphic_table","displayName":"Comparison of reoperation rates after laparoscopic lavage","title":"Comparison of reoperation rates after laparoscopic lavage versus sigmoidectomy for purulent perforated diverticulitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of reoperation rates after laparoscopic lavage versus sigmoidectomy for purulent perforated diverticulitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Trial</td> <td class=\"subtitle1\" rowspan=\"2\">Follow-up period</td> <td class=\"subtitle1\" colspan=\"2\">Reoperation rate after</td> <td class=\"subtitle1\" rowspan=\"2\">Trial conclusion</td> </tr> <tr> <td class=\"subtitle2\">Laparoscopic lavage</td> <td class=\"subtitle2\">Sigmoidectomy</td> </tr> <tr class=\"divider_bottom\"> <td>SCANDIV</td> <td>90 days</td> <td>20 percent</td> <td>6 percent</td> <td>Favors sigmoidectomy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">LOLA</td> <td>30 days</td> <td>20 percent</td> <td>7 percent</td> <td class=\"divider_bottom\" rowspan=\"2\">Favors sigmoidectomy</td> </tr> <tr class=\"divider_bottom\"> <td>1 year</td> <td>48 percent</td> <td>19 percent*</td> </tr> <tr> <td rowspan=\"2\">DILALA</td> <td>30 days</td> <td>13 percent</td> <td>17 percent</td> <td rowspan=\"2\">Favors laparoscopic lavage</td> </tr> <tr> <td>1 year</td> <td>28 percent</td> <td>63 percent<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Excludes colostomy reversals.<br />&para; Includes colostomy reversals.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Schultz JK, Yaqub S, Wallon C, et al. Laparoscopic Lavage vs Primary Resection for Acute Perforated Diverticulitis: The SCANDIV Randomized Clinical Trial. JAMA 2015; 314:1364.</li>&#xD;&#xA;    <li>Vennix S, Musters GD, Mulder IM, et al. Laparoscopic peritoneal lavage or sigmoidectomy for perforated diverticulitis with purulent peritonitis: a multicentre, parallel-group, randomised, open-label trial. Lancet 2015; 386:1269.</li>&#xD;&#xA;    <li>Angenete E, Thornell A, Burcharth J, et al. Laparoscopic Lavage Is Feasible and Safe for the Treatment of Perforated Diverticulitis With Purulent Peritonitis: The First Results From the Randomized Controlled Trial DILALA. Ann Surg 2016; 263:117.</li>&#xD;&#xA;    <li>Thornell A, Angenete E, Bisgaard T, et al. Laparoscopic Lavage for Perforated Diverticulitis With Purulent Peritonitis: A Randomized Trial. Ann Intern Med 2016; 164:137.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 107990 Version 1.0</div></div></div>"},"107991":{"type":"graphic_figure","displayName":"Division of the upper, middle, and lower rectum","title":"Division of the upper, middle, and lower rectum","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Division of the upper, middle, and lower rectum</div><div class=\"cntnt\"><img style=\"width:488px; height:613px;\" src=\"images/SURG/107991_Division_of_the_upper_middle_and_lower_rectum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical decision-making for sphincter preservation is determined mostly by the distance from the lower border of the tumor to the top of the anorectal ring, rather than the anal verge or the dentate line.</div><div class=\"graphic_reference\">Modified from: Schaffzin DM, Smith LE. Rectal cancer. In: Current Surgical Therapy, 8th ed, Cameron JL (Ed), Philadelphia, Mosby 2004.</div><div id=\"graphicVersion\">Graphic 107991 Version 3.0</div></div></div>"},"107993":{"type":"graphic_picture","displayName":"Supernumerary nostril in a newborn infant","title":"Supernumerary nostril in a newborn infant","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Supernumerary nostril in a newborn infant</div><div class=\"cntnt\"><img style=\"width:598px; height:535px;\" src=\"images/PEDS/107993_Sprnm_nstrl_nwbrn_infn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Supernumerary nostril is a rare malformation of the nose, characterized by an accessory, eccentric nasal opening, either connecting to the ipsilateral nasal cavity or terminating in a blind pouch.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 107993 Version 1.0</div></div></div>"},"107994":{"type":"graphic_diagnosticimage","displayName":"Retinoblastoma on magnetic resonance imaging","title":"Retinoblastoma on magnetic resonance imaging","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Retinoblastoma on magnetic resonance imaging</div><div class=\"cntnt\"><img style=\"width:680px; height:417px;\" src=\"images/PEDS/107994_Rtnblst_mgnt_rsnc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial images of magnetic resonance imaging (MRI) of the brain and orbits in a child with retinoblastoma. The tumor (arrows) appears bright on postcontrast T1 weighted image (panel A) and dark compared with the vitreous on the fat-suppressed T2 weighted image (panel B).</div><div id=\"graphicVersion\">Graphic 107994 Version 1.0</div></div></div>"},"107997":{"type":"graphic_picture","displayName":"Granulation tissue in TTO","title":"Granulation tissue in a child with chronic tympanostomy tube otorrhea","html":"<div class=\"graphic\"><div style=\"width: 671px\" class=\"figure\"><div class=\"ttl\">Granulation tissue in a child with chronic tympanostomy tube otorrhea</div><div class=\"cntnt\"><img style=\"width:651px; height:342px;\" src=\"images/PEDS/107997_Grnl_tss_chld_chr_TTO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Tympanic membrane of a child with a tympanostomy tube (arrow) showing extensive granulation tissue surrounding the tube.<br />Panel B: Healthy-appearing tympanic membrane in a child with a tympanostomy tube (arrow).</div><div class=\"graphic_reference\"><EM>Courtesy of Glenn Isaacson, MD, FAAP.</EM></div><div id=\"graphicVersion\">Graphic 107997 Version 1.0</div></div></div>"}};